US20180186801A1 - Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators - Google Patents
Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators Download PDFInfo
- Publication number
- US20180186801A1 US20180186801A1 US15/904,993 US201815904993A US2018186801A1 US 20180186801 A1 US20180186801 A1 US 20180186801A1 US 201815904993 A US201815904993 A US 201815904993A US 2018186801 A1 US2018186801 A1 US 2018186801A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- substituted
- halo
- phenyl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000002619 bicyclic group Chemical group 0.000 title abstract description 14
- 102000011990 Sirtuin Human genes 0.000 title description 181
- 108050002485 Sirtuin Proteins 0.000 title description 181
- 150000001875 compounds Chemical class 0.000 claims abstract description 341
- 238000000034 method Methods 0.000 claims abstract description 159
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 107
- 201000010099 disease Diseases 0.000 claims abstract description 64
- 208000035475 disorder Diseases 0.000 claims abstract description 41
- 230000001965 increasing effect Effects 0.000 claims abstract description 41
- 238000011010 flushing procedure Methods 0.000 claims abstract description 32
- 230000035882 stress Effects 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 208000008589 Obesity Diseases 0.000 claims abstract description 16
- 230000032683 aging Effects 0.000 claims abstract description 16
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 16
- 235000020824 obesity Nutrition 0.000 claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 13
- 230000004054 inflammatory process Effects 0.000 claims abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 230000023555 blood coagulation Effects 0.000 claims abstract description 9
- 206010053567 Coagulopathies Diseases 0.000 claims abstract description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 288
- 230000000694 effects Effects 0.000 claims description 141
- -1 C≡N Chemical group 0.000 claims description 102
- 125000000623 heterocyclic group Chemical group 0.000 claims description 74
- 229910052757 nitrogen Inorganic materials 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 48
- 102000000344 Sirtuin 1 Human genes 0.000 claims description 37
- 108010041191 Sirtuin 1 Proteins 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 229910052796 boron Inorganic materials 0.000 claims description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- 125000004209 (C1-C8) alkyl group Chemical class 0.000 claims description 16
- 206010022489 Insulin Resistance Diseases 0.000 claims description 14
- 208000022873 Ocular disease Diseases 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 230000000302 ischemic effect Effects 0.000 claims description 11
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical class [H]C([H])([H])* 0.000 claims description 9
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 125000006645 (C3-C4) cycloalkyl group Chemical class 0.000 claims description 5
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 abstract description 157
- 239000003814 drug Substances 0.000 abstract description 37
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- 201000011510 cancer Diseases 0.000 abstract description 19
- 230000002438 mitochondrial effect Effects 0.000 abstract description 19
- 229940124597 therapeutic agent Drugs 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 12
- 208000037765 diseases and disorders Diseases 0.000 abstract description 8
- 201000006417 multiple sclerosis Diseases 0.000 description 105
- 230000015572 biosynthetic process Effects 0.000 description 99
- 238000003786 synthesis reaction Methods 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 89
- 229910001868 water Inorganic materials 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 85
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 238000002360 preparation method Methods 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- 239000003795 chemical substances by application Substances 0.000 description 53
- 239000000243 solution Substances 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 44
- 239000007787 solid Substances 0.000 description 40
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- 102000000478 Sirtuin 3 Human genes 0.000 description 32
- 238000010168 coupling process Methods 0.000 description 32
- 238000005859 coupling reaction Methods 0.000 description 32
- 239000000758 substrate Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 31
- 230000008878 coupling Effects 0.000 description 30
- 238000001816 cooling Methods 0.000 description 28
- 108091005770 SIRT3 Proteins 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 238000001914 filtration Methods 0.000 description 25
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000007821 HATU Substances 0.000 description 22
- 239000007832 Na2SO4 Substances 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 125000004429 atom Chemical group 0.000 description 21
- 230000006378 damage Effects 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- 239000012267 brine Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 150000001412 amines Chemical group 0.000 description 17
- 210000003169 central nervous system Anatomy 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 16
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
- 208000006011 Stroke Diseases 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 16
- 238000003381 deacetylation reaction Methods 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 15
- 230000006196 deacetylation Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 102000003964 Histone deacetylase Human genes 0.000 description 14
- 108090000353 Histone deacetylase Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 208000007536 Thrombosis Diseases 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 11
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 238000002648 combination therapy Methods 0.000 description 11
- AVYSSBABIUPEMY-UHFFFAOYSA-N ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound C1=CC(Cl)=NN2C(C(=O)OCC)=CN=C21 AVYSSBABIUPEMY-UHFFFAOYSA-N 0.000 description 11
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 10
- LAMQVIQMVKWXOC-UHFFFAOYSA-N 4-methyl-n-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(=O)NC1=CC=CC=C1C(N=C1SC=2)=CN1C=2CN1CCOCC1 LAMQVIQMVKWXOC-UHFFFAOYSA-N 0.000 description 10
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 10
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 10
- 102000000477 Sirtuin 2 Human genes 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 229940127089 cytotoxic agent Drugs 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 101000863566 Homo sapiens NAD-dependent protein deacetylase sirtuin-3, mitochondrial Proteins 0.000 description 9
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 102000056482 human SIRT1 Human genes 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 8
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- 230000021736 acetylation Effects 0.000 description 8
- 238000006640 acetylation reaction Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 229940000425 combination drug Drugs 0.000 description 8
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 8
- 230000006735 deficit Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 229950006238 nadide Drugs 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- 125000006574 non-aromatic ring group Chemical group 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 7
- MBTSBTZZRUHMJV-UHFFFAOYSA-N 6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(=O)O)=CN=C2C=CC=1C1=CC=CC=C1C(F)(F)F MBTSBTZZRUHMJV-UHFFFAOYSA-N 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 241000206602 Eukaryota Species 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101000825628 Homo sapiens NAD-dependent protein deacetylase sirtuin-2 Proteins 0.000 description 7
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 208000017442 Retinal disease Diseases 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 229940107161 cholesterol Drugs 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000002780 macular degeneration Diseases 0.000 description 7
- WRCFRKLAXYLKGJ-UHFFFAOYSA-N n-pyridin-2-yl-6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C2=NN3C(C(=O)NC=4N=CC=CC=4)=CN=C3C=C2)=C1 WRCFRKLAXYLKGJ-UHFFFAOYSA-N 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 210000001428 peripheral nervous system Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 231100001274 therapeutic index Toxicity 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- UWZQLLLBBWBROM-UHFFFAOYSA-N 2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C=CC=1C1=CC=CC=C1C(F)(F)F UWZQLLLBBWBROM-UHFFFAOYSA-N 0.000 description 6
- ZHIVNIULVLLUSM-UHFFFAOYSA-N 6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-amine Chemical compound N=1N2C(N)=CN=C2C=CC=1C1=CC=CC=C1C(F)(F)F ZHIVNIULVLLUSM-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 6
- 101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 6
- 101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 206010038923 Retinopathy Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000010931 ester hydrolysis Methods 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- RIGIWEGXTTUCIQ-UHFFFAOYSA-N hydroxy-imino-diphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=O)(N)C1=CC=CC=C1 RIGIWEGXTTUCIQ-UHFFFAOYSA-N 0.000 description 6
- QEGQVQZIQPAJSF-UHFFFAOYSA-N imidazo[1,2-b]pyridazin-3-ylcarbamic acid Chemical compound C1=CC2=NC=C(N2N=C1)NC(=O)O QEGQVQZIQPAJSF-UHFFFAOYSA-N 0.000 description 6
- YCLUMBJQKREDFM-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C1=CC=NN2C(C(=O)N)=CN=C21 YCLUMBJQKREDFM-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000004065 mitochondrial dysfunction Effects 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229940081066 picolinic acid Drugs 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- BFNOPXRXIQJDHO-YDKGJHSESA-N 2''-O-acetyl-ADP-D-ribose Chemical compound O[C@H]1[C@@H](OC(=O)C)C(O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1 BFNOPXRXIQJDHO-YDKGJHSESA-N 0.000 description 5
- LEHGLOAZKUXCRH-UHFFFAOYSA-N 8-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=CN=C2C(C)=CC=1C1=CC=CC=C1C(F)(F)F LEHGLOAZKUXCRH-UHFFFAOYSA-N 0.000 description 5
- BUOIAQCORJLCSL-UHFFFAOYSA-N 8-methyl-n-pyridin-4-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C=1N=C2C(C)=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=NC=C1 BUOIAQCORJLCSL-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 5
- 206010038848 Retinal detachment Diseases 0.000 description 5
- 108010041216 Sirtuin 2 Proteins 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- DWXKSCKBUSAOKS-UHFFFAOYSA-N ethyl 2-chloro-3-oxopropanoate Chemical compound CCOC(=O)C(Cl)C=O DWXKSCKBUSAOKS-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 5
- 102000055034 human SIRT4 Human genes 0.000 description 5
- 102000055198 human SIRT5 Human genes 0.000 description 5
- 102000049192 human SIRT6 Human genes 0.000 description 5
- 102000044649 human SIRT7 Human genes 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 229960003966 nicotinamide Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 235000021283 resveratrol Nutrition 0.000 description 5
- 229940016667 resveratrol Drugs 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 4
- LKEQKBIXHPLDMH-IBGZPJMESA-N (4-nitrophenyl) 6-[2-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound Cc1nc2ccc(nn2c1C(=O)Oc1ccc(cc1)[N+]([O-])=O)-c1ccccc1OC[C@H]1COC(C)(C)O1 LKEQKBIXHPLDMH-IBGZPJMESA-N 0.000 description 4
- BXZMGZBWQPMZBO-UHFFFAOYSA-N 2,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C(C)=CC=1C1=CC=CC=C1C(F)(F)F BXZMGZBWQPMZBO-UHFFFAOYSA-N 0.000 description 4
- SKZWLXXZUZOIIZ-UHFFFAOYSA-N 2,8-dimethyl-n-pyridazin-3-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C(C)=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=CN=N1 SKZWLXXZUZOIIZ-UHFFFAOYSA-N 0.000 description 4
- JKJSZZROFISIOH-UHFFFAOYSA-N 2-methyl-8-morpholin-4-yl-n-pyridazin-3-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C(N3CCOCC3)=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=CN=N1 JKJSZZROFISIOH-UHFFFAOYSA-N 0.000 description 4
- UELODEFCTAVCHD-UHFFFAOYSA-N 2-methyl-n-pyridazin-3-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=CN=N1 UELODEFCTAVCHD-UHFFFAOYSA-N 0.000 description 4
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 4
- PNCILNQZLOGLHB-UHFFFAOYSA-N 4-bromo-6-[2-(trifluoromethyl)phenyl]pyridazin-3-amine Chemical compound C1=C(Br)C(N)=NN=C1C1=CC=CC=C1C(F)(F)F PNCILNQZLOGLHB-UHFFFAOYSA-N 0.000 description 4
- RUEZOOLBSMSUFU-UHFFFAOYSA-N 6-(2,3-dihydroxypropoxy)-n-[7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound N12N=C(C=3C(=CC=CC=3)C(F)(F)F)C(C)=C(C)C2=NC=C1NC(=O)C1=CC=CC(OCC(O)CO)=N1 RUEZOOLBSMSUFU-UHFFFAOYSA-N 0.000 description 4
- KZRYAYILVMVNFT-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-n-(2-pyrrolidin-1-ylpyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC1=NOC(C)=C1C1=NN2C(C(=O)NC=3C=C(N=CC=3)N3CCCC3)=CN=C2C=C1 KZRYAYILVMVNFT-UHFFFAOYSA-N 0.000 description 4
- FXNSGNFBVIUTOI-AWEZNQCLSA-N 6-[(3s)-3-fluoropyrrolidin-1-yl]-n-(6-morpholin-4-ylpyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C1[C@@H](F)CCN1C1=NN2C(C(=O)NC=3N=C(C=CC=3)N3CCOCC3)=CN=C2C=C1 FXNSGNFBVIUTOI-AWEZNQCLSA-N 0.000 description 4
- GVDUJBMSWQPOMK-ZETCQYMHSA-N 6-[(3s)-3-fluoropyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(=O)O)=CN=C2C=CC=1N1CC[C@H](F)C1 GVDUJBMSWQPOMK-ZETCQYMHSA-N 0.000 description 4
- IXIFPGOFZZCOCA-UHFFFAOYSA-N 6-[2-(2,3-dihydroxypropoxy)phenyl]-n-(6-morpholin-4-ylpyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OCC(O)COC1=CC=CC=C1C1=NN2C(C(=O)NC=3N=C(C=CC=3)N3CCOCC3)=CN=C2C=C1 IXIFPGOFZZCOCA-UHFFFAOYSA-N 0.000 description 4
- DFRQZJFBKVSTIE-OAHLLOKOSA-N 6-[2-[(2r)-2,3-dihydroxypropoxy]phenyl]-2-methyl-n-pyridin-2-ylimidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C=CC(C=3C(=CC=CC=3)OC[C@H](O)CO)=NN2C=1C(=O)NC1=CC=CC=N1 DFRQZJFBKVSTIE-OAHLLOKOSA-N 0.000 description 4
- DHVICGQVKKQKOE-INIZCTEOSA-N 6-[2-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methyl-N-pyrimidin-4-ylimidazo[1,2-b]pyridazine-3-carboxamide Chemical compound Cc1nc2ccc(nn2c1C(=O)Nc1ccncn1)-c1ccccc1OC[C@H]1COC(C)(C)O1 DHVICGQVKKQKOE-INIZCTEOSA-N 0.000 description 4
- QKKDSMXBHPVHSD-ZDUSSCGKSA-N 6-[2-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C=CC=1C1=CC=CC=C1OC[C@H]1COC(C)(C)O1 QKKDSMXBHPVHSD-ZDUSSCGKSA-N 0.000 description 4
- WLQDXAXNHHDFHA-MRXNPFEDSA-N 6-[3-[(2r)-2,3-dihydroxypropoxy]phenyl]-2-methyl-n-pyridin-2-ylimidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C=CC(C=3C=C(OC[C@H](O)CO)C=CC=3)=NN2C=1C(=O)NC1=CC=CC=N1 WLQDXAXNHHDFHA-MRXNPFEDSA-N 0.000 description 4
- QTNAQVUQRIXAEL-UHFFFAOYSA-N 7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound CC1=C(C)C2=NC=C(C(O)=O)N2N=C1C1=CC=CC=C1C(F)(F)F QTNAQVUQRIXAEL-UHFFFAOYSA-N 0.000 description 4
- OCMQJABRDBRGPL-UHFFFAOYSA-N 7-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-amine Chemical compound CC1=CC2=NC=C(N)N2N=C1C1=CC=CC=C1C(F)(F)F OCMQJABRDBRGPL-UHFFFAOYSA-N 0.000 description 4
- KBINSARXLXOFEW-UHFFFAOYSA-N 7-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound CC1=CC2=NC=C(C(O)=O)N2N=C1C1=CC=CC=C1C(F)(F)F KBINSARXLXOFEW-UHFFFAOYSA-N 0.000 description 4
- RNMPOBLZBWULCS-UHFFFAOYSA-N 7-methyl-n-pyridin-4-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound N12N=C(C=3C(=CC=CC=3)C(F)(F)F)C(C)=CC2=NC=C1C(=O)NC1=CC=NC=C1 RNMPOBLZBWULCS-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- BZFNOWXWUYJFBI-CYBMUJFWSA-N 8-[(2R)-2,3-dihydroxypropoxy]-2-methyl-N-pyridazin-3-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound Cc1nc2c(OC[C@H](O)CO)cc(nn2c1C(=O)Nc1cccnn1)-c1ccccc1C(F)(F)F BZFNOWXWUYJFBI-CYBMUJFWSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 208000033830 Hot Flashes Diseases 0.000 description 4
- 206010060800 Hot flush Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- 108010042046 Mitochondrial processing peptidase Proteins 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- 206010057430 Retinal injury Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000015294 blood coagulation disease Diseases 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 4
- OJHHQMWNFHWAFR-UHFFFAOYSA-N ethyl 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical group C1=CC(Cl)=NN2C(C(=O)OCC)=C(C)N=C21 OJHHQMWNFHWAFR-UHFFFAOYSA-N 0.000 description 4
- 229960004979 fampridine Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- VQTLNJVPMWFXHO-UHFFFAOYSA-N n-(2-methoxypyrimidin-4-yl)-2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound COC1=NC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2C)C=2C(=CC=CC=2)C(F)(F)F)=N1 VQTLNJVPMWFXHO-UHFFFAOYSA-N 0.000 description 4
- WJZBUOYAVGKSRT-UHFFFAOYSA-N n-[2,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]-6-methoxypyridine-2-carboxamide Chemical compound COC1=CC=CC(C(=O)NC=2N3N=C(C=C(C)C3=NC=2C)C=2C(=CC=CC=2)C(F)(F)F)=N1 WJZBUOYAVGKSRT-UHFFFAOYSA-N 0.000 description 4
- QGBXGVASUGCUSS-UHFFFAOYSA-N n-[6-(1,3-dihydroxypropan-2-yloxy)pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OCC(CO)OC1=CC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 QGBXGVASUGCUSS-UHFFFAOYSA-N 0.000 description 4
- GTMNLAJGORZBDD-UHFFFAOYSA-N n-[6-(2,3-dihydroxypropoxy)pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OCC(O)COC1=CC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 GTMNLAJGORZBDD-UHFFFAOYSA-N 0.000 description 4
- UWAZCYRCDHYWHO-OAHLLOKOSA-N n-[6-[(2r)-2,3-dihydroxypropoxy]pyridin-2-yl]-7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound N12N=C(C=3C(=CC=CC=3)C(F)(F)F)C(C)=C(C)C2=NC=C1C(=O)NC1=CC=CC(OC[C@H](O)CO)=N1 UWAZCYRCDHYWHO-OAHLLOKOSA-N 0.000 description 4
- LJEPHRLYEDGSGP-UHFFFAOYSA-N n-[7-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound N12N=C(C=3C(=CC=CC=3)C(F)(F)F)C(C)=CC2=NC=C1NC(=O)C1=CC=CC=N1 LJEPHRLYEDGSGP-UHFFFAOYSA-N 0.000 description 4
- RMZBZCZEOQSXFY-UHFFFAOYSA-N n-[8-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound C=1N=C2C(C)=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1NC(=O)C1=CC=CC=N1 RMZBZCZEOQSXFY-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 230000004264 retinal detachment Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 101150089009 sir2 gene Proteins 0.000 description 4
- 230000037078 sports performance Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- XPESVQZPCXPBTP-UHFFFAOYSA-N 2,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-amine Chemical compound N=1N2C(N)=C(C)N=C2C(C)=CC=1C1=CC=CC=C1C(F)(F)F XPESVQZPCXPBTP-UHFFFAOYSA-N 0.000 description 3
- ZBQSTLFXINKFQZ-UHFFFAOYSA-N 2-hydroxy-n-pyridin-2-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC=1N=C2C=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=CC=N1 ZBQSTLFXINKFQZ-UHFFFAOYSA-N 0.000 description 3
- SQPDLGYVISZCJT-UHFFFAOYSA-N 2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-amine Chemical compound N=1N2C(N)=C(C)N=C2C=CC=1C1=CC=CC=C1C(F)(F)F SQPDLGYVISZCJT-UHFFFAOYSA-N 0.000 description 3
- VGLUSCFAOJSDNI-UHFFFAOYSA-N 2-methyl-8-morpholin-4-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C(N2CCOCC2)=CC=1C1=CC=CC=C1C(F)(F)F VGLUSCFAOJSDNI-UHFFFAOYSA-N 0.000 description 3
- GWOMJUSUTDREAF-UHFFFAOYSA-N 4-morpholin-4-yl-6-[2-(trifluoromethyl)phenyl]pyridazin-3-amine Chemical compound NC1=NN=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1N1CCOCC1 GWOMJUSUTDREAF-UHFFFAOYSA-N 0.000 description 3
- UTCJYLGDJFRQJM-UHFFFAOYSA-N 5-methyl-n-[6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)NC1=CN=C2N1N=C(C=1C(=CC=CC=1)C(F)(F)F)C=C2 UTCJYLGDJFRQJM-UHFFFAOYSA-N 0.000 description 3
- YRPJLCVYPNAELE-UHFFFAOYSA-N 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound C1=CC(OCCC(F)(F)F)=NN2C(C(=O)O)=CN=C21 YRPJLCVYPNAELE-UHFFFAOYSA-N 0.000 description 3
- BKTZESJXEDCVIM-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=NN2C(C(O)=O)=CN=C2C=C1 BKTZESJXEDCVIM-UHFFFAOYSA-N 0.000 description 3
- SMNNFDOTGWXTML-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-n-[7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound N12N=C(C=3C(=CC=CC=3)C(F)(F)F)C(C)=C(C)C2=NC=C1NC(=O)C(N=1)=CC=CC=1OCC1COC(C)(C)O1 SMNNFDOTGWXTML-UHFFFAOYSA-N 0.000 description 3
- FRUXWYXOZMHAOC-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridin-2-amine Chemical compound O1C(C)(C)OCC1COC1=CC=CC(N)=N1 FRUXWYXOZMHAOC-UHFFFAOYSA-N 0.000 description 3
- FDDGQXUGQJYEJP-YDALLXLXSA-N 6-[(2s)-2,3-dihydroxypropoxy]-n-[6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyrazine-2-carboxamide;hydrochloride Chemical compound Cl.OC[C@H](O)COC1=CN=CC(C(=O)NC=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 FDDGQXUGQJYEJP-YDALLXLXSA-N 0.000 description 3
- DHILIOBVFQDHTL-UHFFFAOYSA-N 6-[2-(difluoromethyl)phenyl]-n-(1,3-thiazol-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound FC(F)C1=CC=CC=C1C1=NN2C(C(=O)NC=3SC=CN=3)=CN=C2C=C1 DHILIOBVFQDHTL-UHFFFAOYSA-N 0.000 description 3
- URKLZGVQZROJAR-UHFFFAOYSA-N 6-[2-(difluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(=O)O)=CN=C2C=CC=1C1=CC=CC=C1C(F)F URKLZGVQZROJAR-UHFFFAOYSA-N 0.000 description 3
- JCTONZAPWKDLLD-UHFFFAOYSA-N 6-[2-(trifluoromethyl)phenyl]pyridazin-3-amine Chemical compound N1=NC(N)=CC=C1C1=CC=CC=C1C(F)(F)F JCTONZAPWKDLLD-UHFFFAOYSA-N 0.000 description 3
- NTFPLIRTJUXKAG-UHFFFAOYSA-N 6-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl]-n-(6-morpholin-4-ylpyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC=CC=C1C1=NN2C(C(=O)NC=3N=C(C=CC=3)N3CCOCC3)=CN=C2C=C1 NTFPLIRTJUXKAG-UHFFFAOYSA-N 0.000 description 3
- ABVTUTGIWGSUDK-UHFFFAOYSA-N 6-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound O1C(C)(C)OCC1COC1=CC=CC=C1C1=NN2C(C(O)=O)=CN=C2C=C1 ABVTUTGIWGSUDK-UHFFFAOYSA-N 0.000 description 3
- PZVNAMCPLAKESC-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(=O)O)=CN=C2C=CC=1C1=CC=CC(C(F)(F)F)=C1 PZVNAMCPLAKESC-UHFFFAOYSA-N 0.000 description 3
- CCWYMNFQFKYUQT-IBGZPJMESA-N 6-[3-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methyl-n-pyridin-2-ylimidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C=CC(C=3C=C(OC[C@@H]4OC(C)(C)OC4)C=CC=3)=NN2C=1C(=O)NC1=CC=CC=N1 CCWYMNFQFKYUQT-IBGZPJMESA-N 0.000 description 3
- GLNUCSQNXMLYRH-CQSZACIVSA-N 6-[[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-N-[6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyrazine-2-carboxamide Chemical compound CC1(C)OC[C@@H](COc2cncc(n2)C(=O)Nc2cnc3ccc(nn23)-c2ccccc2C(F)(F)F)O1 GLNUCSQNXMLYRH-CQSZACIVSA-N 0.000 description 3
- HSAHCMOZFNSMLH-UHFFFAOYSA-N 6-chloro-4-methylpyridazin-3-amine Chemical compound CC1=CC(Cl)=NN=C1N HSAHCMOZFNSMLH-UHFFFAOYSA-N 0.000 description 3
- UWDLNRUFHRYMSE-UHFFFAOYSA-N 6-chloro-5-methylpyridazin-3-amine Chemical compound CC1=CC(N)=NN=C1Cl UWDLNRUFHRYMSE-UHFFFAOYSA-N 0.000 description 3
- LEZFYYWHNXICNC-UHFFFAOYSA-N 6-morpholin-4-ylpyridin-2-amine Chemical compound NC1=CC=CC(N2CCOCC2)=N1 LEZFYYWHNXICNC-UHFFFAOYSA-N 0.000 description 3
- MABQGMWYVQKYSP-UHFFFAOYSA-N 7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-amine Chemical compound CC1=C(C)C2=NC=C(N)N2N=C1C1=CC=CC=C1C(F)(F)F MABQGMWYVQKYSP-UHFFFAOYSA-N 0.000 description 3
- XIAPRJILOXWKKP-HNNXBMFYSA-N 8-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-2-methyl-n-pyridazin-3-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C=1C(C=2C(=CC=CC=2)C(F)(F)F)=NN2C(C(=O)NC=3N=NC=CC=3)=C(C)N=C2C=1OC[C@H]1COC(C)(C)O1 XIAPRJILOXWKKP-HNNXBMFYSA-N 0.000 description 3
- LQRGSCKVSPRLCD-UHFFFAOYSA-N 8-bromo-2-methyl-n-pyridazin-3-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C(Br)=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=CN=N1 LQRGSCKVSPRLCD-UHFFFAOYSA-N 0.000 description 3
- MHPDAQMBCVLNSL-UHFFFAOYSA-N 8-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-amine Chemical compound N=1N2C(N)=CN=C2C(C)=CC=1C1=CC=CC=C1C(F)(F)F MHPDAQMBCVLNSL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 3
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 206010029240 Neuritis Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- 206010036105 Polyneuropathy Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000007845 axonopathy Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 235000020934 caloric restriction Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 101150018117 cobB gene Proteins 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- BPGXMLRZVCVOBM-UHFFFAOYSA-N ethyl 2,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=C(C)N=C2C(C)=CC=1C1=CC=CC=C1C(F)(F)F BPGXMLRZVCVOBM-UHFFFAOYSA-N 0.000 description 3
- OBCRYAMLHLACHS-UHFFFAOYSA-N ethyl 2-hydroxy-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CCOC(=O)c1c(O)nc2ccc(nn12)-c1ccccc1C(F)(F)F OBCRYAMLHLACHS-UHFFFAOYSA-N 0.000 description 3
- TXJSXWYGRFMXPR-UHFFFAOYSA-N ethyl 2-methyl-8-morpholin-4-yl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=C(C)N=C2C(N2CCOCC2)=CC=1C1=CC=CC=C1C(F)(F)F TXJSXWYGRFMXPR-UHFFFAOYSA-N 0.000 description 3
- QWZUIBLHROMLFC-UHFFFAOYSA-N ethyl 6-(2-formylphenyl)imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=CC=1C1=CC=CC=C1C=O QWZUIBLHROMLFC-UHFFFAOYSA-N 0.000 description 3
- LHVDFYYYDOABRC-UHFFFAOYSA-N ethyl 6-(2-hydroxyphenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CCOC(=O)c1c(C)nc2ccc(nn12)-c1ccccc1O LHVDFYYYDOABRC-UHFFFAOYSA-N 0.000 description 3
- RVLCODBKULMXFL-UHFFFAOYSA-N ethyl 6-(2-hydroxyphenyl)imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CCOC(=O)c1cnc2ccc(nn12)-c1ccccc1O RVLCODBKULMXFL-UHFFFAOYSA-N 0.000 description 3
- NVNMDZWDXCPSBE-UHFFFAOYSA-N ethyl 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound C1=CC(OCCC(F)(F)F)=NN2C(C(=O)OCC)=CN=C21 NVNMDZWDXCPSBE-UHFFFAOYSA-N 0.000 description 3
- DDZPAPSQJBKCKI-VIFPVBQESA-N ethyl 6-[(3s)-3-fluoropyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=CC=1N1CC[C@H](F)C1 DDZPAPSQJBKCKI-VIFPVBQESA-N 0.000 description 3
- JBRXXERNADSCAK-UHFFFAOYSA-N ethyl 6-[2-(difluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=CC=1C1=CC=CC=C1C(F)F JBRXXERNADSCAK-UHFFFAOYSA-N 0.000 description 3
- XWDALWFNSGLSQB-UHFFFAOYSA-N ethyl 6-[2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=CC=1C1=CC=CC=C1OCC1COC(C)(C)O1 XWDALWFNSGLSQB-UHFFFAOYSA-N 0.000 description 3
- GZWQMUDCSAMGCN-HNNXBMFYSA-N ethyl 6-[2-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CCOC(=O)c1c(C)nc2ccc(nn12)-c1ccccc1OC[C@H]1COC(C)(C)O1 GZWQMUDCSAMGCN-HNNXBMFYSA-N 0.000 description 3
- XENCYAYSBJATTR-UHFFFAOYSA-N ethyl 6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=CC=1C1=CC=CC(C(F)(F)F)=C1 XENCYAYSBJATTR-UHFFFAOYSA-N 0.000 description 3
- NEENOBLHXFGXJH-UHFFFAOYSA-N ethyl 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CC1=CC(Cl)=NN2C(C(=O)OCC)=C(C)N=C21 NEENOBLHXFGXJH-UHFFFAOYSA-N 0.000 description 3
- UJOCRMHGWWVERH-UHFFFAOYSA-N ethyl 6-chloro-2-hydroxyimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound ClC=1C=CC=2N(N1)C(=C(N2)O)C(=O)OCC UJOCRMHGWWVERH-UHFFFAOYSA-N 0.000 description 3
- BXZPIYFUHRULHH-UHFFFAOYSA-N ethyl 6-chloro-7,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CC1=C(C)C(Cl)=NN2C(C(=O)OCC)=CN=C21 BXZPIYFUHRULHH-UHFFFAOYSA-N 0.000 description 3
- RYXCTLLFRRJFCH-UHFFFAOYSA-N ethyl 6-chloro-7-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound C1=C(C)C(Cl)=NN2C(C(=O)OCC)=CN=C21 RYXCTLLFRRJFCH-UHFFFAOYSA-N 0.000 description 3
- GLMRPSKOIJGKNP-UHFFFAOYSA-N ethyl 6-chloro-8-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound CC1=CC(Cl)=NN2C(C(=O)OCC)=CN=C21 GLMRPSKOIJGKNP-UHFFFAOYSA-N 0.000 description 3
- NBNWRWHAUSWWLY-UHFFFAOYSA-N ethyl 7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C(C)=C(C)C=1C1=CC=CC=C1C(F)(F)F NBNWRWHAUSWWLY-UHFFFAOYSA-N 0.000 description 3
- YKAMMESSGGSILO-UHFFFAOYSA-N ethyl 7-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=C(C)C=1C1=CC=CC=C1C(F)(F)F YKAMMESSGGSILO-UHFFFAOYSA-N 0.000 description 3
- MYFRQKRURTVKOI-UHFFFAOYSA-N ethyl 8-bromo-2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=C(C)N=C2C(Br)=CC=1C1=CC=CC=C1C(F)(F)F MYFRQKRURTVKOI-UHFFFAOYSA-N 0.000 description 3
- CNYPRLNGGMJOBM-UHFFFAOYSA-N ethyl 8-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C(C)=CC=1C1=CC=CC=C1C(F)(F)F CNYPRLNGGMJOBM-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000045076 human SIRT3 Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 208000006132 lipodystrophy Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- VXBIWACJXHZXHA-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=C(Cl)C=N1 VXBIWACJXHZXHA-UHFFFAOYSA-N 0.000 description 3
- DJRNYUUROQTOPH-UHFFFAOYSA-N n-[2-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyrimidin-4-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OCC(C)(CO)COC1=NC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 DJRNYUUROQTOPH-UHFFFAOYSA-N 0.000 description 3
- URYCYLQZCAPIDK-UHFFFAOYSA-N n-[2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound CC=1N=C2C=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1NC(=O)C1=CC=CC=N1 URYCYLQZCAPIDK-UHFFFAOYSA-N 0.000 description 3
- DGNHGCKJGIKRCY-UHFFFAOYSA-N n-[4-(2,3-dihydroxypropoxy)pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OCC(O)COC1=CC=NC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1 DGNHGCKJGIKRCY-UHFFFAOYSA-N 0.000 description 3
- IVLQVUBERAWFTM-UHFFFAOYSA-N n-[6-(morpholin-4-ylmethyl)pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(C(=O)NC=3N=C(CN4CCOCC4)C=CC=3)=CN=C2C=C1 IVLQVUBERAWFTM-UHFFFAOYSA-N 0.000 description 3
- SIWPNZYROCUTKQ-UHFFFAOYSA-N n-[6-[(2-phenyl-1,3-dioxan-5-yl)oxy]pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(C(=O)NC=3N=C(OC4COC(OC4)C=4C=CC=CC=4)C=CC=3)=CN=C2C=C1 SIWPNZYROCUTKQ-UHFFFAOYSA-N 0.000 description 3
- OGGBCFQJXKLFFK-LBPRGKRZSA-N n-[6-[(2s)-2,3-dihydroxypropoxy]pyrazin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC[C@H](O)COC1=CN=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 OGGBCFQJXKLFFK-LBPRGKRZSA-N 0.000 description 3
- VJMCLMFCTBHRMU-CQSZACIVSA-N n-[6-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]pyrazin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound O1C(C)(C)OC[C@H]1COC1=CN=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 VJMCLMFCTBHRMU-CQSZACIVSA-N 0.000 description 3
- FDSBATKDBDIVFN-KRWDZBQOSA-N n-[6-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]pyridin-2-yl]-7,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound N12N=C(C=3C(=CC=CC=3)C(F)(F)F)C(C)=C(C)C2=NC=C1C(=O)NC(N=1)=CC=CC=1OC[C@H]1COC(C)(C)O1 FDSBATKDBDIVFN-KRWDZBQOSA-N 0.000 description 3
- VQPYFDCGKPTNIY-UHFFFAOYSA-N n-pyridin-3-yl-6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound N12N=C(OCCC(F)(F)F)C=CC2=NC=C1C(=O)NC1=CC=CN=C1 VQPYFDCGKPTNIY-UHFFFAOYSA-N 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- 101150084733 sir-2.1 gene Proteins 0.000 description 3
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- DIIFZCPZIRQDIJ-UHFFFAOYSA-N (3,5-dimethyl-1,2-oxazol-4-yl)boronic acid Chemical compound CC1=NOC(C)=C1B(O)O DIIFZCPZIRQDIJ-UHFFFAOYSA-N 0.000 description 2
- WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 2
- LENYOXXELREKGZ-WCCKRBBISA-N (3s)-3-fluoropyrrolidin-1-ium;chloride Chemical compound Cl.F[C@H]1CCNC1 LENYOXXELREKGZ-WCCKRBBISA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 2
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 2
- ZBSQRSAMKYIVHH-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyridin-4-amine Chemical compound NC1=CC=NC(N2CCCC2)=C1 ZBSQRSAMKYIVHH-UHFFFAOYSA-N 0.000 description 2
- DAUDKKRRVXKFEK-UHFFFAOYSA-N 3,4,7-trimethyl-2-[3-(trifluoromethyl)phenyl]pyrazolo[3,4-d]pyridazine Chemical compound N1=C2C(C)=NN=C(C)C2=C(C)N1C1=CC=CC(C(F)(F)F)=C1 DAUDKKRRVXKFEK-UHFFFAOYSA-N 0.000 description 2
- RMFVVPBBEDMZQI-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1,3-benzothiazole Chemical compound C1CCCC2=C1N=CS2 RMFVVPBBEDMZQI-UHFFFAOYSA-N 0.000 description 2
- QSVDFJNXDKTKTJ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indene Chemical compound C1CCCC2=C1CC=C2 QSVDFJNXDKTKTJ-UHFFFAOYSA-N 0.000 description 2
- RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 description 2
- XNZNRLCQBNNPFA-UHFFFAOYSA-N 6-(1,3-thiazol-2-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(=O)O)=CN=C2C=CC=1C1=NC=CS1 XNZNRLCQBNNPFA-UHFFFAOYSA-N 0.000 description 2
- SJLNIHJGRQJZAJ-UHFFFAOYSA-N 6-(morpholin-4-ylmethyl)pyridin-2-amine Chemical compound NC1=CC=CC(CN2CCOCC2)=N1 SJLNIHJGRQJZAJ-UHFFFAOYSA-N 0.000 description 2
- SAHLVKZNPSBQQE-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridine-2-carboxylic acid Chemical compound O1C(C)(C)OCC1COC1=CC=CC(C(O)=O)=N1 SAHLVKZNPSBQQE-UHFFFAOYSA-N 0.000 description 2
- VPAPSEYKVPULKR-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenyl]pyridine-3-carboxylic acid Chemical group N1=CC(C(=O)O)=CC=C1C1=CC=CC(C(F)(F)F)=C1 VPAPSEYKVPULKR-UHFFFAOYSA-N 0.000 description 2
- QWEZOFPPFQXANB-UHFFFAOYSA-N 6-[3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C=CC=1C(C=1)=CC=CC=1OCC1COC(C)(C)O1 QWEZOFPPFQXANB-UHFFFAOYSA-N 0.000 description 2
- QWEZOFPPFQXANB-HNNXBMFYSA-N 6-[3-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C=CC=1C(C=1)=CC=CC=1OC[C@H]1COC(C)(C)O1 QWEZOFPPFQXANB-HNNXBMFYSA-N 0.000 description 2
- MBJNZBBROALMBH-SSDOTTSWSA-N 6-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]pyrazine-2-carboxylic acid Chemical compound O1C(C)(C)OC[C@H]1COC1=CN=CC(C(O)=O)=N1 MBJNZBBROALMBH-SSDOTTSWSA-N 0.000 description 2
- FRUXWYXOZMHAOC-QMMMGPOBSA-N 6-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]pyridin-2-amine Chemical compound O1C(C)(C)OC[C@@H]1COC1=CC=CC(N)=N1 FRUXWYXOZMHAOC-QMMMGPOBSA-N 0.000 description 2
- QPUBOGNHAFQPOP-UHFFFAOYSA-N 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound C1=CC(Cl)=NN2C(C(O)=O)=C(C)N=C21 QPUBOGNHAFQPOP-UHFFFAOYSA-N 0.000 description 2
- NGPRIAYSHXIPBS-UHFFFAOYSA-N 8-bromo-2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound N=1N2C(C(O)=O)=C(C)N=C2C(Br)=CC=1C1=CC=CC=C1C(F)(F)F NGPRIAYSHXIPBS-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229910014263 BrF3 Inorganic materials 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010008616 Cholecystitis and cholelithiasis Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- 206010067276 Cytotoxic oedema Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- ZHPLPRUARZZBET-UHFFFAOYSA-N Gossypetin Natural products O1C2=C(O)C(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 ZHPLPRUARZZBET-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000009564 MELAS Syndrome Diseases 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 102100026934 Mitochondrial intermediate peptidase Human genes 0.000 description 2
- 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036049 Polycystic ovaries Diseases 0.000 description 2
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000007527 Retinal artery occlusion Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- AESZIZFAJBWXSP-UHFFFAOYSA-N benzyl n-[6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]carbamate Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(NC(=O)OCC=3C=CC=CC=3)=CN=C2C=C1 AESZIZFAJBWXSP-UHFFFAOYSA-N 0.000 description 2
- JBFDZEJAJZJORO-UHFFFAOYSA-N bicyclo[4.1.0]hept-3-ene Chemical compound C1C=CCC2CC21 JBFDZEJAJZJORO-UHFFFAOYSA-N 0.000 description 2
- DCRRIOWFXXDTHV-UHFFFAOYSA-N bicyclo[4.2.0]oct-3-ene Chemical compound C1C=CCC2CCC21 DCRRIOWFXXDTHV-UHFFFAOYSA-N 0.000 description 2
- RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001201 calcium accumulation Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 235000020827 calorie restriction Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- GSKKHHLGIJZYHC-UHFFFAOYSA-N ethyl 6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxylate Chemical compound N=1N2C(C(=O)OCC)=CN=C2C=CC=1C1=CC=CC=C1C(F)(F)F GSKKHHLGIJZYHC-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000037957 feline spongiform encephalopathy Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- YRRAGUMVDQQZIY-UHFFFAOYSA-N gossypetin Chemical compound C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(O)=C2O1 YRRAGUMVDQQZIY-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000050401 human SIRT2 Human genes 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- SGRMUAZFOWNSGE-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical class C1=CC=NN2C(C(=O)O)=CN=C21 SGRMUAZFOWNSGE-UHFFFAOYSA-N 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000037805 labour Diseases 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 229960004011 methenamine Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000008437 mitochondrial biogenesis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- IMXFKNAFXLVDIY-UHFFFAOYSA-N n-[6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(C(=O)NC=3N=C(C=CC=3)N3CC4(COC4)C3)=CN=C2C=C1 IMXFKNAFXLVDIY-UHFFFAOYSA-N 0.000 description 2
- CICHKIJONUMLDF-LBPRGKRZSA-N n-[6-[(3s)-3-fluoropyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]-6-methylpyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NC=2N3N=C(C=CC3=NC=2)N2C[C@@H](F)CC2)=N1 CICHKIJONUMLDF-LBPRGKRZSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009933 reproductive health Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 201000007714 retinoschisis Diseases 0.000 description 2
- SOEDEYVDCDYMMH-UHFFFAOYSA-N robinetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 SOEDEYVDCDYMMH-UHFFFAOYSA-N 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 101150006137 sir gene Proteins 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ROWMQJJMCWDJDT-UHFFFAOYSA-N tribromomethane Chemical compound Br[C](Br)Br ROWMQJJMCWDJDT-UHFFFAOYSA-N 0.000 description 2
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 244000000190 yeast pathogen Species 0.000 description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 1
- JFCBEFFZEOHJDG-MLWJPKLSSA-N (2s)-2,6-diamino-7-oxooctanoic acid Chemical compound CC(=O)C(N)CCC[C@H](N)C(O)=O JFCBEFFZEOHJDG-MLWJPKLSSA-N 0.000 description 1
- WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 description 1
- DHMKOYHULYWPHR-NRFANRHFSA-N (4-nitrophenyl) 6-[3-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound Cc1nc2ccc(nn2c1C(=O)Oc1ccc(cc1)[N+]([O-])=O)-c1cccc(OC[C@H]2COC(C)(C)O2)c1 DHMKOYHULYWPHR-NRFANRHFSA-N 0.000 description 1
- BNPOTXLWPZOESZ-YFKPBYRVSA-N (4r)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OC[C@H](CCl)O1 BNPOTXLWPZOESZ-YFKPBYRVSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
- HCYLFYASAYLVBO-UHFFFAOYSA-N 1-oxa-7-azaspiro[3.4]octane Chemical compound O1CCC11CNCC1 HCYLFYASAYLVBO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- ZRLPPXISDJOAMD-UHFFFAOYSA-N 2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-6-methylpyridin-4-amine Chemical group CC1=CC(N)=CC(OCC2OC(C)(C)OC2)=N1 ZRLPPXISDJOAMD-UHFFFAOYSA-N 0.000 description 1
- VGVARAVGVXKREJ-UHFFFAOYSA-N 2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridin-4-amine Chemical compound O1C(C)(C)OCC1COC1=CC(N)=CC=N1 VGVARAVGVXKREJ-UHFFFAOYSA-N 0.000 description 1
- XDPCTCHIKHASBX-UHFFFAOYSA-N 2-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyrimidin-4-amine Chemical compound O1C(C)(C)OCC1COC1=NC=CC(N)=N1 XDPCTCHIKHASBX-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- QDXRNBCJLCOEIW-UHFFFAOYSA-N 2-methyl-n-(2-methylpyrazol-3-yl)-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC=1N=C2C=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1C(=O)NC1=CC=NN1C QDXRNBCJLCOEIW-UHFFFAOYSA-N 0.000 description 1
- DWNSTHNBTITFKK-UHFFFAOYSA-N 2-methyl-n-(2-propan-2-ylpyrazol-3-yl)-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC(C)N1N=CC=C1NC(=O)C1=C(C)N=C2N1N=C(C=1C(=CC=CC=1)C(F)(F)F)C=C2 DWNSTHNBTITFKK-UHFFFAOYSA-N 0.000 description 1
- HDBGBTNNPRCVND-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-ol Chemical compound OCCC(F)(F)F HDBGBTNNPRCVND-UHFFFAOYSA-N 0.000 description 1
- ROYHWGZNGMXQEU-UHFFFAOYSA-N 3,6-dichloro-4-methylpyridazine Chemical compound CC1=CC(Cl)=NN=C1Cl ROYHWGZNGMXQEU-UHFFFAOYSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KJXMTKNZTBVNTC-UHFFFAOYSA-N 4-(4-bromophenyl)-6-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC(C=2C=CC(Br)=CC=2)=C1 KJXMTKNZTBVNTC-UHFFFAOYSA-N 0.000 description 1
- DVQDHDJUHCONAQ-UHFFFAOYSA-N 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-6-methylpyrimidin-2-amine Chemical compound NC1=NC(C)=CC(OCC2OC(C)(C)OC2)=N1 DVQDHDJUHCONAQ-UHFFFAOYSA-N 0.000 description 1
- OXYIHRSZXWMHPH-UHFFFAOYSA-N 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridin-2-amine Chemical compound O1C(C)(C)OCC1COC1=CC=NC(N)=C1 OXYIHRSZXWMHPH-UHFFFAOYSA-N 0.000 description 1
- CVMSHWKEAVOEOU-UHFFFAOYSA-N 4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyrimidin-2-amine Chemical compound O1C(C)(C)OCC1COC1=CC=NC(N)=N1 CVMSHWKEAVOEOU-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- NYTQYHCWNBFMNE-UHFFFAOYSA-N 4-chloro-5a,7,8,9,9a,10-hexahydropyrimido[5,4-b][1,4]benzoxazin-6-one Chemical compound N1C2CCCC(=O)C2OC2=C1N=CN=C2Cl NYTQYHCWNBFMNE-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QYGHXDAYBIFGKI-UHFFFAOYSA-N 4-oxo-1h-pyrimidine-6-carboxylic acid Chemical compound OC(=O)C1=CC(=O)N=CN1 QYGHXDAYBIFGKI-UHFFFAOYSA-N 0.000 description 1
- DYWUNJPHTINNDD-UHFFFAOYSA-N 4-oxo-n-[6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]-1h-pyrimidine-6-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(NC(=O)C=3NC=NC(=O)C=3)=CN=C2C=C1 DYWUNJPHTINNDD-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- OGELTFZRACUWNA-UHFFFAOYSA-N 5,6,7,8-tetramethyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound O1C(C(O)=O)CCC2=C(C)C(C)=C(C)C(C)=C21 OGELTFZRACUWNA-UHFFFAOYSA-N 0.000 description 1
- PHXGREHLVAUCOB-UHFFFAOYSA-N 5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyrazin-2-amine Chemical compound O1C(C)(C)OCC1COC1=CN=C(N)C=N1 PHXGREHLVAUCOB-UHFFFAOYSA-N 0.000 description 1
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 description 1
- SPUZVXXVGVRJDA-UHFFFAOYSA-N 6-(2-chloro-6-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical class N=1N2C(C(=O)N)=CN=C2C=CC=1C1=C(F)C=CC=C1Cl SPUZVXXVGVRJDA-UHFFFAOYSA-N 0.000 description 1
- RWBLMXMTSNGUCT-UHFFFAOYSA-N 6-(2-chloro-6-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical class ClC1=C(C(=CC=C1)F)C=1C=CC=2N(N=1)C(=CN=2)C(=O)O RWBLMXMTSNGUCT-UHFFFAOYSA-N 0.000 description 1
- FCLXOWMYWROWIR-UHFFFAOYSA-N 6-(2-cyanophenyl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical class N=1N2C(C(=O)N)=CN=C2C=CC=1C1=CC=CC=C1C#N FCLXOWMYWROWIR-UHFFFAOYSA-N 0.000 description 1
- AQPXDUGVGDBQJG-UHFFFAOYSA-N 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-amine Chemical compound NC1=CC=CC(N2CC3(COC3)C2)=N1 AQPXDUGVGDBQJG-UHFFFAOYSA-N 0.000 description 1
- KJGZTSAQHQLJMW-UHFFFAOYSA-N 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxamide Chemical class C1=CC(OCCC(F)(F)F)=NN2C(C(=O)N)=CN=C21 KJGZTSAQHQLJMW-UHFFFAOYSA-N 0.000 description 1
- IHTSOJFQSCQFNA-UHFFFAOYSA-N 6-(3-fluoropiperidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid Chemical class N=1N2C(C(=O)O)=CN=C2C=CC=1N1CCCC(F)C1 IHTSOJFQSCQFNA-UHFFFAOYSA-N 0.000 description 1
- FFCWLAWSUWSSTQ-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyrazin-2-amine Chemical compound O1C(C)(C)OCC1COC1=CN=CC(N)=N1 FFCWLAWSUWSSTQ-UHFFFAOYSA-N 0.000 description 1
- YJEIOZOLUZIHPX-UHFFFAOYSA-N 6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridin-3-amine Chemical compound O1C(C)(C)OCC1COC1=CC=C(N)C=N1 YJEIOZOLUZIHPX-UHFFFAOYSA-N 0.000 description 1
- USUBSHOAVKXPLT-UHFFFAOYSA-N 6-[(2-phenyl-1,3-dioxan-5-yl)oxy]pyridin-2-amine Chemical compound NC1=CC=CC(OC2COC(OC2)C=2C=CC=CC=2)=N1 USUBSHOAVKXPLT-UHFFFAOYSA-N 0.000 description 1
- VNPUPSDLJZDKOE-QMMMGPOBSA-N 6-[(3S)-3-fluoropyrrolidin-1-yl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound Cc1nc2ccc(nn2c1C(O)=O)N1CC[C@H](F)C1 VNPUPSDLJZDKOE-QMMMGPOBSA-N 0.000 description 1
- FPIYTEWIXHJHSQ-UHFFFAOYSA-N 6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carbonyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(C(Cl)=O)=CN=C2C=C1 FPIYTEWIXHJHSQ-UHFFFAOYSA-N 0.000 description 1
- QWEZOFPPFQXANB-OAHLLOKOSA-N 6-[3-[[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]phenyl]-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound Cc1nc2ccc(nn2c1C(O)=O)-c1cccc(OC[C@@H]2COC(C)(C)O2)c1 QWEZOFPPFQXANB-OAHLLOKOSA-N 0.000 description 1
- FFCWLAWSUWSSTQ-SSDOTTSWSA-N 6-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]pyrazin-2-amine Chemical compound O1C(C)(C)OC[C@H]1COC1=CN=CC(N)=N1 FFCWLAWSUWSSTQ-SSDOTTSWSA-N 0.000 description 1
- NYQKWJMDQIXMEE-UHFFFAOYSA-N 6-chloro-4,5-dimethylpyridazin-3-amine Chemical compound CC1=C(C)C(Cl)=NN=C1N NYQKWJMDQIXMEE-UHFFFAOYSA-N 0.000 description 1
- KCIGXZXAPJTRTG-UHFFFAOYSA-N 6-chloroimidazo[1,2-b]pyridazine-3-carboxylic acid Chemical compound C1=CC(Cl)=NN2C(C(=O)O)=CN=C21 KCIGXZXAPJTRTG-UHFFFAOYSA-N 0.000 description 1
- OBYJTLDIQBWBHM-UHFFFAOYSA-N 6-chloropyridin-2-amine Chemical compound NC1=CC=CC(Cl)=N1 OBYJTLDIQBWBHM-UHFFFAOYSA-N 0.000 description 1
- KSWBODXXZITTPO-UHFFFAOYSA-N 6-methoxypyridine-2-carboxylic acid Chemical compound COC1=CC=CC(C(O)=O)=N1 KSWBODXXZITTPO-UHFFFAOYSA-N 0.000 description 1
- VELRBZDRGTVGGT-UHFFFAOYSA-N 6-methoxypyrimidin-4-amine Chemical compound COC1=CC(N)=NC=N1 VELRBZDRGTVGGT-UHFFFAOYSA-N 0.000 description 1
- VIMZIFADQPNHIQ-UHFFFAOYSA-N 6-morpholin-4-yl-n-[6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]pyrazine-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(NC(=O)C=3N=C(C=NC=3)N3CCOCC3)=CN=C2C=C1 VIMZIFADQPNHIQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
- 208000001395 Acute radiation syndrome Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000007370 Ataxin2 Human genes 0.000 description 1
- 108010032951 Ataxin2 Proteins 0.000 description 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 101000832687 Cavia porcellus 3-alpha-hydroxysteroid sulfotransferase Proteins 0.000 description 1
- 101000643834 Cavia porcellus 3-beta-hydroxysteroid sulfotransferase Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000033895 Choreoacanthocytosis Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012643 Diabetic amyotrophy Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000019878 Eales disease Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010069808 Electrical burn Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283087 Equus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 101150021206 HST3 gene Proteins 0.000 description 1
- 101150077931 HST4 gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- ZPFXBGIJKDANBP-UHFFFAOYSA-N Hibiscetin Natural products OC1=C(O)C(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C(O)=C3O2)O)=C1 ZPFXBGIJKDANBP-UHFFFAOYSA-N 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 201000009035 MERRF syndrome Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010070909 Metabolic cardiomyopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100477601 Mus musculus Sirt3 gene Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 1
- 102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 1
- 102100030709 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010065119 Necrotising herpetic retinopathy Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000020424 Polyglandular disease Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010068142 Radiation sickness syndrome Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 201000003622 Spinocerebellar ataxia type 2 Diseases 0.000 description 1
- 201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 206010056697 Tissue anoxia Diseases 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000029977 White Dot Syndromes Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- RNVYQYLELCKWAN-YFKPBYRVSA-N [(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@H](CO)O1 RNVYQYLELCKWAN-YFKPBYRVSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000001509 acute urate nephropathy Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000007293 brain stem infarction Diseases 0.000 description 1
- 201000005845 branch retinal artery occlusion Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 201000008675 chorea-acanthocytosis Diseases 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical class OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 150000001925 cycloalkenes Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WLWCQKMQYZFTDR-UHFFFAOYSA-N diethyl 2-chloropropanedioate Chemical compound CCOC(=O)C(Cl)C(=O)OCC WLWCQKMQYZFTDR-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- RQDRTNYFCCJKAK-SREVYHEPSA-N ethyl (2z)-2-(3-chloro-1h-pyridazin-6-ylidene)-2-cyanoacetate Chemical compound CCOC(=O)C(\C#N)=C1/NN=C(Cl)C=C1 RQDRTNYFCCJKAK-SREVYHEPSA-N 0.000 description 1
- AAERLDKQKGBTJZ-UHFFFAOYSA-N ethyl 6-chloro-2,7-dimethylimidazo[1,2-b]pyridazine-3-carboxylate Chemical compound C1=C(C)C(Cl)=NN2C(C(=O)OCC)=C(C)N=C21 AAERLDKQKGBTJZ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- GCRUEXFJNQVIJM-UHFFFAOYSA-N hydron;pyridazin-3-amine;chloride Chemical compound Cl.NC1=CC=CN=N1 GCRUEXFJNQVIJM-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000010522 hyperproinsulinemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 229940040504 lipotropic agent Drugs 0.000 description 1
- 239000003912 lipotropic agent Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000002003 mononeuritis multiplex Diseases 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- UXWIBDNRSAGDLP-UHFFFAOYSA-N n-(2-ethylpyrazol-3-yl)-2-methyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CCN1N=CC=C1NC(=O)C1=C(C)N=C2N1N=C(C=1C(=CC=CC=1)C(F)(F)F)C=C2 UXWIBDNRSAGDLP-UHFFFAOYSA-N 0.000 description 1
- GQJXVULNXLZGGH-UHFFFAOYSA-N n-(2-methoxypyrimidin-4-yl)-2-methyl-6-[2-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound COC1=NC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2C)C=2C(=CC=CC=2)OC(F)(F)F)=N1 GQJXVULNXLZGGH-UHFFFAOYSA-N 0.000 description 1
- HRIYTANRUVVPGB-UHFFFAOYSA-N n-(6-morpholin-4-ylpyridin-2-yl)-6-(1,3-thiazol-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C=1N=C2C=CC(C=3SC=CN=3)=NN2C=1C(=O)NC(N=1)=CC=CC=1N1CCOCC1 HRIYTANRUVVPGB-UHFFFAOYSA-N 0.000 description 1
- SIVSJECKJJTDMB-UHFFFAOYSA-N n-[2,8-dimethyl-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]-6-oxo-1h-pyridine-2-carboxamide Chemical compound CC=1N=C2C(C)=CC(C=3C(=CC=CC=3)C(F)(F)F)=NN2C=1NC(=O)C1=CC=CC(=O)N1 SIVSJECKJJTDMB-UHFFFAOYSA-N 0.000 description 1
- PWHRHBDBHJKIQL-UHFFFAOYSA-N n-[2-(1-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=NN2C(C(=O)NC=3N=C(N=CC=3)N3CC4(OCC4)C3)=CN=C2C=C1 PWHRHBDBHJKIQL-UHFFFAOYSA-N 0.000 description 1
- SJELOAWCXKZOAF-UHFFFAOYSA-N n-[2-(2,3-dihydroxypropoxy)pyridin-4-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C1=NC(OCC(O)CO)=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1 SJELOAWCXKZOAF-UHFFFAOYSA-N 0.000 description 1
- REKODKOQQKNRPH-OAHLLOKOSA-N n-[2-[(2r)-2,3-dihydroxypropoxy]-6-methylpyridin-4-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC[C@@H](O)COC1=NC(C)=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1 REKODKOQQKNRPH-OAHLLOKOSA-N 0.000 description 1
- REKODKOQQKNRPH-HNNXBMFYSA-N n-[2-[(2s)-2,3-dihydroxypropoxy]-6-methylpyridin-4-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC[C@H](O)COC1=NC(C)=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=C1 REKODKOQQKNRPH-HNNXBMFYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- UQLPNVCULXKVEI-UHFFFAOYSA-N n-[4-(2,3-dihydroxypropoxy)-6-methylpyrimidin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound CC1=CC(OCC(O)CO)=NC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 UQLPNVCULXKVEI-UHFFFAOYSA-N 0.000 description 1
- UCDCNTZTYIJNGP-UHFFFAOYSA-N n-[6-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound O1C(C)(C)OCC1COC1=CC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 UCDCNTZTYIJNGP-UHFFFAOYSA-N 0.000 description 1
- OGGBCFQJXKLFFK-GFCCVEGCSA-N n-[6-[(2r)-2,3-dihydroxypropoxy]pyrazin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC[C@@H](O)COC1=CN=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 OGGBCFQJXKLFFK-GFCCVEGCSA-N 0.000 description 1
- GTMNLAJGORZBDD-CYBMUJFWSA-N n-[6-[(2r)-2,3-dihydroxypropoxy]pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC[C@@H](O)COC1=CC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 GTMNLAJGORZBDD-CYBMUJFWSA-N 0.000 description 1
- GTMNLAJGORZBDD-ZDUSSCGKSA-N n-[6-[(2s)-2,3-dihydroxypropoxy]pyridin-2-yl]-6-[2-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound OC[C@H](O)COC1=CC=CC(NC(=O)C=2N3N=C(C=CC3=NC=2)C=2C(=CC=CC=2)C(F)(F)F)=N1 GTMNLAJGORZBDD-ZDUSSCGKSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000002165 neuroretinitis Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 235000020956 nicotinamide riboside Nutrition 0.000 description 1
- 239000011618 nicotinamide riboside Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- MCWJNNPTXYYMSA-UHFFFAOYSA-N propan-2-yl 5-(4-bromophenyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxylate Chemical compound C1=C(C(F)(F)F)N2N=C(C(=O)OC(C)C)C=C2N=C1C1=CC=C(Br)C=C1 MCWJNNPTXYYMSA-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229940121374 purinergic receptor antagonist Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 description 1
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000034986 regulation of gene silencing Effects 0.000 description 1
- 230000009076 regulation of hemostasis Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 1
- 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- OGNAOIGAPPSUMG-UHFFFAOYSA-N spiro[2.2]pentane Chemical compound C1CC11CC1 OGNAOIGAPPSUMG-UHFFFAOYSA-N 0.000 description 1
- ISFPDBUKMJDAJH-UHFFFAOYSA-N splitomicin Chemical compound C1=CC2=CC=CC=C2C2=C1OC(=O)CC2 ISFPDBUKMJDAJH-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WUOFQGMXQCSPPV-UHFFFAOYSA-N tributyl(1,3-thiazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CS1 WUOFQGMXQCSPPV-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001125 vasa nervorum Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F138/00—Homopolymers of compounds having one or more carbon-to-carbon triple bonds
- C08F138/02—Acetylene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F238/00—Copolymers of compounds having one or more carbon-to-carbon triple bonds
- C08F238/02—Acetylene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F38/00—Homopolymers and copolymers of compounds having one or more carbon-to-carbon triple bonds
- C08F38/02—Acetylene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/18—Introducing halogen atoms or halogen-containing groups
- C08F8/20—Halogenation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/18—Introducing halogen atoms or halogen-containing groups
- C08F8/20—Halogenation
- C08F8/22—Halogenation by reaction with free halogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the Silent Information Regulator (SIR) family of genes represents a highly conserved group of genes present in the genomes of organisms ranging from archaebacteria to eukaryotes.
- the encoded SIR proteins are involved in diverse processes from regulation of gene silencing to DNA repair.
- a well-characterized gene in this family is S. cerevisiae SIR2, which is involved in silencing HM loci that contain information specifying yeast mating type, telomere position effects and cell aging.
- the yeast Sir2 protein belongs to a family of histone deacetylases.
- the proteins encoded by members of the SIR gene family show high sequence conservation in a 250 amino acid core domain.
- the Sir2 homolog, CobB, in Salmonella typhimurium functions as an NAD (nicotinamide adenine dinucleotide)-dependent ADP-ribosyl transferase.
- the Sir2 protein is a class III deacetylase which uses NAD as a cosubstrate. Unlike other deacetylases, many of which are involved in gene silencing, Sir2 is insensitive to class I and II histone deacetylase inhibitors like trichostatin A (TSA).
- TSA trichostatin A
- acetylation of acetyl-lysine by Sir2 is tightly coupled to NAD hydrolysis, producing nicotinamide and a novel acetyl-ADP ribose compound.
- the NAD-dependent deacetylase activity of Sir2 is essential for its functions, which can connect its biological role with cellular metabolism in yeast.
- Mammalian Sir2 homologs have NAD-dependent histone deacetylase activity.
- SIRT1-SIRT7 are seven Sir2-like genes that share the conserved catalytic domain of Sir2.
- SIRT1 is a nuclear protein with the highest degree of sequence similarity to Sir2.
- SIRT1 regulates multiple cellular targets by deacetylation including the tumor suppressor p53, the cellular signaling factor NF- ⁇ B, and the FOXO transcription factor.
- SIRT3 is a homolog of SIRT1 that is conserved in prokaryotes and eukaryotes.
- the SIRT3 protein is targeted to the mitochondrial cristae by a unique domain located at the N-terminus.
- SIRT3 has NAD + -dependent protein deacetylase activity and is ubiquitously expressed, particularly in metabolically active tissues. Upon transfer to the mitochondria, SIRT3 is believed to be cleaved into a smaller, active form by a mitochondrial matrix processing peptidase (MPP).
- MPP mitochondrial matrix processing peptidase
- Caloric restriction has been known for over 70 years to improve the health and extend the lifespan of mammals. Yeast life span, like that of metazoans, is also extended by interventions that resemble caloric restriction, such as low glucose. The discovery that both yeast and flies lacking the SIR2 gene do not live longer when calorically restricted provides evidence that SIR2 genes mediate the beneficial health effects of a restricted calorie diet. Moreover, mutations that reduce the activity of the yeast glucose-responsive cAMP (adenosine 3′,5′-monophosphate)-dependent (PKA) pathway extend life span in wild type cells but not in mutant sir2 strains, demonstrating that SIR2 is likely to be a key downstream component of the caloric restriction pathway.
- yeast glucose-responsive cAMP adenosine 3′,5′-monophosphate
- novel sirtuin-modulating compounds and methods of use thereof.
- the invention provides sirtuin-modulating compounds of Structural Formulas (I) and (II) as are described in detail below.
- the invention provides methods for using sirtuin-modulating compounds, or compositions comprising sirtuin-modulating compounds.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for a variety of therapeutic applications including, for example, increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic-induced neuropathy, neuropathy associated with an ischemic event, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, and/or flushing, etc.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used for treating a disease or disorder in a subject that would benefit from increased mitochondrial activity, for enhancing muscle performance, for increasing muscle ATP levels, or for treating or preventing muscle tissue damage associated with hypoxia or ischemia.
- sirtuin-modulating compounds that decrease the level and/or activity of a sirtuin protein may be used for a variety of therapeutic applications including, for example, increasing cellular sensitivity to stress, increasing apoptosis, treatment of cancer, stimulation of appetite, and/or stimulation of weight gain, etc.
- the methods comprise administering to a subject in need thereof a pharmaceutically effective amount of a sirtuin-modulating compound.
- the sirtuin-modulating compounds may be administered alone or in combination with other compounds, including other sirtuin-modulating compounds, or other therapeutic agents.
- agent is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule (such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues.
- a biological macromolecule such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide
- an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues.
- bioavailable when referring to a compound, is art-recognized and refers to a form of a compound that allows for all or a portion of the amount of compound administered to be absorbed by, incorporated into, or otherwise physiologically available to a subject or patient to whom it is administered.
- Biologically active portion of a sirtuin refers to a portion of a sirtuin protein having a biological activity, such as the ability to deacetylate (“catalytically active”).
- Catalytically active portions of a sirtuin may comprise the core domain of sirtuins.
- Catalytically active portions of SIRT1 having GenBank Accession No. NP_036370 that encompass the NAD + binding domain and the substrate binding domain for example, may include without limitation, amino acids 240-664 or 240-505 of GenBank Accession No. NP_036370, which are encoded by the polynucleotide of GenBank Accession No. NM_012238. Therefore, this region is sometimes referred to as the core domain.
- SIRT1 also sometimes referred to as core domains
- core domains include about amino acids 261 to 447 of GenBank Accession No. NP_036370, which are encoded by nucleotides 834 to 1394 of GenBank Accession No. NM_012238; about amino acids 242 to 493 of GenBank Accession No. NP_036370, which are encoded by nucleotides 777 to 1532 of GenBank Accession No. NM_012238; or about amino acids 254 to 495 of GenBank Accession No. NP_036370, which are encoded by nucleotides 813 to 1538 of GenBank Accession No. NM_012238.
- Another “biologically active” portion of SIRT1 is amino acids 62-293 or 183-225 of GenBank Accession No. NP_036370, which comprise a domain N-terminal to the core domain that is important to the compound binding site.
- cat(s) refers to a feline animal including domestic cats and other members of the family Felidae, genus Felis.
- Diabetes refers to high blood sugar or ketoacidosis, as well as chronic, general metabolic abnormalities arising from a prolonged high blood sugar status or a decrease in glucose tolerance. “Diabetes” encompasses both the type I and type II (Non Insulin Dependent Diabetes Mellitus or NIDDM) forms of the disease.
- the risk factors for diabetes include the following factors: waistline of more than 40 inches for men or 35 inches for women, blood pressure of 130/85 mmHg or higher, triglycerides above 150 mg/dl, fasting blood glucose greater than 100 mg/dl or high-density lipoprotein of less than 40 mg/dl in men or 50 mg/dl in women.
- ED 50 refers to the art-recognized measure of effective dose. In certain embodiments, ED 50 means the dose of a drug which produces 50% of its maximum response or effect, or alternatively, the dose which produces a pre-determined response in 50% of test subjects or preparations, such as isolated tissue or cells.
- LD 50 refers to the art-recognized measure of lethal dose. In certain embodiments, LD 50 means the dose of a drug which is lethal in 50% of test subjects.
- therapeutic index is an art-recognized term which refers to the therapeutic index of a drug, defined as LD 50 /ED 50 .
- hyperinsulinemia refers to a state in an individual in which the level of insulin in the blood is higher than normal.
- insulin resistance refers to a state in which a normal amount of insulin produces a subnormal biologic response relative to the biological response in a subject that does not have insulin resistance.
- insulin resistance disorder refers to any disease or condition that is caused by or contributed to by insulin resistance. Examples include: diabetes, obesity, metabolic syndrome, insulin-resistance syndromes, syndrome X, insulin resistance, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, hyperlipidemia, atherosclerotic disease including stroke, coronary artery disease or myocardial infarction, hyperglycemia, hyperinsulinemia and/or hyperproinsulinemia, impaired glucose tolerance, delayed insulin release, diabetic complications, including coronary heart disease, angina pectoris, congestive heart failure, stroke, cognitive functions in dementia, retinopathy, peripheral neuropathy, nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation, polycys
- livestock animals refers to domesticated quadrupeds, which includes those being raised for meat and various byproducts, e.g., a bovine animal including cattle and other members of the genus Bos, a porcine animal including domestic swine and other members of the genus Sus, an ovine animal including sheep and other members of the genus Ovis , domestic goats and other members of the genus Capra; domesticated quadrupeds being raised for specialized tasks such as use as a beast of burden, e.g., an equine animal including domestic horses and other members of the family Equidae, genus Equus.
- mammals include humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).
- livestock animals including bovines, porcines, etc.
- companion animals e.g., canines, felines, etc.
- rodents e.g., mice and rats.
- Obese individuals or individuals suffering from obesity are generally individuals having a body mass index (BMI) of at least 25 or greater. Obesity may or may not be associated with insulin resistance.
- BMI body mass index
- parenteral administration and “administered parenterally” are art-recognized and refer to modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal, and intrastemal injection and infusion.
- a “patient”, “subject”, “individual” or “host” refers to either a human or a non-human animal.
- pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
- a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
- Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
- materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
- preventing is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition.
- a condition such as a local recurrence (e.g., pain)
- a disease such as cancer
- a syndrome complex such as heart failure or any other medical condition
- prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount.
- Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population.
- Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.
- prophylactic or therapeutic treatment refers to administration of a drug to a host. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects therefrom).
- the unwanted condition e.g., disease or other unwanted state of the host animal
- pyrogen-free refers to a composition that does not contain a pyrogen in an amount that would lead to an adverse effect (e.g., irritation, fever, inflammation, diarrhea, respiratory distress, endotoxic shock, etc.) in a subject to which the composition has been administered.
- an adverse effect e.g., irritation, fever, inflammation, diarrhea, respiratory distress, endotoxic shock, etc.
- the term is meant to encompass compositions that are free of, or substantially free of, an endotoxin such as, for example, a lipopolysaccharide (LPS).
- LPS lipopolysaccharide
- Replicative lifespan of a cell refers to the number of daughter cells produced by an individual “mother cell.” “Chronological aging” or “chronological lifespan,” on the other hand, refers to the length of time a population of non-dividing cells remains viable when deprived of nutrients.
- Increasing the lifespan of a cell” or “extending the lifespan of a cell,” as applied to cells or organisms, refers to increasing the number of daughter cells produced by one cell; increasing the ability of cells or organisms to cope with stresses and combat damage, e.g., to DNA, proteins; and/or increasing the ability of cells or organisms to survive and exist in a living state for longer under a particular condition, e.g., stress (for example, heatshock, osmotic stress, high energy radiation, chemically-induced stress, DNA damage, inadequate salt level, inadequate nitrogen level, or inadequate nutrient level). Lifespan can be increased by at least about 10%, 20%, 30%, 40%, 50%, 60% or between 20% and 70%, 30% and 60%, 40% and 60% or more using methods described herein.
- sirtuin-modulating compound refers to a compound that increases the level of a sirtuin protein and/or increases at least one activity of a sirtuin protein.
- a sirtuin-modulating compound may increase at least one biological activity of a sirtuin protein by at least about 10%, 25%, 50%, 75%, 100%, or more.
- Exemplary biological activities of sirtuin proteins include deacetylation, e.g., of histones and p53; extending lifespan; increasing genomic stability; silencing transcription; and controlling the segregation of oxidized proteins between mother and daughter cells.
- “Sirtuin protein” refers to a member of the sirtuin deacetylase protein family, or preferably to the sir2 family, which include yeast Sir2 (GenBank Accession No. P53685), C. elegans Sir-2.1 (GenBank Accession No. NP_501912), and human SIRT1 (GenBank Accession No. NM_012238 and NP_036370 (or AF083106)) and SIRT2 (GenBank Accession No. NM_012237, NM_030593, NP_036369, NP_085096, and AF083107) proteins.
- HST genes additional yeast Sir2-like genes termed “HST genes” (homologues of Sir two) HST1, HST2, HST3 and HST4, and the five other human homologues hSIRT3, hSIRT4, hSIRT5, hSIRT6 and hSIRT7 (Brachmann et al. (1995) Genes Dev. 9:2888 and Frye et al. (1999) BBRC 260:273).
- HST genes homologues of Sir two HST1, HST2, HST3 and HST4
- Preferred sirtuins are those that share more similarities with SIRT1, i.e., hSIRT1, and/or Sir2 than with SIRT2, such as those members having at least part of the N-terminal sequence present in SIRT1 and absent in SIRT2 such as SIRT3 has.
- SIRT1 protein refers to a member of the sir2 family of sirtuin deacetylases.
- a SIRT1 protein includes yeast Sir2 (GenBank Accession No. P53685), C. elegans Sir-2.1 (GenBank Accession No. NP_501912), human SIRT1 (GenBank Accession No. NM_012238 or NP_036370 (or AF083106)), and equivalents and fragments thereof.
- a SIRT1 protein includes a polypeptide comprising a sequence consisting of, or consisting essentially of, the amino acid sequence set forth in GenBank Accession Nos.
- SIRT1 proteins include polypeptides comprising all or a portion of the amino acid sequence set forth in GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685; the amino acid sequence set forth in GenBank Accession Nos.
- Polypeptides of the invention also include homologs (e.g., orthologs and paralogs), variants, or fragments, of GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685.
- SIRT2 protein As used herein “SIRT2 protein”, “SIRT3 protein”, “SIRT4 protein”, SIRT5 protein”, “SIRT6 protein”, and “SIRT7 protein” refer to other mammalian, e.g. human, sirtuin deacetylase proteins that are homologous to SIRT1 protein, particularly in the approximately 275 amino acid conserved catalytic domain.
- SIRT3 protein refers to a member of the sirtuin deacetylase protein family that is homologous to SIRT1 protein.
- a SIRT3 protein includes human SIRT3 (GenBank Accession No.
- a SIRT3 protein includes a polypeptide comprising a sequence consisting of, or consisting essentially of, the amino acid sequence set forth in GenBank Accession Nos. AAH01042, NP_036371, NP_001017524, or NP_071878.
- SIRT3 proteins include polypeptides comprising all or a portion of the amino acid sequence set forth in GenBank Accession AAH01042, NP_036371, NP_001017524, or NP_071878; the amino acid sequence set forth in GenBank Accession Nos. AAH01042, NP_036371, NP_001017524, or NP_071878 with 1 to about 2, 3, 5, 7, 10, 15, 20, 30, 50, 75 or more conservative amino acid substitutions; an amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to GenBank Accession Nos.
- a SIRT3 protein includes a fragment of SIRT3 protein that is produced by cleavage with a mitochondrial matrix processing peptidase (MPP) and/or a mitochondrial intermediate peptidase (MIP).
- MIP mitochondrial matrix processing peptidase
- stereoisomer refers to any portion of the compound or the compound in its entirety.
- diastereomers and enantiomers are stereoisomers.
- systemic administration and “administered systemically,” are art-recognized and refer to the administration of a subject composition, therapeutic or other material enterally or parenterally.
- tautomer as used herein is art-recognized and refers to any one of the possible alternative structures that may exist as a result of tautomerism, which refers to a form of constitutional isomerism in which a structure may exist in two or more constitutional arrangements, particularly with respect to the position of hydrogens bonded to oxygen.
- tautomer is readily interconvertible and exists in equilibrium. For example, keto and enol tautomers exist in proportions determined by the equilibrium position for any given condition, or set of conditions:
- therapeutic agent refers to any biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject.
- the term also means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and/or conditions in an animal or human.
- therapeutic effect is art-recognized and refers to a beneficial local or systemic effect in animals, particularly mammals, and more particularly humans, caused by a pharmacologically active substance.
- therapeutically-effective amount means that amount of such a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment.
- the therapeutically effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of skill in the art. For example, certain compositions described herein may be administered in a sufficient amount to produce a desired effect at a reasonable benefit/risk ratio applicable to such treatment.
- Treating” a condition or disease refers to curing as well as ameliorating at least one symptom of the condition or disease.
- vision impairment refers to diminished vision, which is often only partially reversible or irreversible upon treatment (e.g., surgery). Particularly severe vision impairment is termed “blindness” or “vision loss”, which refers to a complete loss of vision, vision worse than 20/200 that cannot be improved with corrective lenses, or a visual field of less than 20 degrees diameter (10 degrees radius).
- the invention provides novel compounds for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, ocular diseases and disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc.
- Subject compounds such as sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein, may also be used for treating a disease or disorder in a subject that would benefit from increased mitochondrial activity, for enhancing muscle performance, for increasing muscle ATP levels, or for treating or preventing muscle tissue damage associated with hypoxia or ischemia.
- Compounds disclosed herein may be suitable for use in pharmaceutical compositions and/or one or more methods disclosed herein.
- compounds of the invention are represented by Structural Formula (I):
- each R is independently selected from hydrogen, halo, OH, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 2 -C 4 alkyl, C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, OR 3 , O—(C 1 -C 4 alkyl)-OR 3 , S—(C 1 -C 2 alkyl), S-(halo-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 alkyl) 2 , N(methoxy-substituted C 1 -C 4 alkyl) 2 , N(C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)(methoxy-substituted C 1 -C 4 alkyl
- R 1 is an aromatic heterocycle or a fused carbocycle, wherein R 1 is optionally substituted with one or more substituents independently selected from halo, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, O—R 3 , O—(C 1 -C 4 alkyl)-OR 3 , ⁇ O, C 3 -C 7 cycloalkyl, SO 2 R 3 , S—R 3 , (C 1 -C 4 alkyl)-N(R 3 )(R 3 ), N(R 3 )(R 3 ), O—(C 1 -C 4 alkyl)-N(R 3 )(R 3 ), O—(C 0 -C 4 alkyl)-CR 3 R 3 —(C 0 -
- R 2 is a carbocycle or a heterocycle, wherein R 2 is optionally substituted with one or more substituents independently selected from halo, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, O—R 3 , O—(C 1 -C 4 alkyl)-OR 3 , ⁇ O, C 3 -C 7 cycloalkyl, SO 2 R 3 , S—R 3 , (C 1 -C 4 alkyl)-N(R 3 )(R 3 ), N(R 3 )(R 3 ), O—(C 1 -C 4 alkyl)-N(R 3 )(R 3 ), O—(C 0 -C 4 alkyl)-CR 3 R 3 —(C 0 -C 4
- each R 3 is independently selected from hydrogen and C 1 -C 4 alkyl optionally substituted with one or more of OH, —O—(C 1 -C 4 alkyl), halo, NH 2 , NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl) 2 , NH(methoxy-substituted C 1 -C 4 alkyl), NH(hydroxy-substituted C 1 -C 4 alkyl), N(methoxy-substituted C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 alkyl) 2 and N(methoxy-substituted C 1 -C 4 alkyl) 2 ; or
- two R 3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom selected independently from N, S, S( ⁇ O), S( ⁇ O) 2 , and O, wherein the heterocycle formed by two R 3 is optionally substituted at any carbon atom with one or more of OH, halo, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, NH 2 , NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl) 2 , O(C 1 -C 4 alkyl), NH(hydroxy-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 alkyl) 2 , N(methoxy-substituted C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), NH(me
- X is selected from C( ⁇ O)—NH- ⁇ , NH—C( ⁇ O)- ⁇ , NH—CR 4 R 5 - ⁇ , C( ⁇ O)—NH—CR 4 R 5 - ⁇ , S( ⁇ O)—NH- ⁇ , S( ⁇ O) 2 —NH- ⁇ , CR 4 R 5 —NH- ⁇ , NH—C( ⁇ O)—O—CR 4 R 5 - ⁇ , NH- ⁇ , NH—C( ⁇ S)- ⁇ , C( ⁇ S)—NH- ⁇ , NH—S( ⁇ O)- ⁇ , NH—S( ⁇ O) 2 - ⁇ , NH—S( ⁇ O) 2 —NR 4 - ⁇ , NR 4 —S(O) 2 —NH- ⁇ , NH—C( ⁇ O)—O- ⁇ , O—C( ⁇ O)—NH- ⁇ , NH—C( ⁇ O)—NH- ⁇ , NH—C( ⁇ O)—NR 4 -
- ⁇ represents where X is bound to R 1 ;
- each R 4 and R 5 is independently selected from hydrogen, C 1 -C 4 alkyl, CF 3 and (C 1 -C 3 alkyl)-CF 3 .
- both E and B are N.
- E, B and A are N.
- the compound of Structural Formula (I) is represented by Structural Formula (Ia):
- E and B are N and A is CR.
- the compound of Structural Formula (I) is represented by Structural Formula (Ib):
- both D and B are N and A is CR.
- the compound of Structural Formula (I) is represented by Structural Formula (Ic):
- both D and A are N and B is CR.
- the compound of Structural Formula (I) is represented by Structural Formula (Id):
- R at each occurrence may be selected from hydrogen, halo, C 1 -C 4 alkyl, O—R 3 and 4- to 8-membered non-aromatic heterocycle, such as selected from hydrogen, C 1 -C 4 alkyl, and 4- to 8-membered non-aromatic heterocycle.
- R 1 may be selected from optionally substituted aromatic heterocycle, such as pyridinyl, thiazolyl, oxazolyl, pyrimidinyl, pyrazole, triazole, imidazole, pyrazine and pyridazine.
- R 1 may be selected from optionally substituted
- R 1 may be selected from
- R 1 is selected from:
- R 2 may be selected from optionally substituted carbocycle and optionally substituted non-aromatic heterocycle. In particular, R 2 may be selected from optionally substituted aromatic carbocycle and optionally substituted non-aromatic heterocycle.
- R 2 may be selected from optionally substituted non-aromatic carbocycle and optionally substituted non-aromatic heterocycle.
- R 2 may be selected from an optionally substituted non-aromatic heterocycle and R 2 may be attached to the remainder of the compound by a nitrogen atom of R 2 .
- R 2 may be selected from optionally substituted aromatic carbocycle, such as phenyl.
- R 2 may be selected from optionally substituted non-aromatic heterocycle, e.g., nitrogen-containing heterocycles, such as pyrrolidine, piperidine and azetidine.
- R 2 may be selected from optionally substituted
- R 2 may be selected from:
- R 2 is selected from
- X may be selected from amide such as C( ⁇ O)—NH— ⁇ or NH—C( ⁇ O) ⁇ .
- X is C( ⁇ O)—NH— ⁇ .
- X is —NH—C( ⁇ O)- ⁇ .
- R at each occurrence may be selected from hydrogen, halo, OH, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 2 -C 4 alkyl, C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, OR 3 , O—(C 1 -C 4 alkyl)-OR 3 , S—(C 1 -C 2 alkyl), S-(halo-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 alkyl) 2 , N(methoxy-substituted C 1 -C 4 alkyl) 2 , N(C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), C 5 -C 7 cycloalkyl, and 4- to 8-membere
- the compound is any one of Compound Numbers 14, 94, 97, 98, 99, 100, 105, 119, 143, 159, 164, 165, 224, 225, 226, 230, 233, 301, 308, 318, 342, 344, 355, 370, 379, 424, 474, 479, 537, 577, 581, 586, 601, 638, 661, 665, 668, 684, 703, 761, 801, 806, 811, 812, 870, 880, 890, 918, 924, 925 928, 945, 953, 957, 958, 959, 966, 968, 969, 970, 974, 978, 979, 986, 990, 994, 998, 999, 1000, 1001, 1005, 1007, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1020, 1024, 1025, 1026,
- the invention includes pharmaceutical compositions of any of the compounds of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), or as otherwise set forth above.
- the pharmaceutical composition of the compound of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id) may comprise one or more pharmaceutically acceptable carriers or diluents.
- compounds of the invention are represented by Structural Formula (II):
- each R′ is independently selected from hydrogen, halo, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, O—R 3 , O—(C 1 -C 4 alkyl)-OR 3 , S—(C 1 -C 4 alkyl), S-(halo-substituted C 1 -C 4 alkyl), C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, N(hydroxy-substituted C 1 -C 4 alkyl) 2 , N(methoxy-substituted C 1 -C 4 alkyl) 2 , N(C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)(methoxy-substituted C 1 -C 4 alkyl
- each R′′ is independently selected from hydrogen, halo, C ⁇ N, chloro- or bromo-substituted C 1 -C 4 alkyl, O-(halo-substituted C 1 -C 4 alkyl), O—(C 1 -C 4 alkyl)-OR 3 , C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, S—(C 1 -C 4 alkyl), S-(halo-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 alkyl) 2 , N(methoxy-substituted C 1 -C 4 alkyl) 2 , N(C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)(methoxy-substituted
- R 1 is an aromatic heterocycle, wherein R 1 is optionally substituted with one or more substituents independently selected from halo, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 alkyl, O—R 3 , —O—(C 1 -C 4 alkyl)-OR 3 , ⁇ O, C 3 -C 7 cycloalkyl, SO 2 R 3 , S—R 3 , (C 1 -C 4 alkyl)-N(R 3 )(R 3 ), N(R 3 )(R 3 ), O—(C 1 -C 4 alkyl)-N(R 3 )(R 3 ), O—(C 0 -C 4 alkyl)-CR 3 R 3 (C 0 -C 4 alkyl), (C
- R 2 is a carbocycle or a heterocycle, wherein R 2 is optionally substituted with one or more substituents independently selected from halo, C ⁇ N, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 1 -C 8 , O—R 3 , O—(C 1 -C 4 alkyl)-OR 3 , ⁇ O, C 3 -C 7 cycloalkyl, SO 2 R 3 , S—R 3 , (C 1 -C 4 alkyl)-N(R 3 )(R 3 ), N(R 3 )(R 3 ), O—(C 1 -C 4 alkyl)-N(R 3 )(R 3 ), O—(C 0 -C 4 alkyl)-CR 3 R 3 —(C 0 -C 4 alky
- each R 3 is independently selected from hydrogen and C 1 -C 4 alkyl optionally substituted with one or more of OH, O—(C 1 -C 4 alkyl), halo, NH 2 , NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl) 2 , NH(methoxy-substituted C 1 -C 4 alkyl), NH(hydroxy-substituted C 1 -C 4 alkyl), N(methoxy-substituted C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 alkyl) 2 and N(methoxy-substituted C 1 -C 4 alkyl) 2 ; or
- two R 3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom independently selected from N, S, S( ⁇ O), S( ⁇ O) 2 , and O, wherein the heterocycle formed by two R 3 is optionally substituted at any carbon atom with one or more of OH, halo, C 1 -C 4 alkyl, halo-substituted C 1 -C 4 alkyl, NH 2 , NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl) 2 , NH(methoxy-substituted C 1 -C 4 alkyl), NH(hydroxy-substituted C 1 -C 4 alkyl), N(methoxy-substituted C 1 -C 4 alkyl)(hydroxy-substituted C 1 -C 4 alkyl), N(hydroxy-substituted C 1 -C 4 al
- X is selected from NH—C( ⁇ S)- ⁇ , C( ⁇ S)—NH- ⁇ , NH—S( ⁇ O)- ⁇ , NH—S( ⁇ O) 2 - ⁇ , NH—S( ⁇ O) 2 —NR 4 - ⁇ , NR 4 —S( ⁇ O) 2 —NH- ⁇ , NH—C( ⁇ O)O- ⁇ , O—C( ⁇ O)—NH- ⁇ , NH—C( ⁇ O)NH- ⁇ , NH—C( ⁇ O)NR 4 - ⁇ , NR 4 —C( ⁇ O)NH- ⁇ , CR 4 R 5 —NH—C( ⁇ O)- ⁇ , NH—C( ⁇ S)—CR 4 R 5 - ⁇ , CR 4 R 5 —C( ⁇ S)—NH- ⁇ , NH—S( ⁇ O)—CR 4 R 5 - ⁇ , CR 4 R 5 —C( ⁇ S)—NH- ⁇ , NH—S( ⁇ O)—CR 4 R 5 - ⁇ , CR 4 R
- ⁇ represents where X is bound to R 1 ;
- each R 4 and R 5 is independently hydrogen, C 1 -C 4 alkyl, CF 3 or (C 1 -C 3 alkyl)-CF 3 .
- a C 1 -C 4 alkoxy-substituted group may include one or more alkoxy substituents such as one, two or three methoxy groups or a methoxy group and an ethoxy group, for example.
- alkoxy substituents include methoxy, ethoxy, isopropoxy, and tert-butoxy.
- a hydroxy-substituted group may include one or more hydroxy substituents, such as two or three hydroxy groups.
- a “halo-substituted” group includes from one halo substituent up to perhalo substitution.
- Exemplary halo-substituted C 1 -C 4 alkyl includes CFH 2 , CClH 2 , CBrH 2 , CF 2 H, CCl 2 H, CBr 2 H, CF 3 , CCl 3 , CBr 3 , CH 2 CH 2 F, CH 2 CH 2 Cl, CH 2 CH 2 Br, CH 2 CHF 2 , CHFCH 3 , CHClCH 3 , CHBrCH 3 , CF 2 CHF 2 , CF 2 CHCl 2 , CF 2 CHBr 2 , CH(CF 3 ) 2 , and C(CF 3 ) 3 .
- Perhalo-substituted C 1 -C 4 alkyl for example, includes CF 3 , CCl 3 , CBr 3 , CF 2 CF 3 , CCl 2 CF 3 and CBr 2 CF 3 .
- a “carbocycle” group may refer to a monocyclic carbocycle embodiment and/or a polycyclic carbocycle embodiment, such as a fused, bridged or bicyclic carbocycle embodiment.
- “Carbocycle” groups of the invention may further refer to an aromatic carbocycle embodiment and/or a non-aromatic carbocycle embodiment, or, in the case of polycyclic embodiments, a carbocycle having both one or more aromatic rings and/or one or more non-aromatic rings.
- Polycyclic carbocycle embodiments may be a bicyclic ring, a fused ring or a bridged bicycle.
- Non-limiting exemplary carbocycles include phenyl, cyclohexane, cyclopentane, or cyclohexene, amantadine, cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-ttrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene, adamantane, decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, norbomane, decalin, spiropentane, memantine, biperiden, rimantadine, camphor, cholesterol, 4-phenylcyclcohexanol, bicyclo[4.2.0]octane, memantine and 4,5,6,7-tetrahydro-1H-indene and bicyclo[4.1.0]hept-3-ene.
- a “heterocycle” group may refer to a monocyclic heterocycle embodiment and/or a polycyclic heterocyclic embodiment, such as a fused, bridged or bicyclic heterocycle embodiment.
- “Heterocycle” groups of the invention may further refer to an aromatic heterocycle embodiment and/or a non-aromatic heterocycle embodiment, or, in the case of polycyclic embodiments, a heterocycle having both one or more aromatic rings and/or one or more non-aromatic rings.
- Polycyclic heterocycle embodiments may be a bicyclic ring, a fused ring or a bridged bicycle.
- Non-limiting exemplary heterocycles include pyridyl, pyrrolidine, piperidine, piperazine, pyrrolidine, morpholine, pyrimidine, benzofuran, indole, quinoline, lactones, lactams, benzodiazepine, indole, quinoline, purine, adenine, guanine, 4,5,6,7-tetrahydrobenzo[d]thiazole, hexamine and methenamine.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- the compounds and salts thereof described herein can also be present as the corresponding hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate) or solvates.
- Suitable solvents for preparation of solvates and hydrates can generally be selected by a skilled artisan.
- the compounds and salts thereof can be present in amorphous or crystalline (including co-crystalline and polymorph) forms.
- Sirtuin-modulating compounds of the invention advantageously modulate the level and/or activity of a sirtuin protein, particularly the deacetylase activity of the sirtuin protein.
- sirtuin-modulating compounds of the invention do not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for modulating the deacetylation activity of a sirtuin protein (e.g., such as a SIRT1 and/or a SIRT3 protein).
- a sirtuin protein e.g., such as a SIRT1 and/or a SIRT3 protein.
- alkyl group or “alkane” is a straight chained or branched non-aromatic hydrocarbon which is completely saturated. Typically, a straight chained or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10 unless otherwise defined. Examples of straight chained and branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. A C 1 -C 4 straight chained or branched alkyl group is also referred to as a “lower alkyl” group.
- alkenyl (“alkene”) and “alkynyl” (“alkyne”) refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyl groups described above, but that contain at least one double or triple bond respectively.
- aromatic carbocycle refers to an aromatic hydrocarbon ring system containing at least one aromatic ring.
- the ring may be fused or otherwise attached to other aromatic carbocyclic rings or non-aromatic carbocyclic rings.
- aromatic carbocyclegroups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl.
- Azabicyclo refers to a bicyclic molecule that contains a nitrogen atom in the ring skeleton.
- the two rings of the bicycle may be fused at two mutually bonded atoms, e.g., indole, across a sequence of atoms, e.g., azabicyclo[2.2.1]heptane, or joined at a single atom, e.g., spirocycle.
- Bicycle or “bicyclic” refers to a two-ring system in which one, two or three or more atoms are shared between the two rings.
- Bicycle includes fused bicycles in which two adjacent atoms are shared by each of the two rings, e.g., decalin, indole.
- Bicycle also includes spiro bicycles in which two rings share a single atom, e.g., spiro[2.2]pentane, 1-oxa-6-azaspiro[3.4]octane.
- Bicycle further includes bridged bicycles in which at least three atoms are shared between two rings, e.g., norbornane.
- Bridged bicycle compounds are bicyclic ring systems in which at least three atoms are shared by both rings of the system, i.e., they include at least one bridge of one or more atoms connecting two bridgehead atoms.
- Bridged azabicyclo refers to a bridged bicyclic molecule that contains a nitrogen atom in at least one of the rings.
- carbocycle refers to a saturated or unsaturated ring in which each atom of the ring is carbon.
- carbocycle includes both aromatic carbocycles and non-aromatic carbocycles.
- Non-aromatic carbocycles include both cycloalkane rings, in which all carbon atoms are saturated, and cycloalkene rings, which contain at least one double bond.
- Carbocycle includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from non-aromatic and aromatic rings.
- Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings.
- the term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring.
- Each ring of a fused carbocycle may be selected from non-aromaticaromatic rings.
- an aromatic ring e.g., phenyl
- carbocyclic Any combination of non-aromtatic and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic.
- exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane.
- Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene and bicyclo[4.1.0]hept-3-ene.
- “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.
- a “cycloalkyl” group is a cyclic hydrocarbon which is completely saturated (non-aromatic). Typically, a cycloalkyl group has from 3 to about 10 carbon atoms, more typically 3 to 8 carbon atoms unless otherwise defined.
- a “cycloalkenyl” group is a cyclic hydrocarbon containing one or more double bonds.
- a “halogen” designates F, Cl, Br or I.
- halogen-substitution or “halo” substitution designates replacement of one or more hydrogens with F, Cl, Br or I.
- heteroaryl or “aromatic heterocycle” includes substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
- heteroaryl also includes ring systems having one or two rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aromatic carbocycle, heteroaryl, and/or heterocyclyl.
- Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine.
- heterocycle refers to a non-aromatic or aromatic ring comprising one or more heteroatoms selected from, for example, N, O, B and S atoms, preferably N, O, or S.
- heterocycle includes both “aromatic heterocycles” and “non-aromatic heterocycles.”
- Heterocycles include 4-7 membered monocyclic and 8-12 membered bicyclic rings.
- Heterocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. Each ring of a bicyclic heterocycle may be selected from non-aromatic and aromatic rings.
- fused heterocycle refers to a bicyclic heterocycle in which each of the rings shares two adjacent atoms with the other ring.
- Each ring of a fused heterocycle may be selected from non-aromatic and aromatic rings.
- an aromatic ring e.g., pyridyl
- a non-aromatic or aromatic ring e.g., cyclohexane, cyclopentane, pyrrolidine, 2,3-dihydrofuran or cyclohexene.
- Heterocycle groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, pyrimidine, benzofuran, indole, quinoline, lactones, and lactams.
- exemplary “fused heterocycles” include benzodiazepine, indole, quinoline, purine, and 4,5,6,7-tetrahydrobenzo[d]thiazole.
- Heterocycles may be substituted at any one or more positions capable of bearing a hydrogen atom.
- “Monocyclic rings” include 5-7 membered aromatic carbocycle or heteroaryl, 3-7 membered cycloalkyl or cycloalkenyl, and 5-7 membered non-aromatic heterocyclyl.
- Exemplary monocyclic groups include substituted or unsubstituted heterocycles or carbocycles such as thiazolyl, oxazolyl, oxazinyl, thiazinyl, dithianyl, dioxanyl, isoxazolyl, isothiazolyl, triazolyl, furanyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrazolyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, pyridinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrimidinyl,
- substituted means substituting a hydrogen atom in a structure with an atom or molecule other than hydrogen.
- a substitutable atom such as a “substitutable nitrogen” is an atom that bears a hydrogen atom in at least one resonance form.
- the hydrogen atom may be substituted for another atom or group such as a CH 3 or an OH group.
- the nitrogen in a piperidine molecule is substitutable if the nitrogen is bound to a hydrogen atom. If, for example, the nitrogen of a piperidine is bound to an atom other than hydrogen, the nitrogen is not substitutable.
- An atom that is not capable of bearing a hydrogen atom in any resonance form is not substitutable.
- the compounds disclosed herein also include partially and fully deuterated variants.
- deuterated variants may be used for kinetic studies.
- One of skill in the art can select the sites at which such deuterium atoms are present.
- salts particularly pharmaceutically acceptable salts, of the compounds described herein.
- the compounds of the present invention that possess a sufficiently acidic, a sufficiently basic, or both functional groups can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt.
- compounds that are inherently charged, such as those with a quaternary nitrogen can form a salt with an appropriate counterion (e.g., a halide such as bromide, chloride, or fluoride, particularly bromide).
- Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
- organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate
- Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
- bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.
- the present invention provides methods of producing the above-defined compounds.
- the compounds may be synthesized using conventional techniques.
- these compounds are conveniently synthesized from readily available starting materials.
- Synthetic chemistry transformations and methodologies useful in synthesizing the compounds described herein are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed. (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995).
- a therapeutic compound may traverse the cytoplasmic membrane of a cell.
- a compound may have a cell-permeability of at least about 20%, 50%, 75%, 80%, 90% or 95%.
- the compound may be essentially non-toxic to a cell or subject; the compound may be an organic molecule or a small molecule of 2000 amu or less, 1000 amu or less; a compound may have a half-life under normal atmospheric conditions of at least about 30 days, 60 days, 120 days, 6 months or 1 year; the compound may have a half-life in solution of at least about 30 days, 60 days, 120 days, 6 months or 1 year; a compound may be more stable in solution than resveratrol by at least a factor of about 50%, 2 fold, 5 fold, 10 fold, 30 fold, 50 fold or 100 fold; a compound may promote deacetylation of the DNA repair factor Ku70; a compound may promote deacetylation of RelA/p65; a compound may increase general turnover rates and enhance the sensitivity of cells to TNF-induced apoptosis.
- a sirtuin-modulating compound does not have any substantial ability to inhibit a histone deacetylase (HDAC) class I, and/or an HDAC class II at concentrations (e.g., in vivo) effective for modulating the deacetylase activity of the sirtuin.
- HDAC histone deacetylase
- the sirtuin-modulating compound is a sirtuin-modulating compound and is chosen to have an EC 50 for activating sirtuin deacetylase activity that is at least 5 fold less than the EC 50 for inhibition of an HDAC I and/or HDAC II, and even more preferably at least 10 fold, 100 fold or even 1000 fold less.
- kits to perform such assays may be purchased commercially. See e.g., BioVision, Inc. (Mountain View, Calif.; world wide web at biovision.com) and Thomas Scientific (Swedesboro, N.J.; world wide web at tomassci.com).
- a sirtuin-modulating compound does not have any substantial ability to modulate sirtuin homologs.
- an activator of a human sirtuin protein may not have any substantial ability to activate a sirtuin protein from lower eukaryotes, particularly yeast or human pathogens, at concentrations (e.g., in vivo) effective for activating the deacetylase activity of human sirtuin.
- a sirtuin-modulating compound may be chosen to have an EC 50 for activating a human sirtuin, such as SIRT1 and/or SIRT3, deacetylase activity that is at least 5 fold less than the EC 50 for activating a yeast sirtuin, such as Sir2 (such as Candida, S. cerevisiae , etc.), and even more preferably at least 10 fold, 100 fold or even 1000 fold less.
- a human sirtuin such as SIRT1 and/or SIRT3
- deacetylase activity that is at least 5 fold less than the EC 50 for activating a yeast sirtuin, such as Sir2 (such as Candida, S. cerevisiae , etc.)
- Sir2 such as Candida, S. cerevisiae , etc.
- an inhibitor of a sirtuin protein from lower eukaryotes, particularly yeast or human pathogens does not have any substantial ability to inhibit a sirtuin protein from humans at concentrations (e.g., in vivo) effective for inhibiting the deacetylase activity of a sirtuin protein from a lower eukaryote.
- a sirtuin-inhibiting compound may be chosen to have an IC 50 for inhibiting a human sirtuin, such as SIRT1 and/or SIRT3, deacetylase activity that is at least 5 fold less than the IC 50 for inhibiting a yeast sirtuin, such as Sir2 (such as Candida, S. cerevisiae , etc.), and even more preferably at least 10 fold, 100 fold or even 1000 fold less.
- a sirtuin-modulating compound may have the ability to modulate one or more sirtuin protein homologs, such as, for example, one or more of human SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7.
- a sirtuin-modulating compound has the ability to modulate both a SIRT1 and a SIRT3 protein.
- a SIRT1 modulator does not have any substantial ability to modulate other sirtuin protein homologs, such as, for example, one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, at concentrations (e.g., in vivo) effective for modulating the deacetylase activity of human SIRT1.
- a sirtuin-modulating compound may be chosen to have an ED 50 for modulating human SIRT1 deacetylase activity that is at least 5 fold less than the ED 50 for modulating one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, and even more preferably at least 10 fold, 100 fold or even 1000 fold less.
- a SIRT1 modulator does not have any substantial ability to modulate a SIRT3 protein.
- a SIRT3 modulator does not have any substantial ability to modulate other sirtuin protein homologs, such as, for example, one or more of human SIRT1, SIRT2, SIRT4, SIRT5, SIRT6, or SIRT7, at concentrations (e.g., in vivo) effective for modulating the deacetylase activity of human SIRT3.
- a sirtuin-modulating compound may be chosen to have an ED 50 for modulating human SIRT3 deacetylase activity that is at least 5 fold less than the ED 50 for modulating one or more of human SIRT1, SIRT2, SIRT4, SIRT5, SIRT6, or SIRT7, and even more preferably at least 10 fold, 100 fold or even 1000 fold less.
- a SIRT3 modulator does not have any substantial ability to modulate a SIRT1 protein.
- a sirtuin-modulating compound may have a binding affinity for a sirtuin protein of about 10 ⁇ 9 M, 10 ⁇ 10 M, 10 ⁇ 11 M, 10 ⁇ 12 M or less.
- a sirtuin-modulating compound may reduce (activator) or increase (inhibitor) the apparent Km of a sirtuin protein for its substrate or NAD + (or other cofactor) by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100.
- Km values are determined using the mass spectrometry assay described herein.
- Preferred activating compounds reduce the Km of a sirtuin for its substrate or cofactor to a greater extent than caused by resveratrol at a similar concentration or reduce the Km of a sirtuin for its substrate or cofactor similar to that caused by resveratrol at a lower concentration.
- a sirtuin-modulating compound may increase the Vmax of a sirtuin protein by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100.
- a sirtuin-modulating compound may have an ED 50 for modulating the deacetylase activity of a SIRT1 and/or SIRT3 protein of less than about 1 nM, less than about 10 nM, less than about 100 nM, less than about 1 ⁇ M, less than about 10 ⁇ M, less than about 100 ⁇ M, or from about 1-10 nM, from about 10-100 nM, from about 0.1-1 ⁇ M, from about 1-10 ⁇ M or from about 10-100 ⁇ M.
- a sirtuin-modulating compound may modulate the deacetylase activity of a SIRT1 and/or SIRT3 protein by a factor of at least about 5, 10, 20, 30, 50, or 100, as measured in a cellular assay or in a cell based assay.
- a sirtuin-modulating compound may cause at least about 10%, 30%, 50%, 80%, 2 fold, 5 fold, 10 fold, 50 fold or 100 fold greater induction of the deacetylase activity of a sirtuin protein relative to the same concentration of resveratrol.
- a sirtuin-modulating compound may have an ED 50 for modulating SIRT5 that is at least about 10 fold, 20 fold, 30 fold, 50 fold greater than that for modulating SIRT1 and/or SIRT3.
- the invention provides methods for modulating the level and/or activity of a sirtuin protein and methods of use thereof.
- the invention provides methods for using sirtuin-modulating compounds wherein the sirtuin-modulating compounds activate a sirtuin protein, e.g., increase the level and/or activity of a sirtuin protein.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be useful for a variety of therapeutic applications including, for example, increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc.
- the methods comprise administering to a subject in need thereof a pharmaceutically effective amount of a sirtuin-modulating compound, e.g., a sirtuin-modulating compound.
- activators of the instant invention may interact with a sirtuin at the same location within the sirtuin protein (e.g., active site or site affecting the Km or Vmax of the active site). It is believed that this is the reason why certain classes of sirtuin activators and inhibitors can have substantial structural similarity.
- the sirtuin-modulating compounds described herein may be taken alone or in combination with other compounds.
- a mixture of two or more sirtuin-modulating compounds may be administered to a subject in need thereof.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered with one or more of the following compounds: resveratrol, butein, fisetin, piceatannol, or quercetin.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered in combination with nicotinic acid or nicotinamide riboside.
- a sirtuin-modulating compound that decreases the level and/or activity of a sirtuin protein may be administered with one or more of the following compounds: nicotinamide (NAM), suramin; NF023 (a G-protein antagonist); NF279 (a purinergic receptor antagonist); Trolox (6-hydroxy-2,5,7,8,tetramethylchroman-2-carboxylic acid); ( ⁇ )-epigallocatechin (hydroxy on sites 3,5,7,3′,4′, 5′); ( ⁇ )-epigallocatechin gallate (Hydroxy sites 5,7,3′,4′,5′ and gallate ester on 3); cyanidin chloride (3,5,7,3′,4′-pentahydroxyflavylium chloride); delphinidin chloride (3,5,7,3′,4′,5′-hexahydroxyflavylium chloride); myricetin (cannabiscetin; 3,5,7,3′,4′,
- one or more sirtuin-modulating compounds may be administered with one or more therapeutic agents for the treatment or prevention of various diseases, including, for example, cancer, diabetes, neurodegenerative diseases, cardiovascular disease, blood clotting, inflammation, flushing, obesity, aging, stress, etc.
- combination therapies comprising a sirtuin-modulating compound may refer to (1) pharmaceutical compositions that comprise one or more sirtuin-modulating compounds in combination with one or more therapeutic agents (e.g., one or more therapeutic agents described herein); and (2) co-administration of one or more sirtuin-modulating compounds with one or more therapeutic agents wherein the sirtuin-modulating compound and therapeutic agent have not been formulated in the same compositions (but may be present within the same kit or package, such as a blister pack or other multi-chamber package; connected, separately sealed containers (e.g., foil pouches) that can be separated by the user; or a kit where the compound(s) and other therapeutic agent(s) are in separate vessels).
- the sirtuin-modulating compound may be administered simultaneous with, intermittent with, staggered with, prior to, subsequent to, or combinations thereof, the administration of another therapeutic agent.
- methods for reducing, preventing or treating diseases or disorders using a compound described herein may also comprise increasing the protein level of a sirtuin, such as human SIRT1, SIRT2 and/or SIRT3, or homologs thereof.
- Increasing protein levels can be achieved by introducing into a cell one or more copies of a nucleic acid that encodes a sirtuin.
- the level of a sirtuin can be increased in a mammalian cell by introducing into the mammalian cell a nucleic acid encoding the sirtuin, e.g., increasing the level of SIRT1 by introducing a nucleic acid encoding the amino acid sequence set forth in GenBank Accession No. NP_036370 and/or increasing the level of SIRT3 by introducing a nucleic acid encoding the amino acid sequence set forth in GenBank Accession No. AAH01042.
- a nucleic acid that is introduced into a cell to increase the protein level of a sirtuin may encode a protein that is at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to the sequence of a sirtuin, e.g., SIRT1 and/or SIRT3 protein.
- the nucleic acid encoding the protein may be at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to a nucleic acid encoding a SIRT1 (e.g. GenBank Accession No. NM_012238) and/or SIRT3 (e.g., GenBank Accession No. BC001042) protein.
- the nucleic acid may also be a nucleic acid that hybridizes, preferably under stringent hybridization conditions, to a nucleic acid encoding a wild-type sirtuin, e.g., SIRT1 and/or SIRT3 protein.
- Stringent hybridization conditions may include hybridization and a wash in 0.2 ⁇ SSC at 65° C.
- the protein is preferably biologically active, e.g., is capable of deacetylation. It is only necessary to express in a cell a portion of the sirtuin that is biologically active.
- a protein that differs from wild-type SIRT1 having GenBank Accession No. NP_036370 preferably contains the core structure thereof.
- the core structure sometimes refers to amino acids 62-293 of GenBank Accession No. NP_036370, which are encoded by nucleotides 237 to 932 of GenBank Accession No. NM_012238, which encompasses the NAD binding as well as the substrate binding domains.
- the core domain of SIRT1 may also refer to about amino acids 261 to 447 of GenBank Accession No. NP_036370, which are encoded by nucleotides 834 to 1394 of GenBank Accession No. NM_012238; to about amino acids 242 to 493 of GenBank Accession No.
- NP_036370 which are encoded by nucleotides 777 to 1532 of GenBank Accession No. NM_012238; or to about amino acids 254 to 495 of GenBank Accession No. NP_036370, which are encoded by nucleotides 813 to 1538 of GenBank Accession No. NM_012238. Whether a protein retains a biological function, e.g., deacetylation capabilities, can be determined according to methods known in the art.
- methods for reducing, preventing or treating diseases or disorders using a sirtuin-modulating compound may also comprise decreasing the protein level of a sirtuin, such as human SIRT1, SIRT2 and/or SIRT3, or homologs thereof.
- Decreasing a sirtuin protein level can be achieved according to methods known in the art.
- an siRNA, an antisense nucleic acid, or a ribozyme targeted to the sirtuin can be expressed in the cell.
- a dominant negative sirtuin mutant e.g., a mutant that is not capable of deacetylating, may also be used.
- mutant H363Y of SIRT1 described, e.g., in Luo et al. (2001) Cell 107:137 can be used.
- agents that inhibit transcription can be used.
- Methods for modulating sirtuin protein levels also include methods for modulating the transcription of genes encoding sirtuins, methods for stabilizing/destabilizing the corresponding mRNAs, and other methods known in the art.
- the invention provides a method extending the lifespan of a cell, extending the proliferative capacity of a cell, slowing aging of a cell, promoting the survival of a cell, delaying cellular senescence in a cell, mimicking the effects of calorie restriction, increasing the resistance of a cell to stress, or preventing apoptosis of a cell, by contacting the cell with a sirtuin-modulating compound of the invention that increases the level and/or activity of a sirtuin protein.
- the methods comprise contacting the cell with a sirtuin-modulating compound.
- the methods described herein may be used to increase the amount of time that cells, particularly primary cells (i.e., cells obtained from an organism, e.g., a human), may be kept alive in a cell culture.
- Embryonic stem (ES) cells and pluripotent cells, and cells differentiated therefrom may also be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein to keep the cells, or progeny thereof, in culture for longer periods of time.
- ES Embryonic stem
- Such cells can also be used for transplantation into a subject, e.g., after ex vivo modification.
- cells that are intended to be preserved for long periods of time may be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- the cells may be in suspension (e.g., blood cells, serum, biological growth media, etc.) or in tissues or organs.
- blood collected from an individual for purposes of transfusion may be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein to preserve the blood cells for longer periods of time.
- blood to be used for forensic purposes may also be preserved using a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- Other cells that may be treated to extend their lifespan or protect against apoptosis include cells for consumption, e.g., cells from non-human mammals (such as meat) or plant cells (such as vegetables).
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be applied during developmental and growth phases in mammals, plants, insects or microorganisms, in order to, e.g., alter, retard or accelerate the developmental and/or growth process.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to treat cells useful for transplantation or cell therapy, including, for example, solid tissue grafts, organ transplants, cell suspensions, stem cells, bone marrow cells, etc.
- the cells or tissue may be an autograft, an allograft, a syngraft or a xenograft.
- the cells or tissue may be treated with the sirtuin-modulating compound prior to administration/implantation, concurrently with administration/implantation, and/or post administration/implantation into a subject.
- the cells or tissue may be treated prior to removal of the cells from the donor individual, ex vivo after removal of the cells or tissue from the donor individual, or post implantation into the recipient.
- the donor or recipient individual may be treated systemically with a sirtuin-modulating compound or may have a subset of cells/tissue treated locally with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- the cells or tissue may additionally be treated with another therapeutic agent useful for prolonging graft survival, such as, for example, an immunosuppressive agent, a cytokine, an angiogenic factor, etc.
- cells may be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein in vivo, e.g., to increase their lifespan or prevent apoptosis.
- skin can be protected from aging (e.g., developing wrinkles, loss of elasticity, etc.) by treating skin or epithelial cells with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- skin is contacted with a pharmaceutical or cosmetic composition comprising a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- Exemplary skin afflictions or skin conditions that may be treated in accordance with the methods described herein include disorders or diseases associated with or caused by inflammation, sun damage or natural aging.
- the compositions find utility in the prevention or treatment of contact dermatitis (including irritant contact dermatitis and allergic contact dermatitis), atopic dermatitis (also known as allergic eczema), actinic keratosis, keratinization disorders (including eczema), epidermolysis bullosa diseases (including pemphigus), exfoliative dermatitis, seborrheic dermatitis, erythemas (including erythema multiforme and erythema nodosum), damage caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, psoriasis, skin cancer and the effects of natural aging.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for the treatment of wounds and/or burns to promote healing, including, for example, first-, second- or third-degree burns and/or thermal, chemical or electrical burns.
- the formulations may be administered topically, to the skin or mucosal tissue.
- Topical formulations comprising one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used as preventive, e.g., chemopreventive, compositions.
- preventive e.g., chemopreventive
- susceptible skin is treated prior to any visible condition in a particular individual.
- Sirtuin-modulating compounds may be delivered locally or systemically to a subject.
- a sirtuin-modulating compound is delivered locally to a tissue or organ of a subject by injection, topical formulation, etc.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used for treating or preventing a disease or condition induced or exacerbated by cellular senescence in a subject; methods for decreasing the rate of senescence of a subject, e.g., after onset of senescence; methods for extending the lifespan of a subject; methods for treating or preventing a disease or condition relating to lifespan; methods for treating or preventing a disease or condition relating to the proliferative capacity of cells; and methods for treating or preventing a disease or condition resulting from cell damage or death.
- the method does not act by decreasing the rate of occurrence of diseases that shorten the lifespan of a subject.
- a method does not act by reducing the lethality caused by a disease, such as cancer.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered to a subject in order to generally increase the lifespan of its cells and to protect its cells against stress and/or against apoptosis. It is believed that treating a subject with a compound described herein is similar to subjecting the subject to hormesis, i.e., mild stress that is beneficial to organisms and may extend their lifespan.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to a subject to prevent aging and aging-related consequences or diseases, such as stroke, heart disease, heart failure, arthritis, high blood pressure, and Alzheimer's disease.
- Other conditions that can be treated include ocular disorders, e.g., associated with the aging of the eye, such as cataracts, glaucoma, and macular degeneration.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can also be administered to subjects for treatment of diseases, e.g., chronic diseases, associated with cell death, in order to protect the cells from cell death.
- Exemplary diseases include those associated with neural cell death, neuronal dysfunction, or muscular cell death or dysfunction, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and muscular dystrophy; AIDS; fulminant hepatitis; diseases linked to degeneration of the brain, such as Creutzfeld-Jakob disease, retinitis pigmentosa and cerebellar degeneration; myelodysplasia such as aplastic anemia; ischemic diseases such as myocardial infarction and stroke; hepatic diseases such as alcoholic hepatitis, hepatitis B and hepatitis C; joint-diseases such as osteoarthritis; atherosclerosis; alopecia; damage to the skin due to UV light; lichen planus; atrophy of the skin; cataract; and graft rejections.
- Cell death can also be caused by surgery, drug therapy, chemical exposure or radiation exposure.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can also be administered to a subject suffering from an acute disease, e.g., damage to an organ or tissue, e.g., a subject suffering from stroke or myocardial infarction or a subject suffering from a spinal cord injury.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used to repair an alcoholic's liver.
- the invention provides a method for treating and/or preventing a cardiovascular disease by administering to a subject in need thereof a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- Cardiovascular diseases that can be treated or prevented using the sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein include cardiomyopathy or myocarditis; such as idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy.
- cardiomyopathy or myocarditis such as idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy.
- atheromatous disorders of the major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries.
- vascular diseases that can be treated or prevented include those related to platelet aggregation, the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems.
- the sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used for increasing HDL levels in plasma of an individual.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as part of a combination therapy with another cardiovascular agent.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as part of a combination therapy with an anti-arrhythmia agent.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as part of a combination therapy with another cardiovascular agent.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to subjects who have recently received or are likely to receive a dose of radiation or toxin.
- the dose of radiation or toxin is received as part of a work-related or medical procedure, e.g., administered as a prophylactic measure.
- the radiation or toxin exposure is received unintentionally.
- the compound is preferably administered as soon as possible after the exposure to inhibit apoptosis and the subsequent development of acute radiation syndrome.
- Sirtuin-modulating compounds may also be used for treating and/or preventing cancer.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating and/or preventing cancer.
- Calorie restriction has been linked to a reduction in the incidence of age-related disorders including cancer.
- an increase in the level and/or activity of a sirtuin protein may be useful for treating and/or preventing the incidence of age-related disorders, such as, for example, cancer.
- Exemplary cancers that may be treated using a sirtuin-modulating compound are those of the brain and kidney; hormone-dependent cancers including breast, prostate, testicular, and ovarian cancers; lymphomas, and leukemias.
- a modulating compound may be administered directly into the tumor.
- Cancer of blood cells e.g., leukemia
- Benign cell growth e.g., warts
- Other diseases that can be treated include autoimmune diseases, e.g., systemic lupus erythematosus, scleroderma, and arthritis, in which autoimmune cells should be removed.
- Viral infections such as herpes, HIV, adenovirus, and HTLV-1 associated malignant and benign disorders can also be treated by administration of sirtuin-modulating compound.
- cells can be obtained from a subject, treated ex vivo to remove certain undesirable cells, e.g., cancer cells, and administered back to the same or a different subject.
- Chemotherapeutic agents may be co-administered with modulating compounds described herein as having anti-cancer activity, e.g., compounds that induce apoptosis, compounds that reduce lifespan or compounds that render cells sensitive to stress. Chemotherapeutic agents may be used by themselves with a sirtuin-modulating compound described herein as inducing cell death or reducing lifespan or increasing sensitivity to stress and/or in combination with other chemotherapeutics agents. In addition to conventional chemotherapeutics, the sirtuin-modulating compounds described herein may also be used with antisense RNA, RNAi or other polynucleotides to inhibit the expression of the cellular components that contribute to unwanted cellular proliferation.
- Combination therapies comprising sirtuin-modulating compounds and a conventional chemotherapeutic agent may be advantageous over combination therapies known in the art because the combination allows the conventional chemotherapeutic agent to exert greater effect at lower dosage.
- the effective dose (ED 50 ) for a chemotherapeutic agent, or combination of conventional chemotherapeutic agents, when used in combination with a sirtuin-modulating compound is at least 2 fold less than the ED 50 for the chemotherapeutic agent alone, and even more preferably at 5 fold, 10 fold or even 25 fold less.
- the therapeutic index (TI) for such chemotherapeutic agent or combination of such chemotherapeutic agent when used in combination with a sirtuin-modulating compound described herein can be at least 2 fold greater than the TI for conventional chemotherapeutic regimen alone, and even more preferably at 5 fold, 10 fold or even 25 fold greater.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat patients suffering from neurodegenerative diseases, and traumatic or mechanical injury to the central nervous system (CNS), spinal cord or peripheral nervous system (PNS).
- Neurodegenerative disease typically involves reductions in the mass and volume of the human brain, which may be due to the atrophy and/or death of brain cells, which are far more profound than those in a healthy person that are attributable to aging.
- Neurodegenerative diseases can evolve gradually, after a long period of normal brain function, due to progressive degeneration (e.g., nerve cell dysfunction and death) of specific brain regions.
- neurodegenerative diseases can have a quick onset, such as those associated with trauma or toxins.
- neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, ocular diseases (ocular neuritis), chemotherapy-induced neuropathies (e.g., from vincristine, paclitaxel, bortezomib), diabetes-induced neuropathies and Friedreich's ataxia.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat these disorders and others as described below.
- AD is a CNS disorder that results in memory loss, unusual behavior, personality changes, and a decline in thinking abilities. These losses are related to the death of specific types of brain cells and the breakdown of connections and their supporting network (e.g. glial cells) between them. The earliest symptoms include loss of recent memory, faulty judgment, and changes in personality.
- PD is a CNS disorder that results in uncontrolled body movements, rigidity, tremor, and dyskinesia, and is associated with the death of brain cells in an area of the brain that produces dopamine.
- ALS motor neuron disease
- ALS motor neuron disease
- HD is another neurodegenerative disease that causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance.
- Tay-Sachs disease and Sandhoff disease are glycolipid storage diseases where GM2 ganglioside and related glycolipids substrates for ⁇ -hexosaminidase accumulate in the nervous system and trigger acute neurodegeneration.
- HIV-1 also induces neurological disease, which can be treated with sirtuin-modulating compounds of the invention.
- Neuronal loss is also a salient feature of prion diseases, such as Creutzfeldt-Jakob disease in human, BSE in cattle (mad cow disease), Scrapie Disease in sheep and goats, and feline spongiform encephalopathy (FSE) in cats.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be useful for treating or preventing neuronal loss due to these prior diseases.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to treat or prevent any disease or disorder involving axonopathy.
- Distal axonopathy is a type of peripheral neuropathy that results from some metabolic or toxic derangement of peripheral nervous system (PNS) neurons. It is the most common response of nerves to metabolic or toxic disturbances, and as such may be caused by metabolic diseases such as diabetes, renal failure, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs.
- PNS peripheral nervous system
- Those with distal axonopathies usually present with symmetrical glove-stocking sensori-motor disturbances. Deep tendon reflexes and autonomic nervous system (ANS) functions are also lost or diminished in affected areas.
- ANS autonomic nervous system
- Diabetic neuropathies are neuropathic disorders that are associated with diabetes mellitus. Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy; mononeuropathy; mononeuritis multiplex; diabetic amyotrophy; a painful polyneuropathy; autonomic neuropathy; and thoracoabdominal neuropathy.
- Peripheral neuropathy is the medical term for damage to nerves of the peripheral nervous system, which may be caused either by diseases of the nerve or from the side-effects of systemic illness.
- Maj or causes of peripheral neuropathy include seizures, nutritional deficiencies, and HIV, though diabetes is the most likely cause.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to treat or prevent multiple sclerosis (MS), including relapsing MS and monosymptomatic MS, and other demyelinating conditions, such as, for example, chronic inflammatory demyelinating polyneuropathy (CIDP), or symptoms associated therewith.
- MS multiple sclerosis
- CIDP chronic inflammatory demyelinating polyneuropathy
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to treat trauma to the nerves, including, trauma due to disease, injury (including surgical intervention), or environmental trauma (e.g., neurotoxins, alcoholism, etc.).
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be useful to prevent, treat, and alleviate symptoms of various PNS disorders.
- the term “peripheral neuropathy” encompasses a wide range of disorders in which the nerves outside of the brain and spinal cord—peripheral nerves—have been damaged. Peripheral neuropathy may also be referred to as peripheral neuritis, or if many nerves are involved, the terms polyneuropathy or polyneuritis may be used.
- PNS diseases treatable with sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein include: diabetes, leprosy, Charcot-Marie-Tooth disease, Guillain-Barré syndrome and Brachial Plexus Neuropathies (diseases of the cervical and first thoracic roots, nerve trunks, cords, and peripheral nerve components of the brachial plexus.
- a sirtuin-modulating compound may be used to treat or prevent a polyglutamine disease.
- polyglutamine diseases include Spinobulbar muscular atrophy (Kennedy disease), Huntington's Disease (HD), Dentatorubral-pallidoluysian atrophy (Haw River syndrome), Spinocerebellar ataxia type 1, Spinocerebellar ataxia type 2, Spinocerebellar ataxia type 3 (Machado-Joseph disease), Spinocerebellar ataxia type 6, Spinocerebellar ataxia type 7, and Spinocerebellar ataxia type 17.
- the invention provides a method to treat a central nervous system cell to prevent damage in response to a decrease in blood flow to the cell.
- the severity of damage that may be prevented will depend in large part on the degree of reduction in blood flow to the cell and the duration of the reduction.
- apoptotic or necrotic cell death may be prevented.
- ischemic-mediated damage such as cytotoxic edema or central nervous system tissue anoxemia, may be prevented.
- the central nervous system cell may be a spinal cell or a brain cell.
- the ischemic condition is a stroke that results in any type of ischemic central nervous system damage, such as apoptotic or necrotic cell death, cytotoxic edema or central nervous system tissue anoxia.
- the stroke may impact any area of the brain or be caused by any etiology commonly known to result in the occurrence of a stroke.
- the stroke is a brain stem stroke.
- the stroke is a cerebellar stroke.
- the stroke is an embolic stroke.
- the stroke may be a hemorrhagic stroke.
- the stroke is a thrombotic stroke.
- a sirtuin-modulating compound may be administered to reduce infarct size of the ischemic core following a central nervous system ischemic condition. Moreover, a sirtuin-modulating compound may also be beneficially administered to reduce the size of the ischemic penumbra or transitional zone following a central nervous system ischemic condition.
- a combination drug regimen may include drugs or compounds for the treatment or prevention of neurodegenerative disorders or secondary conditions associated with these conditions.
- a combination drug regimen may include one or more sirtuin activators and one or more anti-neurodegeneration agents.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat or prevent blood coagulation disorders (or hemostatic disorders).
- blood coagulation disorders or hemostatic disorders
- the terms “hemostasis”, “blood coagulation,” and “blood clotting” refer to the control of bleeding, including the physiological properties of vasoconstriction and coagulation. Blood coagulation assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Further, the formation of blood clots does not only limit bleeding in case of an injury (hemostasis), but may lead to serious organ damage and death in the context of atherosclerotic diseases by occlusion of an important artery or vein. Thrombosis is thus blood clot formation at the wrong time and place.
- the present invention provides anticoagulation and antithrombotic treatments aiming at inhibiting the formation of blood clots in order to prevent or treat blood coagulation disorders, such as myocardial infarction, stroke, loss of a limb by peripheral artery disease or pulmonary embolism.
- blood coagulation disorders such as myocardial infarction, stroke, loss of a limb by peripheral artery disease or pulmonary embolism.
- modulating or modulation of hemostasis includes the induction (e.g., stimulation or increase) of hemostasis, as well as the inhibition (e.g., reduction or decrease) of hemostasis.
- the invention provides a method for reducing or inhibiting hemostasis in a subject by administering a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- the compositions and methods disclosed herein are useful for the treatment or prevention of thrombotic disorders.
- thrombotic disorder includes any disorder or condition characterized by excessive or unwanted coagulation or hemostatic activity, or a hypercoagulable state.
- Thrombotic disorders include diseases or disorders involving platelet adhesion and thrombus formation, and may manifest as an increased propensity to form thromboses, e.g., an increased number of thromboses, thrombosis at an early age, a familial tendency towards thrombosis, and thrombosis at unusual sites.
- a combination drug regimen may include drugs or compounds for the treatment or prevention of blood coagulation disorders or secondary conditions associated with these conditions.
- a combination drug regimen may include one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein and one or more anti-coagulation or anti-thrombosis agents.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating or preventing weight gain or obesity in a subject.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used, for example, to treat or prevent hereditary obesity, dietary obesity, hormone related obesity, obesity related to the administration of medication, to reduce the weight of a subject, or to reduce or prevent weight gain in a subject.
- a subject in need of such a treatment may be a subject who is obese, likely to become obese, overweight, or likely to become overweight.
- Subjects who are likely to become obese or overweight can be identified, for example, based on family history, genetics, diet, activity level, medication intake, or various combinations thereof.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to subjects suffering from a variety of other diseases and conditions that may be treated or prevented by promoting weight loss in the subject.
- diseases include, for example, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, type 2 diabetes, insulin resistance, glucose intolerance, hyperinsulinemia, coronary heart disease, angina pectoris, congestive heart failure, stroke, gallstones, cholecystitis and cholelithiasis, gout, osteoarthritis, obstructive sleep apnea and respiratory problems, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation), bladder control problems (such as stress incontinence); uric acid nephrolithiasis; psychological disorders (such as depression, eating disorders, distorted body image,
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for inhibiting adipogenesis or fat cell differentiation, whether in vitro or in vivo. Such methods may be used for treating or preventing obesity.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for reducing appetite and/or increasing satiety, thereby causing weight loss or avoidance of weight gain.
- a subject in need of such a treatment may be a subject who is overweight, obese or a subject likely to become overweight or obese.
- the method may comprise administering daily or, every other day, or once a week, a dose, e.g., in the form of a pill, to a subject.
- the dose may be an “appetite reducing dose.”
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as a combination therapy for treating or preventing weight gain or obesity.
- one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered in combination with one or more anti-obesity agents.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to reduce drug-induced weight gain.
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as a combination therapy with medications that may stimulate appetite or cause weight gain, in particular, weight gain due to factors other than water retention.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating or preventing a metabolic disorder, such as insulin-resistance, a pre-diabetic state, type II diabetes, and/or complications thereof.
- Administration of a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may increase insulin sensitivity and/or decrease insulin levels in a subject.
- a subject in need of such a treatment may be a subject who has insulin resistance or other precursor symptom of type II diabetes, who has type II diabetes, or who is likely to develop any of these conditions.
- the subject may be a subject having insulin resistance, e.g., having high circulating levels of insulin and/or associated conditions, such as hyperlipidemia, dyslipogenesis, hypercholesterolemia, impaired glucose tolerance, high blood glucose sugar level, other manifestations of syndrome X, hypertension, atherosclerosis and lipodystrophy.
- insulin resistance e.g., having high circulating levels of insulin and/or associated conditions, such as hyperlipidemia, dyslipogenesis, hypercholesterolemia, impaired glucose tolerance, high blood glucose sugar level, other manifestations of syndrome X, hypertension, atherosclerosis and lipodystrophy.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as a combination therapy for treating or preventing a metabolic disorder.
- one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered in combination with one or more anti-diabetic agents.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat or prevent a disease or disorder associated with inflammation.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered prior to the onset of, at, or after the initiation of inflammation.
- the compounds are preferably provided in advance of any inflammatory response or symptom. Administration of the compounds may prevent or attenuate inflammatory responses or symptoms.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to treat or prevent allergies and respiratory conditions, including asthma, bronchitis, pulmonary fibrosis, allergic rhinitis, oxygen toxicity, emphysema, chronic bronchitis, acute respiratory distress syndrome, and any chronic obstructive pulmonary disease (COPD).
- the compounds may be used to treat chronic hepatitis infection, including hepatitis B and hepatitis C.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to treat autoimmune diseases, and/or inflammation associated with autoimmune diseases, such as arthritis, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as organ-tissue autoimmune diseases (e.g., Raynaud's syndrome), ulcerative colitis, Crohn's disease, oral mucositis, scleroderma, myasthenia gravis, transplant rejection, endotoxin shock, sepsis, psoriasis, eczema, dermatitis, multiple sclerosis, autoimmune thyroiditis, uveitis, systemic lupus erythematosis, Addison's disease, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), and Grave's disease.
- autoimmune diseases such as arthritis, including rheumatoid arthritis,
- one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be taken alone or in combination with other compounds useful for treating or preventing inflammation.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for reducing the incidence or severity of flushing and/or hot flashes which are symptoms of a disorder.
- the subject method includes the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein, alone or in combination with other agents, for reducing incidence or severity of flushing and/or hot flashes in cancer patients.
- the method provides for the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein to reduce the incidence or severity of flushing and/or hot flashes in menopausal and post-menopausal woman.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used as a therapy for reducing the incidence or severity of flushing and/or hot flashes which are side-effects of another drug therapy, e.g., drug-induced flushing.
- a method for treating and/or preventing drug-induced flushing comprises administering to a patient in need thereof a formulation comprising at least one flushing inducing compound and at least one sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- a method for treating drug induced flushing comprises separately administering one or more compounds that induce flushing and one or more sirtuin-modulating compounds, e.g., wherein the sirtuin-modulating compound and flushing inducing agent have not been formulated in the same compositions.
- the sirtuin-modulating compound may be administered (1) at the same as administration of the flushing inducing agent, (2) intermittently with the flushing inducing agent, (3) staggered relative to administration of the flushing inducing agent, (4) prior to administration of the flushing inducing agent, (5) subsequent to administration of the flushing inducing agent, and (6) various combination thereof.
- Exemplary flushing inducing agents include, for example, niacin, raloxifene, antidepressants, anti-psychotics, chemotherapeutics, calcium channel blockers, and antibiotics.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of a vasodilator or an antilipemic agent (including anticholesteremic agents and lipotropic agents).
- a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to reduce flushing associated with the administration of niacin.
- the invention provides a method for treating and/or preventing hyperlipidemia with reduced flushing side effects.
- the method involves the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein to reduce flushing side effects of raloxifene.
- the method involves the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein to reduce flushing side effects of antidepressants or anti-psychotic agent.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used in conjunction (administered separately or together) with a serotonin reuptake inhibitor, or a 5HT2 receptor antagonist.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used as part of a treatment with a serotonin reuptake inhibitor (SRI) to reduce flushing.
- SRI serotonin reuptake inhibitor
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of chemotherapeutic agents, such as cyclophosphamide and tamoxifen.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of calcium channel blockers, such as amlodipine.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of antibiotics.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used in combination with levofloxacin.
- One aspect of the present invention is a method for inhibiting, reducing or otherwise treating vision impairment by administering to a patient a therapeutic dosage of sirtuin modulator selected from a compound disclosed herein, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.
- the vision impairment is caused by damage to the optic nerve or central nervous system.
- optic nerve damage is caused by high intraocular pressure, such as that created by glaucoma.
- optic nerve damage is caused by swelling of the nerve, which is often associated with an infection or an immune (e.g., autoimmune) response such as in optic neuritis.
- the vision impairment is caused by retinal damage.
- retinal damage is caused by disturbances in blood flow to the eye (e.g., arteriosclerosis, vasculitis).
- retinal damage is caused by disruption of the macula (e.g., exudative or non-exudative macular degeneration).
- Exemplary retinal diseases include Exudative Age Related Macular Degeneration, Nonexudative Age Related Macular Degeneration, Retinal Electronic Prosthesis and RPE Transplantation Age Related Macular Degeneration, Acute Multifocal Placoid Pigment Epitheliopathy, Acute Retinal Necrosis, Best Disease, Branch Retinal Artery Occlusion, Branch Retinal Vein Occlusion, Cancer Associated and Related Autoimmune Retinopathies, Central Retinal Artery Occlusion, Central Retinal Vein Occlusion, Central Serous Chorioretinopathy, Eales Disease, Epimacular Membrane, Lattice Degeneration, Macroaneurysm, Diabetic Macular Edema, Irvine-Gass Macular Edema, Macular Hole, Subretinal Neovascular Membranes, Diffuse Unilateral Subacute Neuroretinitis, Nonpseudophakic Cystoid Macular Edema, Presumed Ocular Histoplasmosis Syndrome,
- exemplary diseases include ocular bacterial infections (e.g. conjunctivitis, keratitis, tuberculosis, syphilis, gonorrhea), viral infections (e.g., Ocular Herpes Simplex Virus, Varicella Zoster Virus, Cytomegalovirus retinitis, Human Immunodeficiency Virus (HIV)) as well as progressive outer retinal necrosis secondary to HIV or other HIV-associated and other immunodeficiency-associated ocular diseases.
- ocular bacterial infections e.g. conjunctivitis, keratitis, tuberculosis, syphilis, gonorrhea
- viral infections e.g., Ocular Herpes Simplex Virus, Varicella Zoster Virus, Cytomegalovirus retinitis, Human Immunodeficiency Virus (HIV)
- HIV Human Immunodeficiency Virus
- ocular diseases include fungal infections (e.g., Candida choroiditis, histoplasmosis), protozoal infections (e.g., toxoplasmosis) and others such as ocular toxocariasis and sarcoidosis.
- fungal infections e.g., Candida choroiditis, histoplasmosis
- protozoal infections e.g., toxoplasmosis
- others such as ocular toxocariasis and sarcoidosis.
- One aspect of the invention is a method for inhibiting, reducing or treating vision impairment in a subject undergoing treatment with a chemotherapeutic drug (e.g., a neurotoxic drug, or a drug that raises intraocular pressure, such as a steroid), by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein.
- a chemotherapeutic drug e.g., a neurotoxic drug, or a drug that raises intraocular pressure, such as a steroid
- Another aspect of the invention is a method for inhibiting, reducing or treating vision impairment in a subject undergoing surgery, including ocular or other surgeries performed in the prone position such as spinal cord surgery, by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein.
- Ocular surgeries include cataract, iridotomy and lens replacements.
- Another aspect of the invention is the treatment, including inhibition and prophylactic treatment, of age related ocular diseases include cataracts, dry eye, age-related macular degeneration (AMD), retinal damage and the like, by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein.
- age related ocular diseases include cataracts, dry eye, age-related macular degeneration (AMD), retinal damage and the like.
- Another aspect of the invention is the prevention or treatment of damage to the eye caused by stress, chemical insult or radiation, by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein.
- Radiation or electromagnetic damage to the eye can include that caused by CRT's or exposure to sunlight or UV.
- a combination drug regimen may include drugs or compounds for the treatment or prevention of ocular disorders or secondary conditions associated with these conditions.
- a combination drug regimen may include one or more sirtuin activators and one or more therapeutic agents for the treatment of an ocular disorder.
- a sirtuin modulator can be administered in conjunction with a therapy for reducing intraocular pressure. In another embodiment, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing glaucoma. In yet another embodiment, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing optic neuritis. In certain embodiments, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing CMV Retinopathy. In another embodiment, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing multiple sclerosis.
- the invention provides methods for treating diseases or disorders that would benefit from increased mitochondrial activity.
- the methods involve administering to a subject in need thereof a therapeutically effective amount of a sirtuin-modulating compound.
- Increased mitochondrial activity refers to increasing activity of the mitochondria while maintaining the overall numbers of mitochondria (e.g., mitochondrial mass), increasing the numbers of mitochondria thereby increasing mitochondrial activity (e.g., by stimulating mitochondrial biogenesis), or combinations thereof.
- diseases and disorders that would benefit from increased mitochondrial activity include diseases or disorders associated with mitochondrial dysfunction.
- methods for treating diseases or disorders that would benefit from increased mitochondrial activity may comprise identifying a subject suffering from a mitochondrial dysfunction.
- Methods for diagnosing a mitochondrial dysfunction may involve molecular genetics, pathologic and/or biochemical analyses.
- Diseases and disorders associated with mitochondrial dysfunction include diseases and disorders in which deficits in mitochondrial respiratory chain activity contribute to the development of pathophysiology of such diseases or disorders in a mammal.
- Diseases or disorders that would benefit from increased mitochondrial activity generally include for example, diseases in which free radical mediated oxidative injury leads to tissue degeneration, diseases in which cells inappropriately undergo apoptosis, and diseases in which cells fail to undergo apoptosis.
- the invention provides methods for treating a disease or disorder that would benefit from increased mitochondrial activity that involves administering to a subject in need thereof one or more sirtuin-modulating compounds in combination with another therapeutic agent such as, for example, an agent useful for treating mitochondrial dysfunction or an agent useful for reducing a symptom associated with a disease or disorder involving mitochondrial dysfunction.
- the invention provides methods for treating diseases or disorders that would benefit from increased mitochondrial activity by administering to a subject a therapeutically effective amount of a sirtuin-modulating compound.
- diseases or disorders include, for example, neuromuscular disorders (e.g., Friedreich's Ataxia, muscular dystrophy, multiple sclerosis, etc.), disorders of neuronal instability (e.g., seizure disorders, migraine, etc.), developmental delay, neurodegenerative disorders (e.g., Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, etc.), ischemia, renal tubular acidosis, age-related neurodegeneration and cognitive decline, chemotherapy fatigue, age-related or chemotherapy-induced menopause or irregularities of menstrual cycling or ovulation, mitochondrial myopathies, mitochondrial damage (e.g., calcium accumulation, excitotoxicity, nitric oxide exposure, hypoxia, etc.), and mitochondrial deregulation.
- mitochondrial myopathies e.g., calcium accumulation, excitotoxicity
- Muscular dystrophy refers to a family of diseases involving deterioration of neuromuscular structure and function, often resulting in atrophy of skeletal muscle and myocardial dysfunction, such as Duchenne muscular dystrophy.
- sirtuin-modulating compounds may be used for reducing the rate of decline in muscular functional capacities and for improving muscular functional status in patients with muscular dystrophy.
- sirtuin-modulating compounds may be useful for treatment mitochondrial myopathies.
- Mitochondrial myopathies range from mild, slowly progressive weakness of the extraocular muscles to severe, fatal infantile myopathies and multisystem encephalomyopathies. Some syndromes have been defined, with some overlap between them.
- Established syndromes affecting muscle include progressive external ophthalmoplegia, the Kearns-Sayre syndrome (with ophthalmoplegia, pigmentary retinopathy, cardiac conduction defects, cerebellar ataxia, and sensorineural deafness), the MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), the MERFF syndrome (myoclonic epilepsy and ragged red fibers), limb-girdle distribution weakness, and infantile myopathy (benign or severe and fatal).
- sirtuin-modulating compounds may be useful for treating patients suffering from toxic damage to mitochondria, such as, toxic damage due to calcium accumulation, excitotoxicity, nitric oxide exposure, drug induced toxic damage, or hypoxia.
- sirtuin-modulating compounds may be useful for treating diseases or disorders associated with mitochondrial deregulation.
- the invention provides methods for enhancing muscle performance by administering a therapeutically effective amount of a sirtuin-modulating compound.
- sirtuin-modulating compounds may be useful for improving physical endurance (e.g., ability to perform a physical task such as exercise, physical labor, sports activities, etc.), inhibiting or retarding physical fatigues, enhancing blood oxygen levels, enhancing energy in healthy individuals, enhance working capacity and endurance, reducing muscle fatigue, reducing stress, enhancing cardiac and cardiovascular function, improving sexual ability, increasing muscle ATP levels, and/or reducing lactic acid in blood.
- the methods involve administering an amount of a sirtuin-modulating compound that increase mitochondrial activity, increase mitochondrial biogenesis, and/or increase mitochondrial mass.
- Sports performance refers to the ability of the athlete's muscles to perform when participating in sports activities. Enhanced sports performance, strength, speed and endurance are measured by an increase in muscular contraction strength, increase in amplitude of muscle contraction, shortening of muscle reaction time between stimulation and contraction. Athlete refers to an individual who participates in sports at any level and who seeks to achieve an improved level of strength, speed and endurance in their performance, such as, for example, body builders, bicyclists, long distance runners, short distance runners, etc. Enhanced sports performance in manifested by the ability to overcome muscle fatigue, ability to maintain activity for longer periods of time, and have a more effective workout.
- the methods of the present invention will also be effective in the treatment of muscle related pathological conditions, including acute sarcopenia, for example, muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery.
- acute sarcopenia for example, muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery.
- the invention provides novel dietary compositions comprising sirtuin modulators, a method for their preparation, and a method of using the compositions for improvement of sports performance. Accordingly, provided are therapeutic compositions, foods and beverages that have actions of improving physical endurance and/or inhibiting physical fatigues for those people involved in broadly-defined exercises including sports requiring endurance and labors requiring repeated muscle exertions. Such dietary compositions may additional comprise electrolytes, caffeine, vitamins, carbohydrates, etc.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating or preventing viral infections (such as infections by influenza, herpes or papilloma virus) or as antifungal agents.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as part of a combination drug therapy with another therapeutic agent for the treatment of viral diseases.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as part of a combination drug therapy with another anti-fungal agent.
- Subjects that may be treated as described herein include eukaryotes, such as mammals, e.g., humans, ovines, bovines, equines, porcines, canines, felines, non-human primate, mice, and rats.
- Cells that may be treated include eukaryotic cells, e.g., from a subject described above, or plant cells, yeast cells and prokaryotic cells, e.g., bacterial cells.
- modulating compounds may be administered to farm animals to improve their ability to withstand farming conditions longer.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used to increase lifespan, stress resistance, and resistance to apoptosis in plants.
- a compound is applied to plants, e.g., on a periodic basis, or to fungi.
- plants are genetically modified to produce a compound.
- plants and fruits are treated with a compound prior to picking and shipping to increase resistance to damage during shipping. Plant seeds may also be contacted with compounds described herein, e.g., to preserve them.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for modulating lifespan in yeast cells.
- Situations in which it may be desirable to extend the lifespan of yeast cells include any process in which yeast is used, e.g., the making of beer, yogurt, and bakery items, e.g., bread.
- Use of yeast having an extended lifespan can result in using less yeast or in having the yeast be active for longer periods of time.
- Yeast or other mammalian cells used for recombinantly producing proteins may also be treated as described herein.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used to increase lifespan, stress resistance and resistance to apoptosis in insects.
- compounds would be applied to useful insects, e.g., bees and other insects that are involved in pollination of plants.
- a compound would be applied to bees involved in the production of honey.
- the methods described herein may be applied to any organism, e.g., eukaryote, which may have commercial importance. For example, they can be applied to fish (aquaculture) and birds (e.g., chicken and fowl).
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used as a pesticide by interfering with the regulation of silenced genes and the regulation of apoptosis during development.
- a compound may be applied to plants using a method known in the art that ensures the compound is bio-available to insect larvae, and not to plants.
- sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be applied to affect the reproduction of organisms such as insects, animals and microorganisms.
- an agent may be a nucleic acid, such as an aptamer.
- Assays may be conducted in a cell based or cell free format.
- an assay may comprise incubating (or contacting) a sirtuin with a test agent under conditions in which a sirtuin can be modulated by an agent known to modulate the sirtuin, and monitoring or determining the level of modulation of the sirtuin in the presence of the test agent relative to the absence of the test agent.
- the level of modulation of a sirtuin can be determined by determining its ability to deacetylate a substrate.
- Exemplary substrates are acetylated peptides which can be obtained from BIOMOL (Plymouth Meeting, Pa.).
- Preferred substrates include peptides of p53, such as those comprising an acetylated K382.
- a particularly preferred substrate is the Fluor de Lys-SIRT1 (BIOMOL), i.e., the acetylated peptide Arg-His-Lys-Lys.
- Other substrates are peptides from human histones H3 and H4 or an acetylated amino acid.
- Substrates may be fluorogenic.
- the sirtuin may be SIRT1, Sir2, SIRT3, or a portion thereof.
- recombinant SIRT1 can be obtained from BIOMOL.
- the reaction may be conducted for about 30 minutes and stopped, e.g., with nicotinamide.
- the HDAC fluorescent activity assay/drug discovery kit (AK-500, BIOMOL Research Laboratories) may be used to determine the level of acetylation. Similar assays are described in Bitterman et al. (2002) J. Biol. Chem. 277:45099.
- the level of modulation of the sirtuin in an assay may be compared to the level of modulation of the sirtuin in the presence of one or more (separately or simultaneously) compounds described herein, which may serve as positive or negative controls.
- Sirtuins for use in the assays may be full length sirtuin proteins or portions thereof.
- proteins for use in the assays include N-terminal portions of sirtuins, e.g., about amino acids 1-176 or 1-255 of SIRT1; about amino acids 1-174 or 1-252 of Sir2.
- a screening assay comprises (i) contacting a sirtuin with a test agent and an acetylated substrate under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent; and (ii) determining the level of acetylation of the substrate, wherein a lower level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, whereas a higher level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin.
- the screening assay may detect the formation of a 2′/3′-O-acetyl-ADP-ribose product of sirtuin-mediated NAD-dependent deacetylation.
- This O-acetyl-ADP-ribose product is formed in equimolar quantities with the deacetylated peptide product of the sirtuin deacetylation reaction.
- the screening assay may include (i) contacting a sirtuin with a test agent and an acetylated substrate under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent; and (ii) determining the amount of O-acetyl-ADP-ribose formation, wherein an increase in O-acetyl-ADP-ribose formation in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, while a decrease in O-acetyl-ADP-ribose formation in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin.
- Methods for identifying an agent that modulates, e.g., stimulates, sirtuins in vivo may comprise (i) contacting a cell with a test agent and a substrate that is capable of entering a cell in the presence of an inhibitor of class I and class II HDACs under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent; and (ii) determining the level of acetylation of the substrate, wherein a lower level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, whereas a higher level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin.
- a preferred substrate is an acetylated peptide, which is also preferably fluorogenic, as further described herein.
- the method may further comprise lysing the cells to determine the level of acetylation of the substrate.
- Substrates may be added to cells at a concentration ranging from about 1 ⁇ M to about 10 mM, preferably from about 10 ⁇ M to 1 mM, even more preferably from about 100 ⁇ M to 1 mM, such as about 200 ⁇ M.
- a preferred substrate is an acetylated lysine, e.g., ⁇ -acetyl lysine (Fluor de Lys, FdL) or Fluor de Lys-SIRT1.
- a preferred inhibitor of class I and class II HDACs is trichostatin A (TSA), which may be used at concentrations ranging from about 0.01 to 100 ⁇ M, preferably from about 0.1 to 10 ⁇ M, such as 1 ⁇ M.
- TSA trichostatin A
- Incubation of cells with the test compound and the substrate may be conducted for about 10 minutes to 5 hours, preferably for about 1-3 hours. Since TSA inhibits all class I and class II HDACs, and that certain substrates, e.g., Fluor de Lys, is a poor substrate for SIRT2 and even less a substrate for SIRT3-7, such an assay may be used to identify modulators of SIRT1 in vivo.
- the compounds described herein may be formulated in a conventional manner using one or more physiologically or pharmaceutically acceptable carriers or excipients.
- compounds and their pharmaceutically acceptable salts and solvates may be formulated for administration by, for example, injection (e.g. SubQ, IM, IP), inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, nasal, parenteral or rectal administration.
- a compound may be administered locally, at the site where the target cells are present, i.e., in a specific tissue, organ, or fluid (e.g., blood, cerebrospinal fluid, etc.).
- the compounds can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, Pa.
- parenteral administration injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous.
- the compounds can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution.
- the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
- the pharmaceutical compositions may take the form of, for example, tablets, lozenges, or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
- binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants e.g
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
- the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- the compounds may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- Controlled release formula also includes patches.
- the compounds described herein can be formulated for delivery to the central nervous system (CNS) (reviewed in Begley, Pharmacology & Therapeutics 104: 29-45 (2004)).
- CNS central nervous system
- Conventional approaches for drug delivery to the CNS include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically
- Liposomes are a further drug delivery system which is easily injectable. Accordingly, in the method of invention the active compounds can also be administered in the form of a liposome delivery system.
- Liposomes are well known by those skilled in the art. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine of phosphatidylcholines. Liposomes usable for the method of invention encompass all types of liposomes including, but not limited to, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- cyclodextrin is meant ⁇ -, ⁇ -, or ⁇ -cyclodextrin.
- Cyclodextrins are described in detail in Pitha et al., U.S. Pat. No. 4,727,064, which is incorporated herein by reference. Cyclodextrins are cyclic oligomers of glucose; these compounds form inclusion complexes with any drug whose molecule can fit into the lipophile-seeking cavities of the cyclodextrin molecule.
- Rapidly disintegrating or dissolving dosage forms are useful for the rapid absorption, particularly buccal and sublingual absorption, of pharmaceutically active agents.
- Fast melt dosage forms are beneficial to patients, such as aged and pediatric patients, who have difficulty in swallowing typical solid dosage forms, such as caplets and tablets. Additionally, fast melt dosage forms circumvent drawbacks associated with, for example, chewable dosage forms, wherein the length of time an active agent remains in a patient's mouth plays an important role in determining the amount of taste masking and the extent to which a patient may object to throat grittiness of the active agent.
- compositions may comprise from about 0.00001 to 100% such as from 0.001 to 10% or from 0.1% to 5% by weight of one or more compounds described herein.
- the pharmaceutical composition comprises: (i) 0.05 to 1000 mg of the compounds of the invention, or a pharmaceutically acceptable salt thereof, and (ii) 0.1 to 2 grams of one or more pharmaceutically acceptable excipients.
- a compound described herein is incorporated into a topical formulation containing a topical carrier that is generally suited to topical drug administration and comprising any such material known in the art.
- the topical carrier may be selected so as to provide the composition in the desired form, e.g., as an ointment, lotion, cream, microemulsion, gel, oil, solution, or the like, and may be comprised of a material of either naturally occurring or synthetic origin. It is preferable that the selected carrier not adversely affect the active agent or other components of the topical formulation.
- suitable topical carriers for use herein include water, alcohols and other nontoxic organic solvents, glycerin, mineral oil, silicone, petroleum jelly, lanolin, fatty acids, vegetable oils, parabens, waxes, and the like.
- Formulations may be colorless, odorless ointments, lotions, creams, microemulsions and gels.
- the compounds may be incorporated into ointments, which generally are semisolid preparations which are typically based on petrolatum or other petroleum derivatives.
- ointments which generally are semisolid preparations which are typically based on petrolatum or other petroleum derivatives.
- the specific ointment base to be used is one that will provide for optimum drug delivery, and, preferably, will provide for other desired characteristics as well, e.g., emolliency or the like.
- an ointment base should be inert, stable, nonirritating and nonsensitizing.
- the compounds may be incorporated into lotions, which generally are preparations to be applied to the skin surface without friction, and are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base.
- Lotions are usually suspensions of solids, and may comprise a liquid oily emulsion of the oil-in-water type.
- the compounds may be incorporated into creams, which generally are viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil.
- Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase.
- the oil phase is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
- the emulsifier in a cream formulation as explained in Remington's, supra, is generally a nonionic, anionic, cationic or amphoteric surfactant.
- microemulsions which generally are thermodynamically stable, isotropically clear dispersions of two immiscible liquids, such as oil and water, stabilized by an interfacial film of surfactant molecules (Encyclopedia of Pharmaceutical Technology (New York: Marcel Dekker, 1992), volume 9).
- the compounds may be incorporated into gel formulations, which generally are semisolid systems consisting of either suspensions made up of small inorganic particles (two-phase systems) or large organic molecules distributed substantially uniformly throughout a carrier liquid (single phase gels). Although gels commonly employ aqueous carrier liquid, alcohols and oils can be used as the carrier liquid as well.
- sunscreen formulations e.g., other anti-inflammatory agents, analgesics, antimicrobial agents, antifungal agents, antibiotics, vitamins, antioxidants, and sunblock agents commonly found in sunscreen formulations including, but not limited to, anthranilates, benzophenones (particularly benzophenone-3), camphor derivatives, cinnamates (e.g., octyl methoxycinnamate), dibenzoyl methanes (e.g., butyl methoxydibenzoyl methane), p-aminobenzoic acid (PABA) and derivatives thereof, and salicylates (e.g., octyl salicylate).
- sunscreen formulations including, but not limited to, anthranilates, benzophenones (particularly benzophenone-3), camphor derivatives, cinnamates (e.g., octyl methoxycinnamate), dibenzoyl methanes (e.g.,
- the active agent is present in an amount in the range of approximately 0.25 wt. % to 75 wt. % of the formulation, preferably in the range of approximately 0.25 wt. % to 30 wt. % of the formulation, more preferably in the range of approximately 0.5 wt. % to 15 wt. % of the formulation, and most preferably in the range of approximately 1.0 wt. % to 10 wt. % of the formulation.
- Conditions of the eye can be treated or prevented by, e.g., systemic, topical, intraocular injection of a compound, or by insertion of a sustained release device that releases a compound.
- a compound may be delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera.
- the pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material.
- the compounds of the invention may be injected directly into the vitreous and aqueous humour.
- the compounds may be administered systemically, such as by intravenous infusion or injection, for treatment of the eye.
- compositions described herein may be stored in oxygen free environment.
- a composition can be prepared in an airtight capsule for oral administration, such as Capsugel from Pfizer, Inc.
- Cells e.g., treated ex vivo with a compound as described herein, can be administered according to methods for administering a graft to a subject, which may be accompanied, e.g., by administration of an immunosuppressant drug, e.g., cyclosporin A.
- an immunosuppressant drug e.g., cyclosporin A.
- the reader is referred to Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and Hematopoietic Stem Cell Therapy, E. D. Ball, J. Lister & P. Law, Churchill Livingstone, 2000.
- Toxicity and therapeutic efficacy of compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
- the LD 50 is the dose lethal to 50% of the population.
- the ED 50 is the dose therapeutically effective in 50% of the population.
- the dose ratio between toxic and therapeutic effects (LD 50 /ED 50 ) is the therapeutic index.
- Compounds that exhibit large therapeutic indexes are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds may lie within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC 50 i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- kits e.g., kits for therapeutic purposes or kits for modulating the lifespan of cells or modulating apoptosis.
- a kit may comprise one or more compounds as described herein, e.g., in premeasured doses.
- a kit may optionally comprise devices for contacting cells with the compounds and instructions for use. Devices include syringes, stents and other devices for introducing a compound into a subject (e.g., the blood vessel of a subject) or applying it to the skin of a subject.
- the invention provides a composition of matter comprising a compound of this invention and another therapeutic agent (the same ones used in combination therapies and combination compositions) in separate dosage forms, but associated with one another.
- a therapeutic agent the same ones used in combination therapies and combination compositions
- associated with one another means that the separate dosage forms are packaged together or otherwise attached to one another such that it is readily apparent that the separate dosage forms are intended to be sold and administered as part of the same regimen.
- the compound and the other agent are preferably packaged together in a blister pack or other multi-chamber package, or as connected, separately sealed containers (such as foil pouches or the like) that can be separated by the user (e.g., by tearing on score lines between the two containers).
- the invention provides a kit comprising in separate vessels, a) a compound of this invention; and b) another therapeutic agent such as those described elsewhere in the specification.
- This general coupling procedure could be used to prepare a variety of 6-(3-trifluoromethylphenyl), 6-(3-trifluoromethoxyphenyl), 6-(3-morpholine), 6-(3-(methylsulfonyl)phenyl and 6-(2-flouro-6-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxyamides by substituting the appropriate amine moiety for pyridine-2-amine.
- This general coupling procedure followed by ester hydrolysis could be used to prepare a variety of 6-(2-substituted phenyl), 6-(3-substituted phenyl), 6-(2,5-disubstituted phenyl), 6-(2,4-disubstituted phenyl), 6-(3,4-disubstituted phenyl), 6-(3,5-disubstituted phenyl), 6-(2,3-disubstituted phenyl) imidazo[1,2-b]pyridazine-3-carboxylic acids by substituting the appropriate boronic acid or boronic ester for 2-(trifluoromethyl)phenylboronic acid.
- This general coupling procedure could be used to prepare a variety of 6-(2-trifluoromethyl)phenyl), 6-(2-trifluoromethoxyphenyl), 6-(3-trifluoromethylphenyl), 6-(3-chlorophenyl), 6-(3-fluorophenyl), 6-(2,5-difluorophenyl), 6-(2,4-difluorophenyl), 6-(3,4-difluorophenyl), 6-(3,5-difluorophenyl), 6-(2,3-difluorophenyl), 6-(2-chloro-3-fluorophenyl), 6-(2-(methylsulfonyl)phenyl and 6-(2-cyanophenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 6-(morpholinomethyl)pyridin-2-amine.
- N-(6-((2-phenyl-1,3-dioxan-5-yl)oxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide was obtained (40.0 mg, 22%) from HATU mediated coupling of 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (100.0 mg, 0.32 mmol) and 6-((2-phenyl-1,3-dioxan-5-yl)oxy)pyridin-2-amine following the same procedure as described for the preparation of Compound 19.
- MS (ESI) calcd for C 28 H 21 F 3 N 5 O 4 : 561.1.
- N-(6-((2-phenyl-1,3-dioxan-5-yl)oxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (40.0 mg, 0.07 mmol) was taken up in EtOH:3N HCl (3:1, 7 mL) and heated to 80° C. for 2 h.
- This general coupling procedure could be used to prepare 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine, 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine, 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-2-amine, 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-3-amine, 5-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine, 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine, 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-methylpyrimidin-2-amine and 2-((
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-amine 110.0 mg, 0.49 mmol was taken up in DMF (1 mL) along with 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.33 mmol), HATU (247.0 mg, 0.65 mmol) and DIEA (84.0 mg, 0.65 mmol). The resulting reaction mixture was stirred at 65° C. for 24 h.
- Ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (903.0 mg, 4 mmol) was taken up in 5 mL of dioxane/water (4:1) along with 2-formylphenylboronic acid (720.0 mg, 4.8 mmol), Pd(PPh 3 ) 4 (231.0 mg, 0.2 mmol) and Na 2 CO 3 (1.02 g, 9.6 mmol).
- the resulting reaction mixture was stirred at 120° C. for 20 min in a microwave reactor. Upon cooling to room temp, the mixture was diluted with methylene chloride (DCM) (20 mL) and filtered. The filtrate was dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- DCM methylene chloride
- 6-(2-Difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid (0.3 mmol) and thiazol-2-amine (0.36 mmol) were subjected to the same general amide coupling procedure described above to prepare 6-(2-difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid thiazol-2-ylamide (yield 61.3%).
- MS (ESI) calcd for C 17 H 11 F 2 N 5 OS: 371.07; found: 372 [M+H].
- This general coupling procedure could be used to prepare 6-(3,5-dimethylisoxazol-4-yl), 6-(1-methyl-1H-pyrazol-4-yl), 6-(2-methylpyridin-3-yl), 6-(5-(difluoromethyl)pyridin-3-yl), 6-(2,4-dimethylthiazole), 6-(2,3,4-trifluromethyl phenyl), 6-(2-fluorophenyl), 6-(2-chlorophenyl), 6-(2-fluoro-3-chlorophenyl) and 6-(2-chloro-6-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 2-(pyrrolidin-1-yl)pyridin-4-amine.
- 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid 80.0 mg, 0.22 mmol
- MS (ESI) calcd for C 28 H 30 N 6 O 5 : 530.2.
- This general procedure could be used to prepare a variety of 6-(2-(2,3-dihydroxypropoxy)phenyl)-N-(substituted), 6-(3-(2,3-dihydroxypropoxy)phenyl)-N-(substituted) and 6-(2-(2,3-dihydroxypropoxy)phenyl)-N-(substituted) imidazo[1,2-b]pyridazine-3-carboxamides.
- This general coupling procedure could be used to prepare a variety of 2-methyl-6-(3-trifluoromethylphenyl), 2-methyl-6-(3-trifluoromethoxyphenyl), 2-methyl-6-(2-trifluoromethoxyphenyl), 2-methyl-6-(2-difluoromethylphenyl), 2-methyl-6-(2-methylphenyl), 2-methyl-6-(3-methylphenyl), 2-methyl-6-(3-fluorophenyl), 2-methyl-6-(2-fluorophenyl), 2-methyl-6-(2-chlorophenyl), 2-methyl-6-(2-bromophenyl), and 2-methyl-6-(3-cyanophenyl) imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for pyridazine-3-amine.
- a pressure tube was charged with a solution of CDI (75.5 mg, 0.47 mmol) in dioxane (2 mL).
- a solution of 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.31 mmol) in dioxane:DMA (1:1, 2 mL) was added and the mixture was heated to 100° C. for 15 h.
- 6-methoxypyrimidin-4-amine 117.0 mg, 0.93 mmol was then added and the heating was continued for 3 d.
- H 2 O was added and suspension was extracted with CH 2 Cl 2 .
- This general procedure could be used to prepare a variety of 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl) and 6-(3-(2,3-dihydroxypropoxy)phenyl)-2-methyl-N-(substituted)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 4-aminopyrimidine.
- Step 2 Synthesis of ethyl 6-chloro-8-methylimidazo[1,2-b]pyridazine-3-carboxylate (and ethyl 6-chloro-7-methylimidazo[1,2-b]pyridazine-3-carboxylate)
- the mixture was refluxed for about 30 h after which it was cooled to room temp, concentrated and purified by column chromatography to separate the regioisomeric ethyl 6-chloro-8-methylimidazo[1,2-b]pyridazine-3-carboxylate and ethyl 6-chloro-7-methylimidazo[1,2-b]pyridazine-3-carboxylate which were carried forward as single regioisomers.
- Ethyl 6-chloro-7,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate 750.0 mg, 2.96 mmol
- 2-(trifluoromethyl)phenylboronic acid 562.0 mg, 2.96 mmol
- Dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine 97.0 mg, 0.236 mmol
- K 3 PO 4 (1.88 g, 8.87 mmol
- Step 1 Synthesis of ethyl 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (and ethyl 6-chloro-2,7-dimethylimidazo[1,2-b]pyridazine-3-carboxylate)
- Ethyl 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (7.4 g, 29 mmol), 2-(trifluoromethyl)phenylboronic acid (6.6 g, 35 mmol), cesium carbonate (19.0 g, 58 mmol), Pd(PPh 3 ) 4 (3.3 g, 3 mmol) were dissolved in a mixture of dioxane:water (4:1) plus 10 drops of EtOH. The mixture was heated to 75° C. for 5 h, then concentrated. Water (200 mL) was added and this was extracted with CH 2 Cl 2 (300 mL).
- Ethyl 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (8.0 g, 22 mmol) was dissolved in dioxane (100 mL). NaOH (1.76 g, 44 mmol) in water (100 mL) was added. The mixture was heated to 60° C. for 2 h, then concentrated. Water (100 mL) was added and the mixture was filtered. The pH was adjusted to 5 with aqueous HCl.
- This general coupling procedure could be used to prepare a variety of 2,8-dimethyl-6-(2-trifluromethyl)phenyl) and 2,8-dimethyl-6-(2-trifluromethoxy)phenyl) imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 3-aminopyridazine.
- 6-chloropyridazin-3-amine (10.0 g, 77.2 mmol) and 2-(trifluoromethyl)phenylboronic acid (29.3 g, 154.4 mmol) were added to a 250 mL flask.
- Cs 2 CO 3 (50.3 g, 154.4 mol), Pd 2 (dba) 3 (3.5 g, 3.82 mmol), and XPhos (1.8 g, 3.82 mmol) were added, followed by dioxane (100 mL) and water (20 mL).
- the reaction was heated to 100° C. for 3 h, followed by cooling to room temp.
- the mixture was concentrated in vacuo, and the residue was resuspended in DCM (500 mL).
- 6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (3.0 g, 12.55 mmol) and NaHCO 3 (2.1 g, 25.1 mmol) were suspended in MeOH (30 mL). Br 2 was added (3.0 g, 0.96 mL, 18.8 mmol) dropwise at room temp. The reaction was allowed to stir for 1 h at room temp, then poured into bicarb (300 mL) after which a precipitate formed. The solid was collected by filtration, washed with water, and dried in vacuo to give 4-bromo-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (3.8 g, 95%). MS (ESI) calcd for C 11 H 7 BrF 3 N 3 : 316.98.
- 4-bromo-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (100.0 mg, 0.314 mmol) was dissolved in DMSO (2.7 mL). Morpholine was added (0.27 mL, 3.14 mmol). The reaction was sealed and allowed to stir at room temp for 1 h, followed by heating to 110° C. for 18 h. The mixture was cooled to room temp and water was added (15 mL).
- Ethyl 2-methyl-8-morpholino-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (26.0 mg, 0.060 mmol) was suspended in THF (1.2 mL) water (2.4 mL) and MeOH (1 mL). Lithium hydroxide was added (7.0 mg, 0.300 mmol) and the mixture was heated to reflux for 3 h, followed by cooling to room temp. HCl was added (1.0 N, 0.35 mL), and the mixture was extracted with EtOAc (3 ⁇ 10 mL).
- This general coupling method could be used to prepare a variety of 2-hydroxy-N-(substituted)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for pyridine-2-amine.
- HATU 109 mg, 0.0.29 mmol
- 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine 50.0 mg, 0.18 mmol
- 5-methylpyrazine-2-carboxylic acid 37.0 mg, 0.27 mmol
- DIEA 78 ⁇ l, 0.44 mmol
- the mixture was stirred at 60° C. for 3 h.
- H 2 O 45 mL was added and the resulting ppt was collected by filtration, rinsed with H 2 O, and dried under vacuum.
- the crude residue was purified by MPLC eluting with CH 2 Cl 2 /MeOH (0-5%).
- This general coupling procedure could be used to prepare a variety of 6-(2-trifluromethyl)phenyl) imidazo[1,2-b]pyridazin-3-yl)pyrazine-2-carboxamides by substituting the appropriate carboxylic acid moiety for 5-methylpyrazine-2-carboxylic acid.
- HATU (203.0 mg, 0.53 mmol) was added to a solution of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (93.0 mg, 0.33 mmol), 6-hydroxypyrimidine-4-carboxylic acid (70.0 mg, 0.50 mmol), and pyridine (81 ⁇ l, 1.00 mmol) in CH 3 CN (15 mL). The reaction mixture was heated at reflux for 72 h. H 2 O was added and the resulting ppt was collected by filtration rinsed with H 2 O and dried under vacuum.
- HATU (200.0 mg, 0.0.53 mmol) was added to a solution of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (91.0 mg, 0.33 mmol), (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carboxylic acid (125.0 mg, 0.49 mmol), and N,N-diisopropylethylamine (DIPEA) (150 ⁇ l, 0.82 mmol) in dimethylacetamide (DMAC) (6 mL). The mixture was stirred at 80° C. for 16 h.
- DIPEA N,N-diisopropylethylamine
- 6-methoxypicolinic acid (40.0 mg, 0.26 mmol) was dissolved in dimethylformamide (1.0 mL).
- HATU 147.0 mg, 0.39 mmol
- diisopropylethylamine (0.18 mL, 1.03 mmol).
- 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (79.0 mg, 0.26 mmol) was dissolved in 2.1 mL dimethylformamide and added to the reaction mixture, which was then warmed to 50° C. for 4 h. The mixture was cooled to room temp and saturated aqueous NaHCO 3 (4 mL) and water (4 mL) were added.
- This general coupling procedure could be used to prepare a variety of N-(substituted)-5-(2-(trifluoromethyl)phenyl) and N-(substituted)-5-(2-(trifluoromethoxy)phenyl) pyrazolo[1,5-a]pyrimidine-3-carboxamides by starting with the appropriate carboxylic acid and substituting the appropriate amine for 2-aminopyridine.
- Chlorotrimethylsilane (32.0 mg, 0.29 mmol) was added to a solution of N-(6-methoxypyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (60.0 mg, 0.15 mmol) and potassium iodide (48.0 mg, 0.29 mmol) in CH 3 CN (10 mL) at room temp. The mixture was heated at 80° C. for 2 h. Sat.
- Diphenylphosphoryl azide (674.0 mg, 2.45 mmol) was added to a solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (500.0 mg, 1.63 mmol) and triethylamine (329.0 mg, 3.26 mmol) in toluene (10 mL). The mixture was stirred for 1 h at 25° C. then heated at reflux for 2 h. tert-Butyl alcohol (1.22 g, 16.30 mmol) was added and the mixture was heated at reflux for 3 h. After cooling to room temp, the reaction mixture was poured into H 2 O.
- This general coupling procedure could be used to prepare 2-methyl-N-(6-methylpyrazin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3,5-dimethylpyrazin-2-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-(5-fluoropyridin-3-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
- This general coupling procedure could be utilized to prepare 6-morpholino-N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)picolinamide, N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)nicotinamide and N-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)pyrimidine-4-carboxamide.
- N-(6-(azetidin-1-yl)pyridin-2-yl)-2-oxo-2-(2-(6-(2-(trifluoromethyl)phenyl)pyridazin-3-yl)hydrazinyl)acetamide 100.0 mg, 0.22 mmol was dissolved in xylene (15 mL), and the reaction was heated in a microwave at 150° C. for 6 h. Upon cooling to room temp, the reaction was poured into H 2 O, and extracted with DCM.
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carbaldehyde was prepared using the same method described above as for the preparation of 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinaldehyde.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Description
- This application is a divisional of U.S. application Ser. No. 14/353,096, filed Apr. 21, 2014, which is a 371 of International Application No. PCT/US2012/061015, filed Oct. 19, 2012, which claims the benefit of U.S. Provisional Application No. 61/549,730, filed Oct. 20, 2011, the disclosures of which are herein incorporated in their entireties.
- The Silent Information Regulator (SIR) family of genes represents a highly conserved group of genes present in the genomes of organisms ranging from archaebacteria to eukaryotes. The encoded SIR proteins are involved in diverse processes from regulation of gene silencing to DNA repair. A well-characterized gene in this family is S. cerevisiae SIR2, which is involved in silencing HM loci that contain information specifying yeast mating type, telomere position effects and cell aging. The yeast Sir2 protein belongs to a family of histone deacetylases. The proteins encoded by members of the SIR gene family show high sequence conservation in a 250 amino acid core domain. The Sir2 homolog, CobB, in Salmonella typhimurium, functions as an NAD (nicotinamide adenine dinucleotide)-dependent ADP-ribosyl transferase.
- The Sir2 protein is a class III deacetylase which uses NAD as a cosubstrate. Unlike other deacetylases, many of which are involved in gene silencing, Sir2 is insensitive to class I and II histone deacetylase inhibitors like trichostatin A (TSA).
- Deacetylation of acetyl-lysine by Sir2 is tightly coupled to NAD hydrolysis, producing nicotinamide and a novel acetyl-ADP ribose compound. The NAD-dependent deacetylase activity of Sir2 is essential for its functions, which can connect its biological role with cellular metabolism in yeast. Mammalian Sir2 homologs have NAD-dependent histone deacetylase activity.
- Biochemical studies have shown that Sir2 can readily deacetylate the amino-terminal tails of histones H3 and H4, resulting in the formation of 2′/3′-O-acetyl-ADP-ribose (OAADPR) and nicotinamide. Strains with additional copies of SIR2 display increased rDNA silencing and a 30% longer life span. It has alsobeen shown that additional copies of the C. elegans SIR2 homolog, sir-2.1, and the D. melanogaster dSir2 gene extend life span in those organisms. This implies that the SIR2-dependent regulatory pathway for aging arose early in evolution and has been well conserved. Today, Sir2 genes are believed to have evolved to enhance an organism's health and stress resistance to increase its chance of surviving adversity.
- In humans, there are seven Sir2-like genes (SIRT1-SIRT7) that share the conserved catalytic domain of Sir2. SIRT1 is a nuclear protein with the highest degree of sequence similarity to Sir2. SIRT1 regulates multiple cellular targets by deacetylation including the tumor suppressor p53, the cellular signaling factor NF-κB, and the FOXO transcription factor.
- SIRT3 is a homolog of SIRT1 that is conserved in prokaryotes and eukaryotes. The SIRT3 protein is targeted to the mitochondrial cristae by a unique domain located at the N-terminus. SIRT3 has NAD+-dependent protein deacetylase activity and is ubiquitously expressed, particularly in metabolically active tissues. Upon transfer to the mitochondria, SIRT3 is believed to be cleaved into a smaller, active form by a mitochondrial matrix processing peptidase (MPP).
- Caloric restriction has been known for over 70 years to improve the health and extend the lifespan of mammals. Yeast life span, like that of metazoans, is also extended by interventions that resemble caloric restriction, such as low glucose. The discovery that both yeast and flies lacking the SIR2 gene do not live longer when calorically restricted provides evidence that SIR2 genes mediate the beneficial health effects of a restricted calorie diet. Moreover, mutations that reduce the activity of the yeast glucose-responsive cAMP (adenosine 3′,5′-monophosphate)-dependent (PKA) pathway extend life span in wild type cells but not in mutant sir2 strains, demonstrating that SIR2 is likely to be a key downstream component of the caloric restriction pathway.
- Provided herein are novel sirtuin-modulating compounds and methods of use thereof.
- In one aspect, the invention provides sirtuin-modulating compounds of Structural Formulas (I) and (II) as are described in detail below.
- In another aspect, the invention provides methods for using sirtuin-modulating compounds, or compositions comprising sirtuin-modulating compounds. In certain embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for a variety of therapeutic applications including, for example, increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic-induced neuropathy, neuropathy associated with an ischemic event, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, and/or flushing, etc. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used for treating a disease or disorder in a subject that would benefit from increased mitochondrial activity, for enhancing muscle performance, for increasing muscle ATP levels, or for treating or preventing muscle tissue damage associated with hypoxia or ischemia. In other embodiments, sirtuin-modulating compounds that decrease the level and/or activity of a sirtuin protein may be used for a variety of therapeutic applications including, for example, increasing cellular sensitivity to stress, increasing apoptosis, treatment of cancer, stimulation of appetite, and/or stimulation of weight gain, etc. As described further below, the methods comprise administering to a subject in need thereof a pharmaceutically effective amount of a sirtuin-modulating compound.
- In certain aspects, the sirtuin-modulating compounds may be administered alone or in combination with other compounds, including other sirtuin-modulating compounds, or other therapeutic agents.
- As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art.
- The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule (such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues.
- The term “bioavailable”, when referring to a compound, is art-recognized and refers to a form of a compound that allows for all or a portion of the amount of compound administered to be absorbed by, incorporated into, or otherwise physiologically available to a subject or patient to whom it is administered.
- “Biologically active portion of a sirtuin” refers to a portion of a sirtuin protein having a biological activity, such as the ability to deacetylate (“catalytically active”). Catalytically active portions of a sirtuin may comprise the core domain of sirtuins. Catalytically active portions of SIRT1 having GenBank Accession No. NP_036370 that encompass the NAD+ binding domain and the substrate binding domain, for example, may include without limitation, amino acids 240-664 or 240-505 of GenBank Accession No. NP_036370, which are encoded by the polynucleotide of GenBank Accession No. NM_012238. Therefore, this region is sometimes referred to as the core domain. Other catalytically active portions of SIRT1, also sometimes referred to as core domains, include about amino acids 261 to 447 of GenBank Accession No. NP_036370, which are encoded by nucleotides 834 to 1394 of GenBank Accession No. NM_012238; about amino acids 242 to 493 of GenBank Accession No. NP_036370, which are encoded by nucleotides 777 to 1532 of GenBank Accession No. NM_012238; or about amino acids 254 to 495 of GenBank Accession No. NP_036370, which are encoded by nucleotides 813 to 1538 of GenBank Accession No. NM_012238. Another “biologically active” portion of SIRT1 is amino acids 62-293 or 183-225 of GenBank Accession No. NP_036370, which comprise a domain N-terminal to the core domain that is important to the compound binding site.
- The term “companion animals” refers to cats and dogs. As used herein, the term “dog(s)” denotes any member of the species Canis familiaris, of which there are a large number of different breeds. The term “cat(s)” refers to a feline animal including domestic cats and other members of the family Felidae, genus Felis.
- “Diabetes” refers to high blood sugar or ketoacidosis, as well as chronic, general metabolic abnormalities arising from a prolonged high blood sugar status or a decrease in glucose tolerance. “Diabetes” encompasses both the type I and type II (Non Insulin Dependent Diabetes Mellitus or NIDDM) forms of the disease. The risk factors for diabetes include the following factors: waistline of more than 40 inches for men or 35 inches for women, blood pressure of 130/85 mmHg or higher, triglycerides above 150 mg/dl, fasting blood glucose greater than 100 mg/dl or high-density lipoprotein of less than 40 mg/dl in men or 50 mg/dl in women.
- The term “ED50” refers to the art-recognized measure of effective dose. In certain embodiments, ED50 means the dose of a drug which produces 50% of its maximum response or effect, or alternatively, the dose which produces a pre-determined response in 50% of test subjects or preparations, such as isolated tissue or cells. The term “LD50” refers to the art-recognized measure of lethal dose. In certain embodiments, LD50 means the dose of a drug which is lethal in 50% of test subjects. The term “therapeutic index” is an art-recognized term which refers to the therapeutic index of a drug, defined as LD50/ED50.
- The term “hyperinsulinemia” refers to a state in an individual in which the level of insulin in the blood is higher than normal.
- The term “insulin resistance” refers to a state in which a normal amount of insulin produces a subnormal biologic response relative to the biological response in a subject that does not have insulin resistance.
- An “insulin resistance disorder,” as discussed herein, refers to any disease or condition that is caused by or contributed to by insulin resistance. Examples include: diabetes, obesity, metabolic syndrome, insulin-resistance syndromes, syndrome X, insulin resistance, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, hyperlipidemia, atherosclerotic disease including stroke, coronary artery disease or myocardial infarction, hyperglycemia, hyperinsulinemia and/or hyperproinsulinemia, impaired glucose tolerance, delayed insulin release, diabetic complications, including coronary heart disease, angina pectoris, congestive heart failure, stroke, cognitive functions in dementia, retinopathy, peripheral neuropathy, nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation, polycystic ovarian syndrome (PCOS)), lipodystrophy, cholesterol-related disorders, such as gallstones, cholecystitis and cholelithiasis, gout, obstructive sleep apnea and respiratory problems, osteoarthritis, and bone loss, e.g., osteoporosis in particular.
- The term “livestock animals” refers to domesticated quadrupeds, which includes those being raised for meat and various byproducts, e.g., a bovine animal including cattle and other members of the genus Bos, a porcine animal including domestic swine and other members of the genus Sus, an ovine animal including sheep and other members of the genus Ovis, domestic goats and other members of the genus Capra; domesticated quadrupeds being raised for specialized tasks such as use as a beast of burden, e.g., an equine animal including domestic horses and other members of the family Equidae, genus Equus.
- The term “mammal” is known in the art, and exemplary mammals include humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).
- “Obese” individuals or individuals suffering from obesity are generally individuals having a body mass index (BMI) of at least 25 or greater. Obesity may or may not be associated with insulin resistance.
- The terms “parenteral administration” and “administered parenterally” are art-recognized and refer to modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal, and intrastemal injection and infusion.
- A “patient”, “subject”, “individual” or “host” refers to either a human or a non-human animal.
- The term “pharmaceutically acceptable carrier” is art-recognized and refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof. Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
- The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount. Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population. Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.
- The term “prophylactic” or “therapeutic” treatment is art-recognized and refers to administration of a drug to a host. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects therefrom).
- The term “pyrogen-free”, with reference to a composition, refers to a composition that does not contain a pyrogen in an amount that would lead to an adverse effect (e.g., irritation, fever, inflammation, diarrhea, respiratory distress, endotoxic shock, etc.) in a subject to which the composition has been administered. For example, the term is meant to encompass compositions that are free of, or substantially free of, an endotoxin such as, for example, a lipopolysaccharide (LPS).
- “Replicative lifespan” of a cell refers to the number of daughter cells produced by an individual “mother cell.” “Chronological aging” or “chronological lifespan,” on the other hand, refers to the length of time a population of non-dividing cells remains viable when deprived of nutrients. “Increasing the lifespan of a cell” or “extending the lifespan of a cell,” as applied to cells or organisms, refers to increasing the number of daughter cells produced by one cell; increasing the ability of cells or organisms to cope with stresses and combat damage, e.g., to DNA, proteins; and/or increasing the ability of cells or organisms to survive and exist in a living state for longer under a particular condition, e.g., stress (for example, heatshock, osmotic stress, high energy radiation, chemically-induced stress, DNA damage, inadequate salt level, inadequate nitrogen level, or inadequate nutrient level). Lifespan can be increased by at least about 10%, 20%, 30%, 40%, 50%, 60% or between 20% and 70%, 30% and 60%, 40% and 60% or more using methods described herein.
- “Sirtuin-modulating compound” refers to a compound that increases the level of a sirtuin protein and/or increases at least one activity of a sirtuin protein. In an exemplary embodiment, a sirtuin-modulating compound may increase at least one biological activity of a sirtuin protein by at least about 10%, 25%, 50%, 75%, 100%, or more. Exemplary biological activities of sirtuin proteins include deacetylation, e.g., of histones and p53; extending lifespan; increasing genomic stability; silencing transcription; and controlling the segregation of oxidized proteins between mother and daughter cells.
- “Sirtuin protein” refers to a member of the sirtuin deacetylase protein family, or preferably to the sir2 family, which include yeast Sir2 (GenBank Accession No. P53685), C. elegans Sir-2.1 (GenBank Accession No. NP_501912), and human SIRT1 (GenBank Accession No. NM_012238 and NP_036370 (or AF083106)) and SIRT2 (GenBank Accession No. NM_012237, NM_030593, NP_036369, NP_085096, and AF083107) proteins. Other family members include the four additional yeast Sir2-like genes termed “HST genes” (homologues of Sir two) HST1, HST2, HST3 and HST4, and the five other human homologues hSIRT3, hSIRT4, hSIRT5, hSIRT6 and hSIRT7 (Brachmann et al. (1995) Genes Dev. 9:2888 and Frye et al. (1999) BBRC 260:273). Preferred sirtuins are those that share more similarities with SIRT1, i.e., hSIRT1, and/or Sir2 than with SIRT2, such as those members having at least part of the N-terminal sequence present in SIRT1 and absent in SIRT2 such as SIRT3 has.
- “SIRT1 protein” refers to a member of the sir2 family of sirtuin deacetylases. In certain embodiments, a SIRT1 protein includes yeast Sir2 (GenBank Accession No. P53685), C. elegans Sir-2.1 (GenBank Accession No. NP_501912), human SIRT1 (GenBank Accession No. NM_012238 or NP_036370 (or AF083106)), and equivalents and fragments thereof. In another embodiment, a SIRT1 protein includes a polypeptide comprising a sequence consisting of, or consisting essentially of, the amino acid sequence set forth in GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685. SIRT1 proteins include polypeptides comprising all or a portion of the amino acid sequence set forth in GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685; the amino acid sequence set forth in GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685 with 1 to about 2, 3, 5, 7, 10, 15, 20, 30, 50, 75 or more conservative amino acid substitutions; an amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685, and functional fragments thereof. Polypeptides of the invention also include homologs (e.g., orthologs and paralogs), variants, or fragments, of GenBank Accession Nos. NP_036370, NP_501912, NP_085096, NP_036369, or P53685.
- As used herein “SIRT2 protein”, “SIRT3 protein”, “SIRT4 protein”, SIRT5 protein”, “SIRT6 protein”, and “SIRT7 protein” refer to other mammalian, e.g. human, sirtuin deacetylase proteins that are homologous to SIRT1 protein, particularly in the approximately 275 amino acid conserved catalytic domain. For example, “SIRT3 protein” refers to a member of the sirtuin deacetylase protein family that is homologous to SIRT1 protein. In certain embodiments, a SIRT3 protein includes human SIRT3 (GenBank Accession No. AAH01042, NP_036371, or NP_001017524) and mouse SIRT3 (GenBank Accession No. NP_071878) proteins, and equivalents and fragments thereof. In another embodiment, a SIRT3 protein includes a polypeptide comprising a sequence consisting of, or consisting essentially of, the amino acid sequence set forth in GenBank Accession Nos. AAH01042, NP_036371, NP_001017524, or NP_071878. SIRT3 proteins include polypeptides comprising all or a portion of the amino acid sequence set forth in GenBank Accession AAH01042, NP_036371, NP_001017524, or NP_071878; the amino acid sequence set forth in GenBank Accession Nos. AAH01042, NP_036371, NP_001017524, or NP_071878 with 1 to about 2, 3, 5, 7, 10, 15, 20, 30, 50, 75 or more conservative amino acid substitutions; an amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to GenBank Accession Nos. AAH01042, NP_036371, NP_001017524, or NP_071878, and functional fragments thereof. Polypeptides of the invention also include homologs (e.g., orthologs and paralogs), variants, or fragments, of GenBank Accession Nos. AAH01042, NP_036371, NP_001017524, orNP 071878. In certain embodiments, a SIRT3 protein includes a fragment of SIRT3 protein that is produced by cleavage with a mitochondrial matrix processing peptidase (MPP) and/or a mitochondrial intermediate peptidase (MIP).
- The term “steroisomer” as used herein is art-recognized and refers to any of two or more isomers that have the same molecular constitution and differ only in the three-dimensional arrangement of their atomic groupings in space. When used herein to describe a compounds or genus of compounds, stereoisomer includes any portion of the compound or the compound in its entirety. For example, diastereomers and enantiomers are stereoisomers.
- The terms “systemic administration” and “administered systemically,” are art-recognized and refer to the administration of a subject composition, therapeutic or other material enterally or parenterally.
- The term “tautomer” as used herein is art-recognized and refers to any one of the possible alternative structures that may exist as a result of tautomerism, which refers to a form of constitutional isomerism in which a structure may exist in two or more constitutional arrangements, particularly with respect to the position of hydrogens bonded to oxygen. When used herein to describe a compound or genus of compounds, it is further understood that a “tautomer” is readily interconvertible and exists in equilibrium. For example, keto and enol tautomers exist in proportions determined by the equilibrium position for any given condition, or set of conditions:
- The term “therapeutic agent” is art-recognized and refers to any biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject. The term also means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and/or conditions in an animal or human.
- The term “therapeutic effect” is art-recognized and refers to a beneficial local or systemic effect in animals, particularly mammals, and more particularly humans, caused by a pharmacologically active substance. The phrase “therapeutically-effective amount” means that amount of such a substance that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment. The therapeutically effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of skill in the art. For example, certain compositions described herein may be administered in a sufficient amount to produce a desired effect at a reasonable benefit/risk ratio applicable to such treatment.
- “Treating” a condition or disease refers to curing as well as ameliorating at least one symptom of the condition or disease.
- The term “vision impairment” refers to diminished vision, which is often only partially reversible or irreversible upon treatment (e.g., surgery). Particularly severe vision impairment is termed “blindness” or “vision loss”, which refers to a complete loss of vision, vision worse than 20/200 that cannot be improved with corrective lenses, or a visual field of less than 20 degrees diameter (10 degrees radius).
- In one aspect, the invention provides novel compounds for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, ocular diseases and disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc. Subject compounds, such as sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein, may also be used for treating a disease or disorder in a subject that would benefit from increased mitochondrial activity, for enhancing muscle performance, for increasing muscle ATP levels, or for treating or preventing muscle tissue damage associated with hypoxia or ischemia. Compounds disclosed herein may be suitable for use in pharmaceutical compositions and/or one or more methods disclosed herein.
- In certain embodiments, compounds of the invention are represented by Structural Formula (I):
- wherein one of D and E is N and the other is C; and
- when D is N, one of A and B is N and the other is CR; and
- when E is N, B is N and A is N or CR;
- or a salt thereof, wherein:
- each R is independently selected from hydrogen, halo, OH, C≡N, C1-C4 alkyl, halo-substituted C2-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, OR3, O—(C1-C4 alkyl)-OR3, S—(C1-C2 alkyl), S-(halo-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), C5-C7 cycloalkyl, and 4- to 8-membered non-aromatic heterocycle, and when one or both of E and A is N, then R can additionally be selected from halo-substituted methyl and C3-C4 cycloalkyl;
- R1 is an aromatic heterocycle or a fused carbocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3—(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O—(C0-C4 alkyl)-CRxRx—(C0-C4 alkyl), CRxRx, phenyl, O-phenyl, second heterocycle, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
- R2 is a carbocycle or a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3—(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O-phenyl, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, and when E is N, substituents on R2 can be additionally selected from a second heterocycle, and when both D and A are N, substituents on R2 can additionally be selected from phenyl and a second heterocycle, wherein any phenyl, saturated heterocycle or second heterocycle substituent of R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
- each R3 is independently selected from hydrogen and C1-C4 alkyl optionally substituted with one or more of OH, —O—(C1-C4 alkyl), halo, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(methoxy-substituted C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(methoxy-substituted C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2 and N(methoxy-substituted C1-C4 alkyl)2; or
- two R3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom selected independently from N, S, S(═O), S(═O)2, and O, wherein the heterocycle formed by two R3 is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, O(C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), NH(methoxy-substituted C1-C4 alkyl), or N(methoxy-substituted C1-C4 alkyl)2, and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl;
- two Rx taken together with the carbon atom to which they are bound form a 4- to 8-membered carbocycle or heterocycle optionally comprising one or two heteroatoms independently selected from N, S, S(═O), S(═O)2, and O, wherein the carbocycle or heterocycle is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, and N(R3)(R3) and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl; and
- when D is N, A is CR, and B is N, then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, and NH—C(═O)—O—CR4R5-†; and when E is N, B is N, and A is N or CR, then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(═O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CH2—NH—C(═O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH-†, CR4R5—NH—C(═O)—O—† and NH—C(═O)—O—CR4R5—; and
- when D is N, A is N, and B is CR, then X is selected from C(═O)—NH-†, NH—C(═O)-†, NH—CR4R5-†, C(═O)—NH—CR4R5-†, S(═O)—NH-†, S(═O)2—NH-†, CR4R5—NH-†, NH—C(═O)—O—CR4R5-†, NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CR4R5—NH—C(O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH† and CR4R5—NH—C(═O)—O-†;
- wherein:
- † represents where X is bound to R1; and
- each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, CF3 and (C1-C3 alkyl)-CF3.
- In certain embodiments both E and B are N. In particular embodiments, E, B and A are N. In such embodiments, the compound of Structural Formula (I) is represented by Structural Formula (Ia):
- In other embodiments, E and B are N and A is CR. In such embodiments, the compound of Structural Formula (I) is represented by Structural Formula (Ib):
- In certain embodiments both D and B are N and A is CR. In such embodiments, the compound of Structural Formula (I) is represented by Structural Formula (Ic):
- In certain embodiments both D and A are N and B is CR. In such embodiments, the compound of Structural Formula (I) is represented by Structural Formula (Id):
- For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R at each occurrence may be selected from hydrogen, halo, C1-C4 alkyl, O—R3 and 4- to 8-membered non-aromatic heterocycle, such as selected from hydrogen, C1-C4 alkyl, and 4- to 8-membered non-aromatic heterocycle. For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R1 may be selected from optionally substituted aromatic heterocycle, such as pyridinyl, thiazolyl, oxazolyl, pyrimidinyl, pyrazole, triazole, imidazole, pyrazine and pyridazine. For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R1 may be selected from optionally substituted
- For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R1 may be selected from
- In more particular embodiments, R1 is selected from:
- For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R2 may be selected from optionally substituted carbocycle and optionally substituted non-aromatic heterocycle. In particular, R2 may be selected from optionally substituted aromatic carbocycle and optionally substituted non-aromatic heterocycle. For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R2 may be selected from optionally substituted non-aromatic carbocycle and optionally substituted non-aromatic heterocycle. For example, R2 may be selected from an optionally substituted non-aromatic heterocycle and R2 may be attached to the remainder of the compound by a nitrogen atom of R2.
- For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R2 may be selected from optionally substituted aromatic carbocycle, such as phenyl. For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R2 may be selected from optionally substituted non-aromatic heterocycle, e.g., nitrogen-containing heterocycles, such as pyrrolidine, piperidine and azetidine.
- For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), R2 may be selected from optionally substituted
- In particular, R2 may be selected from:
- In more particular embodiments, R2 is selected from
- For any of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), X may be selected from amide such as C(═O)—NH—† or NH—C(═O)†. In particular embodiments, X is C(═O)—NH—†. In particular embodiments, X is —NH—C(═O)-†.
- In any of the preceding embodiments, R at each occurrence may be selected from hydrogen, halo, OH, C≡N, C1-C4 alkyl, halo-substituted C2-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, OR3, O—(C1-C4 alkyl)-OR3, S—(C1-C2 alkyl), S-(halo-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), C5-C7 cycloalkyl, and 4- to 8-membered non-aromatic heterocycle, and when one or both of E and A is N, then R can additionally be selected from halo-substituted methyl and C3-C4 cycloalkyl.
- In certain embodiments, the compound is any one of Compound Numbers 14, 94, 97, 98, 99, 100, 105, 119, 143, 159, 164, 165, 224, 225, 226, 230, 233, 301, 308, 318, 342, 344, 355, 370, 379, 424, 474, 479, 537, 577, 581, 586, 601, 638, 661, 665, 668, 684, 703, 761, 801, 806, 811, 812, 870, 880, 890, 918, 924, 925 928, 945, 953, 957, 958, 959, 966, 968, 969, 970, 974, 978, 979, 986, 990, 994, 998, 999, 1000, 1001, 1005, 1007, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1020, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1046, 1047, 1048, 1049, 1050, 1060, 1062, 1063, 1064, 1066, 1069, 1071, 1072, 1073, 1074, 1077, 1080, 1081, 1082, 1083, 1085, 1086, 1087, 1092, 1096 and 1098 in Table 1.
- The invention includes pharmaceutical compositions of any of the compounds of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), or as otherwise set forth above. The pharmaceutical composition of the compound of Structural Formulas (I), (Ia), (Ib), (Ic), or (Id), may comprise one or more pharmaceutically acceptable carriers or diluents.
- In certain embodiments, compounds of the invention are represented by Structural Formula (II):
- or a salt thereof, wherein:
- each R′ is independently selected from hydrogen, halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O—R3, O—(C1-C4 alkyl)-OR3, S—(C1-C4 alkyl), S-(halo-substituted C1-C4 alkyl), C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), C3-C7 cycloalkyl and 4- to 8-membered non-aromatic heterocycle;
- each R″ is independently selected from hydrogen, halo, C≡N, chloro- or bromo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl)-OR3, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, S—(C1-C4 alkyl), S-(halo-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), C3-C7 cycloalkyl and 4- to 8-membered non-aromatic heterocycle;
- R1 is an aromatic heterocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, —O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O(C0-C4 alkyl)-CRxRx—(C0-C4 alkyl), CRxRx, phenyl, O-phenyl, second heterocycle, 0-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R1 is optionally substituted with halo, C≡N, C1-C4 alkyl, halo-substituted C1-C2 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), S-(halo-substituted C1-C4 alkyl), and N(R3)(R3);
- R2 is a carbocycle or a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8, O—R3, O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3—(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(O)—N(R3)(R3), (C1-C4 alkyl)-C(O)—N(R3)(R3), O-phenyl, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle or second heterocycle substituent of R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), S-(halo-substituted C1-C4 alkyl), and N(R3)(R3);
- each R3 is independently selected from hydrogen and C1-C4 alkyl optionally substituted with one or more of OH, O—(C1-C4 alkyl), halo, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(methoxy-substituted C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(methoxy-substituted C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2 and N(methoxy-substituted C1-C4 alkyl)2; or
- two R3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom independently selected from N, S, S(═O), S(═O)2, and O, wherein the heterocycle formed by two R3 is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(methoxy-substituted C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(methoxy-substituted C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2 and N(methoxy-substituted C1-C4 alkyl)2, and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl;
- two Rx taken together with the carbon atom to which they are bound form a 4- to 8-membered carbocycle or heterocycle optionally comprising one or two heteroatoms independently selected from N, S, S(═O), S(═O)2, and O, wherein the carbocycle or heterocycle is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, N(R3)(R3), and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl; and
- X is selected from NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(═O)2—NH-†, NH—C(═O)O-†, O—C(═O)—NH-†, NH—C(═O)NH-†, NH—C(═O)NR4-†, NR4—C(═O)NH-†, CR4R5—NH—C(═O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH† and CR4R5—NH—C(═O)—O-†, wherein:
- † represents where X is bound to R1; and
- each R4 and R5 is independently hydrogen, C1-C4 alkyl, CF3 or (C1-C3 alkyl)-CF3.
- In any of the preceding embodiments, a C1-C4 alkoxy-substituted group may include one or more alkoxy substituents such as one, two or three methoxy groups or a methoxy group and an ethoxy group, for example. Exemplary C1-C4 alkoxy substituents include methoxy, ethoxy, isopropoxy, and tert-butoxy.
- In any of the preceding embodiments, a hydroxy-substituted group may include one or more hydroxy substituents, such as two or three hydroxy groups.
- In any of the preceding embodiments, a “halo-substituted” group includes from one halo substituent up to perhalo substitution. Exemplary halo-substituted C1-C4 alkyl includes CFH2, CClH2, CBrH2, CF2H, CCl2H, CBr2H, CF3, CCl3, CBr3, CH2CH2F, CH2CH2Cl, CH2CH2Br, CH2CHF2, CHFCH3, CHClCH3, CHBrCH3, CF2CHF2, CF2CHCl2, CF2CHBr2, CH(CF3)2, and C(CF3)3. Perhalo-substituted C1-C4 alkyl, for example, includes CF3, CCl3, CBr3, CF2CF3, CCl2CF3 and CBr2CF3.
- In any of the preceding embodiments, a “carbocycle” group may refer to a monocyclic carbocycle embodiment and/or a polycyclic carbocycle embodiment, such as a fused, bridged or bicyclic carbocycle embodiment. “Carbocycle” groups of the invention may further refer to an aromatic carbocycle embodiment and/or a non-aromatic carbocycle embodiment, or, in the case of polycyclic embodiments, a carbocycle having both one or more aromatic rings and/or one or more non-aromatic rings. Polycyclic carbocycle embodiments may be a bicyclic ring, a fused ring or a bridged bicycle. Non-limiting exemplary carbocycles include phenyl, cyclohexane, cyclopentane, or cyclohexene, amantadine, cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-ttrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene, adamantane, decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, norbomane, decalin, spiropentane, memantine, biperiden, rimantadine, camphor, cholesterol, 4-phenylcyclcohexanol, bicyclo[4.2.0]octane, memantine and 4,5,6,7-tetrahydro-1H-indene and bicyclo[4.1.0]hept-3-ene.
- In any of the preceding embodiments, a “heterocycle” group may refer to a monocyclic heterocycle embodiment and/or a polycyclic heterocyclic embodiment, such as a fused, bridged or bicyclic heterocycle embodiment. “Heterocycle” groups of the invention may further refer to an aromatic heterocycle embodiment and/or a non-aromatic heterocycle embodiment, or, in the case of polycyclic embodiments, a heterocycle having both one or more aromatic rings and/or one or more non-aromatic rings. Polycyclic heterocycle embodiments may be a bicyclic ring, a fused ring or a bridged bicycle. Non-limiting exemplary heterocycles include pyridyl, pyrrolidine, piperidine, piperazine, pyrrolidine, morpholine, pyrimidine, benzofuran, indole, quinoline, lactones, lactams, benzodiazepine, indole, quinoline, purine, adenine, guanine, 4,5,6,7-tetrahydrobenzo[d]thiazole, hexamine and methenamine.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Compounds of the invention, including novel compounds of the invention, can also be used in the methods described herein.
- The compounds and salts thereof described herein can also be present as the corresponding hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate) or solvates. Suitable solvents for preparation of solvates and hydrates can generally be selected by a skilled artisan.
- The compounds and salts thereof can be present in amorphous or crystalline (including co-crystalline and polymorph) forms.
- Sirtuin-modulating compounds of the invention advantageously modulate the level and/or activity of a sirtuin protein, particularly the deacetylase activity of the sirtuin protein.
- Separately or in addition to the above properties, certain sirtuin-modulating compounds of the invention do not substantially have one or more of the following activities: inhibition of PI3-kinase, inhibition of aldoreductase, inhibition of tyrosine kinase, transactivation of EGFR tyrosine kinase, coronary dilation, or spasmolytic activity, at concentrations of the compound that are effective for modulating the deacetylation activity of a sirtuin protein (e.g., such as a SIRT1 and/or a SIRT3 protein).
- An “alkyl” group or “alkane” is a straight chained or branched non-aromatic hydrocarbon which is completely saturated. Typically, a straight chained or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10 unless otherwise defined. Examples of straight chained and branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. A C1-C4 straight chained or branched alkyl group is also referred to as a “lower alkyl” group.
- The terms “alkenyl” (“alkene”) and “alkynyl” (“alkyne”) refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyl groups described above, but that contain at least one double or triple bond respectively.
- The term “aromatic carbocycle” refers to an aromatic hydrocarbon ring system containing at least one aromatic ring. The ring may be fused or otherwise attached to other aromatic carbocyclic rings or non-aromatic carbocyclic rings. Examples of aromatic carbocyclegroups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl.
- “Azabicyclo” refers to a bicyclic molecule that contains a nitrogen atom in the ring skeleton. The two rings of the bicycle may be fused at two mutually bonded atoms, e.g., indole, across a sequence of atoms, e.g., azabicyclo[2.2.1]heptane, or joined at a single atom, e.g., spirocycle.
- “Bicycle” or “bicyclic” refers to a two-ring system in which one, two or three or more atoms are shared between the two rings. Bicycle includes fused bicycles in which two adjacent atoms are shared by each of the two rings, e.g., decalin, indole. Bicycle also includes spiro bicycles in which two rings share a single atom, e.g., spiro[2.2]pentane, 1-oxa-6-azaspiro[3.4]octane. Bicycle further includes bridged bicycles in which at least three atoms are shared between two rings, e.g., norbornane.
- “Bridged bicycle” compounds are bicyclic ring systems in which at least three atoms are shared by both rings of the system, i.e., they include at least one bridge of one or more atoms connecting two bridgehead atoms. Bridged azabicyclo refers to a bridged bicyclic molecule that contains a nitrogen atom in at least one of the rings.
- The terms “carbocycle”, and “carbocyclic”, as used herein, refers to a saturated or unsaturated ring in which each atom of the ring is carbon. The term carbocycle includes both aromatic carbocycles and non-aromatic carbocycles. Non-aromatic carbocycles include both cycloalkane rings, in which all carbon atoms are saturated, and cycloalkene rings, which contain at least one double bond. “Carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from non-aromatic and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from non-aromaticaromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a non-aromatic or aromatic ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of non-aromtatic and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.
- A “cycloalkyl” group is a cyclic hydrocarbon which is completely saturated (non-aromatic). Typically, a cycloalkyl group has from 3 to about 10 carbon atoms, more typically 3 to 8 carbon atoms unless otherwise defined. A “cycloalkenyl” group is a cyclic hydrocarbon containing one or more double bonds.
- A “halogen” designates F, Cl, Br or I.
- A “halogen-substitution” or “halo” substitution designates replacement of one or more hydrogens with F, Cl, Br or I.
- The term “heteroaryl” or “aromatic heterocycle” includes substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The term “heteroaryl” also includes ring systems having one or two rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aromatic carbocycle, heteroaryl, and/or heterocyclyl. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine.
- The terms “heterocycle”, and “heterocyclic”, as used herein, refers to a non-aromatic or aromatic ring comprising one or more heteroatoms selected from, for example, N, O, B and S atoms, preferably N, O, or S. The term “heterocycle” includes both “aromatic heterocycles” and “non-aromatic heterocycles.” Heterocycles include 4-7 membered monocyclic and 8-12 membered bicyclic rings. Heterocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. Each ring of a bicyclic heterocycle may be selected from non-aromatic and aromatic rings. The term “fused heterocycle” refers to a bicyclic heterocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused heterocycle may be selected from non-aromatic and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., pyridyl, may be fused to a non-aromatic or aromatic ring, e.g., cyclohexane, cyclopentane, pyrrolidine, 2,3-dihydrofuran or cyclohexene. “Heterocycle” groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, pyrimidine, benzofuran, indole, quinoline, lactones, and lactams. Exemplary “fused heterocycles” include benzodiazepine, indole, quinoline, purine, and 4,5,6,7-tetrahydrobenzo[d]thiazole. “Heterocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.
- “Monocyclic rings” include 5-7 membered aromatic carbocycle or heteroaryl, 3-7 membered cycloalkyl or cycloalkenyl, and 5-7 membered non-aromatic heterocyclyl. Exemplary monocyclic groups include substituted or unsubstituted heterocycles or carbocycles such as thiazolyl, oxazolyl, oxazinyl, thiazinyl, dithianyl, dioxanyl, isoxazolyl, isothiazolyl, triazolyl, furanyl, tetrahydrofuranyl, dihydrofuranyl, pyranyl, tetrazolyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, pyridinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrimidinyl, morpholinyl, tetrahydrothiophenyl, thiophenyl, cyclohexyl, cyclopentyl, cyclopropyl, cyclobutyl, cycloheptanyl, azetidinyl, oxetanyl, thiiranyl, oxiranyl, aziridinyl, and thiomorpholinyl.
- As used herein, “substituted” means substituting a hydrogen atom in a structure with an atom or molecule other than hydrogen. A substitutable atom such as a “substitutable nitrogen” is an atom that bears a hydrogen atom in at least one resonance form. The hydrogen atom may be substituted for another atom or group such as a CH3 or an OH group. For example, the nitrogen in a piperidine molecule is substitutable if the nitrogen is bound to a hydrogen atom. If, for example, the nitrogen of a piperidine is bound to an atom other than hydrogen, the nitrogen is not substitutable. An atom that is not capable of bearing a hydrogen atom in any resonance form is not substitutable.
- Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. As used herein, the term “stable” refers to compounds that possess stability sufficient to allow manufacture and that maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein.
- The compounds disclosed herein also include partially and fully deuterated variants. In certain embodiments, deuterated variants may be used for kinetic studies. One of skill in the art can select the sites at which such deuterium atoms are present.
- Also included in the present invention are salts, particularly pharmaceutically acceptable salts, of the compounds described herein. The compounds of the present invention that possess a sufficiently acidic, a sufficiently basic, or both functional groups, can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt. Alternatively, compounds that are inherently charged, such as those with a quaternary nitrogen, can form a salt with an appropriate counterion (e.g., a halide such as bromide, chloride, or fluoride, particularly bromide).
- Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such salts include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like.
- Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.
- According to another embodiment, the present invention provides methods of producing the above-defined compounds. The compounds may be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials.
- Synthetic chemistry transformations and methodologies useful in synthesizing the compounds described herein are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed. (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995).
- In an exemplary embodiment, a therapeutic compound may traverse the cytoplasmic membrane of a cell. For example, a compound may have a cell-permeability of at least about 20%, 50%, 75%, 80%, 90% or 95%.
- Compounds described herein may also have one or more of the following characteristics: the compound may be essentially non-toxic to a cell or subject; the compound may be an organic molecule or a small molecule of 2000 amu or less, 1000 amu or less; a compound may have a half-life under normal atmospheric conditions of at least about 30 days, 60 days, 120 days, 6 months or 1 year; the compound may have a half-life in solution of at least about 30 days, 60 days, 120 days, 6 months or 1 year; a compound may be more stable in solution than resveratrol by at least a factor of about 50%, 2 fold, 5 fold, 10 fold, 30 fold, 50 fold or 100 fold; a compound may promote deacetylation of the DNA repair factor Ku70; a compound may promote deacetylation of RelA/p65; a compound may increase general turnover rates and enhance the sensitivity of cells to TNF-induced apoptosis.
- In certain embodiments, a sirtuin-modulating compound does not have any substantial ability to inhibit a histone deacetylase (HDAC) class I, and/or an HDAC class II at concentrations (e.g., in vivo) effective for modulating the deacetylase activity of the sirtuin. For instance, in preferred embodiments, the sirtuin-modulating compound is a sirtuin-modulating compound and is chosen to have an EC50 for activating sirtuin deacetylase activity that is at least 5 fold less than the EC50 for inhibition of an HDAC I and/or HDAC II, and even more preferably at least 10 fold, 100 fold or even 1000 fold less. Methods for assaying HDAC I and/or HDAC II activity are well known in the art and kits to perform such assays may be purchased commercially. See e.g., BioVision, Inc. (Mountain View, Calif.; world wide web at biovision.com) and Thomas Scientific (Swedesboro, N.J.; world wide web at tomassci.com).
- In certain embodiments, a sirtuin-modulating compound does not have any substantial ability to modulate sirtuin homologs. In certain embodiments, an activator of a human sirtuin protein may not have any substantial ability to activate a sirtuin protein from lower eukaryotes, particularly yeast or human pathogens, at concentrations (e.g., in vivo) effective for activating the deacetylase activity of human sirtuin. For example, a sirtuin-modulating compound may be chosen to have an EC50 for activating a human sirtuin, such as SIRT1 and/or SIRT3, deacetylase activity that is at least 5 fold less than the EC50 for activating a yeast sirtuin, such as Sir2 (such as Candida, S. cerevisiae, etc.), and even more preferably at least 10 fold, 100 fold or even 1000 fold less. In another embodiment, an inhibitor of a sirtuin protein from lower eukaryotes, particularly yeast or human pathogens, does not have any substantial ability to inhibit a sirtuin protein from humans at concentrations (e.g., in vivo) effective for inhibiting the deacetylase activity of a sirtuin protein from a lower eukaryote. For example, a sirtuin-inhibiting compound may be chosen to have an IC50 for inhibiting a human sirtuin, such as SIRT1 and/or SIRT3, deacetylase activity that is at least 5 fold less than the IC50 for inhibiting a yeast sirtuin, such as Sir2 (such as Candida, S. cerevisiae, etc.), and even more preferably at least 10 fold, 100 fold or even 1000 fold less.
- In certain embodiments, a sirtuin-modulating compound may have the ability to modulate one or more sirtuin protein homologs, such as, for example, one or more of human SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7. In some embodiments, a sirtuin-modulating compound has the ability to modulate both a SIRT1 and a SIRT3 protein.
- In other embodiments, a SIRT1 modulator does not have any substantial ability to modulate other sirtuin protein homologs, such as, for example, one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, at concentrations (e.g., in vivo) effective for modulating the deacetylase activity of human SIRT1. For example, a sirtuin-modulating compound may be chosen to have an ED50 for modulating human SIRT1 deacetylase activity that is at least 5 fold less than the ED50 for modulating one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, and even more preferably at least 10 fold, 100 fold or even 1000 fold less. In some embodiments, a SIRT1 modulator does not have any substantial ability to modulate a SIRT3 protein.
- In other embodiments, a SIRT3 modulator does not have any substantial ability to modulate other sirtuin protein homologs, such as, for example, one or more of human SIRT1, SIRT2, SIRT4, SIRT5, SIRT6, or SIRT7, at concentrations (e.g., in vivo) effective for modulating the deacetylase activity of human SIRT3. For example, a sirtuin-modulating compound may be chosen to have an ED50 for modulating human SIRT3 deacetylase activity that is at least 5 fold less than the ED50 for modulating one or more of human SIRT1, SIRT2, SIRT4, SIRT5, SIRT6, or SIRT7, and even more preferably at least 10 fold, 100 fold or even 1000 fold less. In some embodiments, a SIRT3 modulator does not have any substantial ability to modulate a SIRT1 protein.
- In certain embodiments, a sirtuin-modulating compound may have a binding affinity for a sirtuin protein of about 10−9M, 10−10M, 10−11M, 10−12M or less. A sirtuin-modulating compound may reduce (activator) or increase (inhibitor) the apparent Km of a sirtuin protein for its substrate or NAD+ (or other cofactor) by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100. In certain embodiments, Km values are determined using the mass spectrometry assay described herein. Preferred activating compounds reduce the Km of a sirtuin for its substrate or cofactor to a greater extent than caused by resveratrol at a similar concentration or reduce the Km of a sirtuin for its substrate or cofactor similar to that caused by resveratrol at a lower concentration. A sirtuin-modulating compound may increase the Vmax of a sirtuin protein by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100. A sirtuin-modulating compound may have an ED50 for modulating the deacetylase activity of a SIRT1 and/or SIRT3 protein of less than about 1 nM, less than about 10 nM, less than about 100 nM, less than about 1 μM, less than about 10 μM, less than about 100 μM, or from about 1-10 nM, from about 10-100 nM, from about 0.1-1 μM, from about 1-10 μM or from about 10-100 μM. A sirtuin-modulating compound may modulate the deacetylase activity of a SIRT1 and/or SIRT3 protein by a factor of at least about 5, 10, 20, 30, 50, or 100, as measured in a cellular assay or in a cell based assay. A sirtuin-modulating compound may cause at least about 10%, 30%, 50%, 80%, 2 fold, 5 fold, 10 fold, 50 fold or 100 fold greater induction of the deacetylase activity of a sirtuin protein relative to the same concentration of resveratrol. A sirtuin-modulating compound may have an ED50 for modulating SIRT5 that is at least about 10 fold, 20 fold, 30 fold, 50 fold greater than that for modulating SIRT1 and/or SIRT3.
- In certain aspects, the invention provides methods for modulating the level and/or activity of a sirtuin protein and methods of use thereof.
- In certain embodiments, the invention provides methods for using sirtuin-modulating compounds wherein the sirtuin-modulating compounds activate a sirtuin protein, e.g., increase the level and/or activity of a sirtuin protein. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be useful for a variety of therapeutic applications including, for example, increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing, etc. The methods comprise administering to a subject in need thereof a pharmaceutically effective amount of a sirtuin-modulating compound, e.g., a sirtuin-modulating compound.
- Without wishing to be bound by theory, it is believed that activators of the instant invention may interact with a sirtuin at the same location within the sirtuin protein (e.g., active site or site affecting the Km or Vmax of the active site). It is believed that this is the reason why certain classes of sirtuin activators and inhibitors can have substantial structural similarity.
- In certain embodiments, the sirtuin-modulating compounds described herein may be taken alone or in combination with other compounds. In certain embodiments, a mixture of two or more sirtuin-modulating compounds may be administered to a subject in need thereof. In another embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered with one or more of the following compounds: resveratrol, butein, fisetin, piceatannol, or quercetin. In an exemplary embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered in combination with nicotinic acid or nicotinamide riboside. In another embodiment, a sirtuin-modulating compound that decreases the level and/or activity of a sirtuin protein may be administered with one or more of the following compounds: nicotinamide (NAM), suramin; NF023 (a G-protein antagonist); NF279 (a purinergic receptor antagonist); Trolox (6-hydroxy-2,5,7,8,tetramethylchroman-2-carboxylic acid); (−)-epigallocatechin (hydroxy on sites 3,5,7,3′,4′, 5′); (−)-epigallocatechin gallate (Hydroxy sites 5,7,3′,4′,5′ and gallate ester on 3); cyanidin chloride (3,5,7,3′,4′-pentahydroxyflavylium chloride); delphinidin chloride (3,5,7,3′,4′,5′-hexahydroxyflavylium chloride); myricetin (cannabiscetin; 3,5,7,3′,4′,5′-hexahydroxyflavone); 3,7,3′,4′,5′-pentahydroxyflavone; gossypetin (3,5,7,8,3′,4′-hexahydroxyflavone), sirtinol; and splitomicin. In yet another embodiment, one or more sirtuin-modulating compounds may be administered with one or more therapeutic agents for the treatment or prevention of various diseases, including, for example, cancer, diabetes, neurodegenerative diseases, cardiovascular disease, blood clotting, inflammation, flushing, obesity, aging, stress, etc. In various embodiments, combination therapies comprising a sirtuin-modulating compound may refer to (1) pharmaceutical compositions that comprise one or more sirtuin-modulating compounds in combination with one or more therapeutic agents (e.g., one or more therapeutic agents described herein); and (2) co-administration of one or more sirtuin-modulating compounds with one or more therapeutic agents wherein the sirtuin-modulating compound and therapeutic agent have not been formulated in the same compositions (but may be present within the same kit or package, such as a blister pack or other multi-chamber package; connected, separately sealed containers (e.g., foil pouches) that can be separated by the user; or a kit where the compound(s) and other therapeutic agent(s) are in separate vessels). When using separate formulations, the sirtuin-modulating compound may be administered simultaneous with, intermittent with, staggered with, prior to, subsequent to, or combinations thereof, the administration of another therapeutic agent.
- In certain embodiments, methods for reducing, preventing or treating diseases or disorders using a compound described herein may also comprise increasing the protein level of a sirtuin, such as human SIRT1, SIRT2 and/or SIRT3, or homologs thereof. Increasing protein levels can be achieved by introducing into a cell one or more copies of a nucleic acid that encodes a sirtuin. For example, the level of a sirtuin can be increased in a mammalian cell by introducing into the mammalian cell a nucleic acid encoding the sirtuin, e.g., increasing the level of SIRT1 by introducing a nucleic acid encoding the amino acid sequence set forth in GenBank Accession No. NP_036370 and/or increasing the level of SIRT3 by introducing a nucleic acid encoding the amino acid sequence set forth in GenBank Accession No. AAH01042.
- A nucleic acid that is introduced into a cell to increase the protein level of a sirtuin may encode a protein that is at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to the sequence of a sirtuin, e.g., SIRT1 and/or SIRT3 protein. For example, the nucleic acid encoding the protein may be at least about 80%, 85%, 90%, 95%, 98%, or 99% identical to a nucleic acid encoding a SIRT1 (e.g. GenBank Accession No. NM_012238) and/or SIRT3 (e.g., GenBank Accession No. BC001042) protein. The nucleic acid may also be a nucleic acid that hybridizes, preferably under stringent hybridization conditions, to a nucleic acid encoding a wild-type sirtuin, e.g., SIRT1 and/or SIRT3 protein. Stringent hybridization conditions may include hybridization and a wash in 0.2×SSC at 65° C. When using a nucleic acid that encodes a protein that is different from a wild-type sirtuin protein, such as a protein that is a fragment of a wild-type sirtuin, the protein is preferably biologically active, e.g., is capable of deacetylation. It is only necessary to express in a cell a portion of the sirtuin that is biologically active. For example, a protein that differs from wild-type SIRT1 having GenBank Accession No. NP_036370, preferably contains the core structure thereof. The core structure sometimes refers to amino acids 62-293 of GenBank Accession No. NP_036370, which are encoded by nucleotides 237 to 932 of GenBank Accession No. NM_012238, which encompasses the NAD binding as well as the substrate binding domains. The core domain of SIRT1 may also refer to about amino acids 261 to 447 of GenBank Accession No. NP_036370, which are encoded by nucleotides 834 to 1394 of GenBank Accession No. NM_012238; to about amino acids 242 to 493 of GenBank Accession No. NP_036370, which are encoded by nucleotides 777 to 1532 of GenBank Accession No. NM_012238; or to about amino acids 254 to 495 of GenBank Accession No. NP_036370, which are encoded by nucleotides 813 to 1538 of GenBank Accession No. NM_012238. Whether a protein retains a biological function, e.g., deacetylation capabilities, can be determined according to methods known in the art.
- In certain embodiments, methods for reducing, preventing or treating diseases or disorders using a sirtuin-modulating compound may also comprise decreasing the protein level of a sirtuin, such as human SIRT1, SIRT2 and/or SIRT3, or homologs thereof. Decreasing a sirtuin protein level can be achieved according to methods known in the art. For example, an siRNA, an antisense nucleic acid, or a ribozyme targeted to the sirtuin can be expressed in the cell. A dominant negative sirtuin mutant, e.g., a mutant that is not capable of deacetylating, may also be used. For example, mutant H363Y of SIRT1, described, e.g., in Luo et al. (2001) Cell 107:137 can be used. Alternatively, agents that inhibit transcription can be used.
- Methods for modulating sirtuin protein levels also include methods for modulating the transcription of genes encoding sirtuins, methods for stabilizing/destabilizing the corresponding mRNAs, and other methods known in the art.
- In one aspect, the invention provides a method extending the lifespan of a cell, extending the proliferative capacity of a cell, slowing aging of a cell, promoting the survival of a cell, delaying cellular senescence in a cell, mimicking the effects of calorie restriction, increasing the resistance of a cell to stress, or preventing apoptosis of a cell, by contacting the cell with a sirtuin-modulating compound of the invention that increases the level and/or activity of a sirtuin protein. In an exemplary embodiment, the methods comprise contacting the cell with a sirtuin-modulating compound.
- The methods described herein may be used to increase the amount of time that cells, particularly primary cells (i.e., cells obtained from an organism, e.g., a human), may be kept alive in a cell culture. Embryonic stem (ES) cells and pluripotent cells, and cells differentiated therefrom, may also be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein to keep the cells, or progeny thereof, in culture for longer periods of time. Such cells can also be used for transplantation into a subject, e.g., after ex vivo modification.
- In one aspect, cells that are intended to be preserved for long periods of time may be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. The cells may be in suspension (e.g., blood cells, serum, biological growth media, etc.) or in tissues or organs. For example, blood collected from an individual for purposes of transfusion may be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein to preserve the blood cells for longer periods of time. Additionally, blood to be used for forensic purposes may also be preserved using a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. Other cells that may be treated to extend their lifespan or protect against apoptosis include cells for consumption, e.g., cells from non-human mammals (such as meat) or plant cells (such as vegetables).
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be applied during developmental and growth phases in mammals, plants, insects or microorganisms, in order to, e.g., alter, retard or accelerate the developmental and/or growth process.
- In another aspect, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to treat cells useful for transplantation or cell therapy, including, for example, solid tissue grafts, organ transplants, cell suspensions, stem cells, bone marrow cells, etc. The cells or tissue may be an autograft, an allograft, a syngraft or a xenograft. The cells or tissue may be treated with the sirtuin-modulating compound prior to administration/implantation, concurrently with administration/implantation, and/or post administration/implantation into a subject. The cells or tissue may be treated prior to removal of the cells from the donor individual, ex vivo after removal of the cells or tissue from the donor individual, or post implantation into the recipient. For example, the donor or recipient individual may be treated systemically with a sirtuin-modulating compound or may have a subset of cells/tissue treated locally with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. In certain embodiments, the cells or tissue (or donor/recipient individuals) may additionally be treated with another therapeutic agent useful for prolonging graft survival, such as, for example, an immunosuppressive agent, a cytokine, an angiogenic factor, etc.
- In yet other embodiments, cells may be treated with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein in vivo, e.g., to increase their lifespan or prevent apoptosis. For example, skin can be protected from aging (e.g., developing wrinkles, loss of elasticity, etc.) by treating skin or epithelial cells with a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. In an exemplary embodiment, skin is contacted with a pharmaceutical or cosmetic composition comprising a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. Exemplary skin afflictions or skin conditions that may be treated in accordance with the methods described herein include disorders or diseases associated with or caused by inflammation, sun damage or natural aging. For example, the compositions find utility in the prevention or treatment of contact dermatitis (including irritant contact dermatitis and allergic contact dermatitis), atopic dermatitis (also known as allergic eczema), actinic keratosis, keratinization disorders (including eczema), epidermolysis bullosa diseases (including pemphigus), exfoliative dermatitis, seborrheic dermatitis, erythemas (including erythema multiforme and erythema nodosum), damage caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, psoriasis, skin cancer and the effects of natural aging. In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for the treatment of wounds and/or burns to promote healing, including, for example, first-, second- or third-degree burns and/or thermal, chemical or electrical burns. The formulations may be administered topically, to the skin or mucosal tissue.
- Topical formulations comprising one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used as preventive, e.g., chemopreventive, compositions. When used in a chemopreventive method, susceptible skin is treated prior to any visible condition in a particular individual.
- Sirtuin-modulating compounds may be delivered locally or systemically to a subject. In certain embodiments, a sirtuin-modulating compound is delivered locally to a tissue or organ of a subject by injection, topical formulation, etc.
- In another embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used for treating or preventing a disease or condition induced or exacerbated by cellular senescence in a subject; methods for decreasing the rate of senescence of a subject, e.g., after onset of senescence; methods for extending the lifespan of a subject; methods for treating or preventing a disease or condition relating to lifespan; methods for treating or preventing a disease or condition relating to the proliferative capacity of cells; and methods for treating or preventing a disease or condition resulting from cell damage or death. In certain embodiments, the method does not act by decreasing the rate of occurrence of diseases that shorten the lifespan of a subject. In certain embodiments, a method does not act by reducing the lethality caused by a disease, such as cancer.
- In yet another embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered to a subject in order to generally increase the lifespan of its cells and to protect its cells against stress and/or against apoptosis. It is believed that treating a subject with a compound described herein is similar to subjecting the subject to hormesis, i.e., mild stress that is beneficial to organisms and may extend their lifespan.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to a subject to prevent aging and aging-related consequences or diseases, such as stroke, heart disease, heart failure, arthritis, high blood pressure, and Alzheimer's disease. Other conditions that can be treated include ocular disorders, e.g., associated with the aging of the eye, such as cataracts, glaucoma, and macular degeneration. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can also be administered to subjects for treatment of diseases, e.g., chronic diseases, associated with cell death, in order to protect the cells from cell death. Exemplary diseases include those associated with neural cell death, neuronal dysfunction, or muscular cell death or dysfunction, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and muscular dystrophy; AIDS; fulminant hepatitis; diseases linked to degeneration of the brain, such as Creutzfeld-Jakob disease, retinitis pigmentosa and cerebellar degeneration; myelodysplasia such as aplastic anemia; ischemic diseases such as myocardial infarction and stroke; hepatic diseases such as alcoholic hepatitis, hepatitis B and hepatitis C; joint-diseases such as osteoarthritis; atherosclerosis; alopecia; damage to the skin due to UV light; lichen planus; atrophy of the skin; cataract; and graft rejections. Cell death can also be caused by surgery, drug therapy, chemical exposure or radiation exposure.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can also be administered to a subject suffering from an acute disease, e.g., damage to an organ or tissue, e.g., a subject suffering from stroke or myocardial infarction or a subject suffering from a spinal cord injury. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used to repair an alcoholic's liver.
- In another embodiment, the invention provides a method for treating and/or preventing a cardiovascular disease by administering to a subject in need thereof a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein.
- Cardiovascular diseases that can be treated or prevented using the sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein include cardiomyopathy or myocarditis; such as idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy. Also treatable or preventable using compounds and methods described herein are atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries. Other vascular diseases that can be treated or prevented include those related to platelet aggregation, the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems. The sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used for increasing HDL levels in plasma of an individual.
- Yet other disorders that may be treated with sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein include restenosis, e.g., following coronary intervention, and disorders relating to an abnormal level of high density and low density cholesterol.
- In certain embodiments, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as part of a combination therapy with another cardiovascular agent. In certain embodiments, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as part of a combination therapy with an anti-arrhythmia agent. In another embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as part of a combination therapy with another cardiovascular agent.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to subjects who have recently received or are likely to receive a dose of radiation or toxin. In certain embodiments, the dose of radiation or toxin is received as part of a work-related or medical procedure, e.g., administered as a prophylactic measure. In another embodiment, the radiation or toxin exposure is received unintentionally. In such a case, the compound is preferably administered as soon as possible after the exposure to inhibit apoptosis and the subsequent development of acute radiation syndrome.
- Sirtuin-modulating compounds may also be used for treating and/or preventing cancer. In certain embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating and/or preventing cancer. Calorie restriction has been linked to a reduction in the incidence of age-related disorders including cancer. Accordingly, an increase in the level and/or activity of a sirtuin protein may be useful for treating and/or preventing the incidence of age-related disorders, such as, for example, cancer. Exemplary cancers that may be treated using a sirtuin-modulating compound are those of the brain and kidney; hormone-dependent cancers including breast, prostate, testicular, and ovarian cancers; lymphomas, and leukemias. In cancers associated with solid tumors, a modulating compound may be administered directly into the tumor. Cancer of blood cells, e.g., leukemia, can be treated by administering a modulating compound into the blood stream or into the bone marrow. Benign cell growth, e.g., warts, can also be treated. Other diseases that can be treated include autoimmune diseases, e.g., systemic lupus erythematosus, scleroderma, and arthritis, in which autoimmune cells should be removed. Viral infections such as herpes, HIV, adenovirus, and HTLV-1 associated malignant and benign disorders can also be treated by administration of sirtuin-modulating compound. Alternatively, cells can be obtained from a subject, treated ex vivo to remove certain undesirable cells, e.g., cancer cells, and administered back to the same or a different subject.
- Chemotherapeutic agents may be co-administered with modulating compounds described herein as having anti-cancer activity, e.g., compounds that induce apoptosis, compounds that reduce lifespan or compounds that render cells sensitive to stress. Chemotherapeutic agents may be used by themselves with a sirtuin-modulating compound described herein as inducing cell death or reducing lifespan or increasing sensitivity to stress and/or in combination with other chemotherapeutics agents. In addition to conventional chemotherapeutics, the sirtuin-modulating compounds described herein may also be used with antisense RNA, RNAi or other polynucleotides to inhibit the expression of the cellular components that contribute to unwanted cellular proliferation.
- Combination therapies comprising sirtuin-modulating compounds and a conventional chemotherapeutic agent may be advantageous over combination therapies known in the art because the combination allows the conventional chemotherapeutic agent to exert greater effect at lower dosage. In a preferred embodiment, the effective dose (ED50) for a chemotherapeutic agent, or combination of conventional chemotherapeutic agents, when used in combination with a sirtuin-modulating compound is at least 2 fold less than the ED50 for the chemotherapeutic agent alone, and even more preferably at 5 fold, 10 fold or even 25 fold less. Conversely, the therapeutic index (TI) for such chemotherapeutic agent or combination of such chemotherapeutic agent when used in combination with a sirtuin-modulating compound described herein can be at least 2 fold greater than the TI for conventional chemotherapeutic regimen alone, and even more preferably at 5 fold, 10 fold or even 25 fold greater.
- In certain aspects, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat patients suffering from neurodegenerative diseases, and traumatic or mechanical injury to the central nervous system (CNS), spinal cord or peripheral nervous system (PNS). Neurodegenerative disease typically involves reductions in the mass and volume of the human brain, which may be due to the atrophy and/or death of brain cells, which are far more profound than those in a healthy person that are attributable to aging. Neurodegenerative diseases can evolve gradually, after a long period of normal brain function, due to progressive degeneration (e.g., nerve cell dysfunction and death) of specific brain regions. Alternatively, neurodegenerative diseases can have a quick onset, such as those associated with trauma or toxins. The actual onset of brain degeneration may precede clinical expression by many years. Examples of neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, ocular diseases (ocular neuritis), chemotherapy-induced neuropathies (e.g., from vincristine, paclitaxel, bortezomib), diabetes-induced neuropathies and Friedreich's ataxia. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat these disorders and others as described below.
- AD is a CNS disorder that results in memory loss, unusual behavior, personality changes, and a decline in thinking abilities. These losses are related to the death of specific types of brain cells and the breakdown of connections and their supporting network (e.g. glial cells) between them. The earliest symptoms include loss of recent memory, faulty judgment, and changes in personality. PD is a CNS disorder that results in uncontrolled body movements, rigidity, tremor, and dyskinesia, and is associated with the death of brain cells in an area of the brain that produces dopamine. ALS (motor neuron disease) is a CNS disorder that attacks the motor neurons, components of the CNS that connect the brain to the skeletal muscles.
- HD is another neurodegenerative disease that causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance. Tay-Sachs disease and Sandhoff disease are glycolipid storage diseases where GM2 ganglioside and related glycolipids substrates for β-hexosaminidase accumulate in the nervous system and trigger acute neurodegeneration.
- It is well-known that apoptosis plays a role in AIDS pathogenesis in the immune system. However, HIV-1 also induces neurological disease, which can be treated with sirtuin-modulating compounds of the invention.
- Neuronal loss is also a salient feature of prion diseases, such as Creutzfeldt-Jakob disease in human, BSE in cattle (mad cow disease), Scrapie Disease in sheep and goats, and feline spongiform encephalopathy (FSE) in cats. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be useful for treating or preventing neuronal loss due to these prior diseases.
- In another embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to treat or prevent any disease or disorder involving axonopathy. Distal axonopathy is a type of peripheral neuropathy that results from some metabolic or toxic derangement of peripheral nervous system (PNS) neurons. It is the most common response of nerves to metabolic or toxic disturbances, and as such may be caused by metabolic diseases such as diabetes, renal failure, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs. Those with distal axonopathies usually present with symmetrical glove-stocking sensori-motor disturbances. Deep tendon reflexes and autonomic nervous system (ANS) functions are also lost or diminished in affected areas.
- Diabetic neuropathies are neuropathic disorders that are associated with diabetes mellitus. Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy; mononeuropathy; mononeuritis multiplex; diabetic amyotrophy; a painful polyneuropathy; autonomic neuropathy; and thoracoabdominal neuropathy.
- Peripheral neuropathy is the medical term for damage to nerves of the peripheral nervous system, which may be caused either by diseases of the nerve or from the side-effects of systemic illness. Maj or causes of peripheral neuropathy include seizures, nutritional deficiencies, and HIV, though diabetes is the most likely cause.
- In an exemplary embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to treat or prevent multiple sclerosis (MS), including relapsing MS and monosymptomatic MS, and other demyelinating conditions, such as, for example, chronic inflammatory demyelinating polyneuropathy (CIDP), or symptoms associated therewith.
- In yet another embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to treat trauma to the nerves, including, trauma due to disease, injury (including surgical intervention), or environmental trauma (e.g., neurotoxins, alcoholism, etc.).
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be useful to prevent, treat, and alleviate symptoms of various PNS disorders. The term “peripheral neuropathy” encompasses a wide range of disorders in which the nerves outside of the brain and spinal cord—peripheral nerves—have been damaged. Peripheral neuropathy may also be referred to as peripheral neuritis, or if many nerves are involved, the terms polyneuropathy or polyneuritis may be used.
- PNS diseases treatable with sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein include: diabetes, leprosy, Charcot-Marie-Tooth disease, Guillain-Barré syndrome and Brachial Plexus Neuropathies (diseases of the cervical and first thoracic roots, nerve trunks, cords, and peripheral nerve components of the brachial plexus.
- In another embodiment, a sirtuin-modulating compound may be used to treat or prevent a polyglutamine disease. Exemplary polyglutamine diseases include Spinobulbar muscular atrophy (Kennedy disease), Huntington's Disease (HD), Dentatorubral-pallidoluysian atrophy (Haw River syndrome), Spinocerebellar ataxia type 1, Spinocerebellar ataxia type 2, Spinocerebellar ataxia type 3 (Machado-Joseph disease), Spinocerebellar ataxia type 6, Spinocerebellar ataxia type 7, and Spinocerebellar ataxia type 17.
- In certain embodiments, the invention provides a method to treat a central nervous system cell to prevent damage in response to a decrease in blood flow to the cell. Typically the severity of damage that may be prevented will depend in large part on the degree of reduction in blood flow to the cell and the duration of the reduction. In certain embodiments, apoptotic or necrotic cell death may be prevented. In still a further embodiment, ischemic-mediated damage, such as cytotoxic edema or central nervous system tissue anoxemia, may be prevented. In each embodiment, the central nervous system cell may be a spinal cell or a brain cell.
- Another aspect encompasses administrating a sirtuin-modulating compound to a subject to treat a central nervous system ischemic condition. A number of central nervous system ischemic conditions may be treated by the sirtuin-modulating compounds described herein. In certain embodiments, the ischemic condition is a stroke that results in any type of ischemic central nervous system damage, such as apoptotic or necrotic cell death, cytotoxic edema or central nervous system tissue anoxia. The stroke may impact any area of the brain or be caused by any etiology commonly known to result in the occurrence of a stroke. In one alternative of this embodiment, the stroke is a brain stem stroke. In another alternative of this embodiment, the stroke is a cerebellar stroke. In still another embodiment, the stroke is an embolic stroke. In yet another alternative, the stroke may be a hemorrhagic stroke. In a further embodiment, the stroke is a thrombotic stroke.
- In yet another aspect, a sirtuin-modulating compound may be administered to reduce infarct size of the ischemic core following a central nervous system ischemic condition. Moreover, a sirtuin-modulating compound may also be beneficially administered to reduce the size of the ischemic penumbra or transitional zone following a central nervous system ischemic condition.
- In certain embodiments, a combination drug regimen may include drugs or compounds for the treatment or prevention of neurodegenerative disorders or secondary conditions associated with these conditions. Thus, a combination drug regimen may include one or more sirtuin activators and one or more anti-neurodegeneration agents.
- In other aspects, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat or prevent blood coagulation disorders (or hemostatic disorders). As used interchangeably herein, the terms “hemostasis”, “blood coagulation,” and “blood clotting” refer to the control of bleeding, including the physiological properties of vasoconstriction and coagulation. Blood coagulation assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Further, the formation of blood clots does not only limit bleeding in case of an injury (hemostasis), but may lead to serious organ damage and death in the context of atherosclerotic diseases by occlusion of an important artery or vein. Thrombosis is thus blood clot formation at the wrong time and place.
- Accordingly, the present invention provides anticoagulation and antithrombotic treatments aiming at inhibiting the formation of blood clots in order to prevent or treat blood coagulation disorders, such as myocardial infarction, stroke, loss of a limb by peripheral artery disease or pulmonary embolism.
- As used interchangeably herein, “modulating or modulation of hemostasis” and “regulating or regulation of hemostasis” includes the induction (e.g., stimulation or increase) of hemostasis, as well as the inhibition (e.g., reduction or decrease) of hemostasis.
- In one aspect, the invention provides a method for reducing or inhibiting hemostasis in a subject by administering a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. The compositions and methods disclosed herein are useful for the treatment or prevention of thrombotic disorders. As used herein, the term “thrombotic disorder” includes any disorder or condition characterized by excessive or unwanted coagulation or hemostatic activity, or a hypercoagulable state. Thrombotic disorders include diseases or disorders involving platelet adhesion and thrombus formation, and may manifest as an increased propensity to form thromboses, e.g., an increased number of thromboses, thrombosis at an early age, a familial tendency towards thrombosis, and thrombosis at unusual sites.
- In another embodiment, a combination drug regimen may include drugs or compounds for the treatment or prevention of blood coagulation disorders or secondary conditions associated with these conditions. Thus, a combination drug regimen may include one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein and one or more anti-coagulation or anti-thrombosis agents.
- In another aspect, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating or preventing weight gain or obesity in a subject. For example, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used, for example, to treat or prevent hereditary obesity, dietary obesity, hormone related obesity, obesity related to the administration of medication, to reduce the weight of a subject, or to reduce or prevent weight gain in a subject. A subject in need of such a treatment may be a subject who is obese, likely to become obese, overweight, or likely to become overweight. Subjects who are likely to become obese or overweight can be identified, for example, based on family history, genetics, diet, activity level, medication intake, or various combinations thereof.
- In yet other embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to subjects suffering from a variety of other diseases and conditions that may be treated or prevented by promoting weight loss in the subject. Such diseases include, for example, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, type 2 diabetes, insulin resistance, glucose intolerance, hyperinsulinemia, coronary heart disease, angina pectoris, congestive heart failure, stroke, gallstones, cholecystitis and cholelithiasis, gout, osteoarthritis, obstructive sleep apnea and respiratory problems, some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation), bladder control problems (such as stress incontinence); uric acid nephrolithiasis; psychological disorders (such as depression, eating disorders, distorted body image, and low self-esteem). Finally, patients with AIDS can develop lipodystrophy or insulin resistance in response to combination therapies for AIDS.
- In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for inhibiting adipogenesis or fat cell differentiation, whether in vitro or in vivo. Such methods may be used for treating or preventing obesity.
- In other embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for reducing appetite and/or increasing satiety, thereby causing weight loss or avoidance of weight gain. A subject in need of such a treatment may be a subject who is overweight, obese or a subject likely to become overweight or obese. The method may comprise administering daily or, every other day, or once a week, a dose, e.g., in the form of a pill, to a subject. The dose may be an “appetite reducing dose.”
- In an exemplary embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as a combination therapy for treating or preventing weight gain or obesity. For example, one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered in combination with one or more anti-obesity agents.
- In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered to reduce drug-induced weight gain. For example, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be administered as a combination therapy with medications that may stimulate appetite or cause weight gain, in particular, weight gain due to factors other than water retention.
- In another aspect, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating or preventing a metabolic disorder, such as insulin-resistance, a pre-diabetic state, type II diabetes, and/or complications thereof. Administration of a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may increase insulin sensitivity and/or decrease insulin levels in a subject. A subject in need of such a treatment may be a subject who has insulin resistance or other precursor symptom of type II diabetes, who has type II diabetes, or who is likely to develop any of these conditions. For example, the subject may be a subject having insulin resistance, e.g., having high circulating levels of insulin and/or associated conditions, such as hyperlipidemia, dyslipogenesis, hypercholesterolemia, impaired glucose tolerance, high blood glucose sugar level, other manifestations of syndrome X, hypertension, atherosclerosis and lipodystrophy.
- In an exemplary embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as a combination therapy for treating or preventing a metabolic disorder. For example, one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered in combination with one or more anti-diabetic agents.
- In other aspects, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used to treat or prevent a disease or disorder associated with inflammation. Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered prior to the onset of, at, or after the initiation of inflammation. When used prophylactically, the compounds are preferably provided in advance of any inflammatory response or symptom. Administration of the compounds may prevent or attenuate inflammatory responses or symptoms.
- In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to treat or prevent allergies and respiratory conditions, including asthma, bronchitis, pulmonary fibrosis, allergic rhinitis, oxygen toxicity, emphysema, chronic bronchitis, acute respiratory distress syndrome, and any chronic obstructive pulmonary disease (COPD). The compounds may be used to treat chronic hepatitis infection, including hepatitis B and hepatitis C.
- Additionally, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to treat autoimmune diseases, and/or inflammation associated with autoimmune diseases, such as arthritis, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as organ-tissue autoimmune diseases (e.g., Raynaud's syndrome), ulcerative colitis, Crohn's disease, oral mucositis, scleroderma, myasthenia gravis, transplant rejection, endotoxin shock, sepsis, psoriasis, eczema, dermatitis, multiple sclerosis, autoimmune thyroiditis, uveitis, systemic lupus erythematosis, Addison's disease, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), and Grave's disease.
- In certain embodiments, one or more sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be taken alone or in combination with other compounds useful for treating or preventing inflammation.
- In another aspect, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for reducing the incidence or severity of flushing and/or hot flashes which are symptoms of a disorder. For instance, the subject method includes the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein, alone or in combination with other agents, for reducing incidence or severity of flushing and/or hot flashes in cancer patients. In other embodiments, the method provides for the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein to reduce the incidence or severity of flushing and/or hot flashes in menopausal and post-menopausal woman.
- In another aspect, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used as a therapy for reducing the incidence or severity of flushing and/or hot flashes which are side-effects of another drug therapy, e.g., drug-induced flushing. In certain embodiments, a method for treating and/or preventing drug-induced flushing comprises administering to a patient in need thereof a formulation comprising at least one flushing inducing compound and at least one sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein. In other embodiments, a method for treating drug induced flushing comprises separately administering one or more compounds that induce flushing and one or more sirtuin-modulating compounds, e.g., wherein the sirtuin-modulating compound and flushing inducing agent have not been formulated in the same compositions. When using separate formulations, the sirtuin-modulating compound may be administered (1) at the same as administration of the flushing inducing agent, (2) intermittently with the flushing inducing agent, (3) staggered relative to administration of the flushing inducing agent, (4) prior to administration of the flushing inducing agent, (5) subsequent to administration of the flushing inducing agent, and (6) various combination thereof. Exemplary flushing inducing agents include, for example, niacin, raloxifene, antidepressants, anti-psychotics, chemotherapeutics, calcium channel blockers, and antibiotics.
- In certain embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of a vasodilator or an antilipemic agent (including anticholesteremic agents and lipotropic agents). In an exemplary embodiment, a sirtuin-modulating compound that increases the level and/or activity of a sirtuin protein may be used to reduce flushing associated with the administration of niacin.
- In another embodiment, the invention provides a method for treating and/or preventing hyperlipidemia with reduced flushing side effects. In another representative embodiment, the method involves the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein to reduce flushing side effects of raloxifene. In another representative embodiment, the method involves the use of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein to reduce flushing side effects of antidepressants or anti-psychotic agent. For instance, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used in conjunction (administered separately or together) with a serotonin reuptake inhibitor, or a 5HT2 receptor antagonist.
- In certain embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used as part of a treatment with a serotonin reuptake inhibitor (SRI) to reduce flushing. In still another representative embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of chemotherapeutic agents, such as cyclophosphamide and tamoxifen.
- In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of calcium channel blockers, such as amlodipine.
- In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used to reduce flushing side effects of antibiotics. For example, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be used in combination with levofloxacin.
- One aspect of the present invention is a method for inhibiting, reducing or otherwise treating vision impairment by administering to a patient a therapeutic dosage of sirtuin modulator selected from a compound disclosed herein, or a pharmaceutically acceptable salt, prodrug or a metabolic derivative thereof.
- In certain aspects of the invention, the vision impairment is caused by damage to the optic nerve or central nervous system. In particular embodiments, optic nerve damage is caused by high intraocular pressure, such as that created by glaucoma. In other particular embodiments, optic nerve damage is caused by swelling of the nerve, which is often associated with an infection or an immune (e.g., autoimmune) response such as in optic neuritis.
- In certain aspects of the invention, the vision impairment is caused by retinal damage. In particular embodiments, retinal damage is caused by disturbances in blood flow to the eye (e.g., arteriosclerosis, vasculitis). In particular embodiments, retinal damage is caused by disruption of the macula (e.g., exudative or non-exudative macular degeneration).
- Exemplary retinal diseases include Exudative Age Related Macular Degeneration, Nonexudative Age Related Macular Degeneration, Retinal Electronic Prosthesis and RPE Transplantation Age Related Macular Degeneration, Acute Multifocal Placoid Pigment Epitheliopathy, Acute Retinal Necrosis, Best Disease, Branch Retinal Artery Occlusion, Branch Retinal Vein Occlusion, Cancer Associated and Related Autoimmune Retinopathies, Central Retinal Artery Occlusion, Central Retinal Vein Occlusion, Central Serous Chorioretinopathy, Eales Disease, Epimacular Membrane, Lattice Degeneration, Macroaneurysm, Diabetic Macular Edema, Irvine-Gass Macular Edema, Macular Hole, Subretinal Neovascular Membranes, Diffuse Unilateral Subacute Neuroretinitis, Nonpseudophakic Cystoid Macular Edema, Presumed Ocular Histoplasmosis Syndrome, Exudative Retinal Detachment, Postoperative Retinal Detachment, Proliferative Retinal Detachment, Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, Retinitis Pigmentosa, CMV Retinitis, Retinoblastoma, Retinopathy of Prematurity, Birdshot Retinopathy, Background Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Hemoglobinopathies Retinopathy, Purtscher Retinopathy, Valsalva Retinopathy, Juvenile Retinoschisis, Senile Retinoschisis, Terson Syndrome and White Dot Syndromes.
- Other exemplary diseases include ocular bacterial infections (e.g. conjunctivitis, keratitis, tuberculosis, syphilis, gonorrhea), viral infections (e.g., Ocular Herpes Simplex Virus, Varicella Zoster Virus, Cytomegalovirus retinitis, Human Immunodeficiency Virus (HIV)) as well as progressive outer retinal necrosis secondary to HIV or other HIV-associated and other immunodeficiency-associated ocular diseases. In addition, ocular diseases include fungal infections (e.g., Candida choroiditis, histoplasmosis), protozoal infections (e.g., toxoplasmosis) and others such as ocular toxocariasis and sarcoidosis.
- One aspect of the invention is a method for inhibiting, reducing or treating vision impairment in a subject undergoing treatment with a chemotherapeutic drug (e.g., a neurotoxic drug, or a drug that raises intraocular pressure, such as a steroid), by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein.
- Another aspect of the invention is a method for inhibiting, reducing or treating vision impairment in a subject undergoing surgery, including ocular or other surgeries performed in the prone position such as spinal cord surgery, by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein. Ocular surgeries include cataract, iridotomy and lens replacements.
- Another aspect of the invention is the treatment, including inhibition and prophylactic treatment, of age related ocular diseases include cataracts, dry eye, age-related macular degeneration (AMD), retinal damage and the like, by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein.
- Another aspect of the invention is the prevention or treatment of damage to the eye caused by stress, chemical insult or radiation, by administering to the subject in need of such treatment a therapeutic dosage of a sirtuin modulator disclosed herein. Radiation or electromagnetic damage to the eye can include that caused by CRT's or exposure to sunlight or UV.
- In certain embodiments, a combination drug regimen may include drugs or compounds for the treatment or prevention of ocular disorders or secondary conditions associated with these conditions. Thus, a combination drug regimen may include one or more sirtuin activators and one or more therapeutic agents for the treatment of an ocular disorder.
- In certain embodiments, a sirtuin modulator can be administered in conjunction with a therapy for reducing intraocular pressure. In another embodiment, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing glaucoma. In yet another embodiment, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing optic neuritis. In certain embodiments, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing CMV Retinopathy. In another embodiment, a sirtuin modulator can be administered in conjunction with a therapy for treating and/or preventing multiple sclerosis.
- In certain embodiments, the invention provides methods for treating diseases or disorders that would benefit from increased mitochondrial activity. The methods involve administering to a subject in need thereof a therapeutically effective amount of a sirtuin-modulating compound. Increased mitochondrial activity refers to increasing activity of the mitochondria while maintaining the overall numbers of mitochondria (e.g., mitochondrial mass), increasing the numbers of mitochondria thereby increasing mitochondrial activity (e.g., by stimulating mitochondrial biogenesis), or combinations thereof. In certain embodiments, diseases and disorders that would benefit from increased mitochondrial activity include diseases or disorders associated with mitochondrial dysfunction.
- In certain embodiments, methods for treating diseases or disorders that would benefit from increased mitochondrial activity may comprise identifying a subject suffering from a mitochondrial dysfunction. Methods for diagnosing a mitochondrial dysfunction may involve molecular genetics, pathologic and/or biochemical analyses. Diseases and disorders associated with mitochondrial dysfunction include diseases and disorders in which deficits in mitochondrial respiratory chain activity contribute to the development of pathophysiology of such diseases or disorders in a mammal. Diseases or disorders that would benefit from increased mitochondrial activity generally include for example, diseases in which free radical mediated oxidative injury leads to tissue degeneration, diseases in which cells inappropriately undergo apoptosis, and diseases in which cells fail to undergo apoptosis.
- In certain embodiments, the invention provides methods for treating a disease or disorder that would benefit from increased mitochondrial activity that involves administering to a subject in need thereof one or more sirtuin-modulating compounds in combination with another therapeutic agent such as, for example, an agent useful for treating mitochondrial dysfunction or an agent useful for reducing a symptom associated with a disease or disorder involving mitochondrial dysfunction.
- In exemplary embodiments, the invention provides methods for treating diseases or disorders that would benefit from increased mitochondrial activity by administering to a subject a therapeutically effective amount of a sirtuin-modulating compound. Exemplary diseases or disorders include, for example, neuromuscular disorders (e.g., Friedreich's Ataxia, muscular dystrophy, multiple sclerosis, etc.), disorders of neuronal instability (e.g., seizure disorders, migraine, etc.), developmental delay, neurodegenerative disorders (e.g., Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, etc.), ischemia, renal tubular acidosis, age-related neurodegeneration and cognitive decline, chemotherapy fatigue, age-related or chemotherapy-induced menopause or irregularities of menstrual cycling or ovulation, mitochondrial myopathies, mitochondrial damage (e.g., calcium accumulation, excitotoxicity, nitric oxide exposure, hypoxia, etc.), and mitochondrial deregulation.
- Muscular dystrophy refers to a family of diseases involving deterioration of neuromuscular structure and function, often resulting in atrophy of skeletal muscle and myocardial dysfunction, such as Duchenne muscular dystrophy. In certain embodiments, sirtuin-modulating compounds may be used for reducing the rate of decline in muscular functional capacities and for improving muscular functional status in patients with muscular dystrophy.
- In certain embodiments, sirtuin-modulating compounds may be useful for treatment mitochondrial myopathies. Mitochondrial myopathies range from mild, slowly progressive weakness of the extraocular muscles to severe, fatal infantile myopathies and multisystem encephalomyopathies. Some syndromes have been defined, with some overlap between them. Established syndromes affecting muscle include progressive external ophthalmoplegia, the Kearns-Sayre syndrome (with ophthalmoplegia, pigmentary retinopathy, cardiac conduction defects, cerebellar ataxia, and sensorineural deafness), the MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), the MERFF syndrome (myoclonic epilepsy and ragged red fibers), limb-girdle distribution weakness, and infantile myopathy (benign or severe and fatal).
- In certain embodiments, sirtuin-modulating compounds may be useful for treating patients suffering from toxic damage to mitochondria, such as, toxic damage due to calcium accumulation, excitotoxicity, nitric oxide exposure, drug induced toxic damage, or hypoxia.
- In certain embodiments, sirtuin-modulating compounds may be useful for treating diseases or disorders associated with mitochondrial deregulation.
- In other embodiments, the invention provides methods for enhancing muscle performance by administering a therapeutically effective amount of a sirtuin-modulating compound. For example, sirtuin-modulating compounds may be useful for improving physical endurance (e.g., ability to perform a physical task such as exercise, physical labor, sports activities, etc.), inhibiting or retarding physical fatigues, enhancing blood oxygen levels, enhancing energy in healthy individuals, enhance working capacity and endurance, reducing muscle fatigue, reducing stress, enhancing cardiac and cardiovascular function, improving sexual ability, increasing muscle ATP levels, and/or reducing lactic acid in blood. In certain embodiments, the methods involve administering an amount of a sirtuin-modulating compound that increase mitochondrial activity, increase mitochondrial biogenesis, and/or increase mitochondrial mass.
- Sports performance refers to the ability of the athlete's muscles to perform when participating in sports activities. Enhanced sports performance, strength, speed and endurance are measured by an increase in muscular contraction strength, increase in amplitude of muscle contraction, shortening of muscle reaction time between stimulation and contraction. Athlete refers to an individual who participates in sports at any level and who seeks to achieve an improved level of strength, speed and endurance in their performance, such as, for example, body builders, bicyclists, long distance runners, short distance runners, etc. Enhanced sports performance in manifested by the ability to overcome muscle fatigue, ability to maintain activity for longer periods of time, and have a more effective workout.
- In the arena of athlete muscle performance, it is desirable to create conditions that permit competition or training at higher levels of resistance for a prolonged period of time.
- It is contemplated that the methods of the present invention will also be effective in the treatment of muscle related pathological conditions, including acute sarcopenia, for example, muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery.
- In certain embodiments, the invention provides novel dietary compositions comprising sirtuin modulators, a method for their preparation, and a method of using the compositions for improvement of sports performance. Accordingly, provided are therapeutic compositions, foods and beverages that have actions of improving physical endurance and/or inhibiting physical fatigues for those people involved in broadly-defined exercises including sports requiring endurance and labors requiring repeated muscle exertions. Such dietary compositions may additional comprise electrolytes, caffeine, vitamins, carbohydrates, etc.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for treating or preventing viral infections (such as infections by influenza, herpes or papilloma virus) or as antifungal agents. In certain embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as part of a combination drug therapy with another therapeutic agent for the treatment of viral diseases. In another embodiment, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be administered as part of a combination drug therapy with another anti-fungal agent.
- Subjects that may be treated as described herein include eukaryotes, such as mammals, e.g., humans, ovines, bovines, equines, porcines, canines, felines, non-human primate, mice, and rats. Cells that may be treated include eukaryotic cells, e.g., from a subject described above, or plant cells, yeast cells and prokaryotic cells, e.g., bacterial cells. For example, modulating compounds may be administered to farm animals to improve their ability to withstand farming conditions longer.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used to increase lifespan, stress resistance, and resistance to apoptosis in plants. In certain embodiments, a compound is applied to plants, e.g., on a periodic basis, or to fungi. In another embodiment, plants are genetically modified to produce a compound. In another embodiment, plants and fruits are treated with a compound prior to picking and shipping to increase resistance to damage during shipping. Plant seeds may also be contacted with compounds described herein, e.g., to preserve them.
- In other embodiments, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may be used for modulating lifespan in yeast cells. Situations in which it may be desirable to extend the lifespan of yeast cells include any process in which yeast is used, e.g., the making of beer, yogurt, and bakery items, e.g., bread. Use of yeast having an extended lifespan can result in using less yeast or in having the yeast be active for longer periods of time. Yeast or other mammalian cells used for recombinantly producing proteins may also be treated as described herein.
- Sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used to increase lifespan, stress resistance and resistance to apoptosis in insects. In this embodiment, compounds would be applied to useful insects, e.g., bees and other insects that are involved in pollination of plants. In a specific embodiment, a compound would be applied to bees involved in the production of honey. Generally, the methods described herein may be applied to any organism, e.g., eukaryote, which may have commercial importance. For example, they can be applied to fish (aquaculture) and birds (e.g., chicken and fowl).
- Higher doses of sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein may also be used as a pesticide by interfering with the regulation of silenced genes and the regulation of apoptosis during development. In this embodiment, a compound may be applied to plants using a method known in the art that ensures the compound is bio-available to insect larvae, and not to plants.
- At least in view of the link between reproduction and longevity, sirtuin-modulating compounds that increase the level and/or activity of a sirtuin protein can be applied to affect the reproduction of organisms such as insects, animals and microorganisms.
- Yet other methods contemplated herein include screening methods for identifying compounds or agents that modulate sirtuins. An agent may be a nucleic acid, such as an aptamer. Assays may be conducted in a cell based or cell free format. For example, an assay may comprise incubating (or contacting) a sirtuin with a test agent under conditions in which a sirtuin can be modulated by an agent known to modulate the sirtuin, and monitoring or determining the level of modulation of the sirtuin in the presence of the test agent relative to the absence of the test agent. The level of modulation of a sirtuin can be determined by determining its ability to deacetylate a substrate. Exemplary substrates are acetylated peptides which can be obtained from BIOMOL (Plymouth Meeting, Pa.). Preferred substrates include peptides of p53, such as those comprising an acetylated K382. A particularly preferred substrate is the Fluor de Lys-SIRT1 (BIOMOL), i.e., the acetylated peptide Arg-His-Lys-Lys. Other substrates are peptides from human histones H3 and H4 or an acetylated amino acid. Substrates may be fluorogenic. The sirtuin may be SIRT1, Sir2, SIRT3, or a portion thereof. For example, recombinant SIRT1 can be obtained from BIOMOL. The reaction may be conducted for about 30 minutes and stopped, e.g., with nicotinamide. The HDAC fluorescent activity assay/drug discovery kit (AK-500, BIOMOL Research Laboratories) may be used to determine the level of acetylation. Similar assays are described in Bitterman et al. (2002) J. Biol. Chem. 277:45099. The level of modulation of the sirtuin in an assay may be compared to the level of modulation of the sirtuin in the presence of one or more (separately or simultaneously) compounds described herein, which may serve as positive or negative controls. Sirtuins for use in the assays may be full length sirtuin proteins or portions thereof. Since it has been shown herein that activating compounds appear to interact with the N-terminus of SIRT1, proteins for use in the assays include N-terminal portions of sirtuins, e.g., about amino acids 1-176 or 1-255 of SIRT1; about amino acids 1-174 or 1-252 of Sir2.
- In certain embodiments, a screening assay comprises (i) contacting a sirtuin with a test agent and an acetylated substrate under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent; and (ii) determining the level of acetylation of the substrate, wherein a lower level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, whereas a higher level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin.
- In another embodiment, the screening assay may detect the formation of a 2′/3′-O-acetyl-ADP-ribose product of sirtuin-mediated NAD-dependent deacetylation. This O-acetyl-ADP-ribose product is formed in equimolar quantities with the deacetylated peptide product of the sirtuin deacetylation reaction. Accordingly, the screening assay may include (i) contacting a sirtuin with a test agent and an acetylated substrate under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent; and (ii) determining the amount of O-acetyl-ADP-ribose formation, wherein an increase in O-acetyl-ADP-ribose formation in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, while a decrease in O-acetyl-ADP-ribose formation in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin.
- Methods for identifying an agent that modulates, e.g., stimulates, sirtuins in vivo may comprise (i) contacting a cell with a test agent and a substrate that is capable of entering a cell in the presence of an inhibitor of class I and class II HDACs under conditions appropriate for the sirtuin to deacetylate the substrate in the absence of the test agent; and (ii) determining the level of acetylation of the substrate, wherein a lower level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent stimulates deacetylation by the sirtuin, whereas a higher level of acetylation of the substrate in the presence of the test agent relative to the absence of the test agent indicates that the test agent inhibits deacetylation by the sirtuin. A preferred substrate is an acetylated peptide, which is also preferably fluorogenic, as further described herein. The method may further comprise lysing the cells to determine the level of acetylation of the substrate. Substrates may be added to cells at a concentration ranging from about 1 μM to about 10 mM, preferably from about 10 μM to 1 mM, even more preferably from about 100 μM to 1 mM, such as about 200 μM. A preferred substrate is an acetylated lysine, e.g., ε-acetyl lysine (Fluor de Lys, FdL) or Fluor de Lys-SIRT1. A preferred inhibitor of class I and class II HDACs is trichostatin A (TSA), which may be used at concentrations ranging from about 0.01 to 100 μM, preferably from about 0.1 to 10 μM, such as 1 μM. Incubation of cells with the test compound and the substrate may be conducted for about 10 minutes to 5 hours, preferably for about 1-3 hours. Since TSA inhibits all class I and class II HDACs, and that certain substrates, e.g., Fluor de Lys, is a poor substrate for SIRT2 and even less a substrate for SIRT3-7, such an assay may be used to identify modulators of SIRT1 in vivo.
- The compounds described herein may be formulated in a conventional manner using one or more physiologically or pharmaceutically acceptable carriers or excipients. For example, compounds and their pharmaceutically acceptable salts and solvates may be formulated for administration by, for example, injection (e.g. SubQ, IM, IP), inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, nasal, parenteral or rectal administration. In certain embodiments, a compound may be administered locally, at the site where the target cells are present, i.e., in a specific tissue, organ, or fluid (e.g., blood, cerebrospinal fluid, etc.).
- The compounds can be formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, Pa. For parenteral administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
- For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges, or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- For administration by inhalation (e.g., pulmonary delivery), the compounds may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- In addition to the formulations described previously, compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. Controlled release formula also includes patches.
- In certain embodiments, the compounds described herein can be formulated for delivery to the central nervous system (CNS) (reviewed in Begley, Pharmacology & Therapeutics 104: 29-45 (2004)). Conventional approaches for drug delivery to the CNS include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide).
- Liposomes are a further drug delivery system which is easily injectable. Accordingly, in the method of invention the active compounds can also be administered in the form of a liposome delivery system. Liposomes are well known by those skilled in the art. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine of phosphatidylcholines. Liposomes usable for the method of invention encompass all types of liposomes including, but not limited to, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Another way to produce a formulation, particularly a solution, of a compound described herein, is through the use of cyclodextrin. By cyclodextrin is meant α-, β-, or γ-cyclodextrin. Cyclodextrins are described in detail in Pitha et al., U.S. Pat. No. 4,727,064, which is incorporated herein by reference. Cyclodextrins are cyclic oligomers of glucose; these compounds form inclusion complexes with any drug whose molecule can fit into the lipophile-seeking cavities of the cyclodextrin molecule.
- Rapidly disintegrating or dissolving dosage forms are useful for the rapid absorption, particularly buccal and sublingual absorption, of pharmaceutically active agents. Fast melt dosage forms are beneficial to patients, such as aged and pediatric patients, who have difficulty in swallowing typical solid dosage forms, such as caplets and tablets. Additionally, fast melt dosage forms circumvent drawbacks associated with, for example, chewable dosage forms, wherein the length of time an active agent remains in a patient's mouth plays an important role in determining the amount of taste masking and the extent to which a patient may object to throat grittiness of the active agent.
- Pharmaceutical compositions (including cosmetic preparations) may comprise from about 0.00001 to 100% such as from 0.001 to 10% or from 0.1% to 5% by weight of one or more compounds described herein. In other embodiments, the pharmaceutical composition comprises: (i) 0.05 to 1000 mg of the compounds of the invention, or a pharmaceutically acceptable salt thereof, and (ii) 0.1 to 2 grams of one or more pharmaceutically acceptable excipients.
- In some embodiments, a compound described herein is incorporated into a topical formulation containing a topical carrier that is generally suited to topical drug administration and comprising any such material known in the art. The topical carrier may be selected so as to provide the composition in the desired form, e.g., as an ointment, lotion, cream, microemulsion, gel, oil, solution, or the like, and may be comprised of a material of either naturally occurring or synthetic origin. It is preferable that the selected carrier not adversely affect the active agent or other components of the topical formulation. Examples of suitable topical carriers for use herein include water, alcohols and other nontoxic organic solvents, glycerin, mineral oil, silicone, petroleum jelly, lanolin, fatty acids, vegetable oils, parabens, waxes, and the like.
- Formulations may be colorless, odorless ointments, lotions, creams, microemulsions and gels.
- The compounds may be incorporated into ointments, which generally are semisolid preparations which are typically based on petrolatum or other petroleum derivatives. The specific ointment base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum drug delivery, and, preferably, will provide for other desired characteristics as well, e.g., emolliency or the like. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing.
- The compounds may be incorporated into lotions, which generally are preparations to be applied to the skin surface without friction, and are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are usually suspensions of solids, and may comprise a liquid oily emulsion of the oil-in-water type.
- The compounds may be incorporated into creams, which generally are viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation, as explained in Remington's, supra, is generally a nonionic, anionic, cationic or amphoteric surfactant.
- The compounds may be incorporated into microemulsions, which generally are thermodynamically stable, isotropically clear dispersions of two immiscible liquids, such as oil and water, stabilized by an interfacial film of surfactant molecules (Encyclopedia of Pharmaceutical Technology (New York: Marcel Dekker, 1992), volume 9).
- The compounds may be incorporated into gel formulations, which generally are semisolid systems consisting of either suspensions made up of small inorganic particles (two-phase systems) or large organic molecules distributed substantially uniformly throughout a carrier liquid (single phase gels). Although gels commonly employ aqueous carrier liquid, alcohols and oils can be used as the carrier liquid as well.
- Other active agents may also be included in formulations, e.g., other anti-inflammatory agents, analgesics, antimicrobial agents, antifungal agents, antibiotics, vitamins, antioxidants, and sunblock agents commonly found in sunscreen formulations including, but not limited to, anthranilates, benzophenones (particularly benzophenone-3), camphor derivatives, cinnamates (e.g., octyl methoxycinnamate), dibenzoyl methanes (e.g., butyl methoxydibenzoyl methane), p-aminobenzoic acid (PABA) and derivatives thereof, and salicylates (e.g., octyl salicylate).
- In certain topical formulations, the active agent is present in an amount in the range of approximately 0.25 wt. % to 75 wt. % of the formulation, preferably in the range of approximately 0.25 wt. % to 30 wt. % of the formulation, more preferably in the range of approximately 0.5 wt. % to 15 wt. % of the formulation, and most preferably in the range of approximately 1.0 wt. % to 10 wt. % of the formulation.
- Conditions of the eye can be treated or prevented by, e.g., systemic, topical, intraocular injection of a compound, or by insertion of a sustained release device that releases a compound. A compound may be delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material. Alternatively, the compounds of the invention may be injected directly into the vitreous and aqueous humour. In a further alternative, the compounds may be administered systemically, such as by intravenous infusion or injection, for treatment of the eye.
- The compounds described herein may be stored in oxygen free environment. For example, a composition can be prepared in an airtight capsule for oral administration, such as Capsugel from Pfizer, Inc.
- Cells, e.g., treated ex vivo with a compound as described herein, can be administered according to methods for administering a graft to a subject, which may be accompanied, e.g., by administration of an immunosuppressant drug, e.g., cyclosporin A. For general principles in medicinal formulation, the reader is referred to Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and Hematopoietic Stem Cell Therapy, E. D. Ball, J. Lister & P. Law, Churchill Livingstone, 2000.
- Toxicity and therapeutic efficacy of compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The LD50 is the dose lethal to 50% of the population. The ED50 is the dose therapeutically effective in 50% of the population. The dose ratio between toxic and therapeutic effects (LD50/ED50) is the therapeutic index. Compounds that exhibit large therapeutic indexes are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds may lie within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- Also provided herein are kits, e.g., kits for therapeutic purposes or kits for modulating the lifespan of cells or modulating apoptosis. A kit may comprise one or more compounds as described herein, e.g., in premeasured doses. A kit may optionally comprise devices for contacting cells with the compounds and instructions for use. Devices include syringes, stents and other devices for introducing a compound into a subject (e.g., the blood vessel of a subject) or applying it to the skin of a subject.
- In yet another embodiment, the invention provides a composition of matter comprising a compound of this invention and another therapeutic agent (the same ones used in combination therapies and combination compositions) in separate dosage forms, but associated with one another. The term “associated with one another” as used herein means that the separate dosage forms are packaged together or otherwise attached to one another such that it is readily apparent that the separate dosage forms are intended to be sold and administered as part of the same regimen. The compound and the other agent are preferably packaged together in a blister pack or other multi-chamber package, or as connected, separately sealed containers (such as foil pouches or the like) that can be separated by the user (e.g., by tearing on score lines between the two containers).
- In still another embodiment, the invention provides a kit comprising in separate vessels, a) a compound of this invention; and b) another therapeutic agent such as those described elsewhere in the specification.
- The practice of the present methods will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
- The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way.
-
- A suspension of 3,6-dichloropyridazine (23.8 g, 155 mmol) in 25% aqueous ammonia (50 mL) was heated at 100° C. for about 12 h in a PTFE-lined pressure reactor. Upon cooling to room temp, the resulting crystalline solids were collected by filtration, washed with water and dried to afford to 6-chloropyridazin-3-amine (20.0 g, 96%). MS (ESI) calcd for C4H4ClN3: 129.0.
-
- To a mixture containing ethyl formate (6.0 g, 81 mmol) and ethyl chloroacetate (9.89 g, 81 mmol) in 2-isopropoxypropane (200 mL) was added potassium tert-butoxide (t-BuOK) (9.07 g, 81 mmol) at 0° C. The mixture was stirred at room temp for 24 h. The mixture was filtered and the resulting yellow solids were washed with ethoxyethane to afford the potassium salt of ethyl 2-chloro-3-oxopropanoate (8.88 g, 58%).
-
- A mixture containing 6-chloropyridazin-3-amine (1.55 g, 119 mmol) and the potassium salt of ethyl 2-chloro-3-oxopropanoate (6.76 g, 357 mmol) in EtOH (100 mL) was stirred under reflux for 10 h. Upon cooling to room temp, the reaction mixture was concentrated under reduced pressure. Purification by chromatography afforded ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (1.5 g, 56%). MS (ESI) calcd for C9H8ClN3O2: 225.03; found: 226 [M+H].
-
- A mixture containing ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (1.25 g, 5.55 mmol), 3-(trifluoromethyl)phenylboronic acid (5.55 mmol), Cs2CO3 (3.62 g, 11.1 mmol) and Pd(PPh3)4 (0.32 g, 0.277 mmol) in 4:1:1 dioxane/water/ethanol (10 mL) was stirred at 100° C. for 2 h. Upon cooling to room temp, the reaction mixture was concentrated under reduced pressure. Purification by chromatography afforded ethyl 6-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (1.5 g, 80%). MS (ESI) calcd for C16H12F3N3O2: 335.09; found: 336 [M+H].
-
- A mixture containing NaOH (0.36 g, 89.5 mmol) and ethyl 6-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (1.5 g, 4.47 mmol) 1:1 dioxane:H2O (5 mL) was stirred at 0° C. for 4 h. The reaction mixture was concentrated under reduced pressure and enough 2% aqueous HCl was added to adjust the pH=5. The resulting solids were collected by filtration, washed with water and dried to afford 6-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (1.1 g, 81%). MS (ESI) calcd for C14H8F3N3O2: 307.06; found: 308 [M+H].
- This general coupling procedure followed by ester hydrolysis could be used to prepare a variety of 6-(3-substituted phenyl) and 6-(2,6-disubstituted phenyl) imidazo[1,2-b]pyridazine-3-carboxylates by substituting the appropriate boronic acid or boronic ester moiety for 3-(trifluoromethyl)phenylboronic acid.
-
- The following general amide coupling procedure was used:
- A mixture containing 6-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (200.0 mg, 0.65 mmol), 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,33-tetramethyluronium in hexafluorophosphate (HATU) (495.0 mg, 1.3 mmol), pyridin-2-amine (73.0 mg, 0.78 mmol) and N,N-Diisopropylethylamine (DIEA) (336.0 mg, 1.3 mmol) in DMF (5 mL) was stirred at 80° C. for 12 h. After cooling to room temp, the reaction mixture was concentrated and water was added. After extraction with CH2Cl2, the organic layer was dried (Na2SO4) and concentrated under reduced pressure. Purification by chromatography afforded N-(pyridin-2-yl)-6-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (30.0 mg, 12%). MS (ESI) calcd for C19H12F3N5O: 383.10; found: 384 [M+H].
- This general coupling procedure could be used to prepare a variety of 6-(3-trifluoromethylphenyl), 6-(3-trifluoromethoxyphenyl), 6-(3-morpholine), 6-(3-(methylsulfonyl)phenyl and 6-(2-flouro-6-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxyamides by substituting the appropriate amine moiety for pyridine-2-amine.
-
- Dioxane (anhydrous, 30 mL) and Cs2CO3 (21.4 g, 65.6 mmol) were added to a mixture of ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (7.4 g, 32.8 mmol) and 2-(trifluoromethyl)phenylboronic acid (8.1 g, 42.6 mmol). The mixture was then added to Pd(Ph3P)4 (1.9 g, 1.64 mmol), and the reaction was heated to 130° C. in microwave. The mixture was filtered. After cooling to room temp, the filtrate was concentrated, and the residue was purified by column chromatography to give ethyl 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (4.3 g, yield: 58%). MS (ESI) calcd for C16H12F3N3O2: 335.1.
-
- To a solution of compound ethyl 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (2.25 g, 6.71 mmol) in water (25 mL) was added NaOH (4.29 g, 107 mmol). The solution was stirred for 20 min at 70° C. and pH was adjusted to 3 using concentrated HCl. After cooling to room temp, filtration gave 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (1.84 g, 89%). MS (ESI) calcd for C14H8F3N3O2: 335.1.
- This general coupling procedure followed by ester hydrolysis could be used to prepare a variety of 6-(2-substituted phenyl), 6-(3-substituted phenyl), 6-(2,5-disubstituted phenyl), 6-(2,4-disubstituted phenyl), 6-(3,4-disubstituted phenyl), 6-(3,5-disubstituted phenyl), 6-(2,3-disubstituted phenyl) imidazo[1,2-b]pyridazine-3-carboxylic acids by substituting the appropriate boronic acid or boronic ester for 2-(trifluoromethyl)phenylboronic acid.
-
- To 2 mL of DMF were added 6-(morpholinomethyl)pyridin-2-amine (24.4 mg, 0.24 mmol), 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (50.0 mg, 0.16 mmol), HATU (119.0 mg, 0.32 mmol) and DIEA (41.0 mg, 0.32 mmol). The resulting mixture was stirred at 70° C. overnight. Water (20 mL) was added and the product was collected by filtration, washed with H2O and dried to afford N-(6-(morpholinomethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (62.0 mg, 78.9%). MS (ESI) calcd for C24H21F3N6O2: 482.1; found: 483.01 [M+H].
- This general coupling procedure could be used to prepare a variety of 6-(2-trifluoromethyl)phenyl), 6-(2-trifluoromethoxyphenyl), 6-(3-trifluoromethylphenyl), 6-(3-chlorophenyl), 6-(3-fluorophenyl), 6-(2,5-difluorophenyl), 6-(2,4-difluorophenyl), 6-(3,4-difluorophenyl), 6-(3,5-difluorophenyl), 6-(2,3-difluorophenyl), 6-(2-chloro-3-fluorophenyl), 6-(2-(methylsulfonyl)phenyl and 6-(2-cyanophenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 6-(morpholinomethyl)pyridin-2-amine.
-
- To a mixture of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.33 mmol) and HATU (245.0 mg, 0.64 mmol) DMF (2 mL) was added and stirred for 5 min. To this suspension, 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-amine (93.0 mg, 0.49 mmol) and DIEA (0.12 mL) were added and the reaction was stirred at 60° C. for 18 h. After cooling to room temp, MeOH (0.3 mL) was added. The crude product was purified by reverse phase preparative HPLC to afford 53.0 mg (33%) of N-(6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)-6-(2 (trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide. MS (ESI) calcd for C24H19F3N6O2: 480.1; found: 481.2 [M+H].
- This general coupling procedure could also be used to prepare N-(2-(1-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide.
-
- (trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide was prepared using the general coupling method above. The ring opening of the oxetane in the final product (N-(2-(3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy)pyrimidin-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide) occurred during preparative HPLC purification. MS (ESI) calcd for C23H21F3N6O4: 502.1.
-
- N-(6-((2-phenyl-1,3-dioxan-5-yl)oxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide was obtained (40.0 mg, 22%) from HATU mediated coupling of 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (100.0 mg, 0.32 mmol) and 6-((2-phenyl-1,3-dioxan-5-yl)oxy)pyridin-2-amine following the same procedure as described for the preparation of Compound 19. MS (ESI) calcd for C28H21F3N5O4: 561.1.
-
- N-(6-((2-phenyl-1,3-dioxan-5-yl)oxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (40.0 mg, 0.07 mmol) was taken up in EtOH:3N HCl (3:1, 7 mL) and heated to 80° C. for 2 h. After cooling to room temp and evaporating the solvent, the crude product was purified by preparative HPLC to afford N-(6-((1,3-dihydroxypropan-2-yl)oxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (12.0 mg, 35%). MS (ESI) calcd for C22H18F3N5O4: 473.1; found 474.2.
-
- NaH (2.3 g, 60% in mineral oil, 57.5 mmol) was added the mixture of 6-chloropyridin-2-amine (2 g, 15.6 mmol) and solketal (6.0 g, 45.4 mmol) in Dioxane (25 mL) solution at 0° C. The temp was elevated to 120° C. for overnight, filtered the solid and concentrated, purified by column chromatography to give 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-amine (1.3 g, yield: 37.4%). MS (ESI) calcd for C11H16N2O3:
- This general coupling procedure could be used to prepare 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine, 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine, 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-2-amine, 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-3-amine, 5-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine, 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine, 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-methylpyrimidin-2-amine and 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-methylpyridin-4-amine moieties.
-
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-amine (110.0 mg, 0.49 mmol) was taken up in DMF (1 mL) along with 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.33 mmol), HATU (247.0 mg, 0.65 mmol) and DIEA (84.0 mg, 0.65 mmol). The resulting reaction mixture was stirred at 65° C. for 24 h. Water (25 mL) was added and the solid was filtered, purified by flash chromatography to afford the intermediate N-(6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide as a brown solid (80.0 mg). The solid was taken up in MeOH (10 mL), conc. HCl (0.1 mL) was added, and the mixture was stirred for 1 h at room temp. The solvents were evaporated to give a solid which was stirred with saturated Na2CO3 to neutralize the acid. The resulting solid was filtered to afford N-(6-(2,3-dihydroxypropoxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (101.0 mg, 65.6%). MS (ESI) calcd for C22H18F3N5O4: 473.1; found: 473.8 [M+H].
- This general coupling procedure could be used to prepare a variety of N-(2-(2,3-dihydroxypropoxy)pyrimidin-4-yl), N-(6-(2,3-dihydroxypropoxy)pyrazin-2-yl), N-(4-(2,3-dihydroxypropoxy)pyrimidin-2-yl), N-(6-(2,3-dihydroxypropoxy)pyridin-3-yl), N-(5-(2,3-dihydroxypropoxy)pyrazin-2-yl)-6-(2-(substitued)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides, 6-(2-substituted)-N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamides, 6-(2-substituted)-N-(4-(2,3-dihydroxypropoxy)-6-methylpyrimidin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamides and N-(2-(2,3-dihydroxypropoxy)-6-methylpyridin-4-yl)-6-(2-substituted)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides by starting from the appropriate 6-(2-(substituted)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid.
-
- A mixture of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (154.0 mg, 0.5 mmol) and carboxydiimidazole (162.0 mg, 1.0 mmol) in dioxane (4 mL) was heated to 70° C. for 1 h. 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-amine (337.0 mg, 1.5 mmol) was then added and heating was continued at 100° C. for 17 h. After cooling to room temp, the solvent was evaporated and the residue was taken up in EtOH:3 N HCl (3:1). The mixture was stirred at room temp for 1 h, then refluxed for 1 h. After evaporating the solvent and purification by preparative HPLC N-(4-(2,3-dihydroxypropoxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide was obtained (118.0 mg, 50%). MS (ESI) calcd for C22H18F3N5O4: 473.1; found: 473.8 [M+H].
- This general procedure could also be used to prepare N-(4-(2,3-dihydroxypropoxy)-6-methylpyrimidin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide and N-(2-(2,3-dihydroxypropoxy)pyridin-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide.
-
- To a solution of (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine (200.0 mg, 0.89 mmol) in pyridine (10 mL), 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carbonyl chloride (320.0 mg, 0.98 mmol) was added and the reaction was heated to 60° C. for 10 min. After cooling to room temp, H2O (50 mL) was added and the mixture was stirred. The white solid was collected by filtration, washed and dried to afford (R)—N-(6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (250.0 mg, yield 54.6%). MS (ESI) calcd for C24H21F3N6O4: 514.4.
-
- To a solution of (R)—N-(6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (250.0 mg, 0.49 mmol) in MeOH (10 mL) was added conc. HCl (1 mL) at room temp. After stirring for 1 h, 50 mL of cold aqueous NaHCO3 solution was added. White solid separated after stirring and was collected by filtration, washed with water and dried to afford (S)—N-(6-(2,3-dihydroxypropoxy)pyrazin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (200.0 mg, yield 87%). MS (ESI) calcd for C21H17F3N6O4: 474.1.
- This general procedure could be used to prepare (R)—N-(6-(2,3-dihydroxypropoxy)pyrazin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide, (R)—N-(6-(2,3-dihydroxypropoxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide, (S)—N-(6-(2,3-dihydroxypropoxy)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide, (R)—N-(2-(2,3-dihydroxypropoxy)-6-methylpyridin-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide and (S)—N-(2-(2,3-dihydroxypropoxy)-6-methylpyridin-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide.
-
- Ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (903.0 mg, 4 mmol) was taken up in 5 mL of dioxane/water (4:1) along with 2-formylphenylboronic acid (720.0 mg, 4.8 mmol), Pd(PPh3)4 (231.0 mg, 0.2 mmol) and Na2CO3 (1.02 g, 9.6 mmol). The resulting reaction mixture was stirred at 120° C. for 20 min in a microwave reactor. Upon cooling to room temp, the mixture was diluted with methylene chloride (DCM) (20 mL) and filtered. The filtrate was dried (Na2SO4) and concentrated under reduced pressure. The resulting residue was purified by chromatography to afford 6-(2-formyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester (700.0 mg, 59%). MS (ESI) calcd for C18H13N3O3: 295.10; found: 296 [M+H].
-
- To a solution of 6-(2-formyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester (7.40 g, 25 mmol) in CH2Cl2 (160 mL) was added a solution of diethylaminosulfur trifluoride (DAST) (6.05 g, 37.6 mmol) in CH2Cl2 (20 mL) at 0° C. The resulting reaction mixture was stirred under a gentle reflux for 48 h. The mixture was then poured into a saturated aqueous NaHCO3 solution and further extracted with DCM. The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure. Purification by chromatography afforded 6-(2-difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester (1.0 g, 13%). MS (ESI) calcd for C16H13F2N3O2: 317.10; found: 318[M+H].
-
- To a solution of 6-(2-difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester (1.17 g, 3.69 mmol) in MeOH (50 mL) was added a solution of sodium hydroxide (6.0 N, 15 mL). The resulting reaction mixture was stirred under reflux for 90 min. Upon cooling to room temp, the mixture was acidified to pH=4 and then concentrated under reduced pressure. The resulting residue was purified by chromatography to afford 6-(2-difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid (970.0 mg, 90%). MS (ESI) calcd for C14H9F2N3O2: 289.07; found: 290 [M+H].
-
- 6-(2-Difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid (0.3 mmol) and thiazol-2-amine (0.36 mmol) were subjected to the same general amide coupling procedure described above to prepare 6-(2-difluoromethyl-phenyl)-imidazo[1,2-b]pyridazine-3-carboxylic acid thiazol-2-ylamide (yield 61.3%). MS (ESI) calcd for C17H11F2N5OS: 371.07; found: 372 [M+H].
- This general coupling procedure could be used to prepare a variety of 6-(2-(difluoromethyl)phenyl) imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for thiazol-2-amine.
-
- To a solution of ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (500.0 mg, 2.21 mmol) in dioxane:EtOH:H2O (4:1:3, 9 mL), (3,5-dimethylisoxazol-4-yl)boronic acid (404 mg, 2.87 mmol), Cs2CO3 (1.45 g, 4.42 mmol) and Pd(PPh3)4 (127.0 mg, 0.11 mmol) were added and the reaction was refluxed for 15 h. After cooling to room temp, the solvents were evaporated and the solid was taken up in THF (6 mL). A solution of LiOH (106.0 mg, 4.42 mmol) in H2O (3 mL) was added, the mixture was stirred for 15 h. The solvent was removed under reduced pressure and the residue was acidified to pH 4 with 3N HCl. The volatiles were evaporated under reduced pressure and the solid was triturated with MeOH:H2O (1:1). Upon filtration 6-(3,5-dimethylisoxazol-4-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid was obtained (331.0 mg, 58%). MS (ESI) calcd for C12H10N4O3: 258.1; found: 258.9 [M+H].
- This general coupling procedure followed by ester hydrolysis could be used to prepare 6-(1-methyl-1H-pyrazol-4-yl), 6-(2-methylpyridin-3-yl), 6-(5-(difluoromethyl)pyridin-3-yl), 6-(2-methylpyridin-3-yl), 6-(2,4-dimethylthiazole), 6-(2,3,4-trifluromethyl phenyl), 6-(2-fluorophenyl), 6-(2-chlorophenyl) 6-(2-fluoro-3-chlorophenyl) and 6-(2-chloro-6-fluorophenyl) imidazo[1,2-b]pyridazine-3-carboxylic acids by substituting the appropriate boronic acid or boronic ester moiety for (3,5-dimethylisoxazol-4-yl)boronic acid.
-
- A solution of 6-(3,5-dimethylisoxazol-4-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid (75.0 mg, 0.29 mmol), HATU (228.0 mg, 0.6 mmol), 2-(pyrrolidin-1-yl)pyridin-4-amine (72.0 mg, 0.44 mmol) and DIEA (0.11 mL) in DMF (2 mL) was stirred at room temp for 15 h. H2O was added until solid precipitated out, which was collected by filtration, washed with H2O and dried to afford 6-(3,5-dimethylisoxazol-4-yl)-N-(2-(pyrrolidin-1-yl)pyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide (44.0 mg, 38%). MS (ESI) calcd for C21H21N7O2: 403.1; found: 404 [M+H].
- This general coupling procedure could be used to prepare 6-(3,5-dimethylisoxazol-4-yl), 6-(1-methyl-1H-pyrazol-4-yl), 6-(2-methylpyridin-3-yl), 6-(5-(difluoromethyl)pyridin-3-yl), 6-(2,4-dimethylthiazole), 6-(2,3,4-trifluromethyl phenyl), 6-(2-fluorophenyl), 6-(2-chlorophenyl), 6-(2-fluoro-3-chlorophenyl) and 6-(2-chloro-6-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 2-(pyrrolidin-1-yl)pyridin-4-amine.
-
- To a solution of ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (250.0 mg, 1.1 mmol) and 2-(tributylstannyl)thiazole (619.0 mg, 1.65 mmol) in dioxane (5 mL), Pd(PPh3)4 (150.0 mg, 0.17 mmol) was added and the reaction was heated to 80° C. for 17 h. After cooling to room temp, LiOH (53.0 mg, 2.3 mmol) in THF:H2O (3:1) was added and stirred vigorously for 4 h. The solvents were evaporated and 6-(thiazol-2-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid was precipitated out from MeOH:H2O (164.0 mg, yield 66%). MS (ESI) calcd for C10H6N4O2S: 246.02.
- The general amide coupling procedure described above for 6-(3,5-dimethylisoxazol-4-yl)-N-(2-(pyrrolidin-1-yl)pyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide could be used to prepare N-(6-morpholinopyridin-2-yl)-6-(thiazol-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (Compound 64).
-
- A mixture of ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (200.0 mg, 0.89 mmol), 2-hydroxyphenylboronic acid (183.0 mg, 1.33 mmol) Cs2CO3 (342.0 mg, 1.77 mmol), and Pd(PPh3)4 (102.0 mg, 0.09 mmol) was taken up in dioxane (4 mL) and refluxed for 2 h. After cooling to room temp, the reaction was diluted with EtOAc and extracted with H2O. The organic layer was dried over Na2SO4, filtered and evaporated to dryness under reduced pressure. The crude material was purified by vacuum distillation to afford ethyl 6-(2-hydroxyphenyl)imidazo[1,2-b]pyridazine-3-carboxylate (120.0 mg, 47.8%). MS (ESI) calcd for C15H13N3O3: 283.1.
-
- To a solution of ethyl 6-(2-hydroxyphenyl)imidazo[1,2-b]pyridazine-3-carboxylate (50.0 mg, 0.18 mmol), and triphenylphosphine (55.6 mg, 0.21 mmol), (2,2-dimethyl-1,3-dioxolan-4-yl)methanol (25.7 mg, 0.19 mmol) and DIAD (27.7 mg, 0.21 mmol) were added. The mixture was stirred in THF (2 mL) at 60° C. for 2 h. After cooling to room temp, the crude material was purified by column chromatography to give ethyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate. MS (ESI) calcd for C21H23N3O5: 397.2.
-
- Ethyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (2.0 g, 5.03 mmol) was hydrolyzed to 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid following the general procedure described above (1.3 g, 69.9%). MS (ESI) calcd for C19H19N3O5: 369.37.
-
- 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (80.0 mg, 0.22 mmol) and 6-morpholinopyridin-2-amine were coupled using the HATU mediated general amide coupling procedure described above for preparation of Compound 19 to afford 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-N-(6-morpholinopyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (50.0 mg, 43%). MS (ESI) calcd for C28H30N6O5: 530.2.
- This general procedure could be used to prepare (S)-6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl), (R)-6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl), 6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl) and 6-(2-(2,3-dihydroxypropoxy)phenyl)N-(substituted)imidazo[1,2-b]pyridazine-3-carboxylic acids by substituting the appropriate boronic acid for 2-hydroxyphenylboronic acid in step 1, and substituting the appropriate alcohol for (2,2-dimethyl-1,3-dioxolan-4-yl)methanol in step 2.
-
- 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-N-(6-morpholinopyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (50.0 mg, 0.09 mmol) was dissolved in MeOH (2 mL), HCl (0.5 mL) was added and the reaction stirred at room temp for 15 h. The solvents were evaporated, the mixture was washed taken up in Na2CO3 solution and the resultant solids were filtered to give 6-(2-(2,3-dihydroxypropoxy)phenyl)-N-(6-morpholinopyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (40.0 mg, 90%). MS (ESI) calcd for C25H26N6O5: 490.2; found 491.1 [M+H].
- This general procedure could be used to prepare a variety of 6-(2-(2,3-dihydroxypropoxy)phenyl)-N-(substituted), 6-(3-(2,3-dihydroxypropoxy)phenyl)-N-(substituted) and 6-(2-(2,3-dihydroxypropoxy)phenyl)-N-(substituted) imidazo[1,2-b]pyridazine-3-carboxamides.
-
- A mixture of ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (500.0 mg, 2.22 mmol), (S)-3-fluoropyrrolidin hydrochloride (557.0 mg, 4.43 mmol), and K2CO3 (1.53 g, 11.08 mmol) in DMSO (50 mL) was heated at 120° C. for 12 h. The mixture was portioned between H2O and EtOAc and the organic layer was separated and concentrated. The crude residue was purified by flash chromatography to give (S)-ethyl 6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylate (300.0 mg, 49% yield). MS (ESI) calcd for C13H15FN4O2 (m/z): 278.12.
-
- A mixture of (S)-ethyl 6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylate (300.0 mg, 1.08 mmol) and NaOH (172.0 mg, 1.08 mmol) in MeOH/H2O (200 mL, 1:1) was heated at 70° C. for 2 h. The mixture was concentrated and the pH was adjusted to 3 by the addition of 2% aq HCl. The mixture was concentrated to give (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid (240.0 mg, 69% yield). MS (ESI) calcd for C11H11FN4O2 (m/z): 250.09.
- This general coupling procedure followed by ester hydrolysis could be used to prepare a variety of 6-(3-fluoropyrrolidin-1-yl), 6-(3,3-difluoropyrrolidin-1-yl), 6-(3-(trifluoromethyl)piperidin-1-yl), 6-(3-dimethylpyrrolidin-3-amine), 6-(3,3-difluoroazetidin-1-yl), 6-(4,4-difluoropiperidin-1-yl), 6-(3-methylpyrrolidin-1-yl), 6-(3-hydroxypyrrolidin-1-yl), 6-(3-methoxypyrrolidin-1-yl), 6-(3-fluoropiperidin-1-yl), 6-(morpolin-1-yl), 6-(3-methylmorpolin-1-yl), 6-(3,5-dimethylmorpolin-1-yl) and 6-(N-methylpiperazin-1-yl), 6-(3-fluoropiperidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylates by substituting the appropriate amine moiety for (S)-3-fluoropyrrolidine hydrochloride in step 1. This general procedure could also be used to prepare (S)-6-(3-fluoropyrrolidin-1-yl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid by substituting ethyl 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate for ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate in step 1.
-
- A solution of (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.40 mmol), 6-morpholinopyridin-2-amine (107.0 mg, 0.60 mmol), DIPEA (103.0 mg, 0.80 mmol) and HATU (304.0 mg, 0.80 mmol) in DMF (5 mL) was heated at 70° C. for 16 h. H2O was added and the resulting ppt was purified by flash chromatography to give (S)-6-(3-fluoropyrrolidin-1-yl)-N-(6-morpholinopyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (45.0 mg, 27% yield). MS (ESI) calcd for C20H22FN7O2 (m/z): 411.18; found: 412 [M+H].
- This general coupling procedure could be used to prepare a variety of 6-(3-fluoropyrrolidin-1-yl), 6-(3,3-difluoropyrrolidin-1-yl), 6-(3-dimethylpyrrolidin-3-amine), 6-(pyrrolidin-1-yl), 6-(3,3-difluoroazetidin-1-yl), 6-(4,4-difluoropiperidin-1-yl), 6-(3-methylpyrrolidin-1-yl), 6-(3-hydroxypyrrolidin-1-yl), 6-(3-methoxypyrrolidin-1-yl), 6-(3-fluoropiperidin-1-yl), 6-(morpolin-1-yl), 6-(3-methylmorpolin-1-yl), 6-(3,5-dimethylmorpolin-1-yl), 6-(N-methylpiperazin-1-yl) and 6-(3-fluoropiperidin-1-yl) imidazo[1,2-b]pyridazine-3-carboxamides, as well as 6-(substituted)-2-methylimidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 6-morpholinopyridin-2-amine and substituting the appropriate carboxylic acid moiety for (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid. In cases where the carboxylic acid moiety contains a protected glycerol group, and extra deprotection step is used as in previous examples.
-
- To 3,3,3-trifluoropropan-1-ol (19.9 mmol) in DMSO was added NaH (19.9 mmol). The mixture was allowed to stir at room temp under inert atmosphere for 1 h. Ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (3.0 g, 13.3 mmol) was added and the reaction was warmed to 100° C. until coupling was complete. After purification ethyl 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxylate was obtained (1.2 g, 45%). MS (ESI) calcd for C12H12F3N3O3: 303.08.
-
- To a solution of ethyl 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxylate (1.2 g, 3.96 mmol) in water/THF (1:1) was added LiOH (474.0 mg, 19.79 mmol). The reaction was allowed to stir at room temp until hydrolysis was complete. After purification 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxylic acid was obtained (0.9 g, 83%). MS (ESI) calcd for C10H8F3N3O3: 275.05.
-
- 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.36 mmol) was dissolved in DCM. DMF (1 drop) and oxalyl chloride were added and the mixture was allowed to stir 1 h or more. 3-aminopyridine and DIEA were added and after coupling was complete, purification gave N-(pyridin-3-yl)-6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxamide (60.0 mg, 47%). MS (ESI) calcd for C15H12F3N5O2: 351.09.
- This general coupling procedure could be used to prepare a variety of 6-(3,3,3-trifluoropropoxy)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 3-aminopyridine.
-
- 6-chloropyridazin-3-amine (1.0 g, 7.72 mmol), ethyl 2-chloro-3-oxobutanoate (2.53 g, 15.4 mmol) and EtOH (15 mL) was refluxed for 24 h. Upon cooling the mixture to room temp, the reaction was concentrated under reduced pressure. Crude material was adsorbed onto silica gel and purified by column chromatography to give ethyl 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (480.0 mg, 26%). MS (ESI) calcd for C10H10ClN3O2: 239.05.
-
- To a mixture of 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (5.26 g, 22 mmol) and 2-(trifluoromethyl)phenyl-boronic acid (6.26 g, 32.5 mmol) in dioxane:EtOH:H2O (8:1:1, 100 mL) was added Pd(PPh3)4 (2.4 g, 2.1 mmol) and Cs2CO3 (13.7 g, 42 mmol). The reaction was refluxed for 2 h. After cooling to room temp, the reaction was diluted with EtOAc (400 mL) and extracted with H2O. The organic layer was dried, concentrated and the crude product was purified by column chromatography (0-10% CH2Cl2+MeOH). This material was taken up in THF, LiOH (1.58 g, 66 mmol) in H2O was added and the mixture was stirred for 17 h. The solvents were evaporated and the residue was acidified with 3N HCl to pH 3. This aqueous suspension was extracted with EtOAc (2×300 mL). Combined organic layers were evaporated to dryness, the residue was purified by column chromatography (0-10% CH2Cl2+MeOH) to afford 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (4.5 g, 64%). MS (ESI) calcd for C15H10F3N3O2: 321.1; found 322.1 [M+H].
- This general coupling procedure followed by ester hydrolysis could be used to prepare a variety of 2-methyl-6-(3-trifluoromethylphenyl), 2-methyl-6-(3-trifluoromethoxyphenyl), 2-methyl-6-(2-trifluoromethoxyphenyl), 2-methyl-6-(2-difluoromethylphenyl), 2-methyl-6-(2-methylphenyl), 2-methyl-6-(3-methylphenyl), 2-methyl-6-(3-fluorophenyl), 2-methyl-6-(2-fluorophenyl), 2-methyl-6-(2-bromophenyl), and 2-methyl-6-(3-cyanophenyl) imidazo[1,2-b]pyridazine-3-carboxylates by substituting the appropriate boronic acid or boronic ester moiety for 2-(trifluoromethyl)phenylboronic acid.
-
- 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (1.1 g, 3.43 mmol), and HATU (2.6 g, 6.8 mmol) were taken up in DMF (12 mL). Pyridazine-3-amine (530.0 mg, 5.57 mmol) and DIEA (1.3 mL) were added and the resulting reaction mixture was stirred at 60° C. for overnight. After cooling to room temp, water (12 mL) was added and the solid was separated by filtration. The solid was taken up in EtOAc and washed with saturated NaHCO3 solution. The organic layer was dried, evaporated and the crude product was purified by column chromatography (DCM+MeOH 0-5%) to afford 2-methyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (570.0 mg, 42%). MS (ESI) calcd for C19H13F3N6O: 398.1; found: 399.1 [M+H].
- This general coupling procedure could be used to prepare a variety of 2-methyl-6-(3-trifluoromethylphenyl), 2-methyl-6-(3-trifluoromethoxyphenyl), 2-methyl-6-(2-trifluoromethoxyphenyl), 2-methyl-6-(2-difluoromethylphenyl), 2-methyl-6-(2-methylphenyl), 2-methyl-6-(3-methylphenyl), 2-methyl-6-(3-fluorophenyl), 2-methyl-6-(2-fluorophenyl), 2-methyl-6-(2-chlorophenyl), 2-methyl-6-(2-bromophenyl), and 2-methyl-6-(3-cyanophenyl) imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for pyridazine-3-amine.
-
- A pressure tube was charged with a solution of CDI (75.5 mg, 0.47 mmol) in dioxane (2 mL). A solution of 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.31 mmol) in dioxane:DMA (1:1, 2 mL) was added and the mixture was heated to 100° C. for 15 h. 6-methoxypyrimidin-4-amine (117.0 mg, 0.93 mmol) was then added and the heating was continued for 3 d. After cooling to room temp, H2O was added and suspension was extracted with CH2Cl2. The crude material was purified by column chromatography (0-5% CH2Cl2+MeOH) to afford N-(2-methoxypyrimidin-4-yl)-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (71.0 mg, 53%). MS (ESI) calcd for C20H15F3N6O2: 428.1; found: 429.1 [M+H].
- This general procedure could be used to prepare N-(2-methoxypyrimidin-4-yl)-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide and N-(2-methoxypyrimidin-4-yl)-2-methyl-6-(2-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide.
-
- 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (97.0 mg, 0.3 mmol) and HATU (228.0 mg, 0.6 mmol) were taken up in ACN (2 mL) in a pressure tube. 5-Chloropyridine-2-amine (57.4 mg, 0.45 mmol) and pyridine (0.1 mL) were added and the reaction was heated to 100° C. for 15 h. After cooling to room temp, H2O was added and the solid was separated by filtration to afford N-(5-chloropyridin-2-yl)-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (80.0 mg, 43%). MS (ESI) calcd for C20H13ClF3N5O: 431.08; found: 432.1 [M+H].
- This general procedure could be used to prepare N-(1-ethyl-1H-pyrazol-5-yl)-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide, 2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide and N-(1-isopropyl-1H-pyrazol-5-yl)-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide.
-
- (S)-6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.261 mmol) and 2-aminopyridine (37.0 mg, 0.392 mmol) were coupled using the HATU mediated general amide coupling procedure described above for preparation of Compound 19 to afford (S)-6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methyl-N-(pyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (50.0 mg, 43%). MS (ESI) calcd for C25H25N5O4: 459.2. This procedure could be used to prepare (S)-6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid and (R)-6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid by reacting 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate with 3-hydroxyphenylboronic acid. MS (ESI) calculated for C20H21N3O5 383.15.
-
- (S)-6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methyl-N-(pyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (50.0 mg, 0.108 mmol) was taken up in EtOH: 3N HCl (3:1, 4 mL). This clear solution was stirred at room temp for 3 h. The solvent was removed under reduced pressure and the product was purified by reverse phase preparative HPLC to afford (R)-6-(3-(2,3-dihydroxypropoxy)phenyl)-2-methyl-N-(pyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide (20.0 mg, 50%). MS (ESI) calcd for C22H21N5O4: 419.1; found: 420.2 [M+H].
- This general procedure could be used to prepare a variety of 6-(3-(2,3-dihydroxypropoxy)phenyl)-2-methyl-N-(substituted)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 2-aminopyridine.
-
- To the degassed dimethoxyethane (DME) (150 mL) were added ethyl 6-chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (3.8 g, 15.9 mmol), 2-hydroxyphenylboronic acid (3.28 g, 23.8 mmol), Pd(dppf)Cl2 (697.0 mg, 0.95 mmol), and K2CO3 (4.38 g, 31.7 mmol). The mixture was stirred at 100° C. for 12 h. The mixture was concentrated and purified by column chromatography (pet ether:ethyl acetate=4:1) to give ethyl 6-(2-hydroxyphenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (2.0 g, 40% yield). MS (ESI) calcd for C16H15N3O3: 297.1.
-
- To a solution of ethyl 6-(2-hydroxyphenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (2.0 g, 6.7 mmol) and (R)-4-Chloromethyl-2,2-dimethyl-1,3-dioxolane (1.5 g, 10 mmol) in DMF (80 mL) was added K2CO3 (3.7 g, 27 mmol). The mixture was heated to 100° C. for 12 h. After cooling to room temp, the solvent was removed in vacuo and ethyl acetate: H2O (60 mL, 1:1) was added to the mixture. The resulting mixture was extracted with ethyl acetate (30 mL×3), combined organic layers were dried, and crude product was purified by column chromatography (petroleum ether: ethyl acetate=8:1) to give (S)-ethyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (2.0 g, 72% yield). MS (ESI) calcd for C22H25N3O5: 411.2.
-
- A solution of (S)-ethyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (1.9 g, 4.6 mmol) and LiOH H2O (0.97 g, 23 mmol) in THF: H2O (60 mL, 5:1) was stirred at 50° C. overnight. The THF was removed in vacuo and the pH was adjusted to 4 using 1N aq HCl. The resulting precipitate was collected by filtration, rinsed with H2O and dried to give (S)-6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid (1.4 g, 80% yield). MS (ESI) calcd for C20H21N3O5: 383.1.
- This general procedure could be used to prepare 6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid by substituting 3-hydroxyphenylboronic acid for 2-hydroxyphenylboronic acid.
-
- To a solution of (S)-6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid (100.0 mg, 0.26 mmol), 2-aminopyridine (49.0 mg, 0.52 mmol) and HATU (198.0 mg, 0.52 mmol) in DMF (1.5 mL) was added DIEA (0.2 mL), the mixture was stirred at 60° C. overnight. H2O was added and the resulting precipitate was filtered to give the crude product. The crude product was taken up in EtOH:3N HCl (3:1) and stirred overnight. The solvents were evaporated and further purification by using reverse phase preparative HPLC afforded (R)-6-(2-(2,3-dihydroxypropoxy)phenyl)-2-methyl-N-(pyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide as a white solid (16.4 mg, yield 15% over two steps). MS (ESI) calcd for C22H21N5O4: 419.1; found 420.0 [M+H].
-
- To a solution of (S)-6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid (800.0 mg, 2.09 mmol) and 4-dimethylaminopyridine (DMAP) (382.0 mg, 3.13 mmol) in 10 mL of DMF was added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) (EDCI) (600.0 mg, 3.13 mmol) under nitrogen. After stirring at room temp for 2 h, 4-nitrophenol (294.0 mg, 2.09 mmol) was added to the reaction and stirred at room temp for 18 h. Sodium carbonate solution (50 mL) was added to the mixture and aqueous layer was extracted with ethyl acetate (2×30 mL). The combined organic layers were washed with aqueous Na2CO3 (3×20 mL, until the aqueous layer was colorless), brine and then concentrated in vacuo to give a crude solid, which was triturated in pet ether: ethyl acetate (4:1) to give (S)-4-nitrophenyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate as a white solid (0.15 g, 14% yield). MS (ESI) calcd for C26H24N4O7: 504.2.
- This general procedure could be used to prepare (S)-4-nitrophenyl 6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate by starting from 6-(3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid.
-
- To a solution of 4-aminopyrimidine (17.5 mg, 0.14 mmol) in THF (2 mL) at 0° C. was added NaH (8.4 mg, 0.21 mmol) and the reaction stirred for 10 min. (S)-4-nitrophenyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (35.0 mg, 0.07 mmol) was added to the reaction mixture and stirred at room temp for 30 min. Saturated NH4Cl aqueous solution was added and the mixture was extracted with ethyl acetate. The organic layer was washed with aq. Na2CO3, brine, dried over Na2SO4 to give the crude product. Further purification by preparation TLC to give (S)-4-nitrophenyl 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylate (30.2 mg, yield 87%). This material was taken up in EtOH:3N HCl (3:1) and stirred overnight. The solvents were evaporated and washed with aq. Na2CO3, brine to afford as a white solid (S)-6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl)-2-methyl-N-(pyrimidin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide (15.0 mg, two steps yield 50%). MS (ESI) calcd for C21H20N6O4: 420.1; found: 421.2 [M+H].
- This general procedure could be used to prepare a variety of 6-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)phenyl) and 6-(3-(2,3-dihydroxypropoxy)phenyl)-2-methyl-N-(substituted)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 4-aminopyrimidine.
-
- A solution of compound 3,6-dichloro-4-methylpyridazine (20.0 g, 122.7 mmol) and ammonium hydroxide in water (86.60 g, 245 mmol) was refluxed for about 30 h. The mixture was concentrated and used in the next step without purification.
-
- A mixture of potassium salt of ethyl 2-chloro-3-oxopropanoate prepared using the procedure above (13.14 g, 69.7 mmol), 6-chloro-5-methylpyridazin-3-amine and 6-chloro-4-methylpyridazine-3amine (5.0 g, 34.8 mmol) was taken up in conc. sulfuric acid (3.42 g, 34.8 mmol) and EtOH (600 mL). The mixture was refluxed for about 30 h after which it was cooled to room temp, concentrated and purified by column chromatography to separate the regioisomeric ethyl 6-chloro-8-methylimidazo[1,2-b]pyridazine-3-carboxylate and ethyl 6-chloro-7-methylimidazo[1,2-b]pyridazine-3-carboxylate which were carried forward as single regioisomers.
-
- A solution of ethyl 6-chloro-8-methylimidazo[1,2-b]pyridazine-3-carboxylate (1.5 g, 6.26 mmol), 2-(trifluoromethyl)phenylboronic acid (2.38 g, 12.52 mmol), Pd(PPh3)4 (0.362 g, 0.313 mmol), Cs2CO3 (4.08 g, 12.52 mmol) in a mixture solvents (dioxane:EtOH:H2O) was heated at 100° C. for about 30 h. Water was added and the solid was purified by column chromatography to afford ethyl 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate. MS (ESI) calcd for C17H14F3N3O2: 349.10.
-
- To a solution of ethyl 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (0.1 g, 0.29 mmol) in THF (5 mL) and H2O (5.00 mL) was added NaOH (0.18 g, 4.58 mmol) and the reaction mixture was stirred at 70° C. for 2 h. Solvents were removed under reduced pressure and 2% HCl aqueous was added to make pH=3. The solid was separated by filtration to yield 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid. MS (ESI) calcd for C15H10F3N3O2: 321.1.
-
- 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (40.0 mg, 0.13 mmol) and 4-amino pyridine (16.0 mg, 0.16 mmol) were coupled using the general amide coupling reaction described above for Compound 19 to afford 8-methyl-N-(pyridine-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (18 mg, 36% yield). MS (ESI) calcd for C20H14F3N5O: 397.1; found: 397.9 [M+H].
- This general procedure could be used to prepare a variety of 8-methyl-N-(pyridine-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 4-amino pyridine.
-
- To a mixture of ethyl 6-chloro-7-methylimidazo[1,2-b]pyridazine-3-carboxylate (1.0 g, 4.17 mmol) prepared above, 2-(trifluoromethyl)phenylboronic acid (0.95 g, 5.01 mmol), K3PO4 (2.66 g, 12.52 mmol), Pd2(dba)3 (0.19 g, 0.21 mmol) and X-Phos (0.2 g, 0.42 mmol) was added dioxane (4 mL) and the mixture was heated at 120° C. for about 12 h. After cooling to room temp and concentrating under reduced pressure, the crude product was purified by column chromatography to afford ethyl 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate. MS (ESI) calcd for C17H14F3N3O2: 349.10.
-
- Ethyl 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (0.15 g, 0.429 mmol) was hydrolyzed using the general procedure described above for the preparation of 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid to afford 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid. MS (ESI) calcd for C15H10F3N3O2: 321.1.
-
- 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (50.0 mg, 0.16 mmol) and 4-amino pyridine (23.0 mg, 0.24 mmol) were coupled using the general amide coupling reaction described above to afford 7-methyl-N-(pyridin-4-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (45.0 mg, 73% yield). MS (ESI) calcd for C20H14F3N5O: 397.1; found: 397.9 [M+H].
- This general procedure could be used to prepare a variety of 7-methyl-N-(substituted)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 4-amino pyridine.
-
- Concentrated sulfuric acid (1.14 mL, 21.4 mmol) was added to EtOH (39 mL) and cooled to 0° C. The potassium salt of ethyl 2-chloro-3-oxopropanoate (7.81 g, 41.4 mmol) was added, followed by 6-chloro-4,5-dimethylpyridazin-3-amine (2.11 g, 13.4 mmol). The reaction was allowed to stir at 0° C. for 5 min, then warmed to room temp for 5 min, then heated to reflux for 4 h. The mixture was cooled and concentrated in vacuo. Water was added (50 mL) and the aqueous layer was extracted with EtOAc (3×50 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated. Purification by silica gel chromatography (0-100% EtOAc in pentane) gave ethyl 6-chloro-7,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (1.41 g, 42%). MS (ESI) calcd for C11H12ClN3O2: 253.06; found: 254 [M+H].
-
- Ethyl 6-chloro-7,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (750.0 mg, 2.96 mmol) and 2-(trifluoromethyl)phenylboronic acid (562.0 mg, 2.96 mmol) were weighed into a 5 mL microwave vial. Dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (97.0 mg, 0.236 mmol) and K3PO4 (1.88 g, 8.87 mmol) were added, and the mixture was suspended in dioxane (3.6 mL) and water (0.36 mL). The mixture was purged with nitrogen for 5 min., tris(dibenzylideneacetone)dipalladium(0) (108.0 mg, 0.118 mmol) was added, and the mixture purged 5 min more with nitrogen. The vial was sealed and the reaction heated to 120° C. in the microwave for 1.5 h. Saturated aqueous NaHCO3 (5 mL) was added and the mixture was allowed to stir 10 min, then it was extracted with EtOAc (3×20 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated. Purification by silica gel chromatography (0-100% EtOAc in pentane) gave ethyl 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (726.0 mg, 68%). MS (ESI) calcd for C18H16F3N3O2: 363.12; found: 364 [M+H].
-
- Ethyl 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (726.0 mg, 2.0 mmol) was dissolved in THF (38 mL). Water was added (47 mL), followed by LiOH (239.0 mg, 9.98 mmol). The reaction was allowed to stir at room temp for 2 h. 1.0 N aqueous HCl (10.1 mL) was added and the mixture was extracted with EtOAc (3×100 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated to give 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (700.0 mg, quant.). MS (ESI) calcd for C16H12F3N3O2: 335.09; found: 336 [M+H].
-
- 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (150.0 mg, 0.445 mmol) and (S)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-amine (82.0 mg, 0.45 mmol) were coupled according to the general amide coupling procedure above to give (S)—N-(6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-yl)-7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (197.0 mg, 81%). MS (ESI) calcd for C27H26F3N5O4: 541.19; found: 542 [M+H].
- This general procedure could be used to prepare a variety N-(substituted)-7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for (S)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-amine.
-
- (S)—N-(6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-2-yl)-7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (197.0 mg, 0.36 mmol) was dissolved in THF (7.8 mL). Concentrated HCl (aq.) was added (0.12 mL) and the reaction was allowed to stir at room temp for 5 h. Water (5 mL) and saturated aqueous NaHCO3 (5 mL) were added, and the mixture was extracted with EtOAc (3×20 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated. The crude material was purified by silica gel column chromatography (0-10% MeOH/CH2Cl2) to give (R)—N-(6-(2,3-dihydroxypropoxy)pyridin-2-yl)-7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (53.0 mg, 29%). MS (ESI) calcd for C24H22F3N5O4: 501.16; found: 502 [M+H].
-
- A mixture (50.0 g, 349 mmol) of 6-chloro-5-methylpyridazin-3-amine and 6-chloro-4-methylpyridazin-3 amine was dissolved in EtOH (600 mL). Ethyl 2-chloro-3-oxobutanoate (114.0 g, 680 mmol) was added. The mixture was refluxed for 48 h, followed by concentration. Water (500 mL) and CH2Cl2 (500 mL) were added. The organic layer was separated and dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography to separate the methyl isomers, giving pure ethyl 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (9.4 g, 10%). MS (ESI) calcd for C11H12ClN3O2: 253.06; found: 253.96 [M+H].
-
- Ethyl 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (7.4 g, 29 mmol), 2-(trifluoromethyl)phenylboronic acid (6.6 g, 35 mmol), cesium carbonate (19.0 g, 58 mmol), Pd(PPh3)4 (3.3 g, 3 mmol) were dissolved in a mixture of dioxane:water (4:1) plus 10 drops of EtOH. The mixture was heated to 75° C. for 5 h, then concentrated. Water (200 mL) was added and this was extracted with CH2Cl2 (300 mL). The organic layer was concentrated and purified on silica gel to give ethyl 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (8.0 g, 75%). MS (ESI) calcd for C18H16F3N3O2: 363.12.
-
- Ethyl 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (8.0 g, 22 mmol) was dissolved in dioxane (100 mL). NaOH (1.76 g, 44 mmol) in water (100 mL) was added. The mixture was heated to 60° C. for 2 h, then concentrated. Water (100 mL) was added and the mixture was filtered. The pH was adjusted to 5 with aqueous HCl. The mixture was filtered again and the solid was dried under vacuum to give 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (6.2 g, 75%). MS (ESI) calcd for C16H12F3N3O2: 335.09; found: 335.98 [M+H].
- This general coupling procedure followed by ester hydrolysis could be used to prepare a variety of carboxylates, including 2,8-dimethyl-6-(2-trifluromethyl)phenyl) and 2,8-dimethyl-6-(2-trifluromethoxy)phenyl)imidazo[1,2-b]pyridazine-3-carboxylates, by substituting the appropriate boronic acid or boronic ester moiety for 2-(trifluoromethyl)phenylboronic acid.
-
- 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (150.0 mg, 0.45 mmol) was dissolved in DMF (2.4 mL). HATU (255.0 mg, 0.67 mmol) was added, followed by diisopropylethylamine (0.312 mL, 1.79 mmol). 3-aminopyridazine-HCl (59.0 mg, 0.45 mmol) was slurried in DMF (2.4 mL) and diisopropylethylamine (0.078 mL, 0.45 mmol) and added to the reaction mixture. This was warmed to 60° C. and allowed to stir under nitrogen atmosphere for 3.5 h. The mixture was cooled to room temp, and saturated aqueous NaHCO3 was added (6 mL), then water was added (10 mL). This was extracted with EtOAc (3×20 mL) and the combined organics were washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography using a gradient of 0-10% MeOH in CH2Cl2 to give 2,8-dimethyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazine-3-carboxamide (19.6 mg, 11%). MS (ESI) calcd for C20H15F3N6O: 412.13; found: 413.2 [M+H].
- This general coupling procedure could be used to prepare a variety of 2,8-dimethyl-6-(2-trifluromethyl)phenyl) and 2,8-dimethyl-6-(2-trifluromethoxy)phenyl) imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for 3-aminopyridazine.
-
- 6-chloropyridazin-3-amine (10.0 g, 77.2 mmol) and 2-(trifluoromethyl)phenylboronic acid (29.3 g, 154.4 mmol) were added to a 250 mL flask. Cs2CO3 (50.3 g, 154.4 mol), Pd2(dba)3 (3.5 g, 3.82 mmol), and XPhos (1.8 g, 3.82 mmol) were added, followed by dioxane (100 mL) and water (20 mL). The reaction was heated to 100° C. for 3 h, followed by cooling to room temp. The mixture was concentrated in vacuo, and the residue was resuspended in DCM (500 mL). The organic layer was washed with bicarb (150 mL), then brine (150 mL), dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified via silica gel column chromatography (EtOAc: PE 2:1) to give 6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (14.0 g, 76%). MS (ESI) calcd for C11H8F3N3: 239.07.
-
- 6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (3.0 g, 12.55 mmol) and NaHCO3 (2.1 g, 25.1 mmol) were suspended in MeOH (30 mL). Br2 was added (3.0 g, 0.96 mL, 18.8 mmol) dropwise at room temp. The reaction was allowed to stir for 1 h at room temp, then poured into bicarb (300 mL) after which a precipitate formed. The solid was collected by filtration, washed with water, and dried in vacuo to give 4-bromo-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (3.8 g, 95%). MS (ESI) calcd for C11H7BrF3N3: 316.98.
-
- 4-bromo-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (500.0 mg, 1.57 mmol) was dissolved in EtOH (3.0 mL). Ethyl 2-chloro-3-oxobutanoate (285.0 mg, 1.73 mmol) was added and the reaction was heated to reflux under nitrogen atmosphere for 22 h. The mixture was cooled to room temp, concentrated in vacuo and purified via silica gel column chromatography (0-100% EtOAc/pentane) to give ethyl 8-bromo-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (246.0 mg, 36%). MS (ESI) calcd for C17H13BrF3N3O2: 427.01; found: 428 [M+H].
-
- Ethyl 8-bromo-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (246.0 mg, 0.573 mmol) was dissolved in THF (11.0 mL). Water was added (13.0 mL), followed by lithium hydroxide (55.0 mg, 2.29 mmol). The reaction was allowed to stir at room temp for 3.5 h. Aqueous HCl (1.0 N, 2.4 mL) was added, and the mixture was extracted with EtOAc (3×20 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated in vacuo to give 8-bromo-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (242.0 mg, quant.). MS (ESI) calcd for C15H9BrF3N3O2: 398.98.
-
- 8-bromo-2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (75.0 mg, 0.187 mmol) was dissolved in MeCN (2.0 mL) in a vial. HATU (107.0 mg, 0.281 mmol), pyridine (44.0 mg, 0.562 mmol), and 3-aminopyridazine (54.0 mg, 0.562 mmol) were added. The vial was sealed and heated to 50° C. for 1 h, then to 80° C. for 2 h. The reaction was cooled to room temp and bicarb was added (4 mL). The mixture was extracted with EtOAc (3×15 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified via silica gel column chromatography (0-10% MeOH/DCM) to give 8-bromo-2-methyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (53.0 mg, 60%). MS (ESI) calcd for C19H12BrF3N6O: 476.02; found: 477 [M+H].
- This general procedure could be used to prepare a variety of 8-bromo-2-methyl-N-(pyridazin-3-yl)-6-(substituted)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 3-aminopyridazine.
-
- Sodium hydride (60% in oil, 14.0 mg, 350 mmol) was suspended in THF (2.0 mL). (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (46.0 mg, 0.350 mmol) was added dropwise over 5 min. The mixture was allowed to stir at room temp for 30 min. 8-bromo-2-methyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (53.0 mg, 0.111 mmol) was added in THF (2.0 mL). The reaction was allowed to stir for 30 min at room temp, then was heated to reflux for 1.5 h, followed by cooling to room temp. Water was added (10 mL), and the mixture was extracted with EtOAc (3×10 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified via silica gel column chromatography (0-10% MeOH/DCM) to give (S)-8-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-methyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazine-3-carboxamide (50.0 mg, 84%). MS (ESI) calcd for C25H23F3N6O4: 528.17; found: 529 [M+H].
-
- (S)-8-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-methyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (50.0 mg, 0.09 mmol) was dissolved in THF (2.1 mL). Concentrated HCl (0.031 mL) was added, and the reaction was allowed to stir at room temp for 2.5 h, during which time an orange precipitate formed. Bicarb and water were added (5 mL each), and the precipitate dissolved, followed by formation of a new precipitate (white). More water was added (35 mL) and the mixture was allowed to stand 10 min. The solid was collected by filtration, washed with water, and dried in vacuo. The solid was then further purified by trituration with EtOH, filtered and washed with EtOH and then diethyl ether, and dried in vacuo to give (R)-8-(2,3-dihydroxypropoxy)-2-methyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (6.5 mg, 14%). MS (ESI) calcd for C22H19F3N6O4: 488.14; found: 489 [M+H].
- This general procedure could be used to prepare a variety of 8-(2,3-dihydroxypropoxy)-2-methyl-N-(pyridazin-3-yl)-6-(substituted)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for 3-aminopyridazine in step 5 described above.
-
- 4-bromo-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (100.0 mg, 0.314 mmol) was dissolved in DMSO (2.7 mL). Morpholine was added (0.27 mL, 3.14 mmol). The reaction was sealed and allowed to stir at room temp for 1 h, followed by heating to 110° C. for 18 h. The mixture was cooled to room temp and water was added (15 mL). The mixture was extracted with EtOAc (3×20 mL), and the combined organics were washed with brine, dried with Na2SO4, filtered and concentrated in vacuo to give 4-morpholino-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (119.0 mg, quant.) which was used without further purification. MS (ESI) calcd for C15H15F3N4O: 324.12; found: 325 [M+H].
-
- 4-morpholino-6-(2-(trifluoromethyl)phenyl)pyridazin-3-amine (59.0 mg, 0.183 mmol) and ethyl-2-chloroacetoacetate (33.0 mg, 0.201 mmol) were dissolved in EtOH (1.0 mL) and heated to reflux under nitrogen atmosphere for 26 h. The reaction was cooled to room temp, causing a precipitate to form. The solid was collected by filtration, washed with cold EtOH, then diethyl ether, and dried in vacuo to give ethyl 2-methyl-8-morpholino-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (26.0 mg, 33%). MS (ESI) calcd for C21H21F3N4O3: 434.16; found: 435 [M+H].
-
- Ethyl 2-methyl-8-morpholino-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (26.0 mg, 0.060 mmol) was suspended in THF (1.2 mL) water (2.4 mL) and MeOH (1 mL). Lithium hydroxide was added (7.0 mg, 0.300 mmol) and the mixture was heated to reflux for 3 h, followed by cooling to room temp. HCl was added (1.0 N, 0.35 mL), and the mixture was extracted with EtOAc (3×10 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated to give 2-methyl-8-morpholino-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (23.0 mg, 95%). MS (ESI) calcd for C19H17F3N4O3: 406.13; found: 407 [M+H].
-
- 2-methyl-8-morpholino-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (23.0 mg, 0.057 mmol) and 3-aminopyridazine (16.0 mg, 0.170 mmol) were dissolved in MeCN (1.2 mL). HATU (32.0 mg, 0.085 mmol) and pyridine (0.014 mL, 0.170 mmol) were added and the vial was sealed and heated to 50° C. for 1 h, then to 80° C. for 2 h. The reaction was cooled to room temp and bicarb (2 mL) and water (1 mL) were added. The mixture was extracted with EtOAc (3×5 mL) but there was precipitate in the organic layer. The solid was collected by filtration and washed with diethyl ether, and dried in vacuo to give 2-methyl-8-morpholino-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (8.0 mg, 29%). MS (ESI) calcd for C23H20F3N7O2: 483.16; found: 484 [M+H].
-
- A mixture of 6-chloropyridazin-3-amine (2.0 g, 15.44 mmol) and diethyl 2-chloromalonate (4.51 g, 23.16 mmol) in EtOH (30 mL) was refluxed for 48 h. After cooling to room temp, the mixture was concentrated and purified by column chromatography to afford a 2:1 mixture of 6-chloropyridazin-3-amine and ethyl 6-chloro-2-hydroxyimidazo[1,2-b]pyridazine-3-carboxylate which was used without further purification. MS (ESI) calcd for C9H8ClN3O3: 241.03.
-
- A mixture of ethyl 6-chloro-2-hydroxyimidazo[1,2-b]pyridazine-3-carboxylate (500.0 mg, 2.069 mmol), 2-(trifluoromethyl)phenylboronic acid (786.0 mg, 4.14 mmol), K3PO4 (878.0 mg, 4.14 mmol), Pd2dba3 (189.0 mg, 0.21 mmol), and X-Phos (197.0 mg, 0.41 mmol) was taken up in dioxane (30 mL), H2O (8 mL), EtOH (4 mL). The mixture was heated to 130° C. for 24 h. The solids were filtered, the filtrate was concentrated and purified by column chromatography to give ethyl 2-hydroxy-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate. MS (ESI) calcd for C16H12F3N3O3: 351.1.
-
- A mixture of Ethyl 2-hydroxy-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylate (100.0 mg, 0.285 mmol), and pyridin-2-amine (54 mg, 0.57 mmol) was refluxed in toluene (10 mL) for 24 h. NaH (14 mg, 0.57 mmol) was then added and reflux was continued for another 2 h. The mixture was cooled to room temp, concentrated in vacuo and purified by column chromatography to give 2-hydroxy-N-(pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamide (55 mg, 48%). MS (ESI) calcd for C19H12F3N5O2: 399.1; found 399.9 [M+H].
- This general coupling method could be used to prepare a variety of 2-hydroxy-N-(substituted)-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine for pyridine-2-amine.
-
- To a solution of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (1.70 g, 5.53 mmol) in toluene (22 mL) was added diphenylphosphorylamide (1.20 mL, 5.53 mmol), and triethylamine (1.20 mL, 8.29 mmol). The reaction mixture was stirred at 25° C. for 1 h then heated at reflux for 2 h. Benzyl alcohol (630 μl, 6.08 mmol) was added and heating continued for 16 h. The mixture was poured into citric acid (5% aq) and extracted with EtOAc. The combined organic layers were washed with sat. aq NaHCO3, brine, dried (MgSO4) and concentrated. The crude residue was purified by MPLC eluting with pentane/EtOAc (0-100%) to give 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine. (1.07 g, 47% yield). MS (ESI) calcd for C21H15F3N4O2 (m/z): 412.11; found: 413 [M+H].
-
- Pd/C 10 wt % (200 mg) was added to a degassed solution of benzyl 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-ylcarbamate (1.07 g, 2.59 mmol) in THF/MeOH (40 mL, 1:1). The mixture was hydrogenated under balloon pressure at 25° C. for 16 h. The catalyst was removed by filtration and the mixture concentrated. The crude residue was purified by MPLC eluting with CH2Cl2/MeOH (0-5%) to give 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (651 mg, 90% yield). MS (ESI) calcd for C13H9F3N4 (m/z): 278.08; found: 279 [M+H].
-
- HATU (109 mg, 0.0.29 mmol) was added to a solution of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (50.0 mg, 0.18 mmol), 5-methylpyrazine-2-carboxylic acid (37.0 mg, 0.27 mmol), and DIEA (78 μl, 0.44 mmol) in DMAC (7 mL) The mixture was stirred at 60° C. for 3 h. H2O (45 mL) was added and the resulting ppt was collected by filtration, rinsed with H2O, and dried under vacuum. The crude residue was purified by MPLC eluting with CH2Cl2/MeOH (0-5%). The product was further purified by recrystallization from CH3CN to give 5-methyl-N-(6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)pyrazine-2-carboxamide (55.0 mg, 77% yield). MS (ESI) calcd for C19H13F3N6O (m/z): 398.11; found: 399 [M+H].
- This general coupling procedure could be used to prepare a variety of 6-(2-trifluromethyl)phenyl) imidazo[1,2-b]pyridazin-3-yl)pyrazine-2-carboxamides by substituting the appropriate carboxylic acid moiety for 5-methylpyrazine-2-carboxylic acid.
-
- HATU (203.0 mg, 0.53 mmol) was added to a solution of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (93.0 mg, 0.33 mmol), 6-hydroxypyrimidine-4-carboxylic acid (70.0 mg, 0.50 mmol), and pyridine (81 μl, 1.00 mmol) in CH3CN (15 mL). The reaction mixture was heated at reflux for 72 h. H2O was added and the resulting ppt was collected by filtration rinsed with H2O and dried under vacuum. The crude residue was recrystallized from CH3CN to give 6-hydroxy-N-(6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)pyrimidine-4-carboxamide (73.0 mg, 55% yield). MS (ESI) calcd for C18H11F3N6O2 (m/z): 400.09; found: 401 [M+H].
-
- HATU (200.0 mg, 0.0.53 mmol) was added to a solution of 6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (91.0 mg, 0.33 mmol), (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carboxylic acid (125.0 mg, 0.49 mmol), and N,N-diisopropylethylamine (DIPEA) (150 μl, 0.82 mmol) in dimethylacetamide (DMAC) (6 mL). The mixture was stirred at 80° C. for 16 h. H2O was added and the resulting ppt was collected by filtration, rinsed with H2O, and dried under vacuum. The crude residue was purified by MPLC eluting with CH2Cl2/MeOH (0-5%) to give (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-N-(6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)pyrazine-2-carboxamide (113.0 mg, 67% yield). MS (ESI) calcd for C24H21F3N6O4 (m/z): 514.16; found: 515 [M+H].
-
- 3N HCl (100 mL, 0.30 mmol) was added to a suspension of (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-N-(6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)pyrazine-2-carboxamide (113.0 mg, 0.22 mmol) in EtOH (10 mL). The mixture was heated at 60° C. until the mixture became homogenous then stirred at room temp for 16 h. The mixture was concentrated and the crude residue was recrystallized from CH3CN to give (S)-6-(2,3-dihydroxypropoxy)-N-(6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)pyrazine-2-carboxamide hydrochloride (87.0 mg, 78% yield). MS (ESI) calcd for C21H17F3N6O4 (m/z): 474.13; found: 475 [M+H].
- This general coupling procedure followed by acid deprotection could be used to prepare a variety of (6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl) substituted carboxamides by substituting the appropriate acid moiety for (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carboxylic acid in step 1.
-
- To a solution of 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (3.50 g, 10.89 mmol) in DMF (100 mL) was added diphenylphosphorylamide (4.50 g, 16.34 mmol), and triethylamine (2.20 g, 21.79 mmol). The reaction mixture was stirred at 25° C. for 1.5 h. H2O (2 mL) was added and the mixture was heated to 100° C. for 1 h. The mixture was poured into cold H2O (250 mL) and the resulting ppt was collected by filtration to afford 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine. (2.0 g, 63% yield). MS (ESI) calcd for C14H11F3N4 (m/z): 292.09.
- This general procedure could be used to prepare a variety of N-(2-methyl-6-(2-(trifluoromethyl)phenyl) and N-(2-methyl-6-(2-chlorophenyl) imidazo[1,2-b]pyridazine-3-amines by starting with the appropriately substituted carboxylic acid moiety.
-
- A solution of 2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (75.0 mg, 0.26 mmol), picolinic acid (32.0 mg, 0.26 mmol), DIPEA (99.0 mg, 0.77 mmol) and HATU (124.0 mg, 0.51 mmol) in DMF (8 mL) was stirred at 60° C. for 12 h. H2O was added (30 mL) and the resulting ppt was collected by filtration and washed with MeOH to give N-(2-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)picolinamide (38.0 mg, 37%). MS (ESI) calcd for C20H14F3N5O (m/z): 397.12; found: 398 [M+H].
- This general procedure could be used to prepare a variety of N-(2-methyl-6-(2-(trifluoromethyl)phenyl), N-(2-methyl-6-(2-chlorophenyl) imidazo[1,2-b]substituted amides by substituting the appropriate carboxylic acid for picolinic acid. In the case which includes a glycerol moiety, an extra deprotection step is required (see step 2 of the previous preparation).
-
- To a solution of 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (3.0 g, 9.34 mmol) in DMF (10 mL) was added diphenylphosphorylamide (3.85 g, 14.01 mmol), and triethylamine (1.42 g, 14.01 mmol). The reaction mixture was stirred at 25° C. for 10 h. H2O (0.2 mL) was added and stirring continued 24 h. The mixture was poured into 25% aq NaOH, and the resulting ppt was collected by filtration. The crude residue was purified by flash chromatography to afford 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine. (1.50 g, 55% yield). MS (ESI) calcd for C14H1F3N4 (m/z): 292.09.
-
- A solution of 8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (100.0 mg, 0.34 mmol), picolinic acid (63.0 mg, 0.51 mmol), DIPEA (88.0 mg, 0.68 mmol) and HATU (260.0 mg, 0.68 mmol) in DMF (5 mL) was stirred at 70° C. for 16 h and H2O was added. The crude residue was purified by flash chromatography to give N-(8-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)picolinamide (55.0 mg, 41%). MS (ESI) calcd for C20H14F3N5O (m/z): 397.12; found: 398 [M+H].
- This general procedure could be used to prepare a variety of N-substituted-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)amides by substituting the appropriate carboxylic acid for picolinic acid. In cases where this carboxylic acid contains a glycerol moiety, an extra deprotection step is required (as previously shown).
-
- To a solution of 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (1.5 g, 4.67 mmol) in DMF (10 mL) was added diphenylphosphorylamide (1.93 g, 7.00 mmol), and triethylamine (709.0 mg, 7.00 mmol). The reaction mixture was stirred at 25° C. for 10 h. H2O (0.15 mL) was added and the mixture was stirred at room temp for 24 h. The mixture was poured into 25% aq NaOH, and the resulting ppt was collected by filtration. The crude residue was purified by flash chromatography to afford 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (650.0 mg, 48% yield). MS (ESI) calcd for C14H1F3N4 (m/z): 292.09.
-
- A solution of 7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (50.0 mg, 0.17 mmol), picolinic acid (32.0 mg, 0.26 mmol), DIPEA (44.0 mg, 0.34 mmol) and HATU (130.0 mg, 0.34 mmol) in DMF (5 mL) was stirred at 70° C. for 16 h. H2O was added and the resulting ppt was purified by flash chromatography to give N-(7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)picolinamide (45.0 mg, 66%). MS (ESI) calcd for C20H14F3N5O (m/z): 397.12; found: 398 [M+H].
- This general procedure could be used to prepare a variety N-(7-methyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)amides by substituting the appropriate carboxylic acid for picolinic acid.
-
- 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (420.0 mg, 1.25 mmol) was suspended in t-BuOH (2.6 mL) and toluene (2.6 mL). Triethylamine (0.58 mL, 4.13 mmol) was added, followed by dropwise addition of diphenylphosphorylamide (0.45 mL, 2.09 mmol). The mixture was warmed to 65° C. for 1 h, then heated to reflux for 17 h. The reaction was cooled and concentrated, and the residue suspended in EtOAc (50 mL). The organic layer was washed with saturated aqueous NaHCO3 (25 mL) and brine (25 mL), dried with Na2SO4, filtered and concentrated. Purification by silica gel column chromatography (0-100% EtOAc/pentane) gave tert-butyl 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-3-ylcarbamate (280.0 mg, 55%). MS (ESI) calcd for C20H21F3N4O2: 406.16; found: 407 [M+H].
-
- Tert-butyl 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-3-ylcarbamate (280.0 mg, 0.69 mmol) was dissolved in CH2Cl2 (2.0 mL). Trifluoroacetic acid (1.0 mL) was added, and the reaction was allowed to stir for 2 h. The mixture was concentrated and water (5 mL) and saturated aqueous NaHCO3 (5 mL) were added. The aqueous mixture was extracted with EtOAc (3×20 mL), and the combined organics were washed with brine, dried with Na2SO4, filtered and concentrated. The residue was triturated with pentane, and the solid was dried under vacuum to give 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (182.0 mg, 86%). MS (ESI) calcd for C15H13F3N4: 306.11; found: 307 [M+H].
-
- 7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (45.0 mg, 0.15 mmol) and 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid (38.0 mg, 0.15 mmol) were coupled according to the general amide coupling procedure to give 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-N-(7,8-dimethyl-6-(2-(trifluoromethyl) phenyl)imidazo[1,2-b]pyridazin-3-yl)picolinamide (60.0 mg, 75%). MS (ESI) calcd for C27H26F3N5O4: 541.19; found: 542 [M+H].
- This general procedure could be used to prepare a variety of substituted-(7,8-dimethyl-6-(2-(trifluoromethyl) phenyl)imidazo[1,2-b]pyridazin-3-yl)amides by substituting the appropriate carboxylic acid for 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid.
-
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-N-(7,8-dimethyl-6-(2-(trifluoromethyl) phenyl)imidazo[1,2-b]pyridazin-3-yl)picolinamide (60.0 mg, 0.11 mmol) was dissolved in THF (2.4 mL). Concentrated HCl (aq.) (0.04 mL, 0.44 mmol) was added and the reaction was allowed to stir at room temp for 6 h. Water (5 mL) and saturated aqueous NaHCO3 (5 mL) were added and the mixture was extracted with EtOAc (3×20 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated. The crude product was triturated with minimal CH2Cl2 in Et2O, the suspension filtered and the solid washed with Et2O. The solid was dried under vacuum to give 6-(2,3-dihydroxypropoxy)-N-(7,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)picolinamide (30.0 mg, 54%). MS (ESI) calcd for C24H22F3N5O4: 501.16; found: 502 [M+H].
-
- To 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (500.0 mg, 1.49 mmol) suspended in 1:1 t-BuOH/toluene (6.4 mL) was added triethylamine (0.686 mL, 4.92 mmol), followed by dropwise addition of diphenylphosphorylamide (0.537 mL, 2.49 mmol) over 15 min. The mixture was warmed to 55° C. for 2 h, then heated to reflux for 19 h, followed by cooling and concentration, resuspension in EtOAc and saturated aqueous NaHCO3. The layers were separated and the aqueous layer was washed with EtOAc (3×50 mL). The combined organics were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated. Purification by silica gel column chromatography (0-100% gradient EtOAc in pentane) gave tert-butyl 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-3-ylcarbamate (0.22 g, 36%). MS (ESI) calcd for C20H21F3N4O2: 406.16.
-
- Tert-butyl 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-3-ylcarbamate (220.0 mg, 0.54 mmol) was dissolved in CH2Cl2 (1.6 mL). Trifluoroacetic acid (0.784 mL) was added and the mixture was allowed to stir at room temp for 2.5 h. The mixture was concentrated and water (10 mL) was added, as well as saturated aqueous NaHCO3 (10 mL). Extraction with EtOAc (3×20 mL), washing with brine, drying with anhydrous Na2SO4, filtration and concentration gave crude product. Trituration with pentane (5×10 mL) and vacuum drying gave 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (0.158 g, 95%). MS (ESI) calcd for C15H13F3N4: 306.11; found: 307.1 [M+H].
-
- 6-methoxypicolinic acid (40.0 mg, 0.26 mmol) was dissolved in dimethylformamide (1.0 mL). HATU (147.0 mg, 0.39 mmol) was added, followed by diisopropylethylamine (0.18 mL, 1.03 mmol). 2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-amine (79.0 mg, 0.26 mmol) was dissolved in 2.1 mL dimethylformamide and added to the reaction mixture, which was then warmed to 50° C. for 4 h. The mixture was cooled to room temp and saturated aqueous NaHCO3 (4 mL) and water (4 mL) were added. An orange precipitate formed, and the mixture was filtered through a glass frit. The solid was washed with water and dried under vacuum, followed by purification by silica gel column chromatography (0-10% gradient MeOH in CH2Cl2) to give N-(2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)-6-methoxypicolinamide (24.0 mg, 21%). MS (ESI) calcd for C22H18F3N4O2: 441.14; found: 442.1 [M+H].
- This general coupling procedure could be used to prepare N-(2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)-6-hydroxypicolinamide.
-
- To a solution of (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid (600.0 mg, 1.71 mmol) in DMF (20 mL) was added diphenylphosphorylamide (707.0 mg, 2.57 mmol), and triethylamine (346.0 mg, 3.42 mmol). The reaction mixture was stirred at 25° C. for 1 h. H2O (1 mL) was added and the mixture was heated at 70° C. for 1 h. The mixture was poured into 25% aq NaOH, and the resulting ppt was collected by filtration. The crude residue was purified by flash chromatography to afford (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine (250.0 mg, 66% yield). MS (ESI) calcd for C10H12FN5 (m/z): 221.11.
-
- A solution of (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-amine (44.0 mg, 0.20 mmol), 6-methylpicolinic acid (33.0 mg, 0.24 mmol), DIPEA (51.0 mg, 0.40 mmol), and HATU in DMF (8 mL) was heated at 60° C. for 3 h. The crude residue was purified by flash chromatography to afford (S)—N-(6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-6-methylpicolinamide (30 mg, 44% yield). MS (ESI) calcd for C17H17FN6O (m/z): 340.14; found: 341 [M+H].
- This general procedure could be used to prepare a variety of N-(6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl) amides by substituting the appropriate carboxylic acid moiety for 6-methylpicolinic acid.
-
- Cs2CO3 (64.20 g, 197.20 mmol) was added to a solution of ethyl 5-amino-1H-pyrazole-4-carboxylate (20.40 g, 131.40 mmol) and ethyl-3-ethoxyacrylate (28.6 mL, 197.20 mmol) in DMF (250 mL). The reaction mixture was stirred at 110° C. for 16 h. The mixture was cooled to room temp and the pH was adjusted to 4 by the addition of AcOH (80 mL). The mixture was concentrated in vacuo and the residue partitioned between CH2Cl2/H2O (1000 mL, 1:1). The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (3×500 mL). The combined organics were washed with brine, dried (MgSO4) and concentrated. The crude residue was suspended in EtOH (300 mL) and heated to boiling. After cooling to room temperature the solid was collected by filtration, rinsed with EtOH, then Et2O and dried under vacuum to give ethyl 5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate (25.16 g, 92%). MS (ESI) calcd for C9H9N3O3 (m/z): 207.06; found: 208 [M+H].
-
- A mixture of ethyl 5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate (5.70 g, 27.52 mmol) in phosphoryl trichloride (50 mL) was heated at 120° C. for 4 h. The reaction mixture was concentrated in vacuo. The crude residue was partitioned between CH2Cl2 and iced, sat. aq NaHCO3. The organic phase was separated and washed with brine, dried and concentrated to give ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (5.40 g, 94% yield). MS (ESI) calcd for C9H8ClN3O2 (m/z): 225.03.
-
- Nitrogen was bubbled through a solution of ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (5.40 g, 23.94 mmol) in dioxane/EtOH/H2O (130 mL, 20:3:3). 2-(trifluoromethyl)phenylboronic acid (6.80 g, 35.90 mmol), Pd(PPh3)4 (2.80 g, 2.39 mmol), and Cs2CO3 (15.60 g, 47.88 mmol) were added and the reaction mixture was heated at reflux for 2 h. The mixture was cooled to room temp, poured into EtOAc (300 mL) washed with brine, dried (MgSO4), and concentrated. The crude residue was purified by MPLC eluting with pentane/EtOAc (0-100%) to give ethyl 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (6.30 g, 78% yield). MS (ESI) calcd for C16H12F3N3O2 (m/z): 335.09; found: 336 [M+H].
-
- A solution of LiOH (902.0 mg, 37.60 mmol) in H2O (30 mL) was added to a solution of ethyl 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (6.30 g, 18.80 mmol) in THF (75 mL) and MeOH (20 mL). The reaction mixture was stirred at 25° C. for 16 h. The pH was adjusted to 3 by the addition of 3N HCl (13 mL). The mixture was poured into brine, extracted with EtOAc, dried and concentrated. The crude residue was recrystallized from EtOH (70 mL) to give 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (4.20 g, 73% yield). MS (ESI) calcd for C14H8F3N3O2 (m/z): 307.06; found: 308 [M+H].
-
- 4-aminopyridine (122 mg, 1.30 mmol) was added to a solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (100.0 mg, 0.33 mmol), pyridine (105 μl, 1.30 mmol) and HATU (149.0 mg, 0.39 mmol) in CH3CN (15 mL), and the reaction was heated at reflux for 72 h. H2O was added and the resulting precipitate was collected by filtration, rinsed with H2O, and dried under vacuum. The crude residue was purified by recrystallization from CH3CN to give N-(pyridin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (91.0 mg, 73% yield). MS (ESI) calcd for C19H12F3N5O (m/z): 383.10; found: 384 [M+H].
- This general coupling procedure could be used to prepare N-(pyrazin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(pyridazin-3-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-(2-methylpyridin-4-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- A solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (60.0 mg, 0.33 mmol), 2-aminopyridine (40.0 mg, 0.42 mmol), DIEA (84.0 mg, 0.65 mmol) and HATU (186.0 mg, 0.49 mmol) in DMF (5 mL) was stirred at 60° C. for 16 h. H2O was added and the resulting ppt was collected by filtration, rinsed with H2O, and dried under vacuum. The crude residue was purified by flash chromatography to give N-(pyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazzolo[1,5-a]pyrimidine-3-carboxamide (65.0 mg, 52%). MS (ESI) calcd for C19H12F3N5O (m/z): 383.10; found: 384 [M+H].
- This general coupling procedure could be used to prepare a variety of N-(substituted)-5-(2-(trifluoromethyl)phenyl) and N-(substituted)-5-(2-(trifluoromethoxy)phenyl) pyrazolo[1,5-a]pyrimidine-3-carboxamides by starting with the appropriate carboxylic acid and substituting the appropriate amine for 2-aminopyridine.
-
- A solution of 5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic (200.0 mg, 0.62 mmol), 4-aminopyrimidine (71.0 mg, 0.74 mmol), NaH (15.0 mg, 0.62 mmol) and HATU (235.0 mg, 0.62 mmol) in DMF (5 mL) was stirred at 70° C. for 16 h. H2O was added and the crude residue was purified by flash chromatography to give N-(pyrimidin-4-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (20.0 mg, 8% yield). MS (ESI) calcd for C19H11F3N6O2 (m/z): 400.09; found: 401 [M+H].
-
- A solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (60.0 mg, 0.20 mmol), 5-methylpyrazin-2-amine (36.0 mg, 0.24 mmol), B(OH)3 (36.0 mg, 0.60 mmol) in 1,3,5-trimethylbenzene (3 mL) was stirred at 200° C. for 48 h. The reaction mixture was concentrated and the residue was purified by preparative TLC eluting with pentane/EtOAc (2:3) to give N-(5-methylpyrazin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. (13.0 mg, 17% yield). MS (ESI) calcd for C19H13F3N6O (m/z): 398.11; found: 399 [M+H].
- This general coupling procedure could be used to prepare N-(3,5-difluoropyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2,6-dimethylpyrimidin-4-yl)-5-(2-(trifluoromethxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(5-fluoropyridin-3-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(4,6-dimethylpyrimidin-2-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3,5-dimethylpyrazin-2-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3,5-difluoropyridin-2-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-methoxypyrimidin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3,5-dimethylpyrazin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-(3-methylpyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- Oxalyl chloride (186.0 mg, 1.47 mmol) was added to a solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (150.0 mg, 0.49 mmol) in CH2CL2 (5 mL) followed by DMF (3 drops). The reaction mixture was stirred at 25° C. for 8 h then concentrated to dryness to give crude 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride used without further purification. MS (ESI) calcd for C14H7ClF3N3O (m/z): 325.02.
-
- A solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (160.0 mg, 0.49 mmol) and 2-aminopyrimidine (60.0 mg, 0.64 mmol) in pyridine (5 mL) was stirred for 16 h at 25° C. The reaction mixture was poured into H2O and the mixture was concentrated. The crude residue was purified by flash chromatography to give N-(pyrimidin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (40.0 mg, 21% yield). MS (ESI) calcd for C18H11F3N6O (m/z): 384.09; found: 385 [M+H].
- This general coupling procedure could be used to prepare N-(pyrazin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(pyrimidin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-hydroxypyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-methoxypyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-methylpyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(4-methylpyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(4,6-dimethylpyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2,6-dimethylpyrimidin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2,6-dimethylpyridin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(thiazol-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(5-methylthiazol-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(4-methylthiazol-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(4,5-dimethylthiazol-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3-fluoropyridin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(5-fluoropyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2-methoxypyrimidin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(pyrazin-2-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-(pyrimidin-2-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- Chlorotrimethylsilane (32.0 mg, 0.29 mmol) was added to a solution of N-(6-methoxypyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (60.0 mg, 0.15 mmol) and potassium iodide (48.0 mg, 0.29 mmol) in CH3CN (10 mL) at room temp. The mixture was heated at 80° C. for 2 h. Sat. aq NaHCO3 (50 mL) was added and the resulting ppt was collected by filtration, rinsed with EtOH and dried to give N-(pyrimidin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (35.0 mg, 48% yield). MS (ESI) calcd for C19H12F3N5O2 (m/z): 399.09; found: 400 [M+H].
- This general coupling procedure could be used to prepare N-(6-hydroxypyridin-2-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-hydroxypyridin-2-yl)-2-methyl-5-(2-(trifluoromethy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-hydroxypyridin-2-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-hydroxypyrimidin-4-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, 5-hydroxy-N-(5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)pyrazine-2-carboxamide and N-(2-hydroxypyridin-4-yl)-5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- Diphenylphosphoryl azide (674.0 mg, 2.45 mmol) was added to a solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (500.0 mg, 1.63 mmol) and triethylamine (329.0 mg, 3.26 mmol) in toluene (10 mL). The mixture was stirred for 1 h at 25° C. then heated at reflux for 2 h. tert-Butyl alcohol (1.22 g, 16.30 mmol) was added and the mixture was heated at reflux for 3 h. After cooling to room temp, the reaction mixture was poured into H2O. The resulting ppt was collected by filtration, rinsed with H2O and dried. The crude residue was purified by flash chromatography eluting with pentane/EtOAc (10%) to give tert-butyl 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-ylcarbamate (270.0 mg, 44% yield). MS (ESI) calcd for C18H17F3N4O2 (m/z): 378.13.
-
- Tert-butyl 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-ylcarbamate (100.0 mg, 0.26 mmol) was dissolved in 3M HCl/dioxane (2 mL, 6.0 mmol). The reaction mixture was stirred at room temp for 16 h. The mixture was concentrated to give 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-amine hydrochloride (90.0 mg, 100% yield). MS (ESI) calcd for C13H9F3N4 (m/z): 278.08.
-
- A solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-amine (60.0 mg, 0.22 mmol), picolinic acid (27.0 mg, 0.22 mmol), DIPEA (83.0 mg, 0.65 mmol) and HATU (164.0 mg, 0.43 mmol) in DMF (8 mL) was stirred at 60° C. for 16 h. H2O (30 mL) was added and the resulting ppt was collected by filtration and rinsed with MeOH to give N-(5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)picolinamide (60.0 mg, 73%). MS (ESI) calcd for C19H12F3N5O (m/z): 383.10; found: 384 [M+H].
- This general coupling procedure could be used to prepare a variety of N-(5-(2-(trifluoromethyl)phenyl) and N-(5-(2-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)amides by substituting the appropriate carboxylic acid for picolinic acid.
-
- Sodium ethoxide (4.02 g, 59.10 mmol) was added to a solution of ethyl 5-amino-3-methyl-1H-pyrazole-4-carboxylate (10.0 g, 59.10 mmol) and 1,3-dimethyluracil (8.28 g, 59.10 mmol) in EtOH (50 mL). The reaction mixture was stirred at 140° C. for 2 h. After cooling to room temp the solid was collected by filtration. The solid was dissolved in H2O (100 mL) and the pH was adjusted to 7. The resulting precipitate was collected by filtration and dried under vacuum to give ethyl 2-methyl-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate (10.0 g, 76% yield). MS (ESI) calcd for C10H11N3O3 (m/z): 221.08.
-
- A mixture of ethyl 2-methyl-5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carboxylate (10.0 g, 45.20 mmol) in phosphoryl trichloride (50 mL) was heated at reflux for 3 h. The reaction mixture was concentrated in vacuo. The crude residue was dissolved in H2O and the pH was adjusted to 7. The resulting precipitate was collected by filtration and dried under vacuum to give ethyl 2-methyl-5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (10.00 g, 92% yield). MS (ESI) calcd for C10H10ClN3O2 (m/z): 239.05.
-
- A solution of ethyl 2-methyl-5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (9.06 g, 37.70 mmol) 2-(trifluoromethyl)phenylboronic acid (14.25 g, 75.00 mmol), Pd(dppfCl2 (1.51 g, 2.10 mmol), and K2CO3 (10.35 g, 75.00 mmol) in degassed dimethoxyethane (120 mL) was heated at 100° C. for 12 h. The mixture was concentrated and purified by flash chromatography to give ethyl 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (11.70 g, 90% yield). MS (ESI) calcd for C17H14F3N3O2 (m/z): 349.10.
-
- LiOH (14.30 mg, 340.0 mmol) was added to a solution of ethyl 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (11.70 g, 34.00 mmol) in THF/H2O (100 mL, 1:1). The reaction mixture was stirred at 25° C. for 60 h. The mixture was concentrated and the pH was adjusted to 3 by the addition of 1N HCl. The resulting ppt was collected by filtration, rinsed with H2O and dried to give 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (5.00 g, 46% yield). MS (ESI) calcd for C15H10F3N3O2 (m/z): 321.07.
-
- Oxalyl chloride (814 μl, 9.34 mmol) was added to a suspension of 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (1.0 g, 3.11 mmol) in CH2CL2 (20 mL) followed by DMF (3 drops). The reaction mixture was stirred at 25° C. for 2 h then concentrated to dryness to give crude 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride used without further purification (1.10 g, 100% yield). MS (ESI) calcd for C15H9ClF3N3O (m/z): 339.04.
-
- A solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carbonyl chloride (254.0 mg, 0.75 mmol) and 6-methoxypyridine-2-amine (136.0 mg, 1.10 mmol) in pyridine (10 mL) was stirred for 2 h at 50° C. The reaction mixture was poured into H2O and the solid was collected by filtration. The crude residue was purified by flash chromatography to give N-(6-methoxypyridin-2-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (85.0 mg, 27% yield). MS (ESI) calcd for C21H16F3N5O2 (m/z): 427.13; found: 428 [M+H].
- This general coupling procedure could be used to prepare 2-methyl-N-(pyrimidin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-methyl-N-(pyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-methyl-N-(pyridin-3-yl)-5-(2-(trifluoromethy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-methyl-N-(6-(morpholinomethyl)pyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-methyl-N-(6-morpholinopyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and 2-methyl-N-(pyridin-4-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- EDCI (720.0 mg, 3.75 mmol) was added to a solution of 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (800.0 mg, 2.50 mmol) and DMAP (460.0 mg, 3.75 mmol) in DMF (10 mL). The reaction mixture was stirred at 25° C. for 2 h then 4-nitrophenol (350.0 mg, 2.50 mmol) was added and stirring continued for 18 h. The mixture was diluted with sat. aq Na2CO3 (50 mL) and extracted with EtOAc (2×30 mL). The combined organic layers were washed with sat. aq Na2CO3 (3×20 mL), brine, and concentrated. The crude residue was triturated with pentane/EtOAc (5:1) to give 4-nitrophenyl 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate which (960.0 mg, 87% yield). MS (ESI) calcd for C21H13F3N4O4 (m/z): 442.09.
-
- Sodium hydride (11.0 mg, 0.42 mmol) was added to a solution of 2-methoxypyrimidine-4-amine (35.0 mg, 0.28 mmol) in THF (3 mL) at 0° C. The reaction mixture was stirred for 10 min and 4-nitrophenyl 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (60.0 mg, 0.14 mmol) was added and stirring continued for 30 min. The reaction was quenched by the addition of at. aq NH4Cl. The mixture was extracted with EtOAc. The organic layer was washed with sat. aq Na2CO3, brine, dried and concentrated. The crude product was triturated with pentane/EtOAc (4:1) to give N-(2-methoxypyrimidin-4-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (21.0 mg, 36% yield). MS (ESI) calcd for C20H15F3N6O2 (m/z): 428.12; found: 429 [M+H].
- This general coupling procedure could be used to prepare N-(3,5-difluoropyridin-2-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2-hydroxypyridin-4-yl)-2-methyl-5-(2-(trifluoromethy)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2,6-dimethylpyrimidin-4-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(6-methoxypyrimidin-4-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(2-ethoxypyrimidin-4-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-(4,6-dimethylpyrimidin-2-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- A solution of 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic (80.0 mg, 0.25 mmol), 6-methyl-2-aminopyridine (54.0 mg, 0.50 mmol), DIEA (223.0 mg, 1.72 mmol) and HATU (189.0 mg, 0.498 mmol) in DMF (3 mL) was stirred at 60° C. for 16 h. H2O was added. The resulting ppt was collected by filtration, rinsed with H2O, and dried to give 2-methyl-N-(6-methylpyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (26.0 mg, 25% yield). MS (ESI) calcd for C21H16F3N5O (m/z): 411.13; found: 412 [M+H].
- This general coupling procedure could be used to prepare a variety of 2-methyl-N-(substituted)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamides by substituting the appropriate amine for 6-methyl-2-aminopyridine.
-
- B(OH)3 (46.0 mg, 0.74 mmol) was added to a solution of 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic (80.0 mg, 0.25 mmol), and 3-methyl-2-aminopyridine (33.0 mg, 0.30 mmol) in 1,3,5-trimethylbenzene (10 mL). The reaction mixture was heated at 200° C. for 24 h. The reaction mixture was concentrated to dryness and purified by preparative TLC eluting with CH2Cl2/EtOAc (1:1) to give 2-methyl-N-(3-methylpyridin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (12.0 mg, 11% yield). MS (ESI) calcd for C21H16F3N5O (m/z): 411.13; found: 412 [M+H].
- This general coupling procedure could be used to prepare 2-methyl-N-(6-methylpyrazin-2-yl)-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-(3,5-dimethylpyrazin-2-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide and N-(5-fluoropyridin-3-yl)-2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide.
-
- Diphenylphosphoryl azide (1 mL, 4.67 mmol) was added to a solution of 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (1.5 g, 4.67 mmol) and triethylamine (967 μl, 7.01 mmol) in toluene (25 mL). The mixture was stirred for 1 h at 25° C. then heated at reflux for 3 h. Benzyl alcohol (532 μl, 5.14 mmol) was added and the mixture was heated at reflux for 16 h. After cooling to room temp, the reaction mixture was poured into sat. aq NH4Cl and extracted with EtOAc. The combined organics were washed with brine, dried (MgSO4) and concentrated. The crude residue was purified by MPLC eluting with pentane/EtOAc (20-100%) to give benzyl 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-ylcarbamate (1.49 g, 75% yield). MS (ESI) calcd for C22H17F3N4O2 (m/z): 426.13; found: 427 [M+H].
-
- Conc. HCl (15 mL) was added to a solution of benzyl 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-ylcarbamate (1.49 g, 3.49 mmol) in EtOH (25 mL). The reaction mixture was heated at reflux for 2.5 h. After cooling to room temp, the mixture was concentrated to dryness and chased with toluene to give 2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-amine hydrochloride (1.15 g, 100% yield). MS (ESI) calcd for C14H11F3N4 (m/z): 292.09; found: 293 [M+H].
-
- A solution of 5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-amine (50.0 mg, 0.16 mmol), picolinic acid (32.0 mg, 0.26 mmol), DIPEA (44.0 mg, 0.34 mmol) and HATU (129.0 mg, 0.34 mmol) in DMF (20 mL) was stirred at 50° C. for 2 h. H2O was added and the resulting ppt was collected by filtration. The crude residue was purified by flash chromatography to give N-(2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)picolinamide (19.0 mg, 30% yield). MS (ESI) calcd for C20H14F3N5O (m/z): 397.12; found: 398 [M+H].
- This general coupling procedure could be used to prepare a variety of N-(2-methyl-5-(2-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)amides by substituting the appropriate carboxylic acid for picolinic acid.
-
- A mixture of 5-amino-1H-imidazole-4-carboxamide (30.0 g, 238 mmol) and sulfuric acid (70.0 g, 714 mmol) in ethanol (300 mL) was heated to 120° C. in a sealed tube for 24 h. The reaction mixture was cooled to room temp, and the solvent was removed in vacuo. The residue was purified via silica gel column chromatography to give ethyl 5-amino-1H-imidazole-4-carboxylate (20.0 g, 54%). MS (ESI) calcd for C6H9N3O2: 155.07.
-
- A solution of ethyl 5-amino-1H-imidazole-4-carboxylate (10.0 g, 64.5 mmol), 2,5-dioxopyrrolidin-1-yl 3-(2,5-dioxopyrrolidin-1-yloxy)acrylate (20.01 g, 70.9 mmol), and triethylamine (13.02 g, 129 mmol) in anhydrous acetonitrile (200 mL) was heated to 50° C. for 16 h. After concentration in vacuo, the residue was treated with MeOH (100 mL), and the mixture was stirred at 60° C. for 30 min. The mixture was filtered, and the filtrate was concentrated and purified via silica gel column chromatography (MeOH/CHCl3, 4:96 v/v) to give ethyl 2-oxo-1,2-dihydroimidazo[1,5-a]pyrimidine-8-carboxylate (5.0 g, 37.4%) as a white solid. MS (ESI) calcd for C9H9N3O2: 207.06.
-
- A mixture of ethyl 2-oxo-1,2-dihydroimidazo[1,5-a]pyrimidine-8-carboxylate (8.0 g, 38.6 mmol) and phosphoryl trichloride (5.92 g, 38.6 mmol) were heated to 120° C. for 1 h, then cooled to room temp. After concentration in vacuo, water was added (300 mL) and the mixture was extracted with EtOAc. The mixture was concentrated and purified to give ethyl 2-chloroimidazo[1,5-a]pyrimidine-8-carboxylate (4.5 g, 52%). MS (ESI) calcd for C9H8ClN3O2: 225.03.
-
- A mixture of ethyl 2-chloroimidazo[1,5-a]pyrimidine-8-carboxylate (2.0 g, 8.86 mmol), 2-(trifluoromethyl)phenylboronic acid (3.03 g, 15.96 mmol), Pd(PPh3)4 (1.02 g, 0.89 mmol) and Cs2CO3 (5.78 g, 17.73 mmol) in dioxane (50 mL), was heated at 100° C. for 1 h, then cooled to room temp. The mixture was poured into cold water (200 mL) and stirred. The precipitate was collected by filtration to give ethyl 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylate (0.8 g, 27%). MS (ESI) calcd for C16H12F3N3O2: 335.09.
-
- To a mixture of ethyl 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylate (1.5 g, 4.47 mmol) and potassium hydroxide (2.51 g, 44.7 mmol) in water (50 mL) was added MeOH (20 mL). The reaction was heated to reflux for 1 h, then cooled to room temp. The mixture was washed with EtOAc (2×50 mL) and the organics discarded. The aqueous phase was adjusted to pH 4, after which precipitation occurred. The precipitate was collected by filtration to give 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylic acid (1.0 g, 73%). MS (ESI) calcd for C14H8F3N3O2: 307.06.
-
- To a solution of 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylic acid (70.0 mg, 0.228 mmol) in DCM (5 mL) was added DMF (1 drop) and oxalyl dichloride (87.0 mg, 0.684 mmol). The mixture was stirred for 0.5 h and concentrated in vacuo. To the residue was added pyridine (8 mL) and pyridin-3-amine (32.2 mg, 0.342 mmol) at room temp. After 2 h, water was added (20 mL) and the mixture stirred for 1 h. The solid was collected by filtration, washed and dried to give N-(pyridin-3-yl)-2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxamide (24.0 mg, 28%). MS (ESI) calcd for C19H12F3N5O: 383.10.
- This general procedure could be used to prepare N-(pyridin-2-yl)-2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxamide, N-(pyrimidin-4-yl)-2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxamide, N-(pyrimidin-2-yl)-2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxamide and N-(6-morpholinopyridin-2-yl)-2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxamide.
-
- To a mixture of 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidine-8-carboxylic acid (300.0 mg, 0.976 mmol) and triethylamine (197.0 mg, 1.953 mmol) in DMF (30 mL) was added diphenylphosphoryl azide (DPPA) (537.0 mg, 1.953 mmol) at room temp. The mixture was stirred for 1 h, then water (1 mL) was added and the mixture was heated to 100° C. followed by cooling. The reaction mixture was poured into cold water (250 mL) and stirred. The precipitate that formed was collected by filtration, washed with water, and dried in vacuo to give 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-amine (50.0 mg, 18%). MS (ESI) calcd for C13H9F3N4: 278.08.
-
- A mixture of 2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-amine (25.0 mg, 0.90 mmol), picolinic acid (16.6 mg, 0.135 mmol), HATU (43.3 mg, 0.180 mmol) and DIEA (34.8 mg, 0.270 mmol) in DMF (5 mL) was heated to 60° C. for 12 h. The mixture was poured into cold water (30 mL) and stirred. The precipitate that formed was collected by filtration, washed with methanol, and dried in vacuo to give N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)picolinamide (19.0 mg, 55%). MS (ESI) calcd for C19H12F3N5O: 383.10; found: 383.98 [M+H].
- This general coupling procedure could be utilized to prepare 6-morpholino-N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)picolinamide, N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)nicotinamide and N-(2-(2-(trifluoromethyl)phenyl)imidazo[1,5-a]pyrimidin-8-yl)pyrimidine-4-carboxamide.
-
- To a mixture of 3, 6-dichloropyridazine (6.0 g, 40.3 mmol) and 2-(trifluoromethyl)phenyl-boronic acid (9.18 g, 48.3 mmol) were added K2CO3 (8.35 g, 60.4 mmol) and Pd(PPh3)4 (2.33 g, 2.01 mmol). The mixture was stirred in dioxane:H2O (4:1) at 120° C. in a microwave for about 0.5 h. After cooling to room temp, the reaction was diluted with EtOAc and washed with H2O. The combined organic layers were dried over Na2SO4, filtered and evaporated to dryness under reduced pressure. The crude material was purified by vacuum distillation to afford 3-chloro-6-(2-(trifluoromethyl)phenyl)pyridazine (2.8 g, 26.9%). MS (ESI) calcd for C11H6ClF3N2: 258.02.
-
- To a solution of 3-chloro-6-(2-(trifluoromethyl)phenyl)pyridazine (3.0 g, 11.60 mmol) in EtOH was added hydrazine hydrate (13.66 g, 232 mmol). The mixture was stirred at 90° C. for about 24 h. Upon cooling to room temp, the reaction was quenched with H2O and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, filtered and evaporated to dryness under reduced pressure. The crude material was purified by vacuum distillation to afford 3-hydrazinyl-6-(2-(trifluoromethyl)phenyl)pyridazine (2.5 g, 85%). MS (ESI) calcd for C11H9F3N4: 254.1.
-
- 6-(Azetidin-1-yl) pyridin-2-amine (0.1 g, 0.67 mmol) was dissolved in (COCl)2 (2.55 g, 20.11 mmol). The reaction was heated to 50° C. for 1 h, and then cooled to room temp and the volatiles were removed under reduced pressure. Remaining solid was dried under vacuum to provide 2-(6-(azetidin-1-yl)pyridin-2-ylamino)-2-oxoacetyl chloride (0.26 g, 81%). MS (ESI) calcd for C10H10ClN3O2: 239.1.
-
- 2-(6-(Azetidin-1-yl)pyridin-2-ylamino)-2-oxoacetyl chloride (140.0 mg, 0.58 mmol) was dissolved in methylene chloride (15 mL). 3-hydrazinyl-6-(2-(trifluoromethyl)phenyl)pyridazine (149.0 mg, 0.58 mmol), and triethylamine (70.9 mg, 0.701 mmol) were then added. The reaction was stirred at 25° C. for 16 h. Upon completion, the reaction was poured into NaHCO3 solution, and extracted with CH2Cl2. The combined organic layers were dried with Na2SO4, concentrated, and purified by chromatography to give N-(6-(azetidin-1-yl)pyridin-2-yl)-2-oxo-2-(2-(6-(2-(trifluoromethyl)phenyl)pyridazin-3-yl)hydrazinyl)acetamide (180.0 mg, 67.4%). MS (ESI) calcd for C21H18F3N7O2: 457.2.
-
- N-(6-(azetidin-1-yl)pyridin-2-yl)-2-oxo-2-(2-(6-(2-(trifluoromethyl)phenyl)pyridazin-3-yl)hydrazinyl)acetamide (100.0 mg, 0.22 mmol) was dissolved in xylene (15 mL), and the reaction was heated in a microwave at 150° C. for 6 h. Upon cooling to room temp, the reaction was poured into H2O, and extracted with DCM. The combined organic layers were dried with Na2SO4, the solvent was removed in vacuo and residue was purified by chromatography to give N-(6-(azetidin-1-yl)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide (6.0 mg, 6.25%). MS (ESI) calcd for C21H16F3N7O: 439.1; found: 440.0 [M+H].
- This general procedure could be used to prepare N-(6-(pyrrolidin-1-yl)pyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide, N-(6-morpholinopyridin-2-yl)-6-(2-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide and 6-(2-(difluoromethyl)phenyl)-N-(2-morpholinopyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide.
-
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carbaldehyde was prepared using the same method described above as for the preparation of 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinaldehyde.
-
- To a solution of 5-aminopyridiencarboxylic acid (8.4 g, 60.8 mmol) in ethanol (100 mL) was added SOCl2 (14.5 g, 120 mmol) at 0° C. The mixture was refluxed for 12 h. The solvent was removed and saturated Na2CO3 solution was added to adjust pH=9 and filtrated to give a solid. The solid was dried in vacuo to give ethyl 5-aminopicolinate (7.5 g, 75%). MS (ESI) calcd for C8H10N2O2 (m/z): 166.18.
- To a solution of ethyl 5-aminopicolinate (7.5 g, 45 mmol) in t-BuOH (60 mL) and acetone (20 mL) was added DMAP (0.10 g, 0.9 mmol) and di-t-butyl dicarbonate (19.6 g, 90 mmol). The reaction was stirred at room temp overnight. The solvent was removed and hexane (150 mL) was added and cooled to −20° C. for 2 h. The mixture was filtered and the solid was dried in vacuo to give ethyl 5-(tert-butoxycarbonylamino)picolinate (8.9 g, 53%). MS (ESI) calcd for C13H18N2O4: (m/z) 266.29.
-
- To a stirred solution of ethyl 5-(tert-butoxycarbonylamino)picolinate (8.9 g, 24 mmol) in ethyl ether (200 mL) under nitrogen was added LAH (1.8 g, 48 mmol) in ethyl ether (100 mL) over a period of 30 min at 0° C. The reaction mixture was stirred for 3 h, water (1 mL) and 10% NaOH solution (2 mL) was added and the mixture was filtered and the filtrate was dried over Na2SO4 and concentrated under reduced pressure to give compound tert-butyl 6-(hydroxymethyl)pyridin-3-ylcarbamate (4.2 g, 78%). MS (ESI) calcd for C11H16N2O3 (m/z): 224.26.
-
- To a solution of tert-butyl 6-(hydroxymethyl)pyridin-3-ylcarbamate (4.2 g, 18.8 mmol) and DIPEA (7.0 g, 56.4 mmol) in THF (20 mL) was added MsCl (2.8 g, 24.4 mmol) over a period of 30 min at 0° C. and the mixture was stirred for 1 h. The reaction was quenched by adding saturated aqueous NaHCO3 and extracted with EtOAc (3×60 mL). The combined organic layer was washed with brine and dried over Na2SO4. The organic solvent was removed to give compound (5-(tert-butoxycarbonylamino)pyridin-2-yl)methyl methanesulfonate (5.5 g) without further purification for next step.
- A mixture of (5-(tert-butoxycarbonylamino)pyridin-2-yl)methyl methanesulfonate (1.70 g), morpholine (1.0 g, 11.3 mmol) and K2CO3 (2.30 g, 16.9 mmol) acetonitrile (30 mL) was stirred at room temperature for 12 h. Water (30 mL) was added and the mixture was extracted with ethyl acetate (3×30 mL) and dried over MgSO4, concentrated in vacuo and purified by chromatography on silica gel (petroleum ether: ethyl acetate=1:1 to 1:3) to give tert-butyl 6-(morpholinomethyl)pyridin-3-ylcarbamate (1.20 g, 71% for two steps). MS (ESI) calcd for C15H23N3O3 (m/z): 293.36.
-
- To a solution of tert-butyl 6-(morpholinomethyl)pyridin-3-ylcarbamate (1.20 g, 4.1 mmol) in CH2Cl2 (20 mL) was added TFA (6 mL). The mixture was stirred for 12 h at room temp. The solvent was removed in vacuo and the solid was basified to pH=9 with saturated Na2CO3. The mixture was concentrated to dryness and acidified to pH=1, basified to pH=9 and concentrated to dryness. The residue was washed with ethyl acetate (3×25 mL), the combined organic layers were concentrated to give 6-(morpholinomethyl)pyridin-3-amine (450.0 mg, 56%). MS (ESI) calcd for C10H15N3O (m/z): 193.25; found 194[M+H].
- 6-(morpholinomethyl)pyridin-2-amine
- and 2-(morpholinomethyl)pyridin-4-amine
- were prepared by the same sequence above, starting from 6-aminopicolinic acid and 2-aminopicolinic acid respectively. 5-(pyrrolidin-1-ylmethyl)pyridin-2-amine
- 6-(pyrrolidin-1-ylmethyl)pyridin-2-amine
- 6-(pyrrolidin-1-ylmethyl)pyridin-3-amine
- and 2-(pyrrolidin-1-ylmethyl)pyridin-4-amine
- were prepared by the same sequence above, starting from 6-aminonicotinic acid, 6-aminopicolinic acid, 5-aminopicolinic acid and 4-aminopicolinic acid and reacting the resulting mesylate intermediates with pyrrolidine.
-
- A mixture of 6-chloropyridin-2-amine (19.3 g, 150 mmol), K2CO3 (41.7 g, 0.30 mol) and morpholine (38.9 mL, 450 mmol) in DMSO (150 mL) was stirred at 190° C. (oil bath) for 10 h. After cooling to room temp, water (300 mL) was added and extracted with ethyl acetate (4×150 mL). The combined organic layers were washed with water (3×25 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel chromatography (10:1 petroleum ether: ethyl acetate) to give 6-morpholinopyridin-2-amine as a white solid (9.0 g, 54.8 mmol). MS (ESI) calcd for C9H13N3O (m/z): 179.11; found 180 [M+H].
- 4-morpholinopyridin-2-amine
- 5-morpholinopyridin-2-amine
- 2-morpholinopyridin-3-amine
- 5-morpholinopyridin-3-amine
- 6-morpholinopyridin-3-amine
- and 2-morpholinopyridin-4-amine
- were prepared by the same sequence above, starting from 4-chloropyridin-2-amine, 5-chloropyridin-2-amine, 2-chloropyridin-3-amine, 5-chloropyridin-3-amine, 6-chloropyridin-3-amine and 2-chloropyridin-4-amine respectively. 2-(pyrrolidin-1-yl)pyridin-4-amine
- and 6-(pyrrolidin-1-yl)pyridin-2-amine
- were prepared by the same sequence above, starting from 2-chloropyridin-4-amine and 6-chloropyridin-2-amine respectively and reacting with pyrrolidine.
-
- 6-(2,2,2-trifluoroethoxy)pyridin-2-amine was prepared similarly to 2-(2,2,2-trifluoroethoxy)pyridin-4-amine above, using 6-chloropyridin-2-amine. MS (ESI) calcd for C7H7F3N2O: 192.05.
-
- 4-(2,2,2-trifluoroethoxy)pyrimidin-2-amine was prepared the same as above, using 4-chloropyrimidin-2 amine. MS (ESI) calcd for C6H6F3N3O: 193.05.
-
- 4-methyl-6-(2,2,2-trifluoromethoxy)pyrimidin-2-amine was prepared the same as above, using 4-chloro-6-methylpyrimidin-2-amine. MS (ESI) calcd for C7H8F3N3O: 207.06.
-
- 2-(2,2,2-trifluoroethoxy)pyrimidin-4-amine was prepared the same as above, using 2-chloropyrimidin-4-amine. MS (ESI) calcd for C6H6F3N3O: 193.05.
-
- Prepared using the same method as that for 2-(2,2,2-trifluoroethoxy)pyridin-4-amine. MS (ESI) calcd for C6H6F3N3O: 193.05.
-
- NaH (1.15 g, 60% in mineral oil, 28.7 mmol) was added the mixture of 4-chloropyrimidin-2-amine (1.0 g, 7.75 mmol) and solketal (3.07 g, 23.25 mmol) in dioxane (12 mL) solution at 0° C. The temperature was elevated to 120° C. for 15 h. After cooling to room temp, the solids were filtered, filtrate was concentrated and residue purified by column chromatography to give 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-2-amine (1.2 g, 69%). MS (ESI) calcd for C10H15N3O3: 225.11.
-
- The 2-bromopyridin-4-amine (650.0 mg, 3.76 mmol) was taken up in dioxane (25 mL) along with (2,2-dimethyl-1,3-dioxolan-4-yl)methanol (3.97 g, 30.1 mmol) and NaH (451.0 mg, 18.78 mmol). The resulting reaction mixture was stirred at reflux for 48 h, concentrated in vacuo and purified by chromatography to give 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-3-amine as a pale yellow solid (260.0 mg, 40%). MS (ESI) calcd for C11H16N2O3: 224.12; found 224.87 [M+H].
-
- 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyridin-4-amine was prepared using the same method described above using 2-bromopyridin-4-amine. MS (ESI) calcd for C11H16N2O3: 224.12.
-
- 5-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine was prepared the same as above, using 5-bromopyrazin-2-amine. MS (ESI) calcd for C10H15N3O3: 225.11.
-
- To a solution of 2-bromo-6-methylpyridine (40.0 g, 233 mmol) in acetic acid (50 mL) was added CH3CO3H (175 mL, 233 mmol) maintaining temperature below 50° C. After completion of addition the mixture was stirred at 50° C. for 15 h and then cooled to room temp. Crushed ice was added and the pH was adjusted to 12 with 40% aqueous KOH solution. After extraction with CHCl3, the combined organic layers were dried over Na2SO4, concentrated in vacuo and crude product was purified by silica-gel using EtOAc:Pentane=1:1, then DCM:MeOH=10:1 to give 2-bromo-6-methylpyridine 1-oxide. MS (ESI) calcd for C6H6BrNO: 188.96.
-
- Flask charged with solid 2-bromo-6-methylpyridine 1-oxide (16.0 g, 85 mmol) was cooled to 0° C. To this fuming nitric acid (80 mL) was added followed by H2SO4 (98%, 30 mL). The mixture was stirred at 90° C. for 90 min and then cooled to room temp. Crushed ice was added and the pH was adjusted to 12 with 30% aqueous NaOH solution. The solid was filtered to give 2-bromo-6-methyl-4-nitropyridine 1-oxide (16.0 g, 81%) as a pale yellow solid. MS (ESI) calcd for C6H5BrN2O3: 232.0.
-
- A solution of 2-bromo-6-methyl-4-nitropyridine 1-oxide (16.0 g, 68.7 mmol) in acetic acid (300 mL) was treated with powdered iron (25.8 g, 460 mmol), the mixture was slowly heated to 100° C., kept for 2 h at this temperature, then cooled to room temp and filtered. After evaporation of the solvent, the residue was purified by silica-gel using EtOAc: Pet ether=1:1 to give 2-bromo-6-methylpyridin-4-amine. MS (ESI) calcd for C6H7BrN2: 185.98; found: 186.96 [M+H].
-
- 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)6-methylpyridin-4-amine was prepared the same as above, using 2-bromo-6-methylpyridin-4-amine. MS (ESI) calcd for C12H18N2O3: 238.13.
- Each individual enantiomer was also prepared the same as above.
- To make (S)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)6-methylpyridin-4-amine, (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol was used.
- To make (R)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)6-methylpyridin-4-amine, (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol was used.
-
- Solketal (49.5 g, 0.38 mol) was added to a suspension of NaH (15.0 g, 0.38 mol) in THF at 0° C. The resulting mixture was stirred at room temp for 2 h. 4-chloro-6-methylpyrimidin-2-amine (18.0 g, 0.125 mol) was added. The reaction was heated at 70° C. for 17 h. After cooling to room temp, H2O (100 mL) was added. The aqueous layer was extracted with ethyl acetate. Combined organic layers were dried, concentrated and the product was washed with diethyl ether/hexanes (10:1) to afford 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-methylpyrimidin-2-amine (19.0 g, 63% yield). MS (ESI) calcd for C11H17N3O3: 239.1.
-
- This was prepared using the same method as that for 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-6-methylpyrimidin-2-amine except that no solvent was used and heating was at 110° C. for 3 d. MS (ESI) calcd for C11H16N2O3: 224.1.
-
- To a solution of solketal (34.4 g, 260 mmol) in THF (150 mL) was added NaH (10.4 g, 260 mmol) at room temp and the mixture stirred for 1 h. 2-chloro-4-aminopyrimidine (15.0 g, 115 mmol) was then added, and the mixture was stirred at 70° C. for 48 h. The reaction mixture was concentrated and the crude residue was purified by flash chromatography (CH2Cl2:MeOH=15:1-10:1) to give 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine (18.2 g, 70% yield) as an oil. MS (ESI) calcd for C10H15N3O3: 225.11.
-
- (S)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine was prepared the same as above, using 6-chloropyrazin-2-amine and (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol. MS (ESI) calcd for C10H15N3O3: 225.11.
-
- 5-bromo-2-nitropyridine (1.0 g, 4.93 mmol), morpholine (0.47 g, 5.42 mmol), Bu4NI (0.09 g, 0.25 mmol), K2CO3 (0.75 g, 5.42 mmol) were stirred in DMSO (10 mL) at 80° C. for 30 h. Water was added and the solid separated by filtration was purified by column chromatography to give (4-(6-nitropyridin-3-yl)morpholine).
- To a solution of 4-(6-nitropyridin-3-yl)morpholine (0.7 g, 3.35 mmol) in CH3OH (10 mL) Raney nickel (0.20 g, 3.35 mmol) was added at 25° C. and the mixture was stirred under H2 balloon for about 12 h. After filtration and concentration of the solvent, 5-morpholinopyridin-3-amine was obtained and was used without further purification. MS (ESI) calcd for C9H13N3O: 179.11.
-
- 3-morpholinopyridin-2-amine was prepared from 3-bromo-2-nitropyridine using the same two-step procedure described above.
-
- A solution of 4-chloropyridin-3-amine (0.5 g, 3.89 mmol) and morpholine (0.68 g, 7.78 mmol) in DMAC (10 mL) was heated at 200° C. for 30 h. After cooling to room temp, water was added and the solid was purified by column chromatography to give 4-morpholinopyridin-3-amine. MS (ESI) calcd for C9H13N3O: 179.11.
-
- To a mixture of 4-amino-2-chloropyrimidine (300.0 mg, 2.3 mmol) in THF (4 mL), DIEA (0.8 mL) was added. The reaction was refluxed for 15 h. After cooling to room temperature, the solvent was evaporated and the solid was taken up in CH2Cl12. After filtration, the solid was dissolved in CH2Cl2+MeOH (1:1) and adsorbed onto silica gel for purification by column chromatography to afford 2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-amine (160.0 mg, 36%). MS (ESI) calcd for C9H12N4O: 192.1.
-
- To a solution of tert-butyl (6-aminopyridin-2-yl)carbamate (209.0 mg, 1.0 mmol) in dichloroethane (3 mL), a solution of acetaldehyde (0.06 mL, 1.0 mmol) in dichloroethane (0.5 mL) was added. After 1 h at room temp the reaction was quenched with saturated NaHCO3 solution. The aqueous mixture was extracted with dichloromethane (2×50 mL). After concentrating the combined organic layers, the crude product was purified by flash column chromatography (pentane: ethyl acetate=10-30%) to afford tert-butyl (6-(ethylamino)pyridin-2-yl)carbamate (100.0 mg, 42%). MS (ESI) calcd for C12H19N3O2: 237.2.
-
- Tert-butyl (6-(ethylamino)pyridin-2-yl)carbamate (200 mg, 0.84 mmol) was taken up in TFA: CH2Cl12 (1:1, 4 mL) and stirred at room temperature for 2 h. Solvents were evaporated under reduced pressure, the residue was dried on the high vacuum pump upon which 6-(ethylamino)pyridin-2-aminium 2,2,2-trifluoroacetate was obtained as solid (220.0 mg, yield quant.). MS (ESI) calcd for C9H12F3N3O2: 251.1.
-
- NaH (60% in oil, 2.47 g, 61.8 mmol) was washed twice with pentane and dried under vacuum. THF (25 mL) was added, followed by (3-methyloxetan-3-yl)methanol (6.1 mL, 61.8 mmol) dropwise. This was allowed to stir 1 h at room temp before addition of 15 mL more TNF and 4-amino-2-chloropyrimidine (4.0 g, 30.9 mmol). The reaction was heated to reflux for 17 h, cooled and concentrated. Water was added (50 mL), and enough saturated NH4Cl to bring the pH down to 8. The mixture extracted with EtOAc (3×75 mL), and the combined organics were washed with saturated aqueous NaHCO3 and brine, dried with Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (0-10% MeOH/CH2Cl2) to give 2-((3-methyloxetan-3-yl)methoxy)pyrimidin-4-amine (1.84 g, 30%). MS (ESI) calcd for C9H13N3O2: 195.10; found: 196 [M+H].
-
- NaH (60% in oil, 2.23 g, 55.7 mmol) was washed twice with pentane and dried under vacuum. THF (35 mL) was added, followed by (3-methyloxetan-3-yl)methanol (5.5 mL, 55.7 mmol) dropwise. This was allowed to stir 1 h at room temp before addition of 5 mL more THF and 4-chloro-6-methylpyrimidin-2-amine (4.0 g, 27.9 mmol). The reaction was heated to reflux for 17 h, cooled and concentrated. Water was added (50 mL), and the mixture was extracted with EtOAc (3×75 mL), and the combined organics were washed with saturated aqueous NaHCO3 and brine, dried with Na2SO4, filtered and concentrated. The crude product was triturated with Et2O and the white solid was dried under vacuum to give 4-methyl-6-((3-methyloxetan-3-yl)methoxy)pyrimidin-2-amine (2.42 g, 41%). MS (ESI) calcd for C10H15N3O2: 209.12; found: 210 [M+H].
-
- NaH (60% in oil, 1.24 g, 30.9 mmol) was washed twice with pentane and dried under vacuum. Dioxane (50 mL) was added, followed by (3-methyloxetan-3-yl)methanol (3.0 mL, 30.9 mmol) dropwise. This was allowed to stir 2 h at room temp before addition of 6-chloropyrazin-2-amine (2.0 g, 15.4 mmol). The reaction was heated to reflux for 16 h, cooled and concentrated. Water was added (50 mL), and the mixture was extracted with EtOAc (3×75 mL), and the combined organics were washed with water and brine, dried with Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography (0-10% MeOH/CH2Cl2) to give 6-((3-methyloxetan-3-yl)methoxy)pyrazin-2-amine (3.02 g, quant.). MS (ESI) calcd for C9H13N3O2: 195.10; found: 196 [M+H].
-
- NaH (60% in oil, 126.0 mg, 3.15 mmol) was washed twice with pentane and dried under vacuum. THF (3.0 mL) was added, followed by tetrahydro-2H-pyran-4-ol (0.3 mL, 3.15 mmol) dropwise over 5 min. The mixture was allowed to stir at room temp for 1 h. 2-chloro-4-aminopyrimidine (314.0 mg, 2.43 mmol) was added and the reaction was heated to reflux for 18 h. The mixture was cooled to room temp and water was added (5 mL), along with enough saturated aqueous NH4Cl to bring the pH down to 8. Minimal EtOAc was added (2 mL), but there was a precipitate between layers so the entire mixture was filtered and the solid was washed with water. The solid was dried under vacuum to give clean 2-(tetrahydro-2H-pyran-4-yloxy)pyrimidin-4-amine (220.0 mg, 46%). MS (ESI) calcd for C9H13N3O2: 195.10; found: 196 [M+H].
-
- The reaction was run similarly to the above, with NaH (60% in oil, 227.0 mg, 5.67 mmol), THF (5.4 mL), (R)-tetrahydrofuran-3-ol (0.456 mL, 5.67 mmol), and 2-chloro-4-aminopyrimidine (566.0 mg, 4.36 mmol) for 19 h. Water and EtOAc were added (10 mL each), along with enough saturated aqueous NH4Cl to bring the pH down to 8 (about 2 mL). The layers were separated and the aqueous layer was washed twice more with EtOAc (2×10 mL). The combined organics were washed with brine, dried with Na2SO4, filtered and concentrated to give 748.0 mg of crude product. This was triturated with Et2O and filtered. The solid was washed with Et2O and dried under vacuum to give (R)-2-(tetrahydrofuran-3-yloxy)pyrimidin-4-amine (419 mg, 53%). MS (ESI) calcd for C8H11N3O2: 181.09; found: 182 [M+H].
-
- (S)-2-(tetrahydrofuran-3-yloxy)pyrimidin-4-amine was prepared the same as above, using (S)-tetrahydrofuran-3-ol. 53% yield. MS (ESI) calcd for C8H11N3O2: 181.09; found: 182 [M+H].
-
- 2-isopropoxypyrimidin-4-amine was prepared the same as above, using isopropanol. 23% yield. MS (ESI) calcd for C7H11N3O: 153.09; found: 154 [M+H].
-
- 2-(2-methoxyethoxy)pyrimidin-4-amine was prepared the same as above, using 2-methoxyethanol. 73% yield. MS (ESI) calcd for C7H11N3O2: 169.09; found: 170 [M+H].
-
- 6-(2-methoxyethoxy)pyrimidin-4-amine was prepared the same as above, using 4-amino-6-chloropyrimidine. 82% yield. MS (ESI) calcd for C7H11N3O2: 169.09; found: 170 [M+H].
-
- (R)-6-(tetrahydrofuran-3-yloxy)pyrimidin-4-amine was prepared the same as above, using (R)-tetrahydrofuran-3-ol. 45% yield. MS (ESI) calcd for C8H11N3O2: 181.09; found: 182 [M+H].
-
- (S)-6-(tetrahydrofuran-3-yloxy)pyrimidin-4-amine was prepared the same as above, using (S)-tetrahydrofuran-3-ol. 68% yield. MS (ESI) calcd for C8H11N3O2: 181.09; found: 182 [M+H].
-
- A microwave vial was charged with 4-amino-6-chloropyrimidine (1.0 g, 7.72 mmol), and pyrrolidine (10 mL) was added. The vial was sealed, and heated in the microwave at 180° C. for 1 h. After cooling, the reaction was diluted with methanol (30 mL), and silica (15.0 g) was added. All solvents were removed in vacuo, and the remaining silica slurry loaded on a 40.0 g silica column. Elution with a 0% to 10% methanol in dichloromethane gradient yielded 6-(pyrrolidin-1-yl)pyrimidin-4-amine (1.22 g, 96% yield). MS (ESI) calcd for C8H14N4: 164.11.
-
- A microwave vial was charged with 2-amino-4-chloropyrimidine (2.0 g, 15.4 mmol), and pyrrolidine (10 mL) was added. The vial was sealed, and heated in the microwave at 150° C. for 1 h. After cooling, the reaction was diluted with methanol (30 mL), and silica (15 g) was added. All solvents were removed in vacuo, and the remaining silica slurry loaded on a 40.0 g silica column. Elution with a 0% to 10% methanol in dichloromethane gradient yielded 4-(pyrrolidin-1-yl)pyrimidin-2-amine (1.70 g, 67% yield). MS (ESI) calcd for C8H14N4: 164.11.
-
- To a solution of tert-butyl 3-oxoazetidine-1-carboxylate (20.0 g, 117 mmol) in DCM (400 mL) was added (formylmethylene)triphenylphosphorane (40 g, 129 mmol) at room temp, and the reaction mixture was stirred at 40° C. for 6 h, followed by concentration in vacuo. The residue was purified by silica gel column chromatography (hexanes:EtOAc 5:1) to give tert-butyl 3-(2-oxoethylidene)azetidine-1-carboxylate as a yellow oil (23.0 g, quant.). MS (ESI) calcd for C10H15NO3: 197.11.
-
- To a solution of tert-butyl 3-(2-oxoethylidene)azetidine-1-carboxylate (985.0 mg, 5 mmol) in THF (4 mL) was added piperidine (0.035 mL, 0.35 mmol). Thioacetic acid (0.535 mL, 7.5 mmol) was added and the mixture was stirred at room temp for 6 h. The mixture was then directly purified by silica gel column chromatography (hexanes:EtOAc 2:1) to give tert-butyl 3-(acetylthio)-3-(2-oxoethyl)azetidine-1-carboxylate as a yellow oil (1.2 g, 88%). MS (ESI) calcd for C12H19NO4S: 273.10.
-
- To a solution of tert-butyl 3-(acetylthio)-3-(2-oxoethyl)azetidine-1-carboxylate (2.0 g, 7.3 mmol) in Et2O (8 mL) was added dropwise LiAlH4 (4 M in Et2O; 8.4 mL, 8.4 mmol), upon which the mixture immediately turned to a colorless suspension. The mixture was stirred at room temp for 25 min, then it was diluted with Et2O (20 mL) and quenched by addition of saturated aqueous NaHCO3 (40 mL). The organic phase was diluted with EtOAc (40 mL) and to the aqueous phase was added a saturated aqueous solution of Rochelle's salt (40 mL), and the phases were separated. The aqueous phase was saturated with NaCl and extracted with EtOAc (50 mL). The combined organic phases were dried with Na2SO4, filtered, and concentrated in vacuo to afford tert-butyl 3-(2-hydroxyethyl)-3-mercaptoazetidine-1-carboxylate as a yellow oil (1.1 g, 65%). MS (ESI) calcd for C10H19NO3S: 233.11.
-
- To a solution of diethoxytriphenylphosphorane (3.1 g, 5.2 mmol) in toluene (10 mL) was added at −30° C. a solution of tert-butyl 3-(2-hydroxyethyl)-3-mercaptoazetidine-1-carboxylate (1.0 g, 4.3 mmol) in toluene (8 mL), and the mixture was stirred at −30° C. for 1 h, then it was allowed to slowly warm to room temp overnight. After stirring for 13 h, the mixture was diluted with EtOAc (30 mL) and quenched with brine (20 mL). The phases were separated and the organic phase was dried with MgSO4, filtered, and concentrated in vacuo. Purification via silica gel column chromatography (hexanes:EtOAc 6:1) gave tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate as a yellow oil (420.0 mg, 46%). MS (ESI) calcd for C10H17NO2S: 215.10.
-
- To a solution of tert-butyl 1-thia-6-azaspiro[3.3]heptane-6-carboxylate (420.0 mg, 1.96 mmol) in DCM (5 mL) was added at 0° C. m-CPBA (85%, 836.0 mg, 4.12 mmol), and the mixture was stirred at 0° C. for 15 min, followed by warming to room temp, and stirring was continued for 3.5 h. The reaction mixture was diluted with DCM (30 mL) and bicarb (30 mL) was added. The phases were separated, and the organic phase was dried with MgSO4, filtered, and concentrated in vacuo. The product was purified via silica gel column chromatography (hexanes:EtOAc 2:1) to give tert-butyl 1-(dioxothia)-6-azaspiro[3.3]heptane-6-carboxylate as a colorless solid (500.0 mg, 100%). MS (ESI) calcd for C10H17NO4S: 247.09.
-
- To tert-butyl 1-(dioxothia)-6-azaspiro[3.3]heptane-6-carboxylate (500.0 mg, 1.96 mmol) was added HCl/dioxane (4 M, 8 mL), and the mixture was stirred at room temp for 18 h. The mixture was concentrated in vacuo to give 1-(dioxothia)-6-azaspiro[3.3]heptane as a white solid (424.0 mg, ˜100%). MS (ESI) calcd for C5H9NO2S: 147.04; found: 148.0 [M+H].
-
- To a solution of 1-(dioxothia)-6-azaspiro[3.3]heptane (1.7 g, 8.6 mmol) in DMF (20 mL) was added 2-chloropyrimidine-4-ylamine (1.5 g, 11.2 mmol) and CsCO3 (11.2 g, 34.4 mmol), and the mixture stirred at 70° C. for 18 h. The mixture was concentrated in vacuo and the residue dissolved with DCM/MeOH 2:1. This solution was filtered and the filtrate concentrated in vacuo. Purification with prep. TLC (DCM/MeOH 15:1) gave 2-(1-(dioxothia)-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-amine as a white solid (903.0 mg, 43%). MS (ESI) calcd for C9H12N4O2S: 240.07; found: 241.0 [M+H].
-
- A mixture of 5-bromothiazol-2-amine hydrobromide (7.8 g, 30.0 mmol), morpholine (10.5 g, 120 mmol), and Cs2CO3 (48.9 g, 150 mmol) in CH3CN (100 mL) was stirred at room temperature for 1 h. The mixture was poured into H2O (100 mL), extracted with EtOAc, dried (Na2SO4), and concentrated. The crude product was purified by column chromatography to give 5-morpholinothiazol-2-amine (2.0 g, 36% yield). MS (ESI) calcd for C7H11N3OS (m/z): 185.06.
-
- Methanesulfonyl chloride (19.0 g, 165.9 mmol) was added dropwise to a solution of tert-butyl 6-(hydroxymethyl)pyridin-2-ylcarbamate (30.0 g, 133.4 mmol) and diisopropylethylamine (50.0 g, 387.6 mmol) in CH2Cl2 (300 mL) at 0° C. The mixture was stirred for 24 h at room temp. The reaction mixture was concentrated and H2O (300 mL) was added. The mixture was extracted with ethyl acetate (3×200 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude product was purified by column chromatography eluting with pentane/EtOAc to give tert-butyl 6-(chloromethyl)pyridin-2-ylcarbamate (29.5 g, 91% yield). MS (ESI) calcd for C11H15ClN2O2 (m/z): 242.08.
-
- A mixture of tert-butyl 6-(chloromethyl)pyridin-2-ylcarbamate (7.0 g, 28.9 mmol), 4,4-difluoropiperidine hydrochloride (5.2 g, 43.1 mmol), K2CO3 (10.4 g, 75.4 mmol) and potassium iodide (800.0 mg, 4.8 mmol) in DMF (70 mL) was stirred at 60° C. for 16 h. H2O (200 mL) was added and the mixture was extracted with EtOAc then washed with H2O. The crude product was purified by column chromatography eluting with EtOAc/pentane (1:2) to give tert-butyl 6-((4,4-difluoropiperidin-1-yl)methyl)pyridin-2-ylcarbamate (8.0 g, 85% yield). MS (ESI) calcd for C16H23F2N3O2 (m/z): 327.18.
-
- HCl (g) was bubbled through a solution of tert-butyl 6-((4,4-difluoropiperidin-1-yl)methyl)pyridin-2-ylcarbamate (8.0 g, 24.4 mmol) in MeOH (100 mL) at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The crude residue was dissolved in MeOH (5 mL) and a mixture of CH2Cl2/acetone was added to form a ppt which was collected by filtration and rinsed with CH2Cl2. Repeated three times to give 6-((4,4-difluoropiperidin-1-yl)methyl)pyridin-2-amine hydrochloride (6.0 g, 93% yield). MS (ESI) calcd for C11H15F2N3 (m/z): 227.12.
-
- (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (2.50 g, 18.93 mmol) was added to a room temperature suspension of NaH 60 wt % (833.0 mg, 20.82 mmol) in THF (50 mL). The reaction mixture was stirred at room temp for 30 min and a solution of 6-chloropyrazine-2-carboxylic acid (1.0 g, 6.31 mmol) in THF (20 mL) was added. The reaction mixture was stirred at room temp for 30 min then heated at reflux for 2 h. After cooling to room temp, the pH was adjusted to 3 by the addition of 3 N HCl (4 mL). The mixture was poured into brine and extracted with EtOAc. The combined organics were dried and concentrated. The crude product was recrystallized from pentane/EtOAc to give (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carboxylic acid (764.0 mg, 48% yield). MS (ESI) calcd for C11H14N2O6 (m/z): 254.09; found: 255 [M+H].
-
- (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (4.98 g, 37.72 mmol) was added to a room temperature suspension of NaH 60 wt % (1.7 g, 41.5 mmol) in THF. The reaction mixture was stirred at room temp for 30 min and a solution of ethyl 6-chloropicolinate (1.40 g, 7.54 mmol) in THF was added. The reaction mixture was heated at reflux for 16 h. After cooling to room temp, the pH was adjusted to 4 by the addition of 3 N HCl. The mixture was poured into brine and extracted with EtOAc. The combined organics were dried and concentrated. The crude product was recrystallized from pentane/EtOAc to give (S)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carboxylic acid (1.30 g, 68% yield). MS (ESI) calcd for C12H15NO5 (m/z): 253.10.
-
- (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (1.07 g, 8.07 mmol) was added to a room temperature suspension of NaH 60 wt % (385.0 mg, 8.89 mmol) in THF. The reaction mixture was stirred at room temp for 30 min and a solution of ethyl 6-chloropicolinate (500.0 mg, 2.69 mmol) in THF was added. The reaction mixture was heated at reflux for 16 h. After cooling to room temp, the pH was adjusted to 4 by the addition of 3 N HCl. The mixture was poured into brine and extracted with EtOAc. The combined organics were dried and concentrated. The crude product was recrystallized from pentane/EtOAc to give (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazine-2-carboxylic acid (500.0 mg, 74% yield). MS (ESI) calcd for C12H15NO5 (m/z): 253.10.
-
- (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (1.80 mL, 14.95 mmol) was added to a room temperature suspension of NaH 60 wt % (653.0 mg, 16.34 mmol) in THF (30 mL). The reaction mixture was stirred at room temp for 30 min and 2-bromo-nicotinic acid (1.0 g, 4.95 mmol) was added. The reaction mixture was heated at reflux for 16 h. After cooling to room temp, the pH was adjusted to 3 by the addition of 3 N HCl. The mixture was poured into brine and extracted with EtOAc. The combined organics were dried and concentrated. The crude product was recrystallized from pentane/EtOAc to give (R)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid (1.16 g, 92% yield). MS (ESI) calcd for C12H15NO5 (m/z): 253.10.
-
- Solketal (23.5 g, 178 mmol) was added dropwise to a suspension of NaH 60 wt % (7.1 g, 178 mmol) in THF (400 mL) at 0° C. The reaction mixture was stirred for 1 h at 25° C. and 6-bromopicolinic acid (12.0 g, 59.4 mmol) was added. The reaction mixture was heated at reflux for 1.5 h. After cooling to room temp, H2O was added and the pH was adjusted to 2-3. The mixture extracted with EtOAc. The combined organics were washed with H2O, dried and concentrated. The crude product was recrystallized from pentane/EtOAc to give 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid (10.0 g, 66% yield). MS (ESI) calcd for C12H15NO5 (m/z): 253.10; found: 254 [M+H].
-
- Solketal (39.1 g, 300 mmol) was added to a suspension of NaH 60 wt % (12.0 g, 300 mmol) at 0° C. in 1,4-dioxane (1.5 L) at 0° C. The reaction mixture was stirred for 1 h at 25° C. and 2-bromonicotinic acid (20.0 g, 100 mmol) was added. The reaction mixture was heated at reflux. After cooling to room temp, H2O was added and the pH was adjusted to 2-3. The mixture extracted with EtOAc. The combined organics were dried and concentrated. The crude product was purified by column chromatography eluting with MeOH/DCM/AcOH (300:60:1) to give 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid (6.1 g, 24% yield). MS (ESI) calcd for C12H15NO5 (m/z): 253.10; found: 254 [M+H].
-
- A mixture of methyl 6-bromopicolinate (5.0 g, 23.00 mmol), azetidine hydrochloride (4.40 g, 46.0 mmol), K2CO3 (9.70 g, 70.0 mmol), CuI (880.0 mg, 4.60 mmol) and L-proline (1.06 g, 9.20 mmol) in DMSO (50 mL) was stirred at 80° C. 16 h. The mixture was cooled to room temp and the solids were removed by filtration. The filtrate was diluted with CH2Cl2 (800 mL), washed with water, brine, dried and concentrated. The crude residue was purified by flash chromatography to give methyl 6-(azetidin-1-yl)picolinate (2.84 g, 64% yield). MS (ESI) calcd for C10H12N2O2 (m/z): 192.09.
-
- A mixture of methyl 6-(azetidine-1-yl)picolinate (5.67 g, 29.50 mmol) and KOH (3.36 g, 60.0 mmol) in MeOH (100 mL) was stirred at room temp for 16 h. Conc. HCl (5.00 mL) was added. The resulting ppt was removed by filtration and the filtrate was concentrated. The residue was dissolved in CH2Cl2 and the solids removed by filtration. The CH2Cl2 was concentrated and the residue was recrystallized from iPrOH to give 6-(azetidine-1-yl)picolinic acid (4.01 g, 76% yield). MS (ESI) calcd for C9H10N2O2 (m/z): 178.07; found: 179 [M+H].
-
- A mixture of methyl 3-hydroxybenzoate (3.0 g, 19.7 mmol), (S)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (4.5 g, 29.6 mmol) and K2CO3 (5.5 g, 39.4 mmol) in DMF (50 mL) was stirred for 18 h at 160° C. The mixture was diluted with water (150 mL) and the pH was adjusted to 6 by addition of 3N HCl. The mixture was extracted with ethyl acetate (3×200 mL) and the combined organic layers were dried over anhydrous MgSO4, concentrated under reduced pressure to give (R)-methyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzoate (3.0 g, 57% yield). MS (ESI) calcd for C14H18O5 (m/z): 266.12.
-
- A solution of (R)-methyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzoate (5.5 g, 20.7 mmol) in THF/H2O (2:1, 60 mL) was added dropwise to a solution of LiOH (2.3 g, 95.8 mmol) in H2O. The mixture was stirred for 8 h at 40° C. then concentrated and diluted with H2O (20 mL). The mixture was washed with EtOAc (2×50 mL) and the aqueous layer was brought to pH 4 by the addition of 3N HCl. The resulting ppt was collected by filtration and dried. The crude residue was purified by column chromatography eluting with CH2Cl2/MeOH (5%) to give (R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzoic acid (3.0 g, 57% yield). MS (ESI) calcd for C13H16O5 (m/z): 252.10; found 251 [M−H].
-
- A mixture of methyl 3-hydroxybenzoate (6.7 g, 44.3 mmol), (R)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (10.0 g, 66.4 mmol) and K2CO3 (12.2 g, 88.6 mmol) in DMF (100 mL) was stirred for 18 h at 160° C. The mixture was diluted with water (500 mL) and the pH was adjusted to 5 by addition of 3N HCl. The mixture was extracted with ethyl acetate (3×200 mL) and the combined organic layers were dried over anhydrous MgSO4, concentrated under reduced pressure to give (S)-methyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzoate (10.0 g, 85% yield). MS (ESI) calcd for C14H18O5 (m/z): 266.12.
-
- LiOH (5.0 g, 208 mmol) in H2O was added to a solution of (S)-methyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzoate (10.0 g, 37.6 mmol) in THF/H2O (5:1, 120 mL). The mixture was stirred for 15 h at 40° C. then concentrated and diluted with sat. aq Na2CO3 (100 mL). The mixture was washed with EtOAc (2×100 mL) and the aqueous layer was brought to pH 4 by the addition of 3N HCl. The resulting ppt was collected by filtration and dried. The crude residue was purified by column chromatography eluting with pentane/EtOAc (2:1) to give (S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)benzoic acid (4.9 g, 52% yield). MS (ESI) calcd for C13H16O5 (m/z): 252.10; found 251 [M−H].
-
- NaBH(OAc)3 (68.5 g, 0.323 mol) was added to a solution of 6-bromopicolinaldehyde (40 g, 0.22 mol) and morpholine (20.9 g, 0.24 mol) in 1,2-dichloroethane (500 mL). The mixture was stirred at room temp for 16 h. Saturated NaHCO3 (500 mL) was added and the mixture was extracted with EtOAc, washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with petroleum ether: ethyl acetate (10:1) to give 4-((6-bromopyridin-2-yl)methyl)morpholine (38.0 g, 68% yield). MS (ESI) calcd for C10H13BrN2O (m/z): 256.02.
-
- n-BuLi (3.7 mL, 9.30 mmol) in THF was added to a solution of 4-((6-bromopyridin-2-yl)methyl)morpholine (2.0 g, 7.78 mol) in THF (20 mL) at −78° C. The mixture was stirred for 30 min and CO2 (gas) was bubbled through the reaction mixture for 30 min. The volatiles were removed in vacuo and the residue was dissolved in H2O. The pH was adjusted to 5 with 3N HCl then to 7 with sat. aq NaHCO3. The mixture was concentrated to dryness and the residue was taken up in CH2Cl2/MeOH (1:1), passed through a filter and the filtrate was concentrated. The residue was dissolved in CH2Cl2, passed through a filter, concentrated and dried under vacuum to give 6-(morpholinomethyl)picolinic acid (1.0 g, 67% yield). MS (ESI) calcd for C11H14N2O3 (m/z): 222.10; found 223 [M+H].
-
- SOCl2 (1.4 g, 12.0 mmol) was added to a solution of methyl 6-(hydroxymethyl)picolinate (1.0 g, 6.0 mmol) in CH2Cl2 (30 mL) at 25° C. The mixture was stirred at 40° C. for 1 h and sat. aq Na2CO3 was added to adjust the pH to 9. The mixture was extracted with CH2Cl2 and the combined organics were washed with brine, dried (Na2SO4), and concentrated. The crude residue was purified by column chromatography eluting with pentane/EtOAc (3:1) to give methyl 6-(chloromethyl)picolinate (600.0 mg, 55% yield). MS (ESI) calcd for C8H8ClNO2 (m/z): 185.02.
-
- K2CO3 (746.0 mg, 5.40 mmol) was added to a solution of methyl 6-(chloromethyl)picolinate (500.0 mg, 2.70 mmol) and pyrrolidine (288.0 mg, 4.05 mmol) in DMF (20 mL). The reaction mixture was heated at 45° C. for 16 h. Water (20 mL) was added and the mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4) and concentrated. The crude residue was purified by column chromatography eluting with CH2Cl2/MeOH (10-20%) to give methyl 6-(pyrrolidin-1-ylmethyl)picolinate (330.0 mg, 56% yield). MS (ESI) calcd for C12H16N2O2 (m/z): 220.12.
-
- A mixture of methyl 6-(pyrrolidin-1-ylmethyl)picolinate (200.0 mg, 0.91 mmol) and NaOH (200.0 mg, 4.55 mmol) in ethanol/water (2:1, 30 mL) was stirred at 70° C. for 16 h. The pH was adjusted to 7 with 3N HCl and the mixture was concentrated. The residue was dissolved in CH2Cl2/MeOH (5:1), passed through a filter and concentrated to dryness to give 6-(pyrrolidin-1-ylmethyl)picolinic acid (187.0 mg, 99% yield). MS (ESI) calcd for C11H14N2O2 (m/z): 206.11; found 207 [M+H].
-
- A slurry of ethyl 2-aminothiazole-5-carboxylate (8; 145.0 g, 840 mmol), di-tert-butyl dicarbonate (275.0 g, 1260 mmol) and DMAP (5.0 mg, catalytic) in THF (2175 mL) was stirred at 30° C. for 5.5 h. The reaction mixture was concentrated to dryness and EtOAc (1450 mL) was added. The organic solvent was washed with water (2×435 mL) and brine (2×145 mL), dried over MgSO4 and concentrated to give ethyl 2-(tert-butoxycarbonylamino)thiazole-5-carboxylate (227.0 g, 99.23%) as a crude product, which was used for the next step without any further purification. MS (ESI) calcd for C11H16N2O4S (m/z): 272.32.
- A stirred solution of ethyl 2-(tert-butoxycarbonylamino)thiazole-5-carboxylate (227.0 g, 830 mmol) in anhydrous THF (1512 mL) was cooled to −45° C. A solution of superhydride in THF (1.0 M, 1877 mL) was added over 1 hr, and then the reaction mixture was stirred at −45° C. for 2 h, warmed to room temp for 20 h. The reaction was quenched was brine, and warmed to room temp. The mixture was concentrated, taken up in EtOAc and washed with brine, dried over Na2SO4, concentrated and purified by column chromatography on silica gel (petroleum ether/ethyl acetate=1:1) to give tert-butyl 5-(hydroxymethyl)thiazol-2-ylcarbamate (10; 95 g, 49%). MS (ESI) calcd for C9H14N2O3S (m/z): 230.28.
-
- A solution of tert-butyl 5-(hydroxymethyl)thiazol-2-ylcarbamate (37.0 g, 160 mmol), triethylamine (24.2 g, 240 mmol) in CH2Cl2 (231 mL) was cooled to 0° C. Mesyl chloride (23.16 g, 200 mmol) was added and the mixture was extracted with CH2Cl2 (2×93 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give 2-(tert-butoxycarbonylamino)thiazol-5-yl)methyl methanesulfonate (40.0 g, 75%). MS (ESI) calcd for C10H16N2O5S2 (m/z): 308.37.
- To a stirred solution of 2-(tert-butoxycarbonylamino)thiazol-5-yl)methyl methanesulfonate (40.0 g, 0.13 mol) in CH2Cl2 (140 mL) was added pyrrolidine (37.69 g, 530 mmol) at 0° C. and warmed to room temp. The mixture was washed with saturated NaHCO3, and brine (93 mL). The organic solvent was dried over Na2SO4, concentrated and purified by column chromatography on silica gel (petroleum ether: ethyl acetate=1:1) to give 5-(pyrrolidin-1-ylmethyl)thiazol-2-amine (as the free amine)(34.0 g, 75%). MS (ESI) calcd for C8H13N3S (m/z): 183.27.
- A stirred solution of 5-(pyrrolidin-1-ylmethyl)thiazol-2-amine (34.0 g, 190 mmol) in methanol (121 mL) was bubbled with HCl (gas) and monitored by TLC until all material consumed. The solvent was removed and EtOAc (121 mL) was added to form a precipitate. The mixture was filtered and the filter cake was washed successively with EtOAc to give 5-(pyrrolidin-1-ylmethyl)thiazol-2-amine (as the HCl salt) (20.6 g, 67%) as a white solid. MS (ESI) calcd for C8H13N3S.HCl (m/z): 219.73; found 184 [M+H]. 5-(morpholinomethyl)thiazol-2-amine
- was prepared by the same procedure above, by substituting morpholine for pyrroldine.
-
- DAST (8.7 g, 54.1 mmol) was added to a mixture of 2-bromobenzaldehyde (5.0 g, 27.0 mmol) in dichloromethane (100 mL) at 0° C. The reaction mixture was stirred at room temperature for 12 h, poured into sat. aq NaHCO3, and extracted with EtOAc. The organic layer was concentrated to give 1-bromo-2-(difluoromethyl)benzene (5.4 g, 96% yield), which was used in next step with no further purification.
-
- A solution of n-BuLi (4.2 mL, 10.6 mmol) in THF was added to a solution of 1-bromo-2-(difluoromethyl)benzene (2.0 g, 9.7 mmol) in THF (50 mL) at −78° C. The reaction mixture was stirred for 30 min and DMF (1.4 g, 19.3 mmol) was added. Stirring was continued for 1 h at −40° C. and the reaction was quenched by the addition of sat. aq NH4Cl. The crude mixture was extracted with Et2O, dried (MgSO4) and concentrated to give 2-(difluoromethyl)benzaldehyde (1.7 g, 94% yield).
-
- A solution of methyl 2-formylbenzoate (10.0 g, 61 mmol) and bis-(2-methoxyethyl)amino-sulfur trifluoride (40.4 g, 183 mmol) in CH2Cl2 was heated at reflux for 12 h. The reaction mixture was cooled to room temp, concentrated and partitioned between EtOAc (500 mL)/H2O (300 mL). NaHCO3 was added to adjust the pH to 8. The organic phase was separated, washed with brine, dried and concentrated. The residue was purified by flash chromatography to give methyl 2-(difluoromethyl)benzoate (7.0 g, 62% yield).
-
- A mixture of methyl 2-(difluoromethyl)benzoate (7.0 g, 38 mmol) and 10% aq. NaOH (100 mL) in MeOH (50 mL) was heated at reflux for 30 min. The pH was adjusted to 4 by the addition of 3N HCl. The resulting solid was collected by filtration, rinsed with H2O and dried to give 2-(difluoromethyl)benzoic acid (6.0 g, 93% yield).
-
- A solution of 2-(difluoromethyl)benzoic acid (1.8 g, 10 mmol) in thionyl chloride (25 mL) was heated at reflux for 3 h. The reaction mixture was concentrated and dried under vacuum to give 2-(difluoromethyl)benzoyl chloride. The crude acid chloride was used without further purification.
-
- 3-(difluoromethyl)benzoyl chloride was prepared by a procedure similar to that reported for 2-(difluoromethyl)benzoyl chloride in 32% yield.
-
- (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol (1.8 mL, 14.9 mmol) was added to a room temperature suspension of NaH (392.0 mg, 16.3 mmol) in THF (30 mL). The reaction mixture was stirred at room temp for 30 min and 2-bromo-nicotinic acid (1.0 g, 4.95 mmol) was added. The reaction mixture was heated at reflux for 12 h. After cooling to room temp, the pH was adjusted to 3 by the addition of 3 N HCl. The mixture was poured into brine and extracted with EtOAc. The combined organics were dried and concentrated. The crude product was recrystallized from pentane/EtOAc to give (R)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid (1.2 g, 92% yield).
-
- (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid was prepared by a procedure similar to that reported for (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid in 74% yield.
-
- (R)-2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)isonicotinic acid was prepared by a procedure similar to that reported for (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid in 72% yield.
-
- (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid was prepared by a procedure similar to that reported for (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid in 60% yield.
-
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid was prepared by a procedure similar to that reported for (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid in 66% yield.
-
- 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)nicotinic acid was prepared by a procedure similar to that reported for (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)picolinic acid in 23% yield.
-
- NaBH(OAc)3 (68.5 g, 0.323 mol) was added to a solution of 6-bromopicolinaldehyde (40.0 g, 0.22 mol) and morpholine (20.9 g, 0.24 mol) in 1,2-dichloroethane (500 mL). The mixture was stirred at room temperature for 16 h. Saturated NaHCO3 (500 mL) was added and the mixture was extracted with EtOAc, washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by flash chromatography on silica gel eluting with petroleum ether: ethyl acetate (10:1) to give 4-((6-bromopyridin-2-yl)methyl)morpholine (38.0 g, 68% yield).
-
- n-BuLi (56 mL, 0.140 mol) in THF was added to a solution of 4-((6-bromopyridin-2-yl)methyl)morpholine (30.0 g, 0.12 mol) in THF (500 mL) at −78° C. The mixture was stirred for 30 min and CO2 (gas) was bubbled through the reaction mixture for 30 min. The volatiles were removed in vacuo and the residue was extracted with CH2Cl2/MeOH (1:1). The solvent was evaporated and the residue was washed with CH2Cl2 to give 6-(morpholinomethyl)picolinic acid (11.0 g, 42% yield).
-
- SOCl2 (57.0 g, 0.48 mol) was added to a solution of methyl 6-(hydroxymethyl)picolinate (40.0 g, 0.239 mol) in dichloromethane (500 mL) at room temp. The mixture was stirred at 40° C. for 1 h and sat. aq K2CO3 was added to adjust the pH to 9. The mixture was extracted with CH2Cl2 and the combined organics were washed with brine, dried (Na2SO4), and concentrated in vacuo to give methyl 6-(chloromethyl)picolinate (45.0 g).
-
- K2CO3 (66.0 g, 0.48 mol) was added to a solution of methyl 6-(chloromethyl)picolinate (45.0 g) and pyrrolidine (34.0 g, 0.48 mol) in DMF (300 mL). The reaction mixture was heated at 80° C. for 12 h. H2O (300 mL) was added and the mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried (Na2SO4) and concentrated in vacuo to give methyl 6-(pyrrolidin-1-ylmethyl)picolinate (36.0 g).
-
- A mixture of methyl 6-(pyrrolidin-1-ylmethyl)picolinate (36.0 g) and NaOH (40.0 g, 1.0 mol) in ethanol/H2O (320 mL) was stirred at 75° C. for 16 h. The pH was adjusted to 7 with 3N HCl and extracted with EtOAc. The aqueous layer was concentrated to dryness and extracted with dichloromethane/methanol (v:v=3:1), The organic layer was dried to give 6-(pyrrolidin-1-ylmethyl)picolinic acid (27.0 g, 55% yield).
-
- N-methyl proline was prepared by a procedure similar to that reported in J. Org. Chem. 2003, 66, 2652.
-
- 1-methyl-5-oxopyrrolidine-2-carboxylic acid was prepared by a procedure similar to that reported in J. Heterocyclic. Chem. 1991, 28, 1143.
-
- 3-(morpholinomethyl)aniline was prepared by a procedure similar to that reported in J. Med. Chem. 1990, 33(1), 327-36.
-
- To a solution of 2-amino-6-pyridinecarboxylic acid (6.0 g, 43.5 mmol) in ethanol (150 mL) was added thionyl chloride (12.0 g, 101 mmol) at 0° C. The resulting reaction mixture was stirred at reflux for 12 h. Upon cooling to room temp, the reaction mixture was concentrated under reduced pressure. Saturated aqueous Na2CO3 solution was added until the pH of the solution reached 9. The mixture was concentrated under reduced pressure and dichloromethane (150 mL) was added to the resulting residue. The mixture was stirred vigorously at room temp for 30 min and then filtered. The filtrate was concentrated under reduced pressure to afford ethyl 6-aminopicolinate (5.5 g, 76% yield).
-
- To a solution of ethyl 6-aminopicolinate (5.5 g, 33 mmol) in t-BuOH (120 mL) and acetone (40 mL) was added 4-dimethylaminopyridine (0.08 g, 0.66 mmol) and di-tert-butyl dicarbonate (10.8 g, 49.5 mmol). The reaction mixture was stirred at room temp for 18 h. The solvent was removed by concentration under reduced pressure and a mixture of hexane/dichloromethane (180 mL, 3:1) was added. The resulting mixture was cooled to −20° C. for 2 h. The resulting solids were collected by filtration and dried to afford ethyl 6-(tert-butoxycarbonylamino)picolinate (11.0 g, 91% yield).
-
- To a stirred solution of ethyl 6-(bis(tert-butoxycarbonyl)amino)picolinate (11.0 g, 33 mmol) in THF (120 mL) under nitrogen was added LiAlH4 (3.80 g, 100 mmol) in THF (60 mL) over a period of 30 min at 0° C. The reaction mixture was stirred at 0° C. for 6 h and carefully quenched by the addition of H2O (2.0 mL) and 10% NaOH solution (4.0 mL) at 0° C. The reaction mixture was filtered and the filtrate was dried (Na2SO4) and concentrated under reduced pressure. The resulting residue purified by chromatography (1:1 petroleum ether: ethyl acetate) to afford tert-butyl 6-(hydroxymethyl)pyridin-2-ylcarbamate (3.0 g, 41% yield).
-
- To a solution of tert-butyl 6-(hydroxymethyl)pyridin-2-ylcarbamate (3.0 g, 13.4 mmol) and diisopropylethylamine (5.0 g, 40 mmol) in acetonitrile (30 mL) was added methanesulfonyl chloride (2.0 g, 17.4 mmol) over a period of 30 min at 0° C. and the mixture was stirred for 2 h at room temp. The reaction was quenched by adding saturated aqueous NaHCO3 and extracted with ethyl acetate (3×60 mL). The combined organic layers were washed with brine, dried (Na2SO4) and concentrated under reduced pressure to afford (6-(tert-butoxycarbonylamino)pyridin-2-yl)methyl methanesulfonate in quantitative yield of crude.
-
- A mixture containing (6-(tert-butoxycarbonylamino)pyridin-2-yl)methyl methanesulfonate (1.30 g, 3.2 mmol), pyrrolidine (0.46 g, 6.4 mmol) and K2CO3 (1.30 g, 9.6 mmol) in acetonitrile (15 mL) was stirred at room temp for 12 h. Saturated aqueous NaHCO3 was added and the mixture was concentrated under reduced pressure. The resulting aqueous layer was extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to afford tert-butyl 6-(pyrrolidin-1-ylmethyl)pyridin-2-ylcarbamate (0.75 g, 62% yield).
-
- To a solution of tert-butyl 6-(pyrrolidin-1-ylmethyl)pyridin-2-ylcarbamate (750.0 mg, 2.71 mmol) in dichloromethane (10 mL) was added trifluoroacetic acid (4.0 mL) at room temp. The resulting reaction mixture was stirred at room temp for 6 h and then concentrated under reduced pressure. Saturated aqueous Na2CO3 was added to the resulting residue until the solution pH reached 9. The mixture was then extracted with ethyl acetate (3×25 mL). The combined organic layers were dried with Na2SO4 and concentrated under reduced pressure to afford 6-(pyrrolidin-1-ylmethyl)pyridin-2-amine (440.0 mg, 92% yield).
-
- 6-(morpholinomethyl)pyridin-2-amine was prepared by a method similar to that reported for 6-(pyrrolidin-1-ylmethyl)pyridin-2-amine.
-
- (R)-6-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine was prepared by a method similar to that reported for 6-(pyrrolidin-1-ylmethyl)pyridin-2-amine.
-
- (S)-6-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine was prepared by a method similar to that reported for 6-(pyrrolidin-1-ylmethyl)pyridin-2-amine.
-
- 6-(piperazin-1-ylmethyl)pyridin-2-amine was prepared by a method similar to that reported for 6-(pyrrolidin-1-ylmethyl)pyridin-2-amine.
-
- To a solution of 6-(piperazin-1-ylmethyl) 199yridine-2-amine in THF was added di-tert-butyl carbonate (1 eq) and 4-(dimethyl)aminopyridine (catalytic). The reaction mixture was stirred at room temp for 18 h. It was then concentrated under reduced pressure. Pentane was added and the resulting solid was collected by filtration and dried to afford tert-butyl 4-((6-aminopyridin-2-yl)methyl)piperazine-1-carboxylate.
-
- Ethyl 2-aminothiazole-4-carboxylate (10.0 g, 58.1 mmol) was taken up in 150 mL of anhydrous THF along with di-tert-butyl carbonate (12.67 g, 58.1 mmol) and 4-(dimethyl)aminopyridine (DMAP) (10.0 mg, 0.082 mmol). The reaction mixture was stirred at 50° C. for 4 h and then at room temp for 18 h. It was then concentrated under reduced pressure to obtain a thick oil. Pentane was added and the resulting crystalline materials were collected by filtration and dried to afford ethyl 2-(tert-butoxycarbonylamino)thiazole-4-carboxylate (10.5 g, 66% yield).
-
- Ethyl 2-(tert-butoxycarbonylamino)thiazole-4-carboxylate (10.5 g, 38.6 mmol) was dissolved in 300 mL of anhydrous THF and cooled in dry ice-acetonitrile bath. A solution of 1 M Super Hydride™ in THF (85 mL) was then added over a period of 10 min. The resulting reaction mixture was stirred at −45° C. for 2 h. Another portion of 1 M Super Hydride™ in THF (35 mL) was then added and the reaction mixture was stirred for an additional 2 h at −45° C. The reaction was quenched at −45° C. by the addition of 50 mL of brine. Upon warming to room temp, the reaction mixture was concentrated under reduced pressure. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried with Na2SO4, and concentrated under reduced pressure. The resulting residue was purified by chromatography to afford tert-butyl 4-(hydroxymethyl)thiazol-2-ylcarbamate (6.39 g, 72% yield).
-
- tert-Butyl 4-(hydroxymethyl)thiazol-2-ylcarbamate (2.0 g, 8.68 mmol) was taken up in 25 mL of CH2Cl2 along with Et3N (1.82 mL, 13.05 mmol) and cooled to 0° C. Methanesulfonyl chloride (0.85 mL, 10.88 mmol) was added and the resulting reaction mixture was stirred at 0° C. for 60 min. Morpholine (3.0 mL, 35 mmol) was then added and the reaction mixture was stirred at room temp for 18 h. The reaction mixture was concentrated under reduced pressure. The resulting residue was taken up in EtOAc and washed with dilute aqueous NaHCO3, brine, dried with Na2SO4, and concentrated under reduced pressure. This material was purified by filtering through a short column of silica gel. The filtrate was concentrated to afford tert-butyl 4-(morpholinomethyl)thiazol-2-ylcarbamate (1.88 g, 69% yield).
-
- Tert-butyl 4-(morpholinomethyl)thiazol-2-ylcarbamate 1.88 g, 6.28 mmol) was treated with 20 mL of 25% trifluoroacetic acid in CH2Cl2 for 18 h at room temp. After all the solvent had been removed by concentrating and drying under high vacuum, the resulting residue was treated with a mixture of pentane/EtOAc to afford 4-(morpholinomethyl)thiazol-2-amine trifluoroacetate (1.96 g, 100% yield) as a white solid.
-
- 4-(pyrrolidin-1-ylmethyl)thiazol-2-amine trifluoroacetate was prepared by a procedure similar to that reported for 4-(morpholinomethyl)thiazol-2-amine trifluoroacetate.
-
- 5-(morpholinomethyl)thiazol-2-amine trifluoroacetate was prepared by a procedure similar to that reported for 4-(morpholinomethyl)thiazol-2-amine trifluoroacetate.
-
- 5-(pyrrolidin-1-ylmethyl)thiazol-2-amine trifluoroacetate was prepared by a procedure similar to that reported for 4-(morpholinomethyl)thiazol-2-amine trifluoroacetate.
-
- 4-(piperazin-1-ylmethyl)thiazol-2-amine trifluoroacetate was prepared by a procedure similar to that reported for 4-(morpholinomethyl)thiazol-2-amine trifluoroacetate.
-
- tert-butyl 4-((2-aminothiazol-4-yl)methyl)piperazine-1-carboxylate was prepared by a procedure similar to that reported for tert-butyl 4-((6-aminopyridin-2-yl)methyl)piperazine-1-carboxylate.
-
- To a solution of solketal (34.4 g, 260 mmol) in THF (150 mL) was added NaH (10.4 g, 260 mmol) at room temp and the mixture stirred for 1 h. 2-chloro-4-aminopyrimidine (15.0 g, 115 mmol) was then added, and the mixture was stirred at 70° C. for 48 h. The reaction mixture was concentrated and the crude residue was purified by flash chromatography (DCM:MeOH=15:1-10:1) to give 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine (18.2 g, 70% yield) as an oil.
-
- 6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrazin-2-amine was prepared by a method similar to that reported for 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine.
-
- (S)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-aminopyridine was prepared by a method similar to that reported for 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine, using (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol.
- The enantiomer was prepared the same as above, using (R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methanol.
-
- (R)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-aminopyridine was prepared by a method similar to that reported for 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)pyrimidin-4-amine.
-
- A mixture of 3-nitrophenol (2.0 g, 14.4 mmol), potassium carbonate (4.96 g, 35.9 mmol) and (S)-4-(chloromethyl)-2,2-dimethyl-1,3-dioxolane (2.55 mL, 18.7 mmol) in DMF (20 mL) was heated in a microwave reactor at 160° C. for 4 h. The crude reaction mixture was poured into H2O and extracted with dichloromethane (3×15 mL). The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure. The crude residue was purified by chromatography using ethyl acetate: pentane to obtain (R)-2,2-dimethyl-4-((3-nitrophenoxy)methyl)-1,3-dioxolane (1.90 g, 52% yield) as an amber-colored oil.
-
- A mixture of Fe powder (2.38 g, 42.5 mmol), NH4Cl (2.27 g, 42.5 mmol) and (R)-2,2-dimethyl-4-((3-nitrophenoxy)methyl)-1,3-dioxolane (1.80 g, 7.09 mmol) in isopropanol (30 mL)/H2O (10 mL) was heated at reflux for 18 h. The crude material was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The resulting aqueous layer was extracted with dichloromethane (3×15 mL). The combined organic layers were dried with Na2SO4, and concentrated under reduced pressure to afford (R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline (1.25 g, 76% yield).
-
- 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline was prepared by a method similar to that reported for (R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline.
-
- (S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline was prepared by a method similar to that reported for (R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline.
-
- 4-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline was prepared by a method similar to that reported for (R)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)aniline.
-
- A mixture of 2-chloro-4-aminopyridine (2.29 g, 17.8 mmol) and pyrrolidine (5.0 mL) was heated at 200° C. in a microwave reactor for 10 min. After cooling to room temp, the solid was filtered and washed with dichloromethane (10 mL×3). The filter cake was dissolved in aqueous K2CO3 and extracted with CH2Cl2 (40 mL×3). The combined organic layers were dried over Na2SO4 and concentrated to obtain (2-(pyrrolidin-1-yl)pyridin-4-amine (2.30 g, 79% yield).
-
- 2-morpholinopyridin-4-amine was prepared by a method similar to that reported for 2-(pyrrolidin-1-yl)pyridin-4-amine.
-
- 6-morpholinopyridin-2-amine was prepared by a method similar to that reported for 2-(pyrrolidin-1-yl)pyridin-4-amine.
-
- 6-(pyrrolidin-1-yl)pyridin-2-amine was prepared by a method similar to that reported for 2-(pyrrolidin-1-yl)pyridin-4-amine.
-
- To a solution of 2-amino-5-pyridinecarboxylic acid (150.0 g, 1.09 mol) in ethanol (2 L) was added thionyl chloride (259.0 g, 2.18 mol) at 0° C. The mixture was heated at reflux for 12 h. The solvent was removed under reduced pressure. Saturated aq Na2CO3 was added to adjust the pH to 9 and the resulting solid was collected by filtration, rinsed with H2O, and dried to give ethyl 6-aminonicotinate (160.0 g, 88% yield).
-
- To a solution of ethyl 6-aminonicotinate (160.0 g, 963 mmol) in t-BuOH (1.7 L) and acetone (560 mL) was added DMAP (2.38 g, 19.1 mmol) and di-t-butyl dicarbonate (420.0 g, 1.92 mol). The reaction was stirred at room temp overnight. The solvent was removed and hexane/dichloromethane (2.5 L, 3:1) was added. The mixture was cooled to −20° C. for 2 h. The solid was collected by filtration and dried in vacuo to give ethyl 6-(bis(tert-butoxycarbonyl)amino)nicotinate (300.0 g, 85% yield).
-
- To a stirred solution of ethyl 6-(bis(tert-butoxycarbonyl)amino)nicotinate (300.0 g, 819 mmol) in THF (1.2 L) was added LiAlH4 (57.6 g, 1.51 mol) in THF (3 L) over a period of 30 min at 0° C. The reaction mixture was stirred for 6 h, and H2O (30.0 mL) and 10% NaOH solution (60.0 mL) were added. The solids were removed by filtration and the filtrate was dried (Na2SO4) and concentrated. The crude residue was purified by flash chromatography (DCM:MeOH=40:1) to give tert-butyl 5-(hydroxymethyl)pyridin-2-ylcarbamate (85.0 g, 46% yield).
-
- To a solution of tert-butyl 5-(hydroxymethyl)pyridin-2-ylcarbamate (85.0 g, 379 mmol) and diisopropylethylamine (296.0 g, 2.27 mol) in THF (850 mL) was added methanesulfonyl chloride (130.0 g, 1.14 mol) over a period of 30 min at 0° C. The mixture was stirred for 12 h at room temp then washed with H2O (2×100 mL) and dried over Na2SO4. The mixture was concentrated and the crude residue was purified by flash chromatography (petroleum ether: ethyl acetate=10:1) to give tert-butyl 5-(chloromethyl)pyridin-2-ylcarbamate (30.0 g, 63% yield).
-
- A mixture of tert-butyl 5-(chloromethyl)pyridin-2-ylcarbamate (9.5 g, 39.1 mmol), (S)-3-fluoropyrrolidine (4.19 g, 47.0 mmol), potassium carbonate (16.2 g, 117 mmol) and sodium iodide (0.59 g, 3.91 mmol) in DMF (150 mL) was stirred at 60° C. for 2 h. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. H2O (250 mL) was added and the resulting solid was collected by filtration, rinsed with H2O and dried to give (S)-tert-butyl 5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-ylcarbamate (7.0 g, 61% yield).
-
- To a solution of (S)-tert-butyl 5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-ylcarbamate (7.0 g, 23.7 mmol) in dichloromethane (70 mL) was added trifluoroacetic acid (TFA) (15.5 g, 142 mmol). The mixture was stirred for 12 h at room temp. The solvent was removed in vacuo and sat. aq Na2CO3 was added. The mixture was extracted with dichloromethane, dried (MgSO4) and concentrated to give (S)-5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine (4.50 g, 97% yield).
-
- 5-(morpholinomethyl)pyridin-3-amine was prepared by a method similar to that reported for (S)-5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine.
-
- 6-(morpholinomethyl)pyridin-3-amine was prepared by a method similar to that reported for (S)-5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine.
-
- (R)-5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine was prepared by a method similar to that reported for (S)-5-((3-fluoropyrrolidin-1-yl)methyl)pyridin-2-amine.
-
- 2-chloroacetonitrile (300.0 g, 4.0 mol) was added to a solution of sodium (10.0 g, 0.43 mol) in methanol (1000 mL) keeping the temperature below 20° C. The mixture was stirred at room temp for 2 h. NH4Cl (234.0 g, 4.37 mol) was added in 5 batches and stirring continued for another 2 h. The solvent was removed to give 2-chloroacetimidamide dihydrochloride (525.0 g, 79% yield) which was used directly for next step without further purification.
-
- A solution of 2-chloroacetimidamide dihydrochloride (250.0 g, 1.51 mol), 2-chloroacrylonitrile (171.0 g, 1.95 mol) and triethylamine (490.0 g, 4.8 mol) in anhydrous ethanol (600 mL) was heated at reflux for 30 min. The solvent was removed in vacuo and the residue was purified by flash chromatography (DCM MeOH=30:1) to give 2-(chloromethyl)pyrimidin-4-amine (39.0 g, 18% yield).
-
- A solution of 2-(chloromethyl)pyrimidin-4-amine (30.0 g, 209 mmol), morpholine (23.7 g, 272 mmol) and triethylamine (42.3 g, 418 mmol) in anhydrous ethanol (250 mL) was heated at reflux for 16 h. The solvent was removed in vacuo and methanol (400 mL), H2O (100 mL) and sodium bicarbonate (25.0 g) were added. Stirring was continued for 30 min. The mixture was concentrated and purified by flash chromatography (dichloromethane:methanol:triethylamine=100:8:0.5) to give 2-(morpholinomethyl)pyrimidin-4-amine (25.0 g, 62% yield).
-
- tert-butyl 4-((4-aminopyrimidin-2-yl)methyl)piperazine-1-carboxylate was prepared by a method similar to that reported for 2-(morpholinomethyl)pyrimidin-4-amine.
-
- 2-(pyrrolidin-1-ylmethyl)pyrimidin-4-amine was prepared by a method similar to that reported for 2-(morpholinomethyl)pyrimidin-4-amine.
-
- NaH (1.23 g, 0.03 mol) was washed with pentane and dried under vacuum for 15 min. THF (10 mL) was added to the flask under N2 and the mixture was stirred. To this, (3-methyloxetan-3-yl) methanol (3.15 g, 0.03 mmol) was added dropwise. 10 mL of THF was added at room temp and solids were scraped to facilitate stirring. The dense mixture was stirred at room temp for 1 h. A slurry of 4-chloropyrimidin-2-amine (2.0 g, 0.02 mol) in THF was added to the reaction and it was refluxed for 15 h. After cooling to room temp, H2O (100 mL) was added and the aqueous layer was extracted with EtOAc. The crude product was purified by flash chromatography (0-100% EtOAc+pentane). The recovered material was taken up in diethyl ether and the solid that separated was isolated by filtration to afford 4-((3-methyloxetan-3-yl)methoxy)pyrimidin-2-amine (1.9 g, 65%). MS (ESI) calcd for C9H13N3O2 195.1; found 196.0 [M+H].
-
- To 6-chloropyridin-2-amine (2.57 g, 20 mmol), (3-methyloxetan-3-yl) methanol (2.04 g, 20.0 mmol) and NaOH (8.0 g, 0.3 mol) was added 30 mL toluene. The mixture was heated at reflux under N2 for 48 h. After cooling to room temp, H2O (40 mL) was added, the layers were separated and the organic layer was washed with H2O (15 mL), brine (30 mL) and dried over Na2SO4. After removing the solvent in vacuo, the crude product was purified by column chromatography to give 6-((3-methyloxetan-3-yl)methoxy)pyridin-2-amine (2.1 g, 54%). MS (ESI) calcd for C10H14N2O2 194.11; found 195.2 [M+H].
-
- 2-bromopyridin-4-amine (680.0 mg, 3.94 mmol) was taken up in 10 mL of dioxane along with 2,2,2-trifluoroethanol (1.56 g, 15.6 mmol), sodium hydride (373.0 mg, 15.6 mmol). The resulting reaction mixture was stirred refluxed for 15 h, cooled to room temp, concentrated in vacuo and purified by chromatography (EtOAc: Pet ether (1:10)) to afford 2-(2,2,2-trifluoroethoxy)pyridin-4-amine (500.0 mg, 66.2%). MS (ESI) calcd for C7H7F3N2O 192.05.
-
- 5-morpholinopyridin-3-amine was prepared from 3-chloro-5-nitropyridine using the same two-step procedure described above for the synthesis of 5-morpholinopyridin-2-amine.
-
- To a solution of KOH (33.2 g, 0.59 mol) and p-tosylamide (37.9 g, 0.22 mol) in 600 mL ethanol, 3-Bromo-2,2-bis(bromomethyl)propan-1-ol (60.1 g, 0.19 mol) was added at room temp and the reaction mixture was heated to reflux for 90 h. The solvent was removed by evaporation, 500 mL 1M KOH was added and the white suspension was left to stir for another 2 h at room temp. The mixture was filtered and the white filter cake was rinsed with water until the washing water was neutral. The filter cake was dried under high vacuum to give 30.55 g of product containing 10 mol % of tosylamide as a white solid. The overall yield of pure 6-tosyl-2-oxa-6-azaspiro[3.3]heptane was calculated to be 27.4 g (58%). MS (ESI) calcd for C12H15NO3S: 253.3.
-
- 6-tosyl-2-oxa-6-azaspiro[3.3]heptanes (7.30 g, 28.8 mol) and magnesium (4.9 g, 0.2 mol) were sonicated for one h in methanol (500 mL). Almost all solvent was removed from the grey reaction mixture on a rotary evaporator to give a viscous grey residue. Diethyl ether (500 mL) and sodium sulfate (15.0 g) were added and the resulting light grey mixture was stirred vigorously for 30 min before filtration. The filtrate was dried over anhydrous sodium sulfate and anhydrous oxalic acid (1.3 g, 14.4 mol) dissolved in ethanol (˜1 mL) was added to the organic phase. A thick white precipitate formed instantly. It was filtered off and dried under vacuum to give 2-oxa-6-azaspiro[3.3]heptane oxalate 3.37 g (81%) as amorphous white solid.
-
- 2-oxa-6-azaspiro[3.3]heptane oxalate (20 g, 0.23 mol), ethyl 6-bromopicolinate (56.9 g, 0.25 mol) and K2CO3 (62 g, 0.454 mol) were dissolved in DMSO (100 mL). The suspension was heated to 140° C. After cooling to room temp, the reaction was poured into water and extracted with methylene chloride. The organic layer was evaporated to dryness and product was purified on a gel silica to afford ethyl 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)picolinate (7.2 g, 30%). MS (ESI) calcd for C13H16N2O3: 248.1.
-
- Ethyl 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)picolinate (7.2 g, 0.03 mol) was dissolved in dioxane (50 mL), and NaOH (2.3 g, 0.06 mol) in water (50 mL) was added. The suspension was stirred at 50° C. for about 2 h. The solvent was removed and water (50 mL) was added. The pH was adjusted 5 to afford 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)picolinic acid (4.5 g, 70%). MS (ESI) calcd for C11H12N2O3: 220.1; found: 221.2 [M+H].
-
- To a solution of 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)picolinic acid (4.4 g, 0.02 mol) in t-BuOH (50 mL) was added Et3N (2.4 g, 0.02 mol) and DPPA (6.6 g, 0.024 mol). The mixture was refluxed overnight. After cooling to room temp, the solvent was evaporated and crude product was purified column chromatography to afford tert-butyl (6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)carbamate (4.0 g, 70%).
-
- To a solution of tert-butyl (6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)carbamate (4.4 g, 0.015 mol) in DCM (50 mL) was added CF3COOH (20 mL). The mixture was stirred at room temp for about 4 h. The solvent was removed and CH3CN (50 mL) was added. The pH was adjusted to 7. After evaporating the volatiles, 6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-amine was as obtained by purification on a silica gel column (2.05 g, 70%). MS (ESI) calcd for C10H13N3O: 191.1; found 192.2 [M+H].
-
- To a suspension of trimethylsulfoxonium iodide (80 g, 0.37 mol) in dry tert-BuOH (1.4 L) was added at 50° C. potassium tert-butoxide (41.3 g, 0.37 mmol), upon which the mixture turned to a cloudy suspension. The mixture was stirred at that temperature for 1.5 h, after which was added tert-butyl 3-oxoazetidine-1-carboxylate (25.0 g, 0.15 mmol). The suspension was stirred at 50° C. for 48 h. It was cooled to room temp and the mixture was partitioned between saturated aqueous NH4Cl (30 mL) and EtOAc (50 mL). The phases were separated and the aqueous phase was extracted with EtOAc (50 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated in vacuo. tert-Butyl 1-oxa-6-azaspiro[3.3]heptane-6-carboxylate was obtained (8.0 g, 28%) after purification by flash chromatography on silica gel hexanes:EtOAc 2:1-0:1 gradient). MS (ESI) calcd for C24H19F3N6O2: 199.1.
-
- To a solution of tert-butyl 1-oxa-6-azaspiro[3.3]heptane-6-carboxylate (3.0 g, 15.06 mmol) in CH2Cl2 (10 mL) was added 2,2,2-trifluoroacetic acid (34.3 g, 301 mmol) and the mixture was stirred at 20° C. for 30 min. The volatiles were removed in vacuo. The residue 1-oxa-6-azaspiro[3.3]heptanes TFA salt was used without further purification (2.5 g, 85%).
-
- A mixture of tert-butyl 6-bromopyridin-2-ylcarbamate (8.18 g, 30.0 mmol), 1-oxa-6-azoniaspiro[3.3]heptane (3.0 g, 30.0 mmol), DPPF (1.66 g, 3.00 mmol), Pd(OAc)2 (0.34 g, 1.5 mmol), and Cs2CO3 (19.5 g, 59.9 mmol) in 50 mL of toluene was heated to 120° C. for 5 h in a sealed tube and cooled. After evaporation of the solvent tert-butyl (6-(1-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-yl)carbamate was obtained by flash column chromatography (2.7 g, 23%). MS (ESI) calcd for C15H21N3O3: 291.2.
-
- To a solution of tert-butyl 6-(1-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-ylcarbamate (2.0 g, 6.86 mmol) in 20 mL of methylene chloride was added 2,2,2-trifluoroacetic acid (7.83 g, 68.6 mmol) at room temp. The mixture was stirred for further 1 h and 50 ml of saturated aq. Na2CO3 was added. The organic phase was separated and concentrated. 6-(1-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-2-amine was obtained by flash column chromatography (900.0 mg, 69%). MS (ESI) calcd for C10H13N3O: 191.1; found: 192.2.
-
- To a slurry of 6-aminopicolinic acid (10.0 g, 72.5 mmol) in acetonitrile (150 mL) was added N,O-dimethylhydroxylamine hydrochloride (8.52 g, 87.0 mmol), 1-hydroxybenzotriazole (11.8 g, 87.0 mmol), N-(3-dimethylamino)-N′-ethylcarbodiimide hydrochloride (16.7 g, 87.0 mmol), and N,N-diisopropylethylamine (37.7 mL, 217 mmol). The mixture was stirred at room temperature overnight, and the solvent removed in vacuo. The residue was partitioned between 1N NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried with sodium sulfate, and the solvent removed in vacuo. The remaining residue was purified by flash chromatography (ethyl acetate with 0.1% triethylamine) to give 6-amino-N-methoxy-N-methylpicolinamide (4.30 g, 23.7 mmol, 33% yield). MS (ESI) calcd for C8H7N3O: 181.1
-
- Lithium aluminum hydride (1.08 g, 28.5 mmol) was added to a solution of 6-amino-N-methoxy-N-methylpicolinamide (4.30 g, 23.7 mmol) in THF (30 mL). The reaction was stirred at room temperature for 90 min. Ethyl acetate (30 mL) was added slowly, the reaction was filtered, and the filtrate taken and all the solvent removed in vacuo to give 6-aminopicolinaldehyde, which was taken on crude to the next step.
- To a solution of the above aldehyde in methanol (20 mL) was added p-toluenesulfonylmethyl isocyanide (13.9 g, 71.2 mmol) and potassium carbonate (19.4 g, 140 mmol). The reaction was stirred at reflux for 2 h, then all solvent removed in vacuo. The residue was partitioned between ethyl acetate (150 mL) and water (70 mL). The organic layer was washed with brine, dried with sodium sulfate, and the solvent removed in vacuo. The remaining residue was purified by flash chromatography (10% methanol in dichloromethane) to give 6-(oxazol-5-yl)pyridin-2-amine (2.00 g, 12.4 mmol, 52% yield over two steps). MS (ESI) calcd for C8H11N3O2: 161.06
- 4-(oxazol-5-yl)pyridin-2-amine was made according to the same procedure described above for 6-(oxazol-5-yl)pyridin-2-amine, by substituting 6-amino-N-methoxy-N-methylpicolinamide with 2-aminoisonicotinic acid.
-
- A mixture of (S)-6-(3-methoxypyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid (100 mg, 0.38 mmol), HATU (290 mg, 0.76 mmol) and DIEA (0.12 mL, 0.82 mmol) in dry DCM (5 mL) was stirred at rt for 2 h, then evaporated to dryness under reduced pressure, the resulting residue was used directly for the next step. In another flask, pyrimidin-4-amine (40 mg, 0.42 mmol) was treated with NaH (64 mg, 2.6 mmol) in dry THF (5 mL) for 30 min, the crude active ester prepared above was added, stirred for another 2 h, cold water was added carefully, then extracted with ethyl acetate. The combined organic phase was dried over Na2SO4, concentrated. The crude product was purified by prep-TLC (DCM:MeOH=25:1) to give (S)-6-(3-methoxypyrrolidin-1-yl)-N-(pyrimidin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide (12.6 mg, yield 10%) MS (ESI) calcd for C16H17N7O2 (m/z): 339.14.
- This general coupling procedure could be used to prepare a variety of (S)-6-(3-methoxypyrrolidin-1-yl)-N-(substituted)imidazo[1,2-b]pyridazine-3-carboxamides by substituting the appropriate amine moiety for pyrimidin-4-amine.
-
- 6-(3,3-difluoropyrrolidin-1-yl)-2-methylimidazo[1,2-b]pyridazine-3-carboxylic acid (100 mg, 0.35 mmol) was taken up in acetonitrile (2 mL). HATU (269 mg, 0.7 mmol) was added. After stirring for 2 min. 3-aminopyridine (66 mg, 0.7 mmol) and pyridine (0.5 mL) were added. The reaction was heated in a pressure tube at 100° C. for 17 h. After cooling to room temperature, water was added. The aqueous layer was extracted with dichloromethane. Combined organic layers were dried, concentrated and the crude product was purified by HPLC or silica gel column chromatography (yield 35 mg, 25%) MS (ESI) calcd for C17H16F2N6O (m/z): 358.14; found 359.1 [M+H].
- This general coupling procedure could be used to prepare a variety of 6-(3,3-difluoropyrrolidin-1-yl)-2-methyl-N-(substituted)imidazo[1,2-b]pyridazine-3 carboxamides by substituting the appropriate amine moiety for 3-aminopyridine.
-
- Ethyl 6-chloroimidazo[1,2-b]pyridazine-3-carboxylate (600 mg, 2.66 mmol) and 2-(trifluoromethyl)pyrrolidine (1 g, 7.19 mmol) were heated in a sealed tube at 173° C. for 16 h. After cooling to room temperature, water (100 mL) was added. The aqueous layer was extracted with ethyl acetate (2×100 mL). Combined organic layers were dried, concentrated and product was purified by column chromatography to afford ethyl 6-(2-(trifluoromethyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylate (270 mg, 30%). MS (ESI) calcd for C14H15F3N4O2 (m/z): 328.1.
-
- 6-(2-(trifluoromethyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid was prepared using the same procedure that was used to make (S)-6-(3-fluoropyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid described above. (yield 85%) MS (ESI) calcd for C12H11F3N4O2 (m/z): 300.08.
- This general procedure, followed by standard ester hydrolysis could also be used to prepare (S)-6-(2-methylpyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid.
-
- N-(pyridin-3-yl)-6-(2-(trifluoromethyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxamide was prepared using the same procedure that was used to make (S)-6-(3-fluoropyrrolidin-1-yl)-N-(6-morpholinopyridin-2-yl)imidazo[1,2-b]pyridazine-3-carboxamide described above (yield 89%). MS (ESI) calcd for C17H15F3N6O (m/z): 376.1; found 377.1 [M+H].
- This general procedure could be used to prepare a variety of N-(substituted)-6-(2-(trifluoromethyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxamide by substituting the appropriate amine for 3-amino pyridine.
-
- Carboxydiimidazole (33 mg, 0.2 mmol) was taken in a pressure tube and dissolved in dioxane (1 mL). A solution of 6-(2-(trifluoromethyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid (50 mg, 0.167 mmol) in DMA (1 mL) was added and heated to 100° C. for 15 h. After cooling to room temperature 2-aminopyrimidine (48 mg, 0.501 mmol) was added. Heating was continued at 100° C. for 2d. After cooling back to room temperature, water (20 mL) was added upon which a solid separated. The solid was separated by filtration, taken up in MeOH heated and filtered again to afford N-(pyrimidin-4-yl)-6-(2-(trifluoromethyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine-3-carboxamide (29 mg, 46%). MS (ESI) calcd for C16H14F3N7O (m/z): 377.1; found 378.1 [M+H].
-
- A suspension of ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (600 mg, 2.66 mmol) in 2-(trifluoromethyl)piperidine (2.5 mL) was heated at 125° C. for 12 h in a sealed tube. After cooling to room temperature the crude residue was purified by MPLC eluting with pentane/EtOAc (20-100%) to give ethyl 5-(2-(trifluoromethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (575 mg, 63% yield). MS (ESI) calcd for C15H17F3N4O2 (m/z): 342.13.
-
- A solution of LiOH (81 mg, 3.36 mmol) in H2O (1.5 mL) was added to a solution of ethyl 5-(2-(trifluoromethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate carboxylate (575 mg, 1.68 mmol) and LiOH (81 mg, 3.36 mmol) in THF/MeOH (9.5 mL, 1:1) was stirred at room temperature for 12 h. H2O (3 mL) was added and the mixture was heated at 65° C. for 3 h. The mixture was concentrated, H2O added and the pH was adjusted to 2. The mixture was extracted with CH2Cl2, dried (MgSO4) and concentrated. The crude product was recrystallized from heptane/EtOAc to give 5-(2-(trifluoromethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. (429 mg, 81% yield). MS (ESI) calcd for C13H13F3N4O2 (m/z): 314.10.
-
- A mixture of 5-(2-(trifluoromethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (50 mg, 0.16 mmol), 3-amino pyridine (30 mg, 0.32 mmol), pyridine (40 μL mg, 0.48 mmol), and HATU (73 mg, 0.19 mmol) in CH3CN (10 mL) was heated at reflux for 16 h.
- The mixture was poured into brine, extracted with CH2Cl2, dried (MgSO4) and concentrated. The crude product was purified on MPLC eluting with CH2Cl2/MeOH (0-5%) then recrystallized from heptane/EtOAc to give N-(pyridin-3-yl)-5-(2-(trifluoromethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. (48 mg, 77% yield). MS (ESI) calcd for C18H17F3N6O (m/z): 390.14, found: 391.1 [M+H].
- This general procedure could be used to prepare a variety of N-(substituted)-5-(2-(trifluoromethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide by substituting the appropriate amine for 3-amino pyridine.
-
- A mixture of (S)-5-(2-(trifluoromethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (80 mg, 0.27 mmol), HATU (203 mg, 0.53 mmol) and DIEA (0.2 mL) in CH2Cl2 (15 mL) was stirred at room temperature for 0.5 h. The mixture was concentrated to dryness under reduced pressure at room temperature and used directly in the next step. In another flask, 4,5-dimethylthiazol-2-amine (88 mg, 0.53 mmol) was treated with NaH (>2eq) in dry THF for 15 min, the crude activated ester from above was added. Stirring was continued for another 1 h, ice-water was added carefully, then extracted with CH2Cl2. The combined organic phase was dried (Na2SO4) and concentrated. The crude product was purified by prep-TLC (CH2Cl2/MeOH, 25:1) to give (S)—N-(4,5-dimethylthiazol-2-yl)-5-(2-(trifluoromethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (28 mg, 23% yield). MS (ESI) calcd for C17H17F3N6OS (m/z): 410.11, found: 411.0 [M+H].
- This general procedure could be used to prepare a variety of N-(substituted)-5-(2-(trifluoromethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamides by substituting the appropriate amine for 4,5-dimethylthiazol-2-amine.
-
- To a slurry of 6-aminopicolinic acid (10.0 g, 72.5 mmol) in acetonitrile (150 mL) was added N,O-dimethylhydroxylamine hydrochloride (8.52 g, 87.0 mmol), 1-hydroxybenzotriazole (11.8 g, 87.0 mmol), N-(3-dimethylamino)-N′-ethylcarbodiimide hydrochloride (16.7 g, 87.0 mmol), and N,N-diisopropylethylamine (37.7 mL, 217 mmol). The mixture was stirred at room temperature overnight, and the solvent removed in vacuo. The residue was partitioned between 1N NaOH and ethyl acetate, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried with sodium sulfate, and the solvent removed in vacuo. The remaining residue was purified by flash chromatography (ethyl acetate with 0.1% triethylamine) to give 6-amino-N-methoxy-N-methylpicolinamide (4.30 g, 23.7 mmol, 33% yield). MS (ESI) calcd for C8H7N3O: 181.1
-
- Lithium aluminum hydride (1.08 g, 28.5 mmol) was added to a solution of 6-amino-N-methoxy-N-methylpicolinamide (4.30 g, 23.7 mmol) in THF (30 mL). The reaction was stirred at room temperature for 90 min. Ethyl acetate (30 mL) was added slowly, the reaction was filtered, and the filtrate taken and all the solvent removed in vacuo to give 6-aminopicolinaldehyde, which was taken on crude to the next step. To a solution of the above aldehyde in methanol (20 mL) was added p-toluenesulfonylmethyl isocyanide (13.9 g, 71.2 mmol) and potassium carbonate (19.4 g, 140 mmol). The reaction was stirred at reflux for 2 h, then all solvent removed in vacuo. The residue was partitioned between ethyl acetate (150 mL) and water (70 mL). The organic layer was washed with brine, dried with sodium sulfate, and the solvent removed in vacuo. The remaining residue was purified by flash chromatography (10% methanol in dichloromethane) to give 6-(oxazol-5-yl)pyridin-2-amine (2.00 g, 12.4 mmol, 52% yield over two steps). MS (ESI) calcd for C8H11N3O2: 161.06
- 4-(oxazol-5-yl)pyridin-2-amine
- was prepared according to the same procedure provided above,
- Mass spectrometry based assays were used to identify modulators of SIRT1 activity. The TAMRA based assay utilized a peptide having 20 amino acid residues as follows: Ac-EE-K(biotin)-GQSTSSHSK(Ac)NleSTEG-K(5TMR)-EE-NH2 (SEQ ID NO: 1), wherein K(Ac) is an acetylated lysine residue and Nle is a norleucine. The peptide was labeled with the fluorophore 5TMR (excitation 540 nm/emission 580 nm) at the C-terminus. The sequence of the peptide substrate was based on p53 with several modifications. In addition, the methionine residue naturally present in the sequence was replaced with the norleucine because the methionine may be susceptible to oxidation during synthesis and purification. The Trp based assay utilized a peptide having an amino acid residues as follows: Ac-R-H-K-K(Ac)-W-NH2 (SEQ ID NO: 2).
- The TAMRA based mass spectrometry assay was conducted as follows: 0.5 μM peptide substrate and 120 μM βNAD+ was incubated with 10 nM SIRT1 for 25 minutes at 25° C. in a reaction buffer (50 mM Tris-acetate pH 8, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5 mM DTT, 0.05% BSA). The SIRT1 protein was obtained by cloning the SirT1 gene into a T7-promoter containing vector, which was then transformed and expressed in BL21(DE3) bacterial cells. Test compound was added at varying concentrations to this reaction mixture and the resulting reactions were monitored. After the 25 minute incubation with SIRT1, 10 μL of 10% formic acid was added to stop the reaction. The resulting reactions were sealed and frozen for later mass spec analysis. Determination of the amount of deacetylated substrate peptide formed (or, alternatively, the amount of O-acetyl-ADP-ribose (OAADPR) generated) by the sirtuin-mediated NAD-dependent deacetylation reaction allowed for the precise measurement of relative SIRT1 activity in the presence of varying concentrations of the test compound versus control reactions lacking the test compound.
- The Trp mass spectrometry assay was conducted as follows. 0.5 μM peptide substrate and 120 μM βNAD+ were incubated with 10 nM SIRT1 for 25 minutes at 25° C. in a reaction buffer (50 mM HEPES pH 7.5, 1500 mM NaCl, 1 mM DTT, 0.05% BSA). The SIRT1 protein was obtained by cloning the SirT1 gene into a T7-promoter containing vector, which was then expressed in BL21(DE3) bacterial cells and purified as described in further detail below. Test compound was added at varying concentrations to this reaction mixture and the resulting reactions were monitored. After the 25 minute incubation with SIRT1, 10 μL of 10% formic acid was added to stop the reaction. The resulting reactions were sealed and frozen for later mass spec analysis. The relative SIRT1 activity was then determined by measuring the amount of O-acetyl-ADP-ribose (OAADPR) formed (or, alternatively, the amount of deacetylated Trp peptide generated) by the NAD-dependent sirtuin deacetylation reaction in the presence of varying concentrations of the test compound versus control reactions lacking the test compound. The degree to which the test agent activated deacetylation by SIRT1 was expressed as EC1.5 (i.e., the concentration of compound required to increase SIRT1 activity by 50% over the control lacking test compound), and Percent Maximum Activation (i.e., the maximum activity relative to control (100%) obtained for the test compound).
- A control for inhibition of sirtuin activity was conducted by adding 1 μL of 500 mM nicotinamide as a negative control at the start of the reaction (e.g., permits determination of maximum sirtuin inhibition). A control for activation of sirtuin activity was conducted using 10 nM of sirtuin protein, with 1 μL of DMSO in place of compound, to determine the amount of deacetylation of the substrate at a given time point within the linear range of the assay. This time point was the same as that used for test compounds and, within the linear range, the endpoint represents a change in velocity.
- For the above assay, SIRT1 protein was expressed and purified as follows. The SirT1 gene was cloned into a T7-promoter containing vector and transformed into BL21(DE3). The protein was expressed by induction with 1 mM IPTG as an N-terminal His-tag fusion protein at 18° C. overnight and harvested at 30,000×g. Cells were lysed with lysozyme in lysis buffer (50 mM Tris-HCl, 2 mM Tris[2-carboxyethyl]phosphine (TCEP), 10 μM ZnCl2, 200 mM NaCl) and further treated with sonication for 10 min for complete lysis. The protein was purified over a Ni-NTA column (Amersham) and fractions containing pure protein were pooled, concentrated and run over a sizing column (Sephadex S200 26/60 global). The peak containing soluble protein was collected and run on an Ion-exchange column (MonoQ). Gradient elution (200 mM-500 mM NaCl) yielded pure protein. This protein was concentrated and dialyzed against dialysis buffer (20 mM Tris-HCl, 2 mM TCEP) overnight. The protein was aliquoted and frozen at −80° C. until further use.
- Sirtuin-modulating compounds of Formula (I) that activated SIRT1 were identified using the assay described above and are shown below in Table 1. The EC1.5 values represent the concentration of test compounds that result in 150% activation of SIRT1. The EC1.5 values for the activating compounds of Formula (I) are represented by A (EC1.5<1 μM), B (EC1.5 1-25 μM), C (EC1.5>25 μM). The percent maximum fold activation is represented by A (Fold activation >350%) or B (Fold Activation <350%). “NT” means not tested; “ND” means not determinable.
-
TABLE 1 Compounds of Formula (I). TAMRA Trp % % Compound EC1.5 Fold EC1.5 Fold No [M + H]+[Calc] Structure (μM) Act (μM) Act 1 398 B B NT NT 2 384 B B A A 3 390 B B NT NT 4 384 B B NT NT 5 483 A A B B 6 489 A A NT NT 7 406 B B NT NT 8 400 B B B B 9 407 C B NT NT 10 401 B B NT NT 11 400 C B A A 12 394 C B NT NT 13 406 A A NT NT 14 400 A A B A 15 390 B A NT NT 16 384 A A NT NT 17 404 B B B B 18 385 B B NT NT 19 483 A A NT NT 20 489 A A B B 21 469 A A NT NT 22 453 A A NT NT 23 484 B A B B 24 469 B A NT NT 25 453 A A A A 26 449 A A C B 27 455 A A NT NT 28 433 A B NT NT 29 439 B B B B 30 451 B B NT NT 31 457 B B NT NT 32 366 B B B B 33 372 B B NT NT 34 465 A A B B 35 471 B B C B 36 451 A A NT NT 37 435 A A NT NT 38 466 B B C B 39 451 A A NT NT 40 435 A A NT NT 41 451 B B C B 42 457 B B NT NT 43 451 B B C B 44 457 B B B B 45 451 B B NT NT 46 457 B B NT NT 47 451 A A C B 48 457 B A NT NT 49 439 A A NT NT 50 439 A A A A 51 421 A A B A 52 421 A A NT NT 53 420 B B B B 54 404 C B NT NT 55 390 C B NT NT 56 405 B B B B 57 389 C B NT NT 58 416 B B NT NT 59 400 B B C B 60 452 A B NT NT 61 436 B B NT NT 62 422 B B C B 63 386 C B NT NT 64 408 NT NT NT NT 65 436 A B ND ND 66 454 A A NT NT 67 470 A A NT NT 68 452 B B B B 69 453 A A B A 70 467 A A NT NT 71 483 A A A A 72 465 A A NT NT 73 440 A B NT NT 74 475 A A A A 75 474 B A NT NT 76 489 B A NT NT 77 384 B A B B 78 398 A A A A 79 385 B A NT NT 80 385 B A C B 81 483 A A NT NT 82 469 A A NT NT 83 474 A A A A 84 385 B A B A 85 384 A A NT NT 86 384 C B C B 87 384 C B NT NT 88 385 A A NT NT 89 474 A A ND ND 90 385 A A NT NT 91 387 B A NT NT 92 387 B A C B 93 387 C B C B 94 350 B B NT NT 95 435 A A A B 96 405 A A NT NT 97 398 B A NT NT 98 398 B A B A 99 412 A A NT NT 100 402 A A NT NT 101 412 A A B A 102 398 A A B A 103 414 A A NT NT 104 427 A A B B 105 385 NT NT NT NT 106 385 B B NT NT 107 402 B A B B 108 384 B B NT NT 109 404 A A NT NT 110 402 A A B B 111 420 B B NT NT 112 387 B A B B 113 398 B B B B 114 374 B B NT NT 115 387 C B NT NT 116 449 A A C B 117 350 B B NT NT 118 350 B B NT NT 119 351 B B C B 120 470 A A B A 121 385 A A NT NT 122 390 A A B B 123 404 A A NT NT 124 453 A A NT NT 125 412 B B B B 126 455 A B B B 127 469 B B NT NT 128 370 C B C B 129 370 C B NT NT 130 371 NT NT NT NT 131 370 C B C B 132 425 C B NT NT 133 419 A A A B 134 389 A A C B 135 433 A A NT NT 136 334 B B NT NT 137 334 B B ND ND 138 334 B B NT NT 139 335 B B NT NT 140 467 A A B B 141 368 C B C B 142 368 B B NT NT 143 368 C B A B 144 439 A A NT NT 145 467 A A NT NT 146 474 A A B A 147 483 B B NT NT 148 483 C B NT NT 149 467 B B B B 150 489 B B B B 151 475 A A NT NT 152 404 A A A A 153 387 B A NT NT 154 431 B A NT NT 155 444 B B C B 156 458 B B NT NT 157 369 B B NT NT 158 453 A A ND ND 159 423 A B B B 160 467 B A NT NT 161 368 B B C B 162 368 B B NT NT 163 368 C B NT NT 164 453 A A B B 165 423 B A NT NT 166 352 C B NT NT 167 352 C B C B 168 437 A A ND ND 169 352 C B NT NT 170 407 A B B B 171 353 C B NT NT 172 451 B A C B 173 415 A A B A 174 429 A A NT NT 175 415 A A B A 176 469 A B NT NT 177 469 C B C B 178 453 A B NT NT 179 423 A B NT NT 180 467 B A ND ND 181 368 B B NT NT 182 368 B B B B 183 368 B B C B 184 369 B B NT NT 185 479 B B NT NT 186 449 B B C B 187 394 C B NT NT 188 394 C B NT NT 189 394 C B C B 190 395 NT NT NT NT 191 426 A B NT NT 192 483 A A A A 193 398 A A NT NT 194 398 A A NT NT 195 497 A A ND ND 196 445 A A NT NT 197 415 A A B B 198 445 A A B B 199 469 A A NT NT 200 341 B B NT NT 201 396 B A NT NT 202 440 B B NT NT 203 341 B B NT NT 204 341 NT NT NT NT 205 342 B B NT NT 206 398 B A B A 207 453 A A A A 208 399 A A NT NT 209 483 A A NT NT 210 398 B A B A 211 469 C B NT NT 212 474 A A NT NT 213 475 A A A A 214 467 C B C B 215 469 C B C B 216 469 B A NT NT 217 469 A A NT NT 218 390 A A B B 219 399 A A NT NT 220 418 A A NT NT 221 413 A A B B 222 497 A A NT NT 223 398 B A B A 224 398 B A B A 225 453 A A NT NT 226 475 B A NT NT 227 497 A A B A 228 440 A A NT NT 229 463 A A NT NT 230 406 A A C B 231 398 B A B B 232 398 A A NT NT 233 398 A A C B 234 398 A A NT NT 235 474 A A NT NT 236 474 A A A A 237 418 A A NT NT 238 413 A A C B 239 384 B A B A 240 384 A A NT NT 241 469 A A NT NT 242 348 B B B B 243 362 A A NT NT 244 364 B B A B 245 378 A A ND ND 246 399 B A NT NT 247 413 A A NT NT 248 467 B A B B 249 384 A A B B 250 384 C B NT NT 251 384 C B C B 252 385 B A NT NT 253 385 B A NT NT 254 385 B A C B 255 483 A A B B 256 469 A A NT NT 257 362 A B B B 258 432 C B NT NT 259 364 B A NT NT 260 378 A A B B 261 380 A B A B 262 448 C B NT NT 263 474 B A B B 264 482 B A NT NT 265 384 A A NT NT 266 385 B A B B 267 385 A A B B 268 385 A A NT NT 269 483 A A B A 270 399 A A NT NT 271 404 A A NT NT 272 432 A A B B 273 404 A A B A 274 427 A A NT NT 275 413 A A B B 276 399 A A NT NT 277 499 A A NT NT 278 489 B B NT NT 279 334 B B C B 280 335 B B NT NT 281 335 C B C B 282 335 B B NT NT 283 440 A B NT NT 284 424 C B C B 285 455 B B B B 286 439 B B NT NT 287 350 A A C B 288 351 B B NT NT 289 351 B B NT NT 290 351 B A C B 291 356 B A C B 292 370 A A NT NT 293 384 A A C B 294 356 B B NT NT 295 484 A A NT NT 296 482 B B B B 297 475 A A B B 298 340 B B NT NT 299 354 B B ND ND 300 368 A B NT NT 301 419 A A NT NT 302 389 A A ND ND 303 340 B B C B 304 354 B B NT NT 305 424 B B A B 306 370 B A NT NT 307 435 A A NT NT 308 405 A A A B 309 440 A A A B 310 497 A A NT NT 311 483 A A A A 312 400 A A NT NT 313 401 A A NT NT 314 401 A A B B 315 401 A A B A 316 406 A A NT NT 317 420 A A C B 318 434 A A NT NT 319 406 A A NT NT 320 420 A A B B 321 485 A A A A 322 455 A A NT NT 323 490 A A A A 324 400 B B NT NT 325 483 B B NT NT 326 393 A A A B 327 377 A A A B 328 341 A A NT NT 329 342 B B C B 330 342 B B NT NT 331 342 B A NT NT 332 347 B B C B 333 361 B A ND ND 334 375 A A NT NT 335 347 B B B B 336 361 B A NT NT 337 426 A A NT NT 338 396 A A A B 339 431 A A A B 340 485 A A A A 341 428 C B NT NT 342 401 C ND NT NT 343 414 C B NT NT 344 490 B B NT NT 345 491 B A NT NT 346 364 B B C B 347 365 C B NT NT 348 365 C B C B 349 365 C B NT NT 350 370 C B NT NT 351 384 B B C B 352 398 B B C B 353 370 B B NT NT 354 384 B B C B 355 449 A A NT NT 356 419 A B NT NT 357 454 C B C B 358 401 A A B A 359 418 B A NT NT 360 418 B B A B 361 440 A A NT NT 362 401 A A NT NT 363 428 A A A B 364 414 A A A A 365 428 B B NT NT 366 414 B B NT NT 367 491 A A NT NT 368 406 B A NT NT 369 420 A A B A 370 420 B A ND ND 371 434 A A NT NT 372 491 A A A B 373 406 B B NT NT 374 420 B B NT NT 375 398 B A C B 376 399 B B NT NT 377 399 B B C B 378 399 B A NT NT 379 432 B A NT NT 380 404 B A C B 381 418 B A C B 382 483 A A NT NT 383 453 A A B A 384 488 B B NT NT 385 398 A A NT NT 386 447 A A B B 387 502 A A A A 388 407 A A NT NT 389 399 A A B B 390 485 A A NT NT 391 517 A A NT NT 392 398 C B C B 393 398 B B C B 394 412 B B NT NT 395 401 A A A A 396 415 A A NT NT 397 420 A B NT NT 398 429 A A B B 399 429 B A NT NT 400 500 A A NT NT 401 415 A A A A 402 468 A A NT NT 403 432 A A NT NT 404 404 B B NT NT 405 418 B A NT NT 406 488 A A A A 407 398 A A B A 408 399 A A NT NT 409 399 A A ND ND 410 399 A A NT NT 411 404 A A NT NT 412 418 A A A A 413 432 A A A B 414 404 A A NT NT 415 434 A A B A 416 420 A A NT NT 417 434 A A NT NT 418 434 B B C B 419 428 A A A A 420 441 A A NT NT 421 481 A A A A 422 502 A A NT NT 423 474 A A NT NT 424 418 A A B B 425 483 A A A A 426 453 A A NT NT 427 488 A A A A 428 413 A A A A 429 440 A A NT NT 430 431 A A A A 431 414 A A B B 432 440 A A NT NT 433 418 A A C B 434 404 A A NT NT 435 483 A A NT NT 436 412 A A C B 437 414 A A A A 438 451 A A NT NT 439 402 A A A B 440 420 A A NT NT 441 398 A A NT NT 442 399 A A C B 443 399 A A C B 444 399 A A NT NT 445 432 A A B B 446 404 A A NT NT 447 418 A A NT NT 448 453 A A B A 449 488 A A A A 450 384 B A NT NT 451 384 B A B A 452 385 A A NT NT 453 385 B A NT NT 454 469 A A A A 455 384 B B C B 456 469 A A NT NT 457 446 A A A B 458 426 A A NT NT 459 426 A A NT NT 460 413 A A A A 461 399 A A B A 462 399 A A NT NT 463 399 A A B A 464 416 A A NT NT 465 416 A A NT NT 466 432 A A A A 467 400 B A B B 468 503 A A NT NT 469 415 A A B A 470 415 A A NT NT 471 415 A A NT NT 472 432 B B C B 473 430 A A A A 474 430 A A NT NT 475 441 A A B A 476 429 A A NT NT 477 445 A A NT NT 478 429 A A A A 479 429 A A NT NT 480 442 A A B B 481 442 A A A A 482 462 A A NT NT 483 384 NT NT NT NT 484 385 B B C B 485 400 B B NT NT 486 414 A A A A 487 412 B B A A 488 412 B A NT NT 489 430 B B A A 490 355 B A B B 491 355 B B NT NT 492 373 B B NT NT 493 456 A A ND ND 494 446 A A NT NT 495 446 A B ND ND 496 414 A A A B 497 414 A A NT NT 498 398 A A NT NT 499 398 A A A A 500 398 A A NT NT 501 398 A A NT NT 502 412 A A ND ND 503 413 A A NT NT 504 412 A A NT NT 505 385 A A B B 506 390 A A NT NT 507 404 A A B B 508 404 A A A A 509 418 A A NT NT 510 437 B B NT NT 511 437 B B B B 512 380 B B NT NT 513 380 B B C B 514 399 A A A A 515 399 A A NT NT 516 426 A A B B 517 402 B A B B 518 402 A A B B 519 415 A A NT NT 520 400 B B NT NT 521 414 A A A B 522 398 A A NT NT 523 398 A A C B 524 412 A A C B 525 404 A A NT NT 526 418 A A NT NT 527 404 A A B B 528 426 A A NT NT 529 400 A A A B 530 400 A A A A 531 400 A A NT NT 532 401 A A NT NT 533 401 A A B B 534 485 A A NT NT 535 499 A A A A 536 430 A A A B 537 481 A A NT NT 538 481 A A NT NT 539 412 A A ND ND 540 412 A A NT NT 541 416 A A B A 542 416 A A B B 543 443 A A NT NT 544 509 A A NT NT 545 525 A A A A 546 495 A A NT NT 547 399 A A NT NT 548 398 A A ND ND 549 398 A A B A 550 497 A A NT NT 551 428 A A A A 552 483 A A A A 553 474 A A NT NT 554 474 A A NT NT 555 475 A A A A 556 475 A A NT NT 557 488 A A NT NT 558 488 A A A A 559 401 B B B A 560 398 A A NT NT 561 426 B B B A 562 509 A A NT NT 563 390 A A NT NT 564 327 B B NT NT 565 341 B A B B 566 355 B A B B 567 398 B B NT NT 568 398 C B C B 569 398 C B NT NT 570 399 B B NT NT 571 399 C B B B 572 399 C B C B 573 497 B B NT NT 574 483 A A B B 575 414 C B NT NT 576 428 C B NT NT 577 414 B B A B 578 476 A A A A 579 419 B B NT NT 580 416 B A A A 581 400 A A NT NT 582 400 B B NT NT 583 400 B B C B 584 401 B A C B 585 401 B A NT NT 586 413 A A A A 587 499 A A NT NT 588 432 B B NT NT 589 442 B A B B 590 428 B B C B 591 434 A A A B 592 482 A A NT NT 593 513 A A NT NT 594 421 B B B B 595 429 A B NT NT 596 443 A A NT NT 597 421 B B A B 598 485 A A A A 600 429 A A A A 601 485 A A NT NT 602 429 A A NT NT 603 420 B A B B 604 414 A A B B 605 428 A A NT NT 606 418 A A A B 607 406 B B NT NT 608 414 C B NT NT 609 418 C B C B 610 414 B B A A 611 428 A A NT NT 612 414 A A A A 613 428 A B NT NT 614 434 A A NT NT 615 457 A A A A 616 414 A A A A 617 414 A A NT NT 618 398 A A B A 619 398 A A NT NT 620 412 B B NT NT 621 414 A A A A 622 414 B B A A 623 415 A A NT NT 624 401 A A A A 625 428 B B NT NT 626 444 A A NT NT 627 473 A A A A 628 412 A A A A 629 412 A A NT NT 630 398 B B A A 631 398 A A NT NT 632 398 A A NT NT 633 415 A A B B 634 459 A A A A 635 431 A A NT NT 636 445 A A B B 637 412 A A NT NT 638 412 A A NT NT 639 426 A A A A 640 398 B B B B 641 412 B A NT NT 642 402 A A B A 643 428 A A NT NT 644 415 A A B B 645 475 A A A A 646 468 A A NT NT 647 468 A A A A 648 426 A A NT NT 649 412 A B NT NT 650 418 A A A A 651 432 A A NT NT 652 418 A A NT NT 653 398 C B B A 654 399 A A B B 655 399 A A NT NT 656 420 B A B B 657 415 NT NT NT NT 658 429 A A NT NT 659 429 A A B B 660 418 A A NT NT 661 428 B B NT NT 662 473 A B NT NT 663 459 A A B B 664 413 A A NT NT 665 429 A A B B 666 443 A A NT NT 667 400 A A NT NT 668 468 A A A B 669 468 A A NT NT 670 429 A A NT NT 671 428 A A A A 672 443 B B B B 673 432 A A NT NT 674 415 B B B A 675 401 C B NT NT 676 432 A A NT NT 677 429 NT NT NT NT 678 445 NT NT NT NT 679 459 NT NT NT NT 680 429 B B B A 681 413 C B B A 682 413 A A NT NT 683 412 A A A A 684 412 A A NT NT 685 426 A A NT NT 686 416 A A A B 687 412 B B NT NT 688 429 B A B B 689 429 C B NT NT 690 436 C B NT NT 691 544 A A NT NT 692 359 A B A B 693 429 NT NT NT NT 694 359 B A B B 695 399 A A A A 696 429 A A NT NT 697 443 A A NT NT 698 426 A A A A 699 412 A B NT NT 700 415 NT NT NT NT 701 414 B B A A 702 420 A A NT NT 703 431 A A NT NT 704 401 A A B B 705 401 A A NT NT 706 349 B B A B 707 442 A A A A 708 426 B A NT NT 709 404 A A NT NT 710 413 A A A A 711 417 A A NT NT 712 414 NT NT NT NT 713 434 B A B B 714 414 A A NT NT 715 365 B A NT NT 716 363 B B A B 717 370 NT NT NT NT 718 445 A B C B 719 459 NT NT ND ND 720 375 B A NT NT 721 389 B B NT NT 722 412 B B A A 723 399 A A NT NT 724 413 C B B B 725 414 A A B B 726 415 A A NT NT 727 429 A A NT NT 728 443 A A C B 729 427 A A NT NT 730 455 A A A A 731 469 A A A B 732 453 A A NT NT 733 457 A A NT NT 734 415 B A C B 735 417 B A NT NT 736 429 A A C B 737 413 A A A A 738 484 A A NT NT 739 363 NT NT NT NT 740 379 NT NT ND ND 741 393 B B NT NT 742 379 A B C B 743 395 B B C B 744 409 A B NT NT 745 529 A A NT NT 746 398 A A C B 747 402 A A NT NT 748 451 A A B B 749 420 A A B B 750 428 A A NT NT 751 430 A A NT NT 752 420 B A B B 753 427 B A NT NT 754 418 A A B B 755 436 A A B B 756 420 B A NT NT 757 448 B A NT NT 758 438 A A B B 759 375 A B NT NT 760 389 A B ND ND 761 379 C B A B 762 393 B B NT NT 763 409 A A NT NT 764 423 A A ND ND 765 439 A A NT NT 766 345 A B A B 767 349 B B A A 768 416 A A NT NT 769 467 A A NT NT 770 474 B A C B 771 448 A A NT NT 772 420 B A B A 773 489 A A A A 774 421 A B NT NT 775 421 A A NT NT 776 417 B A C B 777 427 A A NT NT 778 429 A A A B 779 416 A A A A 780 460 A A NT NT 781 406 B A NT NT 782 420 A A C B 783 475 A A NT NT 784 414 A A A A 785 406 B A C B 786 443 A A NT NT 787 427 A A NT NT 788 434 B A B A 789 416 A A NT NT 790 434 A A A A 791 448 A A B B 792 434 A A NT NT 793 429 A A NT NT 794 399 A A B B 795 413 A A NT NT 796 427 A A B B 797 431 A A A A 798 434 A A NT NT 799 445 NT NT NT NT 800 399 B A C B 801 413 A A NT NT 802 390 B A C B 803 404 B A C B 804 420 A A NT NT 805 434 A A NT NT 806 413 A A B A 807 429 A A NT NT 808 432 A A B B 809 458 A A C B 810 444 A A NT NT 811 420 A A NT NT 812 406 A A A A 813 401 A A NT NT 814 424 B A B B 815 420 A A A A 816 434 A A A A 817 434 A A NT NT 818 449 A A B B 819 438 A A NT NT 820 426 B A B B 821 438 B B A B 822 438 A B NT NT 823 440 A B A B 824 422 B A A A 825 422 NT NT ND ND 826 436 B A A B 827 422 A A A B 828 401 A A C B 829 440 A A A B 830 401 A A C B 831 424 B A B B 832 435 A A B B 833 407 B A B B 834 516 NT NT A A 835 506 NT NT A A 836 327 NT NT B A 837 327 NT NT B B 838 345 NT NT B B 839 345 NT NT B B 840 341 NT NT B A 841 341 NT NT A A 842 488 NT NT A A 843 506 NT NT A A 844 359 NT NT B B 845 342 NT NT B B 846 359 NT NT A B 847 406 NT NT A A 848 420 NT NT A A 849 502 NT NT A A 850 517 NT NT A A 851 328 NT NT B B 852 342 NT NT B A 853 328 NT NT C B 854 328 NT NT B B 855 342 NT NT B A 856 328 NT NT B B 857 342 NT NT A A 858 406 NT NT B B 859 502 NT NT A A 860 516 NT NT A A 861 508 NT NT A A 862 488 NT NT A A 863 488 NT NT A A 864 502 NT NT A A 865 502 NT NT A A 866 352 NT NT B A 867 366 NT NT B A 868 352 NT NT B B 869 370 NT NT B B 870 384 NT NT C B 871 367 NT NT B B 872 384 NT NT C B 873 353 NT NT B A 874 370 NT NT A B 875 420 NT NT C B 876 449 NT NT A A 877 366 NT NT B B 878 449 NT NT B B 879 353 NT NT B B 880 367 NT NT B B 881 367 NT NT C B 882 353 NT NT B B 883 424 NT NT A B 884 424 NT NT B B 885 367 NT NT B B 886 353 NT NT B B 887 407 NT NT A B 888 328 NT NT C B 889 341 NT NT B B 890 345 NT NT B B 891 330 NT NT B A 892 361 NT NT A B 893 356 NT NT C B 894 310 NT NT B B 895 310 NT NT C B 896 309 NT NT B B 897 327 NT NT C B 898 327 NT NT C B 900 409 NT NT A B 901 405 NT NT A A 902 392 NT NT A A 903 363 NT NT C B 904 346 NT NT B A 905 346 NT NT B B 906 346 NT NT B B 907 363 NT NT B B 908 345 NT NT B B 909 345 NT NT B A 910 409 NT NT A A 911 370 NT NT A A 912 331 NT NT B B 913 331 NT NT B B 914 349 NT NT C B 915 349 NT NT C B 916 332 NT NT C B 917 418 NT NT B B 918 358 NT NT B B 919 395 NT NT C B 920 341 NT NT B B 921 332 NT NT C B 922 358 NT NT C B 923 371 NT NT A A 924 371 NT NT B B 926 332 NT NT C B 927 359 NT NT B A 928 359 NT NT B B 929 377 NT NT B A 930 360 NT NT B A 931 409 NT NT A A 932 391 NT NT A A 933 339 NT NT B B 934 339 NT NT B B 935 357 NT NT B B 936 357 NT NT B B 937 357 NT NT B A 938 325 NT NT B B 939 343 NT NT B B 940 325 NT NT C B 941 343 NT NT B B 942 326 NT NT B B 943 343 NT NT B B 944 340 NT NT B B 945 391 NT NT A A 946 338 NT NT C B 947 355 NT NT B B 948 337 NT NT B B 949 355 NT NT C B 950 338 NT NT C B 951 355 NT NT C B 952 336 NT NT B A 953 336 NT NT A A 954 354 NT NT B B 955 337 NT NT B A 956 354 NT NT B B 957 390 NT NT A A 958 376 NT NT A A 959 394 NT NT A A 960 354 NT NT A B 961 325 NT NT C B 962 376 NT NT B B 963 376 NT NT B B 964 359 NT NT B B 965 424 NT NT B A 966 376 NT NT A A 967 394 NT NT B A 968 377 NT NT A A 969 410 NT NT A A 970 377 NT NT A A 971 338 NT NT C B 972 337 NT NT B B 973 339 NT NT C B 974 376 NT NT A A 975 322 NT NT B B 976 322 NT NT B A 977 340 NT NT B B 978 323 NT NT A A 979 340 NT NT A A 980 358 NT NT B A 981 324 NT NT B B 982 324 NT NT B B 983 342 NT NT B B 984 325 NT NT B B 985 342 NT NT B B 986 340 NT NT A A 987 340 NT NT B A 988 358 NT NT B A 989 341 NT NT B A 990 358 NT NT A A 991 376 NT NT B B 992 323 NT NT C B 993 341 NT NT B A 994 373 NT NT A A 995 352 NT NT B A 996 353 NT NT B A 997 370 NT NT B A 998 391 NT NT A A 999 376 NT NT A A 1000 376 NT NT A A 1001 394 NT NT A A 1002 338 NT NT B A 1003 339 NT NT B A 1004 356 NT NT B A 1005 359 NT NT A A 1006 391 NT NT B A 1007 390 NT NT A A 1008 390 NT NT B A 1009 408 NT NT A A 1010 408 NT NT A A 1011 376 NT NT A A 1012 376 NT NT A A 1013 394 NT NT A A 1014 377 NT NT A A 1015 390 NT NT A A 1016 390 NT NT A A 1017 408 NT NT A A 1018 391 NT NT A A 1019 376 NT NT B A 1020 429 NT NT A A 1021 391 NT NT B A 1022 377 NT NT B A 1023 391 NT NT B A 1024 407 NT NT A A 1025 377 NT NT A A 1026 376 NT NT A A 1027 390 NT NT A A 1028 394 NT NT A A 1029 376 NT NT A A 1030 377 NT NT A A 1031 377 NT NT A A 1032 410 NT NT A A 1033 424 NT NT A A 1034 391 NT NT A A 1035 390 NT NT A A 1036 404 NT NT A A 1037 322 NT NT B A 1038 356 NT NT B B 1039 340 NT NT B A 1040 323 NT NT B A 1041 323 NT NT B B 1042 323 NT NT B B 1043 353 NT NT B B 1044 322 NT NT B A 1045 336 NT NT B B 1046 391 NT NT A A 1047 390 NT NT A A 1048 391 NT NT A A 1049 421 NT NT A A 1050 408 NT NT A A 1051 353 NT NT C B 1052 340 NT NT B B 1053 322 NT NT B A 1054 323 NT NT C B 1055 323 NT NT B A 1056 322 NT NT B B 1057 323 NT NT C B 1058 336 NT NT B B 1059 340 NT NT B B 1060 390 NT NT A A 1061 391 NT NT B A 1062 391 NT NT A A 1063 391 NT NT A A 1064 421 NT NT A A 1065 424 NT NT B A 1066 390 NT NT A A 1067 408 NT NT B A 1068 391 NT NT B A 1069 408 NT NT A A 1070 390 NT NT B A 1071 390 NT NT A A 1072 404 NT NT A A 1073 404 NT NT A A 1074 457 NT NT A A 1075 391 NT NT B A 1076 376 NT NT B A 1077 390 NT NT A A 1078 377 NT NT B A 1079 377 NT NT B A 1080 407 NT NT A B 1081 443 NT NT A A 1082 424 NT NT A A 1083 457 NT NT A A 1084 391 NT NT B A 1085 421 NT NT A A 1086 457 NT NT A A 1087 457 NT NT A A 1088 410 NT NT B A 1089 394 NT NT B B 1090 376 NT NT C B 1091 443 NT NT B A 1092 429 NT NT A A 1093 377 NT NT B B 1094 445 NT NT B A 1095 432 NT NT B A 1096 436 NT NT A A 1097 431 NT NT B A 1098 443 NT NT A A 1099 443 NT NT A A - In certain embodiments, the compound is any one of Compound Numbers 14, 94, 97, 98, 99, 100, 105, 119, 143, 159, 164, 165, 224, 225, 226, 230, 233, 301, 308, 318, 342, 344, 355, 370, 379, 424, 474, 479, 537, 577, 581, 586, 601, 638, 661, 665, 668, 684, 703, 761, 801, 806, 811, 812, 870, 880, 890, 918, 924, 925 928, 945, 953, 957, 958, 959, 966, 968, 969, 970, 974, 978, 979, 986, 990, 994, 998, 999, 1000, 1001, 1005, 1007, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1020, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1046, 1047, 1048, 1049, 1050, 1060, 1062, 1063, 1064, 1066, 1069, 1071, 1072, 1073, 1074, 1077, 1080, 1081, 1082, 1083, 1085, 1086, 1087, 1092, 1096 and 1098.
- The present invention provides among other things sirtuin-modulating compounds and methods of use thereof. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
- All publications and patents mentioned herein, including those items listed below, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) (www.tigr.org) and/or the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov).
Claims (23)
1. A method of increasing sirtuin-1 activity in a cell comprising the step of contacting the cell with a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of formula (I)
wherein:
one of D and E is N and the other is C; and
when D is N, one of A and B is N and the other is CR; and
when E is N, B is N and A is N or CR; or
a salt thereof, wherein:
each R is independently selected from hydrogen, halo, OH, C≡N, C1-C4 alkyl, halo-substituted C2-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, OR3, O—(C1-C4 alkyl)-OR3, S—(C1-C2 alkyl), S-(halo-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), C5-C7 cycloalkyl, and 4- to 8-membered non-aromatic heterocycle, and when one or both of E and A is N, then R can additionally be selected from halo-substituted methyl and C3-C4 cycloalkyl;
R1 is an aromatic heterocycle or a fused carbocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O—(C0-C4 alkyl)-CRxRx—(C0-C4 alkyl), CRxRx, phenyl, O-phenyl, second heterocycle, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 lkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
R2 is a carbocycle or a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, —O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O-phenyl, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, and when E is N, substituents on R2 can additionally be selected from a second heterocycle, and when both D and A are N, substituents on R2 can additionally be selected from phenyl and a second heterocycle, wherein any phenyl, saturated heterocycle or second heterocycle substituent of R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
each R3 is independently selected from hydrogen and C1-C4 alkyl optionally substituted with one or more of OH, O—(C1-C4 alkyl), halo, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(methoxy-substituted C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2 and N(methoxy-substituted C1-C4 alkyl)2; or
two R3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom independently selected from N, S, S(═O), S(═O)2, and O, wherein the heterocycle formed by two R3 is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, —O(C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2NH(methoxy-substituted C1-C4 alkyl), or N(methoxy-substituted C1-C4 alkyl)2, and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl;
two Rx taken together with the carbon atom to which they are bound form a 4- to 8-membered carbocycle or heterocycle optionally comprising one or two heteroatoms independently selected from N, S, S(═O), S(═O)2, and O, wherein the carbocycle or heterocycle is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, and N(R3)(R3) and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl; and
when D is N, A is CR and B is N, then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, and NH—C(═O)—O—CR4R5-†; and
when E is N, B is N and A is N or CR then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(═O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CH2—NH—C(═O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH-†, CR4R5—NH—C(═O)—O—† and NH—C(═O)—O—CR4R5—; and
when D is N, A is N and B is CR then X is selected from C(═O)—NH-†, NH—C(═O)†, NH—CR4R5-†, C(═O)—NH—CR4R5-†, S(═O)—NH-†, S(═O)2—NH-†, CR4R5—NH-†, —NH—C(═O)O—CR4R5-†, NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CR4R5—NH—C(O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH† and CR4R5—NH—C(═O)—O-†;
wherein:
† represents where X is bound to R1; and
each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, CF3 and (C1-C3 alkyl)-CF3.
2. A method for treating a subject suffering from or susceptible to insulin resistance, a metabolic syndrome, diabetes, or complications thereof, or for increasing insulin sensitivity in a subject, comprising administering to the subject in need thereof of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of formula (I):
wherein:
one of D and E is N and the other is C; and
when D is N, one of A and B is N and the other is CR; and
when E is N, B is N and A is N or CR; or
a salt thereof, wherein:
each R is independently selected from hydrogen, halo, OH, C≡N, C1-C4 alkyl, halo-substituted C2-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, OR3, O—(C1-C4 alkyl)-OR3, S—(C1-C2 alkyl), S-(halo-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), C5-C7 cycloalkyl, and 4- to 8-membered non-aromatic heterocycle, and when one or both of E and A is N, then R can additionally be selected from halo-substituted methyl and C3-C4 cycloalkyl;
R1 is an aromatic heterocycle or a fused carbocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O—(C0-C4 alkyl)-CRxRx—(C0-C4 alkyl), CRxRx, phenyl, O-phenyl, second heterocycle, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 lkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
R2 is a carbocycle or a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, —O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O-phenyl, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, and when E is N, substituents on R2 can additionally be selected from a second heterocycle, and when both D and A are N, substituents on R2 can additionally be selected from phenyl and a second heterocycle, wherein any phenyl, saturated heterocycle or second heterocycle substituent of R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
each R3 is independently selected from hydrogen and C1-C4 alkyl optionally substituted with one or more of OH, O—(C1-C4 alkyl), halo, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(methoxy-substituted C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2 and N(methoxy-substituted C1-C4 alkyl)2; or
two R3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom independently selected from N, S, S(═O), S(═O)2, and O, wherein the heterocycle formed by two R3 is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, —O(C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2NH(methoxy-substituted C1-C4 alkyl), or N(methoxy-substituted C1-C4 alkyl)2, and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl;
two Rx taken together with the carbon atom to which they are bound form a 4- to 8-membered carbocycle or heterocycle optionally comprising one or two heteroatoms independently selected from N, S, S(═O), S(═O)2, and O, wherein the carbocycle or heterocycle is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, and N(R3)(R3) and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl; and
when D is N, A is CR and B is N, then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, and NH—C(═O)—O—CR4R5-†; and
when E is N, B is N and A is N or CR then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(═O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CH2—NH—C(═O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH-†, CR4R5—NH—C(═O)—O—† and NH—C(═O)—O—CR4R5—; and
when D is N, A is N and B is CR then X is selected from C(═O)—NH-†, NH—C(═O)†, NH—CR4R5-†, C(═O)—NH—CR4R5-†, S(═O)—NH-†, S(═O)2—NH-†, CR4R5—NH-†, —NH—C(═O)O—CR4R5-†, NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CR4R5—NH—C(O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH—, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH† and CR4R5—NH—C(═O)—O-†;
wherein:
† represents where X is bound to R1; and
each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, CF3 and (C1-C3 alkyl)-CF3.
3. A method for treating a subject suffering from or susceptible to diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic-induced neuropathy, neuropathy associated with an ischemic event, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, and/or flushing, comprising administering to the subject in need thereof of a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of formula (I):
wherein:
one of D and E is N and the other is C; and
when D is N, one of A and B is N and the other is CR; and
when E is N, B is N and A is N or CR; or
a salt thereof, wherein:
each R is independently selected from hydrogen, halo, OH, C≡N, C1-C4 alkyl, halo-substituted C2-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, OR3, O—(C1-C4 alkyl)-OR3, S—(C1-C2 alkyl), S-(halo-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2, N(methoxy-substituted C1-C4 alkyl)2, N(C1-C4 alkyl)(hydroxy-substituted C1-C4 alkyl), N(C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)(methoxy-substituted C1-C4 alkyl), C5-C7 cycloalkyl, and 4- to 8-membered non-aromatic heterocycle, and when one or both of E and A is N, then R can additionally be selected from halo-substituted methyl and C3-C4 cycloalkyl;
R1 is an aromatic heterocycle or a fused carbocycle, wherein R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O—(C0-C4 alkyl)-CRxRx—(C0-C4 alkyl), CRxRx, phenyl, O-phenyl, second heterocycle, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo substituted 3,4-ethylenedioxy, wherein any phenyl, saturated heterocycle, or second heterocycle substituent of R1 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 lkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
R2 is a carbocycle or a heterocycle, wherein R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, C1-C4 alkoxy-substituted C1-C4 alkyl, hydroxy-substituted C1-C8 alkyl, O—R3, —O—(C1-C4 alkyl)-OR3, ═O, C3-C7 cycloalkyl, SO2R3, S—R3, (C1-C4 alkyl)-N(R3)(R3), N(R3)(R3), O—(C1-C4 alkyl)-N(R3)(R3), O—(C0-C4 alkyl)-CR3R3(C0-C4 alkyl), (C1-C4 alkyl)-O—(C1-C4 alkyl)-N(R3)(R3), C(═O)—N(R3)(R3), (C1-C4 alkyl)-C(═O)—N(R3)(R3), O-phenyl, O-(second heterocycle), 3,4-methylenedioxy, halo-substituted 3,4-methylenedioxy, 3,4-ethylenedioxy, and halo-substituted 3,4-ethylenedioxy, and when E is N, substituents on R2 can additionally be selected from a second heterocycle, and when both D and A are N, substituents on R2 can additionally be selected from phenyl and a second heterocycle, wherein any phenyl, saturated heterocycle or second heterocycle substituent of R2 is optionally substituted with one or more substituents independently selected from halo, C≡N, C1-C4 alkyl, halo-substituted C1-C4 alkyl, O-(halo-substituted C1-C4 alkyl), O—(C1-C4 alkyl), S—(C1-C4 alkyl), and S-(halo-substituted C1-C4 alkyl);
each R3 is independently selected from hydrogen and C1-C4 alkyl optionally substituted with one or more of OH, O—(C1-C4 alkyl), halo, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(methoxy-substituted C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2 and N(methoxy-substituted C1-C4 alkyl)2; or
two R3 are taken together with the nitrogen or carbon atom to which they are bound to form a 4- to 8-membered saturated heterocycle optionally comprising one additional heteroatom independently selected from N, S, S(═O), S(═O)2, and O, wherein the heterocycle formed by two R3 is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, —O(C1-C4 alkyl), NH(hydroxy-substituted C1-C4 alkyl), N(hydroxy-substituted C1-C4 alkyl)2NH(methoxy-substituted C1-C4 alkyl), or N(methoxy-substituted C1-C4 alkyl)2, and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl;
two Rx taken together with the carbon atom to which they are bound form a 4- to 8-membered carbocycle or heterocycle optionally comprising one or two heteroatoms independently selected from N, S, S(═O), S(═O)2, and O, wherein the carbocycle or heterocycle is optionally substituted at any carbon atom with one or more of OH, halo, C1-C4 alkyl, halo-substituted C1-C4 alkyl, NH2, and N(R3)(R3) and optionally substituted at any substitutable nitrogen atom with C1-C4 alkyl or halo-substituted C1-C4 alkyl; and
when D is N, A is CR and B is N, then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, and NH—C(═O)—O—CR4R5-†; and
when E is N, B is N and A is N or CR then X is selected from C(═O)—NH-†, NH—C(═O)-†, S(═O)—NH-†, S(═O)2—NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(═O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CH2—NH—C(═O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH-†, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH-†, CR4R5—NH—C(═O)—O—† and NH—C(═O)—O—CR4R5—; and
when D is N, A is N and B is CR then X is selected from C(═O)—NH-†, NH—C(═O)†, NH—CR4R5-†, C(═O)—NH—CR4R5-†, S(═O)—NH-†, S(═O)2—NH-†, CR4R5—NH-†, —NH—C(═O)O—CR4R5-†, NH-†, NH—C(═S)-†, C(═S)—NH-†, NH—S(═O)-†, NH—S(═O)2-†, NH—S(═O)2—NR4-†, NR4—S(O)2—NH-†, NH—C(═O)—O-†, O—C(═O)—NH-†, NH—C(═O)—NH-†, NH—C(═O)—NR4-†, NR4—C(═O)—NH-†, CR4R5—NH—C(O)-†, NH—C(═S)—CR4R5-†, CR4R5—C(═S)—NH-†, NH—S(═O)—CR4R5-†, CR4R5—S(═O)—NH-†, NH—S(═O)2—CR4R5-†, CR4R5—S(═O)2—NH—, CR4R5—O—C(═O)—NH-†, NH—C(═O)—CR4R5-†, NH—C(═O)—CR4R5—NH† and CR4R5—NH—C(═O)—O-†;
wherein:
† represents where X is bound to R1; and
each R4 and R5 is independently selected from hydrogen, C1-C4 alkyl, CF3 and (C1-C3 alkyl)-CF3.
4. The method of claim 1 , wherein both E and B are N, and A is N or CR.
5. The method of claim 4 , wherein A is N.
6. The method of claim 4 , wherein A is CR.
7. The method of claim 1 , wherein both D and B are N and A is CR.
8. The method of claim 1 , wherein both A and D are N and B is CR.
9. The method of claim 1 , wherein R is selected from hydrogen, halo, C1-C4 alkyl, 0-R3 and 4- to 8-membered non-aromatic heterocycle.
16. The method of claim 1 , wherein R2 is selected from optionally substituted carbocycle and optionally substituted non-aromatic heterocycle.
17. The method of claim 1 , wherein R2 is selected from optionally substituted aromatic carbocycle and optionally substituted non-aromatic heterocycle.
18. The method of claim 1 , wherein R2 is selected from optionally substituted non-aromatic carbocycle and optionally substituted non-aromatic heterocycle.
19. The method of claim 16 wherein R2 is an optionally substituted non-aromatic heterocycle.
20. The method of claim 19 , wherein R2 is attached to the remainder of the compound by a nitrogen atom of R2.
21. The method of claim 1 , wherein X is C(═O)—NH—†.
22. The method of claim 1 , wherein X is NH—C(═O)†.
23. The method of claim 1 , wherein the compound is any one of Compound Numbers 14, 94, 97, 98, 99, 100, 105, 119, 143, 159, 164, 165, 224, 225, 226, 230, 233, 301, 308, 318, 342, 344, 355, 370, 379, 424, 474, 479, 537, 577, 581, 586, 601, 638, 661, 665, 668, 684, 703, 761, 801, 806, 811, 812, 870, 880, 890, 918, 924, 925 928, 945, 953, 957, 958, 959, 966, 968, 969, 970, 974, 978, 979, 986, 990, 994, 998, 999, 1000, 1001, 1005, 1007, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1020, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1046, 1047, 1048, 1049, 1050, 1060, 1062, 1063, 1064, 1066, 1069, 1071, 1072, 1073, 1074, 1077, 1080, 1081, 1082, 1083, 1085, 1086, 1087, 1092, 1096 and 1098.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/904,993 US20180186801A1 (en) | 2011-10-20 | 2018-02-26 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549370P | 2011-10-20 | 2011-10-20 | |
| PCT/US2012/061015 WO2013059587A1 (en) | 2011-10-20 | 2012-10-19 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| US201414353096A | 2014-04-21 | 2014-04-21 | |
| US15/904,993 US20180186801A1 (en) | 2011-10-20 | 2018-02-26 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/353,096 Division US9957271B2 (en) | 2011-10-20 | 2012-10-19 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| PCT/US2012/061015 Division WO2013059587A1 (en) | 2011-10-20 | 2012-10-19 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20180186801A1 true US20180186801A1 (en) | 2018-07-05 |
Family
ID=47116451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/352,324 Active 2032-12-05 US9279026B2 (en) | 2011-10-20 | 2012-10-15 | Polyacetylene and chlorinated polyacetylene and production processes thereof |
| US15/904,993 Abandoned US20180186801A1 (en) | 2011-10-20 | 2018-02-26 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/352,324 Active 2032-12-05 US9279026B2 (en) | 2011-10-20 | 2012-10-15 | Polyacetylene and chlorinated polyacetylene and production processes thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9279026B2 (en) |
| EP (1) | EP2771372B1 (en) |
| KR (1) | KR101976783B1 (en) |
| CN (1) | CN103958550B (en) |
| BR (1) | BR112014009544B8 (en) |
| CA (1) | CA2852411C (en) |
| ES (1) | ES2769349T3 (en) |
| MX (1) | MX373159B (en) |
| WO (1) | WO2013059109A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279537A (en) * | 2016-08-05 | 2017-01-04 | 宁波金特信钢铁科技有限公司 | A kind of preparation method of polyacetylene molecular electronic wire |
| CN111978438B (en) * | 2019-05-22 | 2022-07-08 | 齐鲁工业大学 | Chlorinated polyvinyl chloride device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3367925A (en) | 1964-01-27 | 1968-02-06 | Dow Chemical Co | Polymerization of symmetrical dichloroethylene |
| FR2555590B1 (en) * | 1983-11-29 | 1986-06-20 | Elf Aquitaine | PROCESS FOR THE MANUFACTURE OF POLYACETYLENE |
| US4834911A (en) * | 1986-08-25 | 1989-05-30 | Electro-Organic Company | Intrinsically conductive and semiconductive polymers, products formed with such polymers and methods of forming same |
| CN1037073C (en) * | 1994-08-29 | 1998-01-21 | 青岛化工学院 | Preparation method of high melting point nm metal catalyzer |
-
2012
- 2012-10-15 WO PCT/US2012/060204 patent/WO2013059109A1/en not_active Ceased
- 2012-10-15 KR KR1020147013559A patent/KR101976783B1/en active Active
- 2012-10-15 US US14/352,324 patent/US9279026B2/en active Active
- 2012-10-15 ES ES12780984T patent/ES2769349T3/en active Active
- 2012-10-15 CA CA2852411A patent/CA2852411C/en active Active
- 2012-10-15 CN CN201280058337.7A patent/CN103958550B/en active Active
- 2012-10-15 MX MX2014004628A patent/MX373159B/en active IP Right Grant
- 2012-10-15 BR BR112014009544A patent/BR112014009544B8/en active IP Right Grant
- 2012-10-15 EP EP12780984.6A patent/EP2771372B1/en active Active
-
2018
- 2018-02-26 US US15/904,993 patent/US20180186801A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140288243A1 (en) | 2014-09-25 |
| CN103958550B (en) | 2018-04-17 |
| BR112014009544B1 (en) | 2021-06-08 |
| KR20140087016A (en) | 2014-07-08 |
| EP2771372A1 (en) | 2014-09-03 |
| MX373159B (en) | 2020-05-07 |
| MX2014004628A (en) | 2014-11-25 |
| US9279026B2 (en) | 2016-03-08 |
| CN103958550A (en) | 2014-07-30 |
| EP2771372B1 (en) | 2020-01-22 |
| BR112014009544B8 (en) | 2021-07-27 |
| BR112014009544A2 (en) | 2017-04-18 |
| CA2852411C (en) | 2020-07-14 |
| CA2852411A1 (en) | 2013-04-25 |
| ES2769349T3 (en) | 2020-06-25 |
| KR101976783B1 (en) | 2019-05-09 |
| WO2013059109A1 (en) | 2013-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9957271B2 (en) | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | |
| US9556201B2 (en) | Bicyclic pyridines and analogs as sirtuin modulators | |
| US9326986B2 (en) | Quinazolinone, quinolone and related analogs as sirtuin modulators | |
| US20140288052A1 (en) | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | |
| US9765075B2 (en) | Substituted bridged urea analogs as sirtuin modulators | |
| US20110319411A1 (en) | Isoindolinone and related analogs as sirtuin modulators | |
| EP2768834B1 (en) | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | |
| AU2015348944A1 (en) | Substituted bridged urea analogs as sirtuin modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: GLAXOSMITHKLINE LLC, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASAUBON, REBECCA L.;NARAYAN, RADHA;OALMANN, CHRISTOPHER;AND OTHERS;SIGNING DATES FROM 20121214 TO 20130104;REEL/FRAME:046166/0410 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































